

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN (print): 0250-7005; ISSN (online): 1791-7530

INDEX

VOLUME 42

2022

This volume is dedicated to the memory of  
W. DEN OTTER, Amsterdam, The Netherlands

## Editorial Board

<b>P. A. Abrahamsson</b>	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
<b>B. B. Aggarwal</b>	Director, Inflammation Research Center, San Diego, CA, USA
<b>T. Akimoto</b>	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
<b>P. Z. Anastasiadis</b>	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
<b>A. Argiris</b>	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
<b>J. P. Armand</b>	Institut Gustave Roussy, Paris, France
<b>V. I. Avramis</b>	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
<b>D.-T. Bau</b>	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
<b>G. Bauer</b>	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Freiburg, Germany
<b>E. E. Baulieu</b>	INSERM U488 and College de France, Le Kremlin-Bicetre, France
<b>E. J. Benz, Jr.</b>	Dana-Farber Cancer Institute, Boston, MA, USA
<b>J.-Y. Blay</b>	Centre Léon Bérard, Lyon, France
<b>J. Bergh</b>	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
<b>F. T. Bosman</b>	Institute of Pathology, University of Lausanne, Lausanne, Switzerland
<b>M. Bouvet</b>	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
<b>J. Boyd</b>	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
<b>G. Broich</b>	Gruppo Policlinico di Monza, Monza, Italy
<b>Ø. S. Bruland</b>	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
<b>J. M. Buatti</b>	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
<b>M. Carbone</b>	Cancer Research Center of Hawaii, Honolulu, HI, USA
<b>C. Carlberg</b>	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
<b>A. F. Chambers</b>	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
<b>P. Chandra</b>	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
<b>L. Cheng</b>	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
<b>J.-G. Chung</b>	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
<b>R. Clarke</b>	Georgetown University Medical Center, Washington, DC, USA
<b>A.P. Conley</b>	Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
<b>E. De Clercq</b>	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
<b>E. P. Diamandis</b>	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
<b>G. Th. Diamandopoulos</b>	Department of Pathology, Harvard Medical School, Boston, MA, USA
<b>L. Egevad</b>	Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
<b>D. W. Felsher</b>	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
<b>H. Fu</b>	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
<b>B. Fuchs</b>	Balgrist University Hospital, Zurich, Switzerland
<b>D. Fuchs</b>	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria
<b>D. Fukumura</b>	Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
<b>G. Gabbiani</b>	Department of Pathology, University of Geneva, Geneva, Switzerland
<b>R. Ganapathi</b>	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

- A. Giordano** Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
- M. Gnant** Department of Surgery, Medical University of Vienna, Vienna, Austria
- R. H. Goldfarb** R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
- J.S. Greenberger** Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA
- A. Helland** Oslo University Hospital-Radium Hospital, Oslo, Norway
- L. Helson** Sign Path Pharma, Inc., Quakertown, PA, USA
- R. Henriksson** Department of Experimental Oncology, Umeå University, Umeå, Sweden
- R. M. Hoffman** Department of Surgery, University of California, San Diego, CA, USA
- P. Hohenberger** Division of Surgical Oncology and Thoracic Surgery, Medical Faculty, University of Heidelberg, Mannheim, Germany
- F. Janku** Monte Rosa Therapeutics, Boston, MA, USA
- S. C. Jhanwar** Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
- R. Jones** Sarcoma Unit, Royal Marsden Hospital, London, UK
- B. Kaina** Institute of Toxicology, University of Mainz, Mainz, Germany
- D. G. Kieback** Helios Medical Center Schleswig, Schleswig, Germany
- R. Klapdor** Medical Clinic, University of Hamburg, Hamburg, Germany
- K.L. Knutson** Department of Immunology, Mayo Clinic College of Medicine, Jacksonville, FL, USA
- H. Kobayashi** Laboratory of Molecular Theranostics, NCI/NIH, Bethesda, MD, USA
- S. D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- G. R. F. Krueger** Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
- Pat M. Kumar** Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
- Shant Kumar** Department Pathology, University of Manchester Medical School, Manchester, UK
- O. D. Laerum** Department of Pathology, The Gade Institute, University of Bergen, Bergen, Norway
- F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
- S. Linder** Department of Medicine and Health, Linköping University, Linköping, Sweden
- D. M. Lopez** Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
- E. Lundgren** Unit of Applied Cell and Molecular Biology, University of Umeå, Umeå, Sweden
- Y. Maehara** Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- J. Maher** Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
- J. Marescaux** IRCAD, University of Strasbourg, Strasbourg, France
- S. S. Martin** Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
- S. Mitra** The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
- S. Miyamoto** Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
- S. Moncada** Manchester Cancer Research Centre, University of Manchester, Manchester, UK
- M. Mueller** Hochschule Furtwangen University, Villingen-Schwenningen, Germany
- M. Namiki** Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- J. L. Persson** Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden

- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Uppsala, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- D. Rades** Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
- M. Rigaud** Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, Portsmouth, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
- M. Roselli** Department of Medical Oncology, University of Rome "Tor Vergata", Rome, Italy
- S.T. Rosen** Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
- M. Schneider** Department of Organic Chemistry, Bergische University, Wuppertal, Germany
- J. Sehoul** Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
- A. Seth** Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Toronto, Ontario, Canada
- G. V. Sherbet** Cancer Research Unit, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK
- A. Slominski** Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
- G.-I. Soma** Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
- G. S. Stein** Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
- T. Stigbrand** Department of Immunology, Umeå University, Umeå, Sweden
- T. M. Theophanides** Department of Chemistry, Technical University of Athens, Athens, Greece
- P. M. Ueland** Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Bergen, Norway
- H. Van Vlierberghe** Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
- R.G. Vile** Department of Immunology, Mayo Clinic, Rochester, MN, USA
- M. Weller** Department of Neurology, University Hospital Zurich, Zurich, Switzerland
- J. Westermarck** Centre for Biotechnology, University of Turku, Turku, Finland
- B. Westermarck** Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Uppsala, Sweden
- Y. Yen** Taipei Medical University, Taipei, Taiwan, ROC
- M. R. I. Young** Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA

## Acknowledgements

The IIAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 42, 2022.

- Aarhus University Hospital, Aarhus, Denmark  
 Aarne Koskelo Legacy, Helsinki, Finland  
 Academy of Finland, Helsinki, Finland  
 Accelerator Engineering Corporation, Chiba, Japan  
 Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Yonago, Japan  
 Advanced Research Foundation, Department of Neurosurgery, WMCH/New York Medical College, Valhalla, NY, U.S.A.  
 Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, P.R. China  
 Akita University Graduate School of Medicine, Akita, Japan  
 Alberta Cancer Foundation, Calgary, AB, Canada  
 Alliance Grenobloise pour la Biologie Structurale et Cellulaire Intégrée (GRAL), Paris, France  
 American Society for Radiation Oncology (ASTRO), San Diego, CA, U.S.A.  
 ApoQlar GmbH, Hamburg, Germany  
 ARCO Foundation, Winterthur, Switzerland  
 Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea  
 Asia University, Taichung, Taiwan, R.O.C.  
 Asia-Oceania Particle Therapy Cooperative Group (PTCOG-AO), Osaka, Japan  
 Association of Healthcare Corporation, Japan  
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy
- Baden-Württemberg Ministry of Science, Research, and the Arts, Berlin, Germany  
 Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea  
 BIO & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea  
 Biohit Oyj, Helsinki, Finland  
 Biomedical Research Institute Grant, Kyungpook National University Hospital, Daegu, Republic of Korea  
 Biostatistics Center, Kurume University, Kurume, Japan
- BK21 FOUR (Graduate School Innovation), Ministry of Education (MOE), Sejong, Republic of Korea  
 Board of Research, Karolinska Institute, Solna, Sweden  
 Boler Biotech Consulting, LLC., Boston, MA, U.S.A.  
 BONFOR program, Medical Faculty, University of Bonn, Bonn, Germany  
 Brain and Spine Surgeons of New York, White Plains, NY, U.S.A.  
 Brain Korea 21 (BK21) PLUS Program for Creative Veterinary Science, Seoul National University, Seoul, Republic of Korea  
 Brain Research Program, National Research Foundation of Korea (NRF), Ministry of Science, ICT & Future Planning, Seoul, Republic of Korea  
 Breast Cancer Hope Foundation, London, U.K.  
 Bruker Japan, Kanagawa, Japan  
 Buddhist Tzu Chi Medical Foundation, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
- Cancer Tissue Bank, Hwasun Hospital of Chonnam National University, Hwasun, Republic of Korea  
 Canon Foundation, Japan  
 Carbogen Amcis B.V., Veenendaal, the Netherlands  
 Cathay General Hospital, Taipei, Taiwan, R.O.C.  
 Center of Excellence on Medical Biotechnology (CEMB), Bangkok, Thailand  
 Centers for Disease Control (CDC) and Prevention, Atlanta, GA, U.S.A.  
 Central Hospital Karlstad, Karlstad, Sweden  
 Centro de Gastroenterologia, Faculdade de Medicina de Marília (FAMEMA), Marília, Brazil  
 Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan, R.O.C.  
 Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.  
 Chang Gung Research Database, Taoyuan, Taiwan, R.O.C.  
 Charles University Research Fund (Progres Q39), Prague, Czech Republic  
 China Medical University Hospital, Taichung, Taiwan, R.O.C.  
 China Medical University Hsin-Chu Hospital, Zhubei, Taiwan, R.O.C.  
 China Medical University, Taichung, Taiwan, R.O.C.  
 Chosun University, Gwangju, Republic of Korea  
 Chuanghua Christian Hospital, Changhua, Taiwan, R.O.C.

- Chungnam National University Hospital Research Fund, Daejeon, Republic of Korea
- CIF Grant, Faculty of Science, Mahidol University, Salaya, Thailand
- Clinical Rebiopsy Bank Project for Comprehensive Cancer Therapy Development, Ministry of Education, Culture, Sports, Science and Technology Supported Program for the Strategic Research Foundation at Private Universities, Japan
- Clinical Research Center, Danderyd Hospital, Danderyd, Sweden
- Clinical Research Data Center, Tohoku University Hospital, Sendai, Japan
- Clinical Research Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
- Clinical Study Support Center, Wakayama Medical University Hospital (WMUH), Wakayama, Japan
- College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.
- Committee for Research, Karolinska University Hospital, Stockholm, Sweden
- Comparative Pathology Core, Flowcytometry Core, Clinical Proteomics Core, and Laboratory of Animal Research, Convergence mEDICine research cenTer (CREDIT), Asan Medical Center, Seoul, Republic of Korea
- Competitive State Research Financing, Expert Responsibility Area, Tampere University Hospital, Tampere, Finland
- Competitive State Research Financing of the Expert Responsibility Area, Tampere University Hospital, Tampere, Finland
- Computerforum, Elmshorn, Germany
- Conceptual Development of Research Organization, Faculty Hospital in Pilsen (FNPI), Pilsen, Czech Republic
- Consejo Nacional De Ciencia y Tecnología (CONACyT), México, D.F., Mexico
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília, Brazil
- Cooperation Program, Research Area MED/DIAG, Prague, Czech Republic
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, Brazil
- Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
- Cross-ministerial Strategic Innovation Promotion Program, Japan
- CU Graduate School Grant, Chulalongkorn University, Bangkok, Thailand
- Cultivation Project, National Natural Science Foundation of China
- Cyprus Institute of Neurology and Genetics (Telethon Cyprus), Nicosia, Cyprus
- Dalim Medical Corporation, Seoul, Republic of Korea
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston TX, U.S.A.
- Danish CancerBiobank, Copenhagen, Denmark
- Danish Research Center for Skin Cancer, Copenhagen, Denmark
- Debbie's Brain Cancer Research Fund, Syracuse, NY, U.S.A. Lundbeck Foundation, Copenhagen, Denmark
- Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan
- Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, Thailand
- Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
- Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- Department of Cellular and Organ Pathology, Akita University Graduate School of Medicine, Akita, Japan
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Department of Diagnostic and Interventional Radiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
- Department of Gastrointestinal Surgery, Kobe University, Kobe, Japan
- Department of Internal Medicine III, Hematology/Oncology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose, Japan
- Department of Medical Research, China Medical University Hsinchu Hospital, Zhubei, Taiwan, R.O.C.
- Department of Medical Research, National Taiwan University Hospital, Taipei City, Taiwan, R.O.C.
- Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Salaya, Thailand
- Department of Nuclear Medicine/Biotracer Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan



- Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden
- Department of Oral and Maxillofacial Radiology, Hiroshima University Hospital, Hiroshima, Japan
- Department of Pathology, Asan Medical Center, Seoul, Republic of Korea
- Department of Pathology, Fukuoka University Hospital, Fukuoka, Japan
- Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
- Department of Pathology, Naestved Hospital, Næstved, Denmark
- Department of Pathology, Tohoku University Hospital, Sendai, Japan
- Department of Pharmacy, Cork University Hospital, Cork, Ireland
- Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
- Department of Radiation Effects Research, National Institute of Radiological Sciences, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Chiba, Japan
- Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
- Department of Surgery and Department of Surgical Research and Techniques, University of Pécs, Pécs, Hungary
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Department of Surgery and Transplantation, Rigshospitalet, Copenhagen, Denmark
- Department of Surgery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
- Department of Surgery, University College Cork (UCC), Cork, Ireland
- Departments of Neurosurgery and Neuroscience & Physiology, State University of New York (SUNY), Upstate Medical University, Syracuse, NY, U.S.A.
- Des Moines University, Des Moines, IA, U.S.A.
- Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
- Division of Oncology, Medicon Village, Lund University, Lund, Sweden
- Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
- Division of Tumor and Cellular Biochemistry, University of Miyazaki, Miyazaki, Japan
- Doctorado en Ciencias Biológicas Program, Universidad Autónoma de Querétaro, Santiago de Querétaro, Mexico
- Drug Development Center, China Medical University, Taichung, Taiwan, R.O.C.
- Ebiogen Inc., Seoul, Republic of Korea
- Eila Vehmas Foundation, Tampere University Hospital, Tampere, Finland
- Eisai Co., Ltd., Tokyo, Japan
- Elena-Venizelou Therapeutic Institution, Athens, Greece
- Emil Aaltonen Foundation, Tampere, Finland
- Engineering Department, The University of Sunderland, Sunderland, U.K.
- Eskilstuna Hospital, Eskilstuna, Sweden
- European Regional Development Fund (ERDF), Brussels, Belgium
- European Social Fund (ESF), European Commission, Brussels, Belgium
- Faculty of Dentistry, Thammasat University, Bangkok, Thailand
- FALCO Biosystems Ltd., Kyoto, Japan
- Featured Areas Research Center Program, Higher Education Sprout Project, Ministry of Education (MOE), Taipei, Taiwan, R.O.C.
- Fédération Nationale des Centres de Lutte Contre le Cancer (GEFLUC Grenoble-Dauphiné-Savoie), Paris, France
- Finnish Dental Society Apollonia, Helsinki, Finland
- Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy
- Fondazione Pascale (IRCCS), National Cancer Institute, Naples, Italy
- FONDEC, Universidad Autónoma de Querétaro, Santiago de Querétaro, Mexico
- Forschungskredit, University of Zurich, Zürich, Switzerland
- Foundation for Promotion of Cancer Research, Tokyo, Japan
- French Association Against Cancer (ARC Foundation), Paris, France
- French Atomic Energy and Alternative Energies Commission (CEA), Paris, France
- French National Institute of Health and Medical Research INSERM (UMRS 1292), Paris, France
- FUJIFILM Toyama Chemical Co., Ltd., Tokyo, Japan
- Fukuoka Foundation for Sound Health Cancer Research Fund, Fukuoka, Japan



- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), São Paulo, Brazil
- Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal
- Genomics Core Facility and Animal Core Facility, Department of Pathology, National Cancer Center, Goyang, Republic of Korea
- Georg and Ella Ehrnroot Trust, Helsinki, Finland
- George W. Perkins III Research Fund, Syracuse, NY, U.S.A.
- GGA Corporation, Molecular Science and Digital Innovation Center, Taipei, Taiwan, R.O.C.
- Gifu University, Gifu, Japan
- Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung, Taiwan, R.O.C.
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Grant for All Kitasato Project Study, Tokyo, Japan
- Grant for President's Research Promotion, Tokyo University of Science, Tokyo, Japan
- Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare, Japan
- Grant-in-Aid for Early-Career Scientists, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
- Grant-in-Aid for JSPS Research Fellows, Tokyo, Japan
- Grant-in-Aid for Research Activity Start-up, Tokyo, Japan
- Grant-in-Aid for Scientific Research on Innovative Areas, Scientific Support Programs for Cancer Research, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
- Grant-in-Aid for Scientific Research, Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
- Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, Tokyo, Japan
- Grant-in-Aid, Kakihara Science and Technology Foundation, Fukuoka, Japan
- Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
- Greater Copenhagen Health Science Partners (GCHSP), Copenhagen, Denmark
- Greek Ministry of Health, Athens, Greece
- Grenoble University Hospital, Grenoble, France
- Gunma University Heavy-Ion Medical Center (GHMC), Maebashi, Japan
- Gunma University, Gunma, Japan
- Hadassah School of Public Health, Hebrew University, Jerusalem, Israel
- Hallym University Research Fund, Chuncheon, Republic of Korea
- Hamaguchi Foundation for the Advancement of Biochemistry, Chiba, Japan
- Health Age Co., Ltd., Tokyo, Japan
- Health and Welfare Data Science Center, Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan, R.O.C.
- Health Data Science Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
- Health Labor Sciences Research Grant, Ministry of Health, Labor, and Welfare, Tokyo, Japan
- Hellenic Society of Medical Oncology (HeSMO), Athens, Greece
- Hellenic Surgical Society, Athens, Greece
- Helsinki University Hospital District Funds, Helsinki, Finland
- Holoeyes Inc., Tokyo, Japan
- Hospital São Paulo (HSP), São Paulo, Brazil
- Hospital Universitario João de Barros Barreto (HUJBB), Belém, Brazil
- HTLV-1/ATL Research Facility, University of Miyazaki, Miyazaki, Japan
- Ili Prefecture Science and Technology Development Fund Project, P.R. China
- Inje University, Gimhae, Republic of Korea
- Innovation Center for Aging Research (i-CARE), College of Medicine, Yeungnam University, Gyeongsan, Republic of Korea
- Institut de Recherche Interdisciplinaires de Grenoble (IRIG), Grenoble, France
- Institute for Clinical Research, National Hospital Organization Kure Medical Center/Chugoku Cancer Center, Kure, Japan
- Institute of Clinical Medicine Research, Bucheon St. Mary's Hospital, Bucheon-si, Republic of Korea
- Institute of Nutrition, Mahidol University, Salaya, Thailand
- International College of Dentistry, Walailak University, Thai Buri, Thailand
- International Research Network, Thailand Research Fund, Bangkok, Thailand
- Interreg Deutschland-Danmark, Kiel, Germany
- Intractable Disease Research Center, Juntendo University, Tokyo, Japan
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy
- Japan Agency for Medical Research and Development (AMED), Tokyo, Japan

- Japan Clinical Cancer Research Organization (JACCRO)  
Data Center and Support Office, Tokyo, Japan
- Japan Science and Technology Agency (JST), Tokyo,  
Japan
- Japan Society for the Promotion of Science (JSPS), Tokyo,  
Japan
- Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
- Japanese Society of Clinical Research, Tokyo, Japan
- Japanese Society of Hematology, Tokyo, Japan
- Jikei University Research Fund, Tokyo, Japan
- Jilin Province Health Technology Innovation Project,  
P.R. China
- JMDC Co., Ltd., Tokyo, Japan
- Jönköping Hospital, Jönköping, Sweden
- José-Carreras Center and Internal Medicine I, University  
Hospital of Saarland, Homburg, Germany
- J-SHARE Project (39), Quantum and Radiological Science  
and Technology (QST), National Institute of Radiological  
Sciences (NIRS), Chiba, Japan
- KAC Co., Ltd., Kyoto, Japan
- Karolinska Institute, Solna, Sweden
- Karolinska University Hospital, Solna, Sweden
- Kawaguchi Municipal Medical Center, Kawaguchi,  
Japan
- Köln Fortune Fellowship, Cologne, Germany
- Korea Health Industry Development Institute (KHIDI),  
Ministry of Health & Welfare, Seoul,  
Republic of Korea
- Korea Health Technology R&D Project, Korea Health  
Industry Development Institute (KHIDI), Ministry of  
Health & Welfare, Seoul, Republic of Korea
- Korea Institute for Advancement of Technology (KIAT),  
Seoul, Republic of Korea
- Korea Institute of Radiological and Medical Sciences  
(KIRAMS), Ministry of Science, ICT and Future  
Planning (MSIP), Gwacheon, Republic of Korea
- Korea University, Seoul, Republic of Korea
- Korean Association of Hepato-Biliary-Pancreatic Surgery,  
Republic of Korea
- Korean Society of Gynecologic Oncology, Republic of  
Korea
- Korean Society of Surgical Oncology, Republic of Korea
- Korean Surgical Society, Republic of Korea
- Krebsliga Zürich, Zürich, Switzerland
- Kyungpook National University Chilgok Hospital  
Molecular Pathology Laboratory, Daegu, Republic of  
Korea
- Kyushu University, Fukuoka, Japan
- Laboratory Animal and Genome Sciences Section,  
Quantum Life and Medical Science Directorate, National  
Institutes for Quantum Science and Technology, Chiba,  
Japan
- Laboratory of Molecular and Biochemical Research,  
Biomedical Research Core Facilities, Juntendo  
University Graduate School of Medicine, Tokyo,  
Japan
- Lahti City Hospital, Lahti, Finland
- Li Ka Shing Knowledge Institute, St. Michael's Hospital,  
Toronto, ON, Canada
- Lilly Constance and Karl Ingolf Larssons Stiftelse, Oslo,  
Norway
- Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan,  
R.O.C.
- Lithuanian Research Council, Vilnius, Lithuania
- Liver Research Center, Chang Gung Memorial Hospital,  
Taoyuan, Taiwan, R.O.C.
- Lundbeck Foundation, Copenhagen, Denmark
- MacKay Memorial Hospital, Taipei, Taiwan, R.O.C.
- Mahidol University, Salaya, Thailand
- Medical Research Center of Tokyo Medical University,  
Tokyo, Japan
- Medical Research Core Facilities Center, Office of  
Research & Development, China Medical University,  
Taichung, Taiwan, R.O.C.
- Medical University of Warsaw, Warsaw, Poland
- Melvin Markey Discovery Fund, Cleveland Clinic,  
Cleveland, OH, U.S.A.
- Michael Hoefflin Foundation, Santa Clarita, CA, U.S.A.
- Ministry of Education, Culture, Sports, Science and  
Technology (MEXT), Tokyo, Japan
- Ministry of Education, Science and Technology, Seoul,  
Republic of Korea
- Ministry of Health and Welfare of Japan, Tokyo, Japan
- Ministry of Health of the Czech Republic, Prague, Czech  
Republic
- Ministry of Science and ICT (MSIT), Gwacheon, Republic  
of Korea
- Ministry of Science and Technology (MOST), Taipei,  
Taiwan, R.O.C.
- Ministry of Science, Technology and Higher Education  
(MCTES), Portugal
- Ministry of Trade, Industry, and Energy (MOTIE), Sejong,  
Republic of Korea
- Mission Biotech (MB), Taipei, Taiwan, R.O.C.
- Miyata Research Fund, Meikai University School of  
Dentistry, Saitama, Japan

- Molecular Oncology and Therapeutics,  
Osaka Metropolitan University Graduate School of  
Medicine, Osaka, Japan  
Moonshot R&D, Japan Science and Technology Agency  
(JST), Tokyo, Japan
- Nagai Memorial Research Scholarship, Pharmaceutical  
Society of Japan, Tokyo, Japan  
Nagoya City University, Nagoya, Japan  
Nanjing Municipal Health Science and Technology  
Development Special Fund, P.R. China  
National Cancer Institute, National Institutes of Health,  
Bethesda, MD, U.S.A.  
National Hospital Organization Kyushu Cancer Center,  
Fukuoka, Japan  
National Laboratories Excellence Program, Hungary  
National Natural Science Foundation of China (NSFC),  
Guangdong, P.R. China  
National Research Council of Thailand (NRCT), Bangkok,  
Thailand  
National Research, Development and Innovation Office,  
Budapest, Hungary  
National Research Foundation of Korea (NRF), Ministry of  
Education, Science and Technology, Seoul, Republic of  
Korea  
National Taipei University of Technology Joint Research  
Program, Taipei, Taiwan, R.O.C.  
National Yang Ming Chiao Tung University Hospital,  
Taipei, Taiwan, R.O.C.  
NIH Grant, National Institute on Minority Health and  
Health Disparities (NIMHD), Bethesda, MD, U.S.A.  
Nippon Medical School, Tokyo, Japan  
NKFI-EPR National Grant, Hungary  
NorDigHealth, European Regional Development Fund,  
Interreg Deutschland-Danmark, Kiel, Germany  
Novartis Hellas, Athens, Greece  
Novartis Pharmaceuticals Canada Inc., Dorval, Canada  
Nutrifarm Ltd., Toronto, ON, Canada
- Office of Higher Education Commission (OHEC),  
Bangkok, Thailand  
Office of Research and Development, China Medical  
University, Taichung, Taiwan, R.O.C.  
Office of the Permanent Secretary, Ministry of Higher  
Education, Science, Research and Innovation, Bangkok,  
Thailand  
Oita Cancer Research Foundation, Oita, Japan  
Okinaga Research Institute, Teikyo University, Tokyo,  
Japan
- OMEGA Farma and MELON, St. Petersburg, Russian  
Federation  
Oncosuisse, Bern, Switzerland  
Örebro University Hospital, Örebro, Sweden  
Osaka City University Graduate School of Medicine,  
Osaka, Japan  
Osaka Metropolitan University Hospital, Osaka, Japan
- Paavo and Eila Salonen Legacy, Helsinki, Finland  
Päivikki and Sakari Sohlberg Foundation, Helsinki, Finland  
Paulo Foundation, Helsinki, Finland  
Pelotonia IDEA Award, Ohio State University, Columbus,  
OH, U.S.A.  
Pierre Fabre GmbH, Freiburg, Germany  
Platform of Supporting Cohort Study and Biospecimen  
Analysis (CoBiA), Tokyo, Japan  
Polish Ministry of Science and Higher Education, Poland  
Portuguese League Against Cancer–Regional Nucleus of  
the North (Liga Portuguesa Contra o Cancro–Núcleo  
Regional do Norte), Lisbon, Portugal  
Postech-Catholic Biomedical Engineering Institute  
(PCBMI), Seoul, Republic of Korea  
Program for Promotion of Fundamental Studies in Health  
Sciences, National Institute of Biomedical Innovation  
(NIBIO), Ibaraki, Japan  
Project for Cancer Research and Therapeutic Evolution (P-  
CREATE), Japan Agency for Medical Research and  
Development (AMED), Tokyo, Japan  
Promotion and Mutual Aid Corporation for Private School,  
Japan Scholarship Fund for Young/Women Researchers,  
Tokyo, Japan  
Public Trust Surgery Research Fund, Japan  
Public/Private R&D Investment Strategic Expansion  
PrograM (PRISM), Japan
- Qualitis LTD., Athens, Greece
- Radiation Diagnosis Department, Kawaguchi Municipal  
Medical Center, Kawaguchi, Japan  
Rentschler Biotechnologie GmbH (Rentschler Biopharma  
SE), Laupheim, Germany  
Research Center of the Portuguese Oncology Institute of  
Porto, Portugal  
Research Committee, Region Örebro County, Örebro,  
Sweden  
Research Fund, Department of Medical Research, China  
Medical University Hospital, Taichung, Taiwan, R.O.C.  
Research Grant, Inje University Busan Paik Hospital,  
Busan, Republic of Korea

- Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea
- Research Support Center, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
- Riken Genesis Co., Ltd., Tokyo, Japan
- RISE Internship Program, Boston University, Boston, MA, U.S.A.
- Robert M. Hoffman Foundation for Cancer Research, San Diego, CA, U.S.A.
- Roche Diagnostics (Hellas) S.A., Athens, Greece
- Royal Golden Jubilee Ph.D. Program, Thailand Science Research and Innovation, Thailand Research Fund, Bangkok, Thailand
- Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
- S&T Postgraduate Education and Research Development Office (PERDO), Thailand
- Saarland University, Saarbrücken, Germany
- Saitama Medical University International Medical Center, Hidaka, Japan
- Sanofi S.A., Paris, France
- Science and Technology Bureau's Key Research and Development of Xianyang, Xianyang, P.R. China
- Scientific Research Foundation for Doctor, Shaanxi University of Chinese Medicine, Xianyang, P.R. China
- Scientific Research Projects Unit, Gaziantep University, Gaziantep, Turkey
- Second Century Fund (C2F), Chulalongkorn University, Bangkok, Thailand
- Seed Grant, LA BioMed, The Lundquist Institute, Torrance, CA, U.S.A.
- Seinäjäki Central Hospital, Seinäjoki, Finland
- Seppo Nieminen funding, Finland
- Shizuoka Cancer Center Hospital, Shizuoka, Japan
- Shizuoka Cancer Center Medical Fund, Shizuoka, Japan
- Shizuoka Cancer Center Research Institute, Shizuoka, Japan
- Shizuoka Prefectural Government, Shizuoka, Japan
- Siriraj Graduate Scholarship, Bangkok, Thailand
- Siriraj Research Fund of the Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
- Skin Cancer Innovation Clinical Academic Group (SCIN CAG), Greater Copenhagen Health Science Partners (GCHSP), Copenhagen, Denmark
- SMC Laboratories, Inc., Tokyo, Japan
- Smoking Research Foundation, Japan
- Social Health Corporation Foundation Pond Friends Association, Fukuoka Wajiro Hospital, Fukuoka, Japan
- South Tyneside and Sunderland Foundation NHS Trusts, U.K.
- Southeastern Regional Center of Excellence in Vector-Borne Diseases, Gainesville, FL, U.S.A.
- SPRING, Japan Science and Technology Agency (JST), Tokyo, Japan
- St. Michael's Hospital (Unity Health), Toronto, ON, Canada
- State Scholarships Foundation (IKY), Athens, Greece
- Stiftung zur Krebsbekämpfung, Zürich, Switzerland
- SUIGANN Project, Shimane University, Matsue, Japan
- Sumika Chemical Analysis Service Ltd., Osaka, Japan
- Sundsvall Hospital, Sundsvall, Sweden
- Sungkyunkwan University, Seoul, Republic of Korea
- SUNY Upstate Medical University, Syracuse, NY, U.S.A.
- Swiss National Science Foundation (SNSF), Berne, Switzerland
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
- Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
- Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
- Tainan Municipal Hospital, Tainan, Taiwan, R.O.C.
- Taipei Municipal Wanfang Hospital, Taipei, Taiwan, R.O.C.
- Takeda Science Foundation, Japan
- Tampere University Hospital, Tampere, Finland
- Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C.
- Thailand Science Research and Innovation (TSRI), Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailand
- The Finnish Medical Foundation, Helsinki, Finland
- The Holomedicine Association, Brussels, Belgium
- The Smoking Research Foundation, Japan
- The Tokyo Cooperative Oncology Group, Tokyo, Japan
- Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
- Tohoku University, Sendai, Japan
- Tokyo Next-Generation Innovation Creation Project 2020, Tokyo, Japan
- Tokyo University of Science, Tokyo, Japan
- Tottori University Hospital, Yonago, Japan
- Trakia University, Stara Zagora, Bulgaria

TRF-International Research Network (TRF-IRN), Bangkok, Thailand  
Uehara Memorial Foundation, Japan  
Università Cattolica del Sacro Cuore, Milan, Italy  
University Hospital of Tsukuba International Medical Center, Tsukuba, Japan  
University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany  
University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.  
University of Toronto, Toronto, ON, Canada  
University Research Fund (BOF), University of Antwerp, Antwerp, Belgium  
Uppsala University Hospital, Uppsala, Sweden  
Växjö Central Hospital, Växjö, Sweden  
Victor Babes University of Medicine and Pharmacy, Timisoara, Romania  
Vilnius University, Vilnius, Lithuania  
Wellesley College, Wellesley, MA, U.S.A.  
Winicker Norimed GmbH, Nuremberg, Germany  
Wroclaw Medical University, Wroclaw, Poland  
Yakult Honsha Co., Ltd., Tokyo, Japan  
Yamaga City Medical Center, Yamaga, Japan  
Yokohama Surgical Research Group, Yokohama, Japan  
Yoshiki Dermatology Clinic Ginza, Tokyo, Japan

## Contents, Volume 42, 2022

### Number 1, January

#### Reviews

- Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs. E. BISKUP, R.S. WILS, C. HOGDALL, E. HOGDALL (*Herlev; Copenhagen, Denmark*) ..... 1
- Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review. M. ACS, P. PISO, S. PRADER (*Regensburg; Essen, Germany; Brixen, Italy*) ..... 13
- The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review. P. AURELLO, A. MINERVINI, M. PACE, F. D'ANGELO, G. NIGRI, L. ANTOLINO, S. VALABREGA, G. RAMACCIATO, N. PETRUCCIANI (*Rome, Italy*) ..... 25
- Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy. K. YAMAMURA, T. BEPPU, T. MIYATA, H. OKABE, H. NITTA, K. IMAI, H. HAYASHI, S. AKAHOSHI (*Yamaga; Kumamoto, Japan*) .... 35
- Fatigue in Cancer Treatment Studies: Analysis of Placebo Arms. H. HAUCH, B.J. WOLFF, J.E. WOLFF (*Hesse, Germany; Chicago; North Chicago, IL, USA*) ..... 45

#### Clinical Studies

- Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation. M. SAYAN, Z.A. YEHA, I. JAN, A. GUPTA, I. VERGALASOVA, M. REVIELLO, S. KUMAR, B. HAFFTY, N. OHRI (*Boston, MA; New Brunswick, NJ; New York, NY, USA*) ..... 53
- Pre-operative Carboplatin/Paclitaxel *Versus* 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer. M. AL-JUMAYLI, K. CHOUCAIR, A. AL-OBAIDI, R. PARK, A. BANSAL, J. BARANDA, W. SUN, A. SAEED (*Kansas City; Wichita, KS; Tampa, FL; Kansas City, MO; Framingham, MA, USA*) ..... 59
- Determinative Structural Features Identified With Probe-based Confocal Endomicroscopy for the Accurate Diagnosis of Gallbladder Malignancy. T. KOIZUMI, T. AOKI, T. YAMOCHI, Y. TASHIRO, T. YAMAZAKI, T. KUSANO, K. MATSUDA, Y. WADA, H. SHIBATA, K. SAITO, K. NOGAKI, T. HAKOZAKI, K. TOMIOKA, T. HIRAI, A. FUJIMORI, D.A. MANSOUR, A.E.A. GAHIN, R.M. HOFFMAN (*Tokyo, Japan; Cairo, Egypt; San Diego, CA, USA*) ..... 67
- Survival After Minimally Invasive Surgery in Older Women With Endometrial Carcinoma. J. CARDENAS-GOICOECHEA, Y. WANG, J.-H. LEE, M. SHORAKA, S.L. CARBAJAL-MAMANI, D. FISHMAN, A.N. RINER, J.G. TREVINO (*Weston; Gainesville, FL; New York City, NY; Richmond, VI, USA*) ..... 75
- Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. M. LEHTONEN, J. SORMUNEN, M. HJÄLM-ERIKSSON, C. THELLENBERG-KARLSSON, T. HUTTUNEN, C. GINMAN, P.-L. KELLOKUMPU-LEHTINEN (*Tampere; Helsinki; Turku, Finland; Stockholm; Umeå; Karlstad, Sweden*)..... 87
- Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer. M. SAYAN, I. VERGALASOVA, I. JAN, S. KUMAR, N. CHAN, B.G. HAFFTY, N. OHRI (*Boston, MA; New Brunswick, NJ, USA*) ..... 93



The Benefit of Postoperative Radiotherapy and Extending Neck Dissection in pT1-2 Oral Squamous Cell Carcinoma With a Single Ipsilateral Cervical Lymph Node Metastasis (pN1). U. ALSHARIF, D. STELLER, M. FALOUGY, L. THARUN, D. RADES, S.G. HAKIM ( <i>Lübeck; Dortmund; Witten, Germany</i> ) .....	97
Preoperative Risk Factors for Fibrosarcomatous Transformation in Dermatofibrosarcoma Protuberans. K.E. MALLETT, S. ALMUBARAK, R.M. CLAXTON, P.C. FERGUSON, A.M. GRIFFIN, P.S. ROSE, J.S. WUNDER, K. TSOI, M.T. HOUDEK ( <i>Rochester, MN, USA; Toronto, ON, Canada</i> ) .....	105
Prevalence of Diabetes and Impaired Fasting Glycemia in Patients With Oral Cancer: A Retrospective Study in Hungary. A. VEGH, D. BANYAI, M. UJPAL, K.S. SOMOGYI, Z. BICZO, G. KAMMERHOFER, Z. NEMETH, P. HERMANN, M. PAYER, D. VEGH ( <i>Budapest, Hungary; Graz, Austria</i> ) .....	109
Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer. S. HOSOYA, K. UEDA, S. ODAJIMA, K. OGAWA, H. KOMAZAKI, T. SEKI, M. TAKENAKA, M. SAITO, H. TANABE, K. YAMADA, H. TAKANO, Y. IIDA, N. YANAIHARA, A. OKAMOTO ( <i>Tokyo; Chiba, Japan</i> ) .....	115
Clinical Significance of Expression of Immuno-adjunct Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer. Y. ASANO, S. KASHIWAGI, K. TAKADA, S. ISHIHARA, W. GOTO, T. MORISAKI, M. SHIBUTANI, H. TANAKA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ) .....	125
Clinical Impact of CYFRA 21-1 a Marker for Treatment Failure in Patients With Oropharyngeal Cancer Treated by Radio(chemo)therapy. S.A. RUDHART, P. LANGEN, K. THANGAVELU, F. GEHRT, P. STANKOVIC, T. WILHELM, B.A. STUCK, S. HOCH ( <i>Marburg; Borna, Germany</i> ) .....	137
Diagnostic and Prognostic Impact of Crypt Branching in Patients With Ulcerative Colitis: A Validation Study. C. LANG-SCHWARZ, C.A. RUBIO, M. VIETH ( <i>Bayreuth, Germany; Stockholm, Sweden</i> ) .....	147
Prognostic Impact of Upfront Surgery for Locally Advanced Upper Rectal Adenocarcinoma. O. MULLER, R. SINDAYIGAYA, S. CHOMICKI, E. KARAM, N. TABCHOURI, N. MICHOT, D. MOUSSATA, T. LECOMTE, S. CHAPET, G. CALAIS, U. GIGER-PABST, E. SALAME, M. OUAISSI ( <i>Chambray Les Tours; Tours, France; Düsseldorf, Germany</i> ) .....	155
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. R. IACOVELLI, C. CICCARESE, O. CAFFO, U. DE GIORGI, U. BASSO, M. TUCCI, C. MOSILLO, M. MARUZZO, F. MAINES, C. CASADEI, M. MILELLA, G. TORTORA ( <i>Rome; Trento; Meldola; Padua; Turin; Terni; Verona, Italy</i> ) .....	165
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan. N. SHIMOZATO, T. NAMISAKI, A. OKANO, M. OHANA, D. KINOSHITA, T. KAWASAKI, Y. AIHARA, T. NAKATANI, H. KINOSHITA, T. ANN, K. SAITO, M. YOSHIDA, H. YOSHIJI ( <i>Kashiwara; Tenri; Ikoma; Nara; Sakai; Sango, Japan</i> ) .....	173
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. S. QUESADA, E. SAMALIN, S. THEZENAS, L. KHELLAF, A. MOURREGOT, F. PORTALES, T. MAZARD, M. YCHOU, A. ADENIS ( <i>Montpellier, France</i> ) .....	185
ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer. T. YOSHIDA, T. NISHINO, M. GOTO, S. INOUE, S. FUJIWARA, H. TAKIZAWA, A. TANGOKU, H. UEHARA, Y. BANDO ( <i>Tokushima, Japan</i> ) .....	195
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation. R. TOYA, T. WATAKABE, D. MURAKAMI, T. MATSUYAMA, T. SAITO, Y. FUKUGAWA, K. NISHIMOTO, Y. ORITA, N. OYA ( <i>Kumamoto, Japan</i> ) .....	205



The Role of Indocyanine Green in Laparoscopic Low Anterior Resections for Rectal Cancer Previously Treated With Chemo-radiotherapy: A Single-center Retrospective Analysis. A. BRESCIA, E.M. MUTTILLO, I. ANGELICONE, I. MADAFFARI, F. MAGGI, I. SPERDUTI, M. GASPARRINI, M. FALCHETTO OSTI (Rome, Italy) .....	211
Pancreatectomy With Artery <i>En-bloc</i> Resection for Pancreatic Neck/Body Cancer: A Single-arm Pilot Study. K.-I. OKADA, M. KAWAI, S. HIRONO, S. HAYAMI, M. MIYAZAWA, Y. KITAHATA, M. UENO, R. KOBAYASHI, A. MIYAMOTO, Y. WADA, S. ASAMURA, H. YAMAUE (Wakayama, Japan) .....	217
Impact of Tumor Growth Speed of Primary Lesions on the Clinical Outcomes of Appendicular Skeletal Metastases. Y. ASANO, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, S. MIWA, K. IGARASHI, H. YONEZAWA, Y. ARAKI, S. MORINAGA, S. SAITO, T. NOJIMA, H. TSUCHIYA (Kanazawa, Japan).....	229
Tumor Location on the Vertical Section of the Anterior Wall Is Related to Favorable Prognosis and Low Incidence of Lymph Node Metastasis in Lower-third Gastric Cancer. Y. TAKASHIMA, S. KOMATSU, M. KASUGA, T. OHASHI, H. KONISHI, A. SHIOZAKI, T. KUBOTA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI (Kyoto, Japan) .....	237
Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response. N. HARIMOTO, S. ITOH, T. YAMANAKA, K. HAGIWARA, N. ISHII, M. TSUKAGOSHI, A. WATANABE, K. ARAKI, T. YOSHIZUMI, K. SHIRABE (Maebashi; Fukuoka, Japan).....	245
Thyroid Hormones and Morphological Features of Primary Breast Cancer. A. MEIROVITZ, B. NISMAN, T.M. ALLWEIS, E. CARMON, L. KADOURI, B. MALY, O. MAIMON, T. PERETZ (Jerusalem, Israel) ....	253
Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. A. MINATO, H. NOGUCHI, R. KIMURO, H. MIRII, N. YUJIRO, Y. HASEGAWA, I. TOMISAKI, K. HARADA, N. FUJIMOTO (Kitakyushu; Kagoshima, Japan) .....	263
Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma. Y. YASUDA, T. NAGANO, N. JIMBO, T. KIRIU, R. SURAYA, D. HAZAMA, M. YAMAMOTO, Y. MANIWA, Y. NISHIMURA, K. KOBAYASHI (Kobe, Japan).....	271
Clinical Significance of Serglycin Expression in Human Breast Cancer Patients. K. HOSOYA, K. NOSAKA, T. SAKABE, M. WAKAHARA, Y. OSHIMA, Y. SUZUKI, H. NAKAMURA, Y. UMEKITA (Yonago, Japan) .....	279
Predictive Factors of Late Cervical Lymph Node Metastasis Using Intraoral Sonography in Patients With Tongue Cancer. M. KONISHI, M. FUJITA, K. SHIMABUKURO, P. WONGRATWANICH, N. KAKIMOTO (Hiroshima, Japan).....	287
Reirradiation Using <sup>198</sup> Au Grain Brachytherapy for Recurrent Oral Cancer Cases Previously Treated by Definitive Radiotherapy. M. KONISHI, Y. TAKEUCHI, K. KUBO, N. IMANO, I. NISHIBUCHI, Y. MURAKAMI, K. SHIMABUKURO, P. WONGRATWANICH, N. KAKIMOTO, Y. NAGATA (Hiroshima, Japan).....	293
Preoperative Masseter Muscle Sarcopenia Predicts Mortality in Patients With Oesophageal Cancer. T. KAMADA, H. OHDAIRA, E. ITO, Y. FUSE, J. TAKAHASHI, K. NAKASHIMA, Y. NAKASEKO, M. YOSHIDA, K. ETO, Y. SUZUKI (Tochigi; Tokyo, Japan) .....	301
The Effect of Smoking on Progression from Ductal Carcinoma <i>In Situ</i> to Invasive Ductal Breast Carcinoma: A Retrospective Study. K. TAKADA, S. KASHIWAGI, Y. ASANO, W. GOTO, T. MORISAKI, M. SHIBUTANI, H. TANAKA, K. HIRAKAWA, M. OHIRA (Osaka, Japan) .....	311

Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis. K. HAYASHI, O. SUZUKI, H. SHIOMI, M. NAKAI, K. FUJIWARA, E. NAKANISHI, S. TATEKAWA, T. HIRATA, K. TAMARI, H. HIRATA, S. FUNAKI, Y. SEO, Y. TAKEDA, F. ISOHASHI, Y. SHINTANI, K. OGAWA ( <i>Suita; Osaka, Japan</i> ) .....	321
Multiparametric MRI-guided Hypofractionated Intensity-modulated Radiation Therapy With Simultaneous Integrated Boost for Glioblastoma. Y. HAMA, E. TATE ( <i>Tokyo, Japan</i> ) .....	329
Association of <i>MGMT</i> Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type <i>IDH</i> Glioblastoma. M. KIM, J. YOO, J.H. CHANG, S.H. KIM ( <i>Daegu; Seoul, Republic of Korea</i> ) .....	335
A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. K. UCHIYAMA, Y. SAITO, T. SAKAMOTO, Y. TAKEKUMA, Y. KOMATSU, M. SUGAWARA ( <i>Sapporo, Japan</i> ) .....	343
Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer. J. LEE, J.M. KIM, Y.H. LEE, G.O. CHONG, D.G. HONG ( <i>Daegu, Republic of Korea</i> ) .....	349
Prognostic Value of Copine 1 in Patients With Renal Cell Carcinoma. I.M. TALAAT, E. ABU-GHARBIEH, A. HUSSEIN, M. HACHIM, I. SOBHY, M. ELADL, W. EL-HUNEIDI ( <i>Sharjah; Dubai, United Arab Emirates; Alexandria, Egypt</i> ) .....	355
The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study. E.J. LEE, S.J. PARK, J. LEE, J. MUN, H. PAIK, A. SEOL, J. KIM, G.W. YIM, S.-H. SHIM, H.S. KIM, S.-J. CHANG ( <i>Seoul; Goyang; Suwon, Republic of Korea</i> ) .....	363
Excellent Response to MEK Inhibition in an <i>AGK-BRAF</i> Gene Fusion Driven Carcinoma: Case Report and Literature Review. A. DOMEN, C. VAN PAESSCHEN, K. ZWAENPOEL, S. LAMBIN, P. PAUWELS, M. RASSCHAERT, E. SEGELOV, M. PEETERS, H. PRENEN ( <i>Antwerp; Edegem, Belgium; Clayton, VIC, Australia</i> ) .....	373
A Case of Mesenteric Desmoid Tumor Causing Bowel Obstruction After Laparoscopic Surgery. K. ARIMA, Y. KOMOHARA, T. UCHIHARA, K. YAMASHITA, S. UEMURA, N. HANADA, H. BABA ( <i>Kagoshima; Kumamoto, Japan</i> ) .....	381
<i>Experimental Studies</i>	
A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. J. LI, A.K. PERSAUD, J.A. JOHNSON, D.W. SBOROV, M.A. PHELPS, C.C. HOFMEISTER, M.J. POI ( <i>Columbus, OH; Salt Lake City; Atlanta, GA, USA</i> ) .....	385
Moderate Intensity Endurance and Resistance Exercise Attenuates Cachexia in Tumor-bearing Mice. N.R. WOOD, J. GARRITSON, A. MATHIAS, J.M. HAUGHIAN, R. HAYWARD ( <i>Greeley, CO, USA</i> ) .....	397
High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. M. IKEDA, Y. KOH, J. OYANAGI, S. TERAOKA, M. ISHIGE, Y. FUJIMURA, K. TAKEDA, N. TOKUDOME, Y. OZAWA, H. UEDA, N. YAMAMOTO ( <i>Wakayama; Tokyo, Japan</i> ) .....	407
Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software. H. MIYATA, Y. AKIYAMA, A. IIZUKA, R. KONDOU, C. MAEDA, A. KANEMATSU, K. WATANABE, T. ASHIZAWA, T. NAGASHIMA, K. URAKAMI, K. OHSHIMA, T. KAWATA, K. MURAMATSU, A. SHIOMI, M. TERASHIMA, T. SUGINO, A. NOTSU, K. MORI, K. YAMAGUCHI ( <i>Shizuoka; Tokyo, Japan</i> ) .....	419

MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer. B. SAVARESE-BRENNER, M. HEUGL, B. RATH, C. SCHWEIZER, E. OBERMAYR, S. STICKLER, G. HAMILTON ( <i>Vienna, Austria</i> ) .....	429
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring <i>EGFR</i> L747P Mutation With Clinical Response to Multi-targeted Epigenetic and <i>EGFR</i> Inhibition. S.S. MESSEHA, M.A. NEZAMI, S. HAGER, K.F.A. SOLIMAN ( <i>Tallahassee, FL; Newport Beach; Fresno, CA, USA</i> ) .....	441
Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation. S. MIZUOCHI, J. AKIBA, R. KONDO, H. KUSANO, T. SHIOGA, K. KONDO, K. TSUTSUI, M. NAKAYAMA, S. OGASAWARA, Y. NAITO, O. NAKASHIMA, H. YANO ( <i>Kurume; Kitakyushu, Japan</i> ) .....	449
CD15+ Bone Marrow-derived Cells Are Regulators of Immune Response in ARG1-producing Colorectal Cancer Cells. K. MIYOSHI, E. SATO, K. KATSUMATA, G. FUKUSHIMA, R. UDO, E. NISHIMURA, T. TAGO, K. KASAHARA, J. MAZAKI, M. ENOMOTO, T. ISHIZAKI, Y. NAGAKAWA, A. TSUCHIDA ( <i>Tokyo, Japan</i> ) .....	459
Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells. C. KIM, S. LEE, D. KIM, D.S. LEE, E. LEE, C. YOO, K.-P. KIM ( <i>Seoul, Republic of Korea</i> ) .....	471
Eupatilin Suppresses Pancreatic Cancer Cells <i>via</i> Glucose Uptake Inhibition, AMPK Activation, and Cell Cycle Arrest. T.H. PARK, H.S. KIM ( <i>Seoul, Republic of Korea</i> ) .....	483
Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers. M. KACZOROWSKI, J. MATYSIAK, P. KIELB, B. MALKIEWICZ, A. HALON ( <i>Wroclaw, Poland</i> ) .....	493
Dipeptidyl Peptidase-4 from Cancer-associated Fibroblasts Stimulates the Proliferation of Scirrhus-type Gastric Cancer Cells. S. KUSHIYAMA, M. YASHIRO, Y. YAMAMOTO, T. SERA, A. SUGIMOTO, S. NISHIMURA, S. TOGANO, K. KURODA, T. OKUNO, Y. MIKI, M. OHIRA ( <i>Osaka, Japan</i> ) .....	501
Epstein-Barr Virus-induced Gene 3 as a Novel Biomarker in Metastatic Melanoma With Infiltrating CD8 <sup>+</sup> T Cells: A Study Based on The Cancer Genome Atlas (TCGA). S. YONEKURA ( <i>Villejuif, France</i> ) .....	511
14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion <i>via</i> Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer. J.Y. JUNG, S.A. KOH, K.H. LEE, J.R. KIM ( <i>Daegu, Republic of Korea</i> ) .....	519
<i>Helicobacter pylori</i> Targets in AGS Human Gastric Adenocarcinoma: <i>In Situ</i> Proteomic Profiling and Systematic Analysis. J.-S. YANG, C.-Y. KANG, C.-H. SU, C.-J. CHEN, Y.-J. CHIU, Y.-M. HSU ( <i>Taichung; Taipei, Taiwan, ROC</i> ) .....	531
Effect of Alpha-tocopheryl Succinate on the Cytotoxicity of Anticancer Drugs Towards Leukemia Lymphocytes. D. IVANOVA, Z. ZHELEV, G. ZLATEVA, D. LAZAROVA, Z. YANEVA, R. PANOVSKA, I. AOKI, R. BAKALOVA ( <i>Stara Zagora; Sofia, Bulgaria; Chiba, Japan</i> ) .....	547
Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells. S.H. MOON, N.-S. PARK, M.H. NOH, Y.S. KIM, S.H. CHEONG, D.Y. HUR ( <i>Busan, Republic of Korea</i> ) .....	555
Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen. G.B. HENRIQUES PALMA, M. KAUR ( <i>Johannesburg, South Africa</i> ) .....	565
Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis. A. MAZAKI, K. YAMAUCHI, S. ORITA, K. INAGE, M. SUZUKI, K. FUJIMOTO, Y. SHIGA, K. ABE, M. INOUE, M. NORIMOTO, T. UMIMURA, S. OHTORI ( <i>Chiba, Japan</i> ) .....	581

Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stressmediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells. J. HWANG, A. PARK, C. KIM, D. YU, H. BYUN, M. KU, J. YANG, T.I. KIM, K.-S. JEONG, K.Y. KIM, H. LEE, S.J. SHIN (*Seoul; Daejeon, Republic of Korea*) ..... 589

Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma. B. MWESIGE, M.R. LEE, Y.-S. LEE, N.Y. HAN, J.E. IM, J.-K. KIM, S.I. CHOI, E.K. HONG, A.-R. JEON, S.-J. PARK, S.M. WOO, Y.-H. KIM (*Goyang; Seoul, Republic of Korea*) ..... 599

Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet. K.-I. INOUE, H. YAMAGISHI, T. JOJIMA, T. INOUE, S. TOYODA (*Tochigi, Japan*) ..... 609

**Number 2, February**

*Reviews*

Leptomeningeal Metastases of the Spine: A Systematic Review. P. PALMISCIANO, N.S. SAGOO, A.F. KHARBAT, Y.J. KENFACK, O.B. ALAMER, G. SCALIA, G.E. UMANA, S.G. AOUN, A.S. HAIDER (*Catania, Italy; Dallas; Lubbock; Houston, TX, USA; Riyadh, Kingdom of Saudi Arabia*)..... 619

The Role of Surgery for Pancreatic Neuroendocrine Tumors. I.A. ZIOGAS, R. SCHMITZ, D. MORIS, C.J. VATSAAS (*Nashville, TN; Durham, NC, USA*) ..... 629

Methionine Restriction: Ready for Prime Time in the Cancer Clinic? J. YAMAMOTO, Q. HAN, M. SIMON, D. THOMAS, R.M. HOFFMAN (*San Diego; La Jolla; Westlake Village, CA; Mount Dora, FL, USA; Yokohama, Japan*)..... 641

Challenges of Surgical Resection of Carotid Body Tumors - Multiple Feeding Arteries and Preoperative Embolization. K. SHIGA, K. KATAGIRI, A. IKEDA, D. SAITO, S.-I. OIKAWA, K. TSUCHIDA, J. MIYAGUCHI, T. KUSAKA, A. TAMURA (*Yahaba, Japan*) ..... 645

A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. K. TAKAGI, Y. UMEDA, R. YOSHIDA, T. YAGI, T. FUJIWARA (*Okayama, Japan*) ..... 653

The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy. K. MOKBEL, K. MOKBEL (*Exeter; London, UK*) ..... 661

SBRT in Localized Renal Carcinoma: A Review of the Literature. C. DE LA PINTA, R.G. LATORRE, R. FUENTES (*Madrid, Spain*) ..... 667

Minimally Invasive Transcervical Esophagectomy With Mediastinal Lymphadenectomy for Cancer. A Comparison With Standardized Techniques. S. DAVAKIS, A. CHARALABOPOULOS, E. KYROS, P. SAKARELLOS, G. TSOUROUFLIS, D. DIMITROULIS, N. NIKITEAS (*Athens, Greece*) ..... 675

*Experimental Studies*

The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer. C. SONG, A.T. KENDI, V.J. LOWE, S. LEE (*Rochester, MN, USA*)..... 681

CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer. T. HAGIWARA, K. SUGIMOTO, H. MOMOSE, T. IRIE, K. HONJO, Y. OKAZAWA, M. KAWAI, S. KAWANO, S. MUNAKATA, M. TAKAHASHI, Y. KOJIMA, N. SERIZAWA, A. NAGAHARA, R.M. HOFFMAN, M.V. BROCK, K. SAKAMOTO (*Tokyo, Japan; San Diego, CA; Baltimore, MD, USA*) ..... 697

A Novel Molecular Target in <i>EGFR</i> -mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. N. TAKANO, M. SEIKE, T. SUGANO, K. MATSUDA, K. HISAKANE, A. YOSHIKAWA, S. NAKAMICHI, R. NORO, A. GEMMA ( <i>Tokyo, Japan</i> ) .....	709
Ko143 Reverses MDR in Glioblastoma <i>via</i> Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment. S.D. LUSTIG, S.K. KODALI, S.L. LONGO, S. KUNDU, M.S. VIAPIANO ( <i>Nashville, TN; Syracuse, NY, USA</i> ).....	723
Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model. Y. AOKI, Y. TOME, Q. HAN, J. YAMAMOTO, K. HAMADA, N. MASAKI, Y. KUBOTA, M. BOUVET, K. NISHIDA, R.M. HOFFMAN ( <i>San Diego; La Jolla, CA, USA; Okinawa, Japan</i> ) .....	731
High Incidence of Lymph-node Metastasis in a Pancreatic-cancer Patient-derived Orthotopic Xenograft (PDOX) NOG-Mouse Model. N. SUGISAWA, K. MIYAKE, T. HIGUCHI, H. OSHIRO, J.H. PARK, K. KAWAGUCHI, M. BOUVET, M. UNNO, R.M. HOFFMAN ( <i>San Diego, CA, USA; Sendai, Japan</i> ) .....	739
Exosomal p38 Mitogen-activated Protein Kinase Promotes Tumour Repopulation in <i>TP53</i> -mutated Bile Duct Cancer Cells. M. OSAWA, Y. MATSUDA, J. SAKATA, T. WAKAI ( <i>Niigata, Japan</i> ) .....	745
One DNA Methylation Regulates <i>CHIP</i> Gene Expression of Human Breast Cancer and Predicts Recurrence. T. GOHNO, T. HANAMURA, M. KUROSUMI, H. TAKEI, Y. YAMAGUCHI, S.-I. HAYASHI ( <i>Sendai; Saitama, Japan</i> ).....	759
The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma. E. ORTONA, S.L. LOCATELLI, M.T. PAGANO, B. ASCIONE, G. CAREDDU, M.L. DUPUIS, M. MARCONI, C. CARLO-STELLA, W. MALORNI, P. MATARRESE, M. PIERDOMINICI ( <i>Rome; Rozzano, Italy</i> ) .....	767
Inhibition of Neurotoxicity/Anticancer Activity of Bortezomib by Caffeic Acid and Chlorogenic Acid. R. MATSUDA, H. SAKAGAMI, S. AMANO, Y. IJIMA, M. SANO, Y. UESAWA, N. TAMURA, Y. OISHI, H. TAKESHIMA ( <i>Saitama; Tokyo, Japan</i> ).....	781
CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice. Y. MINEGISHI, Y. HIROSHIMA, K. YAZAWA, S. SATO, Y. YABUSHITA, Y. HOMMA, R. MATSUYAMA, I. KATO, Y. GOSHIMA, I. ENDO ( <i>Yokohama, Japan</i> ) .....	791
Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN- $\gamma$ Measurements. M.I. ITA, J.H. WANG, C.C. HEFFRON, D.G. POWER, Y. NOLAN, A. TOULOUSE, C.C.H. LIM, N. FANNING, H.P. REDMOND ( <i>Cork, Ireland</i> ) .....	801
Micro-RNA378a-3p Induces Apoptosis in Sarcomatoid Renal Cell Carcinoma and Regulates <i>POLR2A</i> and <i>RUNX2</i> Expression. W.-H. WENG, K.-J. YU, J.-W. JHAN, S.-N. PANG, Y.-E. CHIOU, S.-T. PANG ( <i>Taipei; Taoyuan; New Taipei City, Taiwan, ROC; Dublin, Ireland</i> ).....	811
A Novel Injectable Hydrogel Matrix Loaded With 90Y Microspheres for the Treatment of Solid Tumors. A. AMATO, P.L. CARRIERO, G. MCVIE, G. PAGANELLI ( <i>Milan; Meldola, Italy; Bristol, UK</i> ) .....	827
Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells. M. KOYAMA, E. OSADA, N. AKIYAMA, K. ETO, Y. MANOME ( <i>Tokyo, Japan</i> ).....	837
Snail Mucus Enhances Chemosensitivity of Triple-negative Breast Cancer <i>Via</i> Activation of the Fas Pathway. C.-Y. HO, D.-W. HU, B.-R. CHEN, C.-C. YANG, C.-H. YAO, T. NI, W.-C. HO, Y.-S. CHEN, C.-Y. TU, W.-C. CHANG, Y.-C. WU, C.-H. TANG, H.-C. HUANG, W.-C. HUANG, T.-S. LI ( <i>Taichung; Hsinchu; Changhua, Taiwan, ROC</i> ) .....	845



Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression. G. GO, H.J. PARK, J.H. LEE, C.W. YUN, S.H. LEE ( <i>Cheonan; Seoul; Asan, Republic of Korea</i> ) .....	857
Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study. W.I. JANG, M.-S. KIM, J.-H. JEONG, W. KIM, J.S. KIM ( <i>Seoul; Seongnam, Republic of Korea</i> ).....	867
Patterns of Tumor Vasculogenesis on a Chick Embryo Chorioallantoic Membrane <i>In Vivo</i> Model of Breast Cancer. S. COMSA, A.-R. CEAUSU, R. POPESCU, A.-M. CIMPEAN, S. SARB, M. RAICA ( <i>Timisoara, Romania</i> ).....	877
<i>BAX</i> But Not <i>BCL2</i> Is Necessary for Apoptosis in Neuroblastoma Cells Treated With Casiopeína® IIIa. L.A. JAIME-MARTINEZ, M.L. MARTINEZ-PACHECO, L. RUIZ-AZUARA, C. MEJIA ( <i>Querétaro; Mexico City, México</i> ) .....	885
<i>Clinical Studies</i>	
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. A. TODAKA, S. NARA, F. MOTOI, S. MORINAGA, R. TOSHIYAMA, R. HIGUCHI, M. KONISHI, H. SHIRAKAWA, H. TSUMURA, H. OKUYAMA, H. NAGANO, K. SHIOJI, K. SUGIMACHI, A. ASAGI, N. MIZUNO, J. FURUSE ( <i>Shizuoka; Tokyo; Miyagi; Yamagata; Kanagawa; Osaka; Chiba; Tochigi; Hyogo; Kagawa; Yamaguchi; Niigata; Fukuoka; Ehime; Aichi, Japan</i> ).....	893
Feasibility and Safety of Laparoscopic Gallbladder Resection for Gallbladder Tumours. H. IMAMURA, T. ADACHI, T. TANAKA, H. MATSUSHIMA, T. HARA, A. SOYAMA, M. HIDAKA, S. EGUCHI ( <i>Nagasaki, Japan</i> ).....	903
Peritumoral Hyperintensity at Hepatobiliary Phase Gadoteric Acid-enhanced MRI in Hepatic Neuroendocrine Tumors. N. FUJITA, A. HANDA, J.M. PARK ( <i>Fukuoka, Japan; Iowa City, IA, USA</i> ) .....	911
Outcomes of Intramedullary Nail Fixation for Metastatic Disease: Impending and Pathologic Fractures. A.R. OWEN, M.E. UVODICH, V. SOMASUNDARAM, B.J. YUAN, P.S. ROSE, M.T. HOUDEK ( <i>Rochester, MN, USA</i> ).....	919
Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort. C. NIEDER, J. RESSHEIM, E.C. HAUKLAND, B. MANNSÅKER ( <i>Bodø; Tromsø; Stavanger, Norway</i> ).....	923
Sacral Chordoma: A Population-based Analysis of Epidemiology and Survival Outcomes. M. SCAMPA, E. TESSITORE, D.E. DOMINGUEZ, D. HANNOUCHE, N.C. BUCHS, D.F. KALBERMATTEN, C.M. ORANGES ( <i>Geneva, Switzerland</i> ) .....	929
Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer. W. GOTO, S. KASHIWAGI, K. TAKADA, Y. ASANO, T. MORISAKI, M. SHIBUTANI, H. TANAKA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ).....	939
Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study. A. GADDUCCI, E. SIMONETTI, F. MEZZAPESA, S. COSIO, M. MICCOLI, J. FREY, R. TINTORI, A. BULLERI, E. NERI ( <i>Pisa, Italy</i> ).....	947
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours. L. FAUSKE, P.H. WÆRSTAD, I. HOMPLAND, Ø.S. BRULAND ( <i>Oslo, Norway</i> ).....	955

Circulating Markers of Neutrophil Extracellular Traps (NETs) in Patients With Ovarian Tumors. A. DOBILAS, C. THALIN, H. WALLEN, C. BORGFELDT ( <i>Lund; Stockholm, Sweden</i> ).....	965
Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma. Y. BANDO, J. FURUKAWA, Y. OKAMURA, T. HARA, T. TERAKAWA, Y. NAKANO, M. FUJISAWA ( <i>Kobe, Japan</i> ).....	973
Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma. K. HASHIMOTO, R. YASUMATSU, R. KUGA, T. HONGO, H. YAMAMOTO, M. MATSUO, T. WAKASAKI, R. JIROMARU, T. MANAKO, S. TOH, M. MASUDA, M. YAMAUCHI, Y. KURATOMI, H. URYU, T. NAKASHIMA, A. TAMAE, R. TANAKA, M. TAURA, T. TAKEUCHI, T. YOSHIDA, T. NAKAGAWA ( <i>Fukuoka; Saga; Kitakyushu; Sasebo, Japan</i> ).....	981
Intensified Total Neoadjuvant Therapy Versus Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis. F. DE FELICE, D. MUSIO, F. IAFRATE, S. CAPONNETTO, V. PICONE, G. D'AMBROSIO, F.M. MAGLIOCCA, F. TOZZI, G. DE TOMA, V. TOMBOLINI, E. CORTESI ( <i>Rome, Italy</i> ).....	991
Second-look Surgery Detects Low Volume Recurrent Disease Following Cytoreductive Surgery for Peritoneal Carcinomatosis. A. MATAR, K. ALTOUKHI, A. TSE, J. SOHN, N. ALZHRANI, D.L. MORRIS ( <i>Sydney, NSW, Australia; Riyadh, Kingdom of Saudi Arabia</i> ).....	1001
Efficacy of Ring Drape and Unused Sterile Instruments for Incisional SSI After Hepatectomy. T. YUSA, Y.-I. YAMASHITA, H. NITTA, Y. NAKAO, R. ITOYAMA, Y. KITANO, T. KAIDA, T. MIYATA, K. MIMA, K. IMAI, H. HAYASHI, H. BABA ( <i>Kumamoto, Japan</i> ).....	1007
Pre-pectoral Immediate Breast Reconstruction Following Conservative Mastectomy Using Acellular Dermal Matrix and Semi-smooth Implants. U. WAZIR, N. PATANI, J. HEENEY, K. MOKBEL, K. MOKBEL ( <i>London, UK</i> ).....	1013
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Doxorubicin for 90 Minutes Versus 60 Minutes After Cytoreductive Surgery (CRS). Does the 30-Minute Difference Matter? A Comparative Study in a High Volume Centre. M. ACS, L. HALMY, S. ISGANDAROVA, S. BLAJ, M. GERKEN, B. HORMANN, P. PISO ( <i>Regensburg, Germany</i> ).....	1019
Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study). A. ALEXOPOULOS, C. KARANIKIOTIS, A. ARDAVANIS, I. BOUKOVINAS, P. MAKRANTONAKIS, C. PAPADIMITRIOU, A. ATHANASIADIS, A. BOUTIS, S. GIASSAS, S. KAKOLYRIS, G. KOUMAKIS, K. PAPAZISIS, A. PSYRRI, N. ZIRAS, S. BAKA, N. KENTEPOZIDIS, V. MICHALAKI ( <i>Athens; Thessaloniki; Larissa; Alexandroupolis; Piraeus, Greece</i> ).....	1031
Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma. K. ABE, A. MAEDA-MINAMI, T. ISHIZU, S. IWATA, E. KOBAYASHI, T. SHIMOI, Y. KAWANO, H. HASHIMOTO, M. YAMAGUCHI, T. FURUKAWA, S. MIYAZAKI, Y. MANO ( <i>Chiba; Tokyo, Japan</i> ).....	1043
Prognostic and Clinicopathological Significance of Lymph Node Metastasis in the Esophagogastric Junction Adenocarcinoma. N. URAKAWA, S. KANAJI, S. SUZUKI, R. SAWADA, H. HARADA, H. GOTO, H. HASEGAWA, K. YAMASHITA, T. MATSUDA, T. OSHIKIRI, Y. KAKEJI ( <i>Kobe; Akashi, Japan</i> ).....	1051
Spontaneous Chromosomal Aberrations in Lymphocytes and Development of Tumor in Hospital Workers. G. FARKAS, Z.S. KOCSIS, G. SZÉKELY, I. KENESSEY, C. POLGÁR, Z. JURÁNYI ( <i>Budapest, Hungary</i> ).....	1059
Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer. T. SHIMADA, K. IZUMI, H. KANO, S. KADOMOTO, T. MAKINO, R. NAITO, H. IWAMOTO, H. YAEGASHI, Y. KADONO, A. MIZOKAMI ( <i>Kanazawa, Japan</i> ).....	1065



Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Nonsmall Cell Lung Cancer. M. HORIUCHI, T. OGURI, Y. KAGAWA, K. SONE, S. FUKUDA, T. UEMURA, O. TAKAKUWA, K. MAENO, K. FUKUMITSU, Y. KANEMITSU, T. TAJIRI, H. OHKUBO, M. TAKEMURA, Y. ITO, A. NIIMI ( <i>Nagoya, Japan</i> ).....	1073
Pretreatment Neutrophil Count and Platelet-lymphocyte Ratio as Predictors of Metastasis in Patients With Osteosarcoma. Y. ARAKI, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, S. MIWA, K. IGARASHI, T. HIGUCHI, K. ABE, Y. TANIGUCHI, H. YONEZAWA, S. MORINAGA, Y. ASANO, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ).....	1081
Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy. N. SHIBATA, K. KAWAKAMI, S. HISANORI, K. KOBAYASHI, M. YUNOKAWA, H. KANAO, I. TAKI, R. MURASE, D. KAMEI, M. YAMAGUCHI ( <i>Tokyo, Japan</i> ).....	1091
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer. H. SEKI, T. SAKURAI, A. SAKURADA, T. KINOSHITA, K. SHIMIZU ( <i>Saitama, Japan</i> ).....	1099
Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer. Y. NAGATA, T. MATSUKAWA, I. TOMISAKI, N. FUJIMOTO ( <i>Kitakyushu, Japan</i> ).....	1107
Increased Transumbilical Incision Complication Rates With Laparoscopic Colorectal Resection: A Single-center Propensity Score-matched Cohort Study. K. TOMIOKA, T. AOKI, M. WATANABE, Y. ENAMI, A. FUJIMORI, T. KOIZUMI, S. GOTO, K. YAMAZAKI, K. OTSUKA, M. MURAKAMI ( <i>Shinagawa, Japan</i> ).....	1115
Risk and Protective Factors for Postoperative Complications in Elderly Patients With Colorectal Cancer. T. SHIRAISHI, H. OGAWA, N. OZAWA, K. SUGA, C. KOMINE, Y. SHIBASAKI, K. OSONE, T. OKADA, Y. ENOKIDA, M. SOHDA, K. SHIRABE, H. SAEKI ( <i>Maebashi, Japan</i> ).....	1123
Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. R. KURASHINA, K. ANDO, M. INOUE, K. IZUMI, R. MARUYAMA, K. MITANI, H. TAKENOBU, M. HARUTA, T. IIZUKA, T. KAMIJO, Y. KAGEYAMA ( <i>Saitama, Japan</i> ).....	1131
Consideration of the Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma. T. TAKENAKA, T. TAGAWA, M. KOHNO, N. HARATAKE, F. KINOSHITA, Y. ONO, S. WAKASU, Y. OKU, M. MORI ( <i>Fukuoka, Japan</i> ).....	1137
High vs. Standard Radiotherapy Dose in Locally Advanced Rectal Adenocarcinoma Patients Treated With Neoadjuvant Long Course Chemoradiotherapy: A Population-based Study. J.-A. LIANG, Y.-C. KUO, K.S.C. CHAO, W.T.-L. CHEN, T.-W. KE, S.-H. CHOU, C.-C. LI, C.-R. CHIEN ( <i>Taichung; Hsinchu, Taiwan, ROC</i> ).....	1143
Awake Surgery for Local Recurrence of Brain Metastasis in the Precentral Gyrus After Fractionated Stereotactic Radiotherapy: A Technical Case Report. R. MATSUDA, F. SATO, M. KOTSUGI, T. MORIMOTO, F. NISHIMURA, I. NAKAGAWA, H. NAKASE ( <i>Kashihara, Japan</i> ).....	1151
Bilateral Lung Transplant for Treatment of Idiopathic Pulmonary Fibrosis With Undetected Lung Adenocarcinoma: A Case Report. U.M. JOGIAT, Q. S. CHU, J. NAGENDRAN, B. LAING, A. HIRJI, B.A. ADAM ( <i>Edmonton, AB, Canada</i> ).....	1157
Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases. A. ICHIDA, N. AKAMATSU, R. NAGATA, Y. MIHARA, Y. KAWAGUCHI, S.K. BAE, T. ISHIZAWA, J. KANEKO, J. ARITA, K. HASEGAWA ( <i>Tokyo, Japan</i> ).....	1161
A Rare Case of Brain Metastasis of Thymic Carcinoma. T. MITSUI, R. MATSUDA, K. GODA, H. ITAMI, I. NAKAGAWA, H. NAKASE ( <i>Kashihara, Japan</i> ).....	1169

Stratified Mucin-producing Intraepithelial Lesions of the Cervix: Clinical Diversity of Cases and Literature Review. C. DELRUE, L. VANWALLEGHEM, P. DE PAEPE, P. VAN TRAPPEN (*Ghent; Bruges, Belgium*)..... 1175

Replication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells – An Analysis for Patients With Incurable Pancreatic Cancer. Y. YAMAGUCHI, Y. KATATA, M. OKAWAKI, A. SAWAKI, M. YAMAMURA (*Okayama, Japan*) ..... 1181

### Number 3, March

#### Review

Pineal Region Gliomas: A Systematic Review of Clinical Features and Treatment Outcomes. O. BIN ALAMER, P. PALMISCIANO, S.E. ROWE, A.D. GUPTA, M. HAIDER, M. ALDUHAYMI, A.A. COHEN-GADOL, K. YU, T.Y. EL AHMADIEH, A.S. HAIDER (*Riyadh, Kingdom of Saudi Arabia; Catania, Italy; Fort Lauderdale, FL; Houston, TX; Indianapolis, IN; New York, NY, USA*)..... 1189

#### Experimental Studies

Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1. A. OKAMOTO, Y. FUNAKOSHI, M. OE, R. TAKAI, H. SUTO, Y. NAGATANI, M. NISHIMURA, Y. IMAMURA, T. KUNIHISA, N. KIYOTA, K. MIKI, K. OHE, H. TANINO, H. MINAMI (*Kobe; Kyoto, Japan*) ..... 1199

The Complement C3a–C3a Receptor Axis Regulates Epithelial-to-Mesenchymal Transition by Activating the ERK Pathway in Pancreatic Ductal Adenocarcinoma. R. SUZUKI, Y. OKUBO, T. TAKAGI, M. SUGIMOTO, Y. SATO, H. IRIE, J. NAKAMURA, M. TAKASUMI, T. KATO, M. HASHIMOTO, R. KOBASHI, T. HIKICHI, H. OHIRA (*Fukushima, Japan*)..... 1207

Kindlin-3 in Immune Cells Is Required to Suppress Prostate Cancer Tumor Growth in Mice. C. LIU, Y. ZHOU, Y. ZHOU, Z. XU, Y.-Q. MA (*Shanghai, PR China; Milwaukee, WI, USA*) ..... 1217

Administration of Gapmer-type Antisense Oligonucleotides Targeting  $\gamma$ -Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts. H. II, Y. KASAHARA, H. YAMAGUMA, S. KAGEYAMA, A. KAWAUCHI, S. OBIKA, S. NAKATA (*Kyoto; Osaka; Ibaraki; Shiga, Japan*)..... 1221

Association of *Interleukin-8* Promoter Genotypes With Taiwan Lung Cancer Risk. C.-H. LI, Y.-C. YANG, T.-C. HSIA, T.-C. SHEN, Y.-C. SHEN, W.-S. CHANG, Y.-C. WANG, C.-W. TSAI, D.-T. BAU (*Taichung, Taiwan, ROC*) ..... 1229

Death Receptor 6 as a Prognostic Marker in Low-grade Glioma. S.K. STEGMANN, S. KUHL, N.G. IM, D.T.D. DINH, L. GOERTZ, R. GOLDBRUNNER, M. TIMMER (*Cologne, Germany*)..... 1237

Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study. R.E. FRIEDRICH, L.K.N. NÖRNBERG, C. HAGEL (*Hamburg; Gießen, Germany*) ..... 1247

Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. S. HAMAYA, S. FUJIHARA, H. IWAMA, K. FUJITA, T. SHI, R. NAKABAYASHI, T. MIZUO, K. TAKUMA, M. NAKAHARA, K. OURA, T. TADOKORO, S. MIMURA, J. TANI, A. MORISHITA, H. KOBARA, M. ONO, T. HIMOTO, T. MASAKI (*Kagawa, Japan*) ..... 1263

The Interaction Between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal Cancer. A. MAEDA, H. TAKAHASHI, S. HARATA, K. WATANABE, T. YANAGITA, T. SUZUKI, H. USHIGOME, N. NAKAI, Y. MAEDA, T. HIROKAWA, K. SHIGA, R. OGAWA, M. HARA, Y. MATSUO, A. MITSUI, M. KIMURA, S. TAKIGUCHI (*Nagoya, Japan*) ..... 1277

Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma. M. YUMURA, T. NAGANO, N. JIMBO, R. DOKUNI, T. KIRIU, Y. TANAKA, M. TACHIHARA, T. ITOH, Y. MANIWA, Y. NISHIMURA, K. KOBAYASHI ( <i>Kobe, Japan</i> ) .....	1289
Impact of PRP and PRF on Viability of Zoledronic Acid Treated Osteoblasts in 2D and 3D Cell Culture. D. STELLER, A. SCHEIBERT, T. STURMHEIT, D. ROSE, S.G. HAKIM ( <i>Lübeck, Germany</i> ) .....	1295
Investigation of Long Non-coding RNAs H19 and LINC00675 in Colorectal Cancers in Terms of Histopathological Features and Correlations With Plasma Markers. G. NACARKAHYA, E. BORAZAN, C. HOROZOGLU, I. YAYLIM ( <i>Gaziantep; Istanbul, Turkey</i> ) .....	1301
Azoxystrobin Induces Apoptosis and Cell Cycle Arrest in Human Leukemia Cells Independent of p53 Expression. S. TAKAHASHI, T. SHINOMIYA, Y. NAGAHARA ( <i>Saitama, Japan</i> ) .....	1307
Anti-chloride Intracellular Channel Protein 1 (CLIC1) Antibodies Induce Tumour Necrosis and Angiogenesis Inhibition on <i>In Vivo</i> Experimental Models of Human Renal Cancer. A.D.R. COSNITA, A. NESIU, P.L. BERZAVA, S. CERBU, A. COSMA, S. COMSA, S. SARB, A.M. FERICIAN, O.C. FERICIAN, A.M. CIMPEAN ( <i>Timisoara; Arad, Romania</i> ) .....	1313
A New Method for Obtaining Tumor Interstitial Fluid Applied to Cytokine Analysis of Breast Carcinoma Samples. F.T. DANTAS, P.H.F. SILVA, H.H.A. CARRARA, F.J.C DOS REIS, M. TABA JUNIOR, S.L.S. DE SOUZA, D.B. PALIOTO ( <i>São Paulo, Brazil</i> ) .....	1327
The Nitrated Form of Nateglinide Induces Apoptosis in Human Pancreatic Cancer Cells Through a Caspase-dependent Mechanism. K. NISHI, S. IMOTO, T. BEPPU, S. UCHIBORI, A. YANO, Y. ISHIMA, T. IKEDA, K. TSUKIGAWA, M. OTAGIRI, K. YAMASAKI ( <i>Kumamoto; Tokushima, Japan</i> ) .....	1333
 <i>Clinical Studies</i> 	
First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report. M.W. SALKINI, X. YANG, F.H. HASHMI, S.J. KANDZARI, T. HOGAN, C. MORLEY, D. ZEKAN, Z. WERNER, D.J. WILLIAMS, Y. GUO, T.L. MATTHEW, M. SPANGLER, J.J. YU ( <i>Morgantown, WV; Bethesda; Easton, MD; Colorado Springs, CO, USA; Beijing, PR China</i> ) .....	1339
Indocyanine Green Labeling of Tumors in the Liver Recurring After Radiofrequency Ablation Enables Complete Resection by Fluorescence-guided Surgery. Y. TASHIRO, T. AOKI, T. HIRAI, T. KOIZUMI, T. KUSANO, K. MATSUDA, K. YAMADA, K. NOGAKI, T. HAKOZAKI, Y. WADA, H. SHIBATA, K. TOMIOKA, T. YAMAZAKI, K. SAITO, A. FUJIMORI, Y. ENAMI, R.M. HOFFMAN ( <i>Tokyo, Japan; San Diego, CA, USA</i> ) .....	1345
Rarely Described Renal Malignancies Associated With Venous Tumor Thrombus. M.C. VELASQUEZ, A. MOUZANNAR, S. SWAIN, G. CIANCIO ( <i>Miami, FL, USA</i> ) .....	1351
Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer. M.C. JIN, Z.J. QIAN, U.C. MEGWALU ( <i>Stanford, CA, USA</i> ) .....	1359
Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer. T. HECKING, T. THIESLER, J. HALBE, L. OTTEN, F. RECKER, H. GEVENSLEBEN, T. MÜLLER, C. SCHILLER, E.K. EGGER, R. FIMMERS, M.B. STOPE, G. KRISTIANSEN, A. MUSTEA ( <i>Bonn, Germany</i> ) .....	1367
Long-term Outcome of Acral Ewing Sarcoma. K.E. MALLETT, M.J. HEIDENREICH, Z.M. JOSEPH, C. COPPER, P.S. ROSE, S.L. MORAN, M.T. HOUDEK ( <i>Rochester, MN, USA</i> ) .....	1377

Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin. J.J. SALLER, M. HAIDER, S. AL DIFFALHA, D. COPPOLA ( <i>Tampa; Bradenton, FL, USA</i> ) .....	1381
Improving Survival Prognostication in Patients With Metastatic Cancer Through Clinical Judgment. J. KAO, A. ZUCKER, M. URSO, P. KARWOWSKI, N. JAIN, S. JAIN, G. BUSTAMANTE, D. LUGO, L. ROWLAND ( <i>West Islip; Glen Head; Commack, NY, USA</i> ) .....	1397
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma. S. KOMATSU, Y. YANO, Y. FUJISHIMA, J. ISHIDA, M. KIDO, K. KURAMITSU, A. YAMAMOTO, T. GOTO, H. YANAGIMOTO, H. TOYAMA, Y. UEDA, Y. KODAMA, T. FUKUMOTO ( <i>Kobe, Japan</i> ) .....	1403
Platelet to Lymphocyte Ratio Correlates With Carcinoma Progression in Pancreatic Intra Epithelial Neoplasia. D. WAGNER, J. HAYBAECK, V. WIENERROITHER, T. BAJRIC, A. TOMBERGER, P. SCHEMMER, H.J. MISCHINGER, P. KORNPAT ( <i>Graz; Innsbruck, Austria</i> ) .....	1413
Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs). S. KASHIWAGI, Y. ASANO, K. TAKADA, W. GOTO, T. MORISAKI, M. SHIBUTANI, H. TANAKA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ) .....	1421
Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series. S. JORIS, C. FONTAINE, L. DECOSTER, J. VANDERAUWERA, K. THIELEMANS, W. WAELPUT, J. DE GRÈVE ( <i>Brussels, Belgium</i> ) .....	1433
Carbon-ion Radiotherapy for Inoperable Head and Neck Bone and Soft-tissue Sarcoma: Prospective Observational Study. A. MUSHA, N. KUBO, H. KAWAMURA, N. OKANO, H. SATO, K. OKADA, N. OSU, H. YUMISAKI, A. ADACHI, Y. TAKAYASU, M. SHINO, O. NIKKUNI, S. IDA, K. SHIRAI, J.-I. SAITOH, S. YOKOO, K. CHIKAMATSU, T. OHNO ( <i>Maebashi; Tochigi; Toyama, Japan</i> ) .....	1439
sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma. V. BARAK, I. KALICKMAN, J. PE'ER ( <i>Jerusalem, Israel</i> ) .....	1447
Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes. S. CLAUSEN, M. FALK, F. OESTERLING, A. FEHR, A. STANG, W. BOECKER, S. GESK, S. SCHATZ, G. STENMAN, K. TIEMANN, T. LOENING, R.E. FRIEDRICH ( <i>Hamburg; Bochum; Essen; Kiel, Germany; Gothenburg, Sweden</i> ) .....	1455
Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. A. MIZOKAMI, K. NISHIMOTO, H. MATSUYAMA, T. ICHIKAWA, S. TAKAHASHI, H. SHIINA, K. HASHINE, Y. SUGIYAMA, M. KAMIYAMA, H. ENOKIDA, K. NAKAJIMA ( <i>Ishikawa; Hidaka; Yamaguchi; Chiba; Tokyo; Matsue; Matsuyama; Kumamoto; Yamanashi; Kagoshima; Kanazawa, Japan</i> ) .....	1465
Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy. C. NIEDER, B. MANNSÅKER, R. YOBUTA ( <i>Bodø; Tromsø, Norway</i> ) .....	1477
Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of <i>PTEN</i> Hamartoma Tumor Syndrome in an Adult Patient With a Novel <i>RECQL4</i> Mutation. A. LIU, P.M. BORGES, Y.S. TAY, L.D.R. THOMPSON, M.X. KONG, J. LAI ( <i>Oakland; Sacramento; Woodland Hills, CA, USA</i> ) .....	1481
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active? C. CICCARESE, R. IACOVELLI, S. BUTI, F. PRIMI, S. ASTORE, F. MASSARI, M.G. FERRARA, G. PALERMO, N. FOSCHI, V. IACOVELLI, E. ROSSI, G. SCHINZARI, P. BOVE, P. BASSI, E. BRIA, G. TORTORA ( <i>Rome; Parma; Viterbo; Bologna, Italy</i> ) .....	1487

Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer? P. PEPE, M. PENNISI ( <i>Catania, Italy</i> ) .....	1495
Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma. M. OHSAWA, Y. HAMAI, M. EMI, Y. IBUKI, T. KUROKAWA, T. YOSHIKAWA, R. HIROHATA, N. KITASAKI, M. OKADA ( <i>Hiroshima, Japan</i> ) .....	1499
Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas. S. JAAMAA, R. NEVALA, K. JAGARLAMUDI, E. TUKIAINEN, C. BLOMQVIST, M. SAMPO ( <i>Helsinki, Finland; Uppsala; Örebro, Sweden</i> ).....	1509
Non-invasive Screening of Autoimmune Atrophic Gastritis in Asymptomatic Subjects by Serological Biomarker Test (GastroPanel®). N. BAKULINA, S. TIKHONOV, V. MALKOV, S. VOROBYEV, I. BELYAKOV, N. PESHKOVA, E. BELKO, K. SYRJÄNEN ( <i>St. Petersburg, Russian Federation; Barretos, Brazil; Kaarina, Finland</i> ).....	1517
Effect of Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer: A Multicenter Propensity Score-matched Analysis. H. KATAYAMA, T. TOMINAGA, T. NONAKA, M. ARAKI, Y. SUMIDA, H. TAKESHITA, H. FUKUOKA, K. TO, K. TANAKA, T. SAWAI, T. NAGAYASU ( <i>Nagasaki; Saga, Japan</i> ) .....	1527
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab. H. SUEMATSU, K. KANO, T. YAMADA, I. HASHIMOTO, H. WATANABE, K. TAKAHASHI, M. WATANABE, K. HAYASHI, Y. KANETA, M. FURUTA, Y. INOKUCHI, N. MACHIDA, T. AOYAMA, H. TAMAGAWA, N. YUKAWA, Y. RINO, M. MASUDA, T. OGATA, T. OSHIMA ( <i>Kanagawa, Japan</i> ) .....	1535
Prognostic Predictors After Surgical Intervention for Stage IV Gastric Cancer. S. SUZUKI, N. URAKAWA, H. HASEGAWA, S. KANAJI, K. YAMASHITA, T. MATSUDA, T. OSHIKIRI, Y. KAKEJI ( <i>Kobe, Japan</i> ) .....	1541
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. T. ITO, I. OKAMOTO, K. TOKASHIKI, H. SATO, T. OKADA, G. YAMASHITA, T. NAGAO, H. HIRAI, N. SAIGUSA, K. TSUKAHARA ( <i>Tokyo, Japan</i> ) .....	1547
Management of Soft-tissue Tumors With a Size of 2-5 cm, Including Malignancy. Y. ARAKI, N. YAMAMOTO, T. MAEDA, H. KIMURA, T. OTA, S. SHIMOZAKI, T. KATO, D. INOUE, T. HIGUCHI, K. ABE, Y. TANIGUCHI, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ) .....	1555
Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer. M. SVATON, M. DROSSLEROVA, O. FISCHER, M. MAREL, M. HRNCIARIK, O. VENCLICEK, P. ZUNA, M. SVOBODA, J. BLAZEK, M. BRATOVA, A. MULLEROVA, B. VANKOVA, D. KREJCI ( <i>Pilsen; Prague; Olomouc; Hradec Kralove; Brno, Czech Republic</i> ).....	1563
Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study. N. FURUBAYASHI, F. MOROKUMA, T. TOMODA, Y. HORI, T. NEGISHI, A. MIURA, H. KOMORI, K. KUROIWA, M. NAKAMURA ( <i>Fukuoka; Saga; Oita; Miyazaki, Japan</i> ).....	1571
Clinical Features and Treatment Outcomes of Pseudoaneurysm Following Pancreatic Resection. Y. FUTAGAWA, S. ONDA, S. FUJIOKA, T. USUBA, Y. NAKABAYASHI, T. MISAWA, T. OKAMOTO, T. IKEGAMI ( <i>Tokyo; Kashiwa; Kawaguchi, Japan</i> ).....	1579
The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma. T. OTOSHI, T. NAGANO, J. PARK, K. HOSOMI, T. YAMASHITA, M. TACHIHARA, T. TABATA, R. SEKIYA, Y. TANAKA, K. KOBAYASHI, K. MIZUGUCHI, T. ITOH, Y. MANIWA, J. KUNISAWA, Y. NISHIMURA ( <i>Kobe; Ibaraki; Suita, Japan</i> ).....	1589



Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab. Y. MASUDA, Y. KANANAZAWA, K. MATSUNO, D. KAKINUMA, N. SAKURAZAWA, F. ANDO, N. HAGIWARA, T. NOMURA, S. KATO, T. YOSHIYUKI, H. YOSHIDA ( <i>Tokyo, Japan</i> ) .....	1599
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. T. OKADA, C. FUSHIMI, T. MATSUKI, I. OKAMOTO, H. SATO, T. KONDO, K. TOKASHIKI, T. KISHIDA, T. ITO, G. YAMASHITA, Y. AIHARA, K. HANYU, Y. KUSHIHASHI, T. MASUBUCHI, Y. TADA, K. MIURA, Y. HARADA, K. MOMIYAMA, T. YAMASHITA, G. OMURA, H. TAKAHASHI, N. ORIDATE, K. TSUKAHARA ( <i>Tokyo; Sagamihara; Yokohama, Japan</i> ).....	1607
First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. M.-H. KIM, C.M. CHOI, S.Y. LEE, C.K. PARK, Y.S. CHANG, K.Y. LEE, S.J. KIM, S.H. YANG, J.S. RYU, J.E. LEE, S.Y. LEE, C.K. PARK, S.H. LEE, S.H. JANG, S.H. YOON, T.W. JANG ( <i>Busan; Seoul; Hwasun; Iksan; Incheon; Daejeon; Daegu; Anyang; Yangsan, Republic of Korea</i> ) .....	1615
Is Preoperative Spirometry Necessary for Gastrointestinal Cancer Surgery? M. MITSUDA, H. SHIMIZU, Y. KURIU, T. KUBOTA, T. ARITA, T. OHASHI, J. KIUCHI, Y. YAMAMOTO, H. KONISHI, R. MORIMURA, A. SHIOZAKI, H. IKOMA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	1623
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma. I. TOMISAKI, M. HARADA, A. MINATO, Y. NAGATA, R. KIMURO, K. HIGASHIJIMA, K. HARADA, N. FUJIMOTO ( <i>Fukuoka, Japan</i> ).....	1629
Primary Malignant Osseous Neoplasms in the Hand. S. IKE, M. MATSUOKA, T. ONODERA, I. YOKOTA, K. IWASAKI, R. HISHIMURA, Y. SUZUKI, E. KONDO, N. IWASAKI ( <i>Sapporo, Japan</i> ) .....	1635
Awake Craniotomy for Subcortical Brain Metastasis Beneath the Speech Center: A Technical Case Report. R. MATSUDA, M. KOTSUGI, K. NAKASE, T. MORIMOTO, F. NISHIMURA, I. NAKAGAWA, H. NAKASE ( <i>Kashihara, Japan</i> ) .....	1641
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation. K. MATSUMURA, K. YAMAMURA, H. MIYAMOTO, Y. HARA, E. ODA, S. AKAHOSHI, K. YOSHIDA, H. YUKI, T. MOTOHARA, K. SAKAMOTO, Y. KOMOHARA, T. BEPPU ( <i>Yamaga; Kumamoto; Toon, Japan</i> ) .....	1645
A Case of Salvage Maxillectomy for Recurrent Oral Cancer After Boron Neutron Capture Therapy During the COVID-19 Pandemic. H. SUZUKI, M. YOKOI, S. HAGIWARA, E. SASAKI, Y. KOBAYASHI, S. IWAKI, D. NISHIKAWA, S. BEPPU, H. TERADA, M. SAWABE, N. HANAI ( <i>Nagoya, Japan</i> ) .....	1653
Erratum .....	1659

## Number 4, April

### Reviews

Intradural Cauda Equina Metastases: A Systematic Review of Clinico-radiological Features, Management, and Treatment Outcomes. P. PALMISCIANO, S.E. ZAIDI, N.A. SHLOBIN, N.S. SAGOO, O.B. ALAMER, G. SCALIA, G. FERINI, G.E. UMANA, S.G. AOUN, A.S. HAIDER ( <i>Catania; Viagrande, Italy; Paris, France; Chicago, IL; Dallas; Houston, TX, USA; Riyadh, Kingdom of Saudi Arabia</i> ) .....	1661
Sun Exposure - Hazards and Benefits. P.G. LINDQVIST, E. EPSTEIN, M. LANDIN-OLSSON ( <i>Stockholm; Lund, Sweden</i> ) .....	1671
Accuracy of Serum Biomarker Panel (GastroPanel®) in the Diagnosis of Atrophic Gastritis of the Corpus. Systematic Review and Meta-analysis. K. SYRJÄNEN ( <i>Kaarina, Finland; Barretos, SP, Brazil</i> ) .....	1679

*Experimental Studies*

Chemotherapy Can Synergize With Adoptive Immunotherapy to Inhibit Medulloblastoma Growth. J.L. LASKY III, K.L. BRADFORD, Y. WANG, Y. PAK, E.H. PANOSYAN (*Torrance, CA, USA*) ..... 1697

Transcriptomic Analysis of Annexin A10 and Chemosensitivity in Gastric Adenocarcinoma Cells. A. ISHIKAWA, K. KURAOKA, J. ZAITSU, A. SAITO, T. KUWAI, H. TAZAWA, T. SUZUKI, H. TASHIRO, K. TANIYAMA, W. YASUI (*Kure; Hiroshima, Japan*)..... 1707

Adenovirus Vector With ADP Gene Induces Cytopathic Effects in HEK293 Cells Without Significant Elevation of Virus Titers. A. SHIOTA, F. NISHIMAE, F. SAKURAI, H. MIZUGUCHI (*Osaka, Japan*)..... 1719

Biological Differences Between Ovarian Cancer-associated Fibroblasts and Contralateral Normal Ovary-derived Mesenchymal Stem Cells. K. OHASHI, T.-S. LI, S. MIURA, Y. HASEGAWA, K. MIURA (*Nagasaki, Japan*).. 1729

Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer. S. ABOBAKER, H. KULBE, E.T. TAUBE, S. DARB-ESFAHANI, R. RICHTER, C. DENKERT, P. JANK, J. SEHOULI, E.I. BRAICU (*Berlin; Marburg, Germany*) ..... 1739

Association of *Matrix Metalloproteinase-2* Genotypes With Risk of Gastric Cancer in Taiwan. C.-K. FU, M.-C. MONG, C.-C. YU, M.-D. YANG, Z.-H. WANG, Y.-C. YANG, J.-C. CHEN, J.-S. PEI, N.-Y. HSIA, C.-W. TSAI, W. -S. CHANG, D.-T. BAU (*Taichung; Taipei; Changhua; Taoyuan, Taiwan, ROC*) ..... 1749

*TYRO3* Knockdown Suppresses the Growth of Myeloid Leukaemia Cells. T. SAITO, M. ITOH, S. TOHDA (*Tokyo, Japan*) ..... 1757

Integrin  $\alpha 6A$  (ITGA6A)-type Splice Variant in Extracellular Vesicles Has a Potential as a Novel Marker of the Early Recurrence of Pancreatic Cancer. T. ASADA, S. NAKAHATA, Y.R. FAUZI, T. ICHIKAWA, K. INOUE, N. SHIBATA, Y. FUJII, N. IMAMURA, M. HIYOSHI, A. NANASHIMA, K. MORISHITA (*Miyazaki; Kagoshima; Osaka; Yokohama, Japan*)..... 1763

Relationship Between the Structure of Alkylpsoralens and Their Antiproliferative Activity in HL60 Cells. S. KAWAII, Y. MATSUOKA, H. NOGUCHI, T. SATO, Y. YOSHIKAWA (*Hatoyama; Akita, Japan*)..... 1777

Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells. W. CHIRAPHAPHAIBOON, P. LUANGWATTANANUN, A. PANYA, N. JIRAPONGWATTANA, P. PUNNAKITIKASHEM, T. CHIEOCHANSIN, M. JUNKING, P.-T. YENCHITSOMANUS (*Bangkok; Chiang Mai, Thailand*)..... 1785

Poly(Alkyloxyethylene-Lactate Phosphate) for Delivery of Doxorubicin: Synthesis and Characterization. K. YOSHIKAWA, T. NII, K. TROEV, K. MAKINO, I. TAKEUCHI (*Chiba; Fukuoka, Japan; Sofia, Bulgaria*)..... 1801

CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer. J.K. HONG, D.Y. KIM, J.-S. SHIN, Y.S. RYU, J.-H. MOON, D.-I. KOH, S. LEE, J. LEE, W.J. LEE, E.Y. LEE, S.-A JUNG, S.C. KIM, H.N. YU, M.J. KIM, S.-W. HONG, S.S. PARK, J. JUNG, S.M. KIM, E.H. KIM, H.-R. JEONG, J.H. GONG, J. KIM, T.W. KIM, D.-H. JIN (*Seoul; Icheon-si, Republic of Korea*) ..... 1813

Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies. T. ZANDER, J. XUE, G. MARKSON, F. DAHM, C. RENNERT (*Steinhausen, Switzerland; Jiangsu, PR China*).... 1821

*N-Trans-p-Coumaroyltyramine* Enhances Indomethacin and Diclofenac-induced Apoptosis Through Endoplasmic Reticulum Stress-dependent Mechanism in MCF-7 Cells. A. WONGSAKUL, N. LERTNITIKUL, R. SUTTISRI, S. JIANMONGKOL (*Bangkok, Thailand*)..... 1833



*Clinical Studies*

Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer. Z.S. MAYO, E.O. ILORI, B. MATIA, T.D. SMILE, C.W. FLEMING, C.A. REDDY, J. SCHARPF, E.D. LAMARRE, B.L. PRENDES, J. KU, B.B. BURKEY, N.P. JOSHI, N.M. WOODY, S.A. KOYFMAN, S.R. CAMPBELL (Cleveland, OH; Chicago, IL, USA) ..... 1845

Hypofractionated Gamma Knife Radiosurgery: Institutional Experience on Benign and Malignant Intracranial Tumors. F. INSERRA, F. BARONE, P. PALMISCIANO, G. SCALIA, V. DA ROS, A. ABDELSALAM, A. CREA, M.G. SABINI, S.O. TOMASI, G. FERINI, R. MAUGERI, L. STRIGARI, G.E. UMANA (Catania; Rome; Pavia; Viagrande; Palermo; Bologna, Italy; Saint Louis, MO, USA; Salzburg, Austria) ..... 1851

A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202). A. KATO, N. MIYOSHI, T. OHTSURU, D. SAKAI, J. HASEGAWA, K. NAKATA, M. IMASATO, T. KATO, M. IKENAGA, T. KUDO, M. TEI, Y. KAGAWA, M. UEMURA, H. TAKAHASHI, T. SATOH, M. MORI, T. MIZUSHIMA, H. YAMAMOTO, K. MURATA, Y. DOKI, H. EGUCHI (Osaka; Hyogo; Kanagawa, Japan) ..... 1859

The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma: A 12-year Population-based Analysis Using Propensity Score. Y. SAMHOURI, M.K.M. ALI, C. KHAN, R. WEGNER, S.T. LEE, J. LISTER (Pittsburgh, PA; Baltimore, MD, USA) ..... 1867

The ColonView (CV) Quick Test for Fecal Occult Blood Shows Significantly Higher Diagnostic Accuracy in Detecting Distal than Proximal Colorectal Cancer. M. ESKELINEN, J. MEKLIN, D.P. GUIMARÃES, T. SELANDER, T. TIUSANEN, K. SYRJÄNEN, M. ESKELINEN (Kuopio; Helsinki; Kaarina, Finland; Barretos, Brazil)..... 1879

Clinical Utility and Cost of Postoperative Hemoglobin Level Testing Following Robotic-assisted Hysterectomy for Endometrial Cancer. M. SHORAKA, S.L. CARBAJAL-MAMANI, B. DIDEBAN, A. ZARRINPAR, C. WARREN, B. AMARO, J. CARDENAS-GOICOECHEA (Gainesville; Weston, FL, USA) ..... 1893

Diabetes Mellitus and Oral Cancer: A Retrospective Study from Austria. B. REMSCHMIDT, M. PAU, J. GAESSLER, W. ZEMANN, N. JAKSE, M. PAYER, D. VÉGH (Graz, Austria; Budapest, Hungary) ..... 1899

Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma. T. KUZUYA, N. KAWABE, S. HASHIMOTO, K. FUNASAKA, M. NAGASAKA, Y. NAKAGAWA, R. MIYAHARA, T. SHIBATA, T. TAKAHARA, Y. KATO, A. SUGIOKA, Y. HIROOKA (Toyoake, Japan) ..... 1905

Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy. M. NEUBERGER, J. SKLADNY, N. GOLY, F. WESSELS, C. WEIß, L. EGEN, P. ERBEN, M. GROß-WEEGE, B. GRÜNE, F. HARTUNG, J. HERRMANN, P. HONECK, J. JARCZYK, K.-F. KOWALEWSKI, J. MÜHLBAUER, K. NITSCHKE, M. NIENTIEDT, M.T. WALACH, F. WALDBILLIG, N. WESTHOFF, J. VON HARDENBERG, M. KRIEGMAIR, T.S. WORST, P. NUHN (Mannheim, Germany) ..... 1911

Diagnostic Impact of Crypt Branching in Patients With Crohn’s Disease: A Validation Study. C. LANG-SCHWARZ, C.A. RUBIO, M. VIETH (Bayreuth, Germany; Stockholm, Sweden) ..... 1919

Improving Breast Conserving Surgery Using the Faxitron® OR Specimen Radiography System – A Complication Analysis, Cost Evaluation and Literature Review. C. EICHLER, A. WESTERHOFF, M. WARM, B. HANSTEIN, J. PUPPE, B. KRUG, W. MALTER (Cologne; Münster, Germany) ..... 1925

Oncogenic Fusions in Gliomas: An Institutional Experience. J. POLIVKA, M. SVAJDLER, V. PRIBAN, J. MRACEK, P. KASIK, P. MARTINEK, N. PTAKOVA, M.S. BAGHERI, D. SHETTI, M. PESTA, P. POTUZNIK, O. TOPOLCAN (Pilsen, Czech Republic; Bratislava, Slovak Republic) ..... 1933

A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The ‘PROTOR’ Study. G. KALTSAS, C. ANDREADIS, P. KOSMIDIS, D. MAVROUDIS, K. PAZAITOU-PANAYIOTOU, M. VASLAMATZIS, I. ATHANASIADIS ( <i>Athens; Thessaloniki; Heraklion, Greece</i> ).....	1941
Impact of Modern Management Strategies on the Clinical Outcome of Patients With Low Rectal Cancer – A Retrospective, Monocentric Cohort Study. E. KARAM, R. SINDAYIGAYA, U. GIGER-PABST, M. GABRIEL, N. MICHOT, L. COURTOT, N. TABCHOURI, D. MOUSSATA, T. LECOMTE, S. CHAPET, G. CALAIS, P. BOURLIER, E. SALAMÉ, M. OUAISSI ( <i>Chambray Les Tours; Tours, France; Düsseldorf, Germany</i> ).....	1949
Photon-based High-dose Single-fraction Radiosurgery, an Effective Treatment Modality for Large and Posterior Uveal Melanoma. C. LALISCIA, F. GENOVESI-EBERT, F. PERRONE, F. GUIDO, F. CRESTI, T. FUENTES, N. COCCIA, R. MATTIONI, R. MORGANTI, F. PAIAR ( <i>Pisa, Italy</i> ) .....	1965
Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer. D. RADES, E. GLATZEL, S. BOHNET, S.E. SCHILD, E.M. WERNER ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	1973
Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery. S. ADDLEY, M. MCGOWAN, V. ASHER, A. BALI, S. ABDUL, V. CULLIMORE, H. CROSSLAND, A. PHILLIPS ( <i>Derby, UK</i> ).....	1979
Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? M. SVATON, M. BRATOVA, L. KOUBKOVA, O. FISCHER, B. MELICHAR, M. HRNCIARIK, D. DOLEZAL, O. BILEK, J. KREJCI, M. DROSSLEROVA, Z. DLOUHA, J. BLAZEK, P. MAJKOVA, L. BROZOVA, M. STASTNY ( <i>Pilsen; Brno; Prague; Olomouc; Hradec Kralove; Usti nad Labem, Czech Republic</i> ).....	1987
Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases. K. TOMITA, N. CHIBA, S. OCHIAI, T. GUNJI, T. KOBAYASHI, T. SANO, E. HIDAKA, S. KAWACHI ( <i>Tokyo, Japan</i> ).....	1997
Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer. V. MITSOPOULOS, A. INNAMAA, J. LIPPIATT, S. COLLINS, I. BILIATIS ( <i>Poole; Salisbury, UK</i> )..	2003
Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial. T. YOSHIOKA, M. TAKAHASHI, Y. SAKAMOTO, A. OKITA, T. FUKUI, Y. MURAKAWA, Y. SHINDO, H. IMAI, H. OHORI, H. SHIROTA, N. CHIBA, Y.(I.) SASAHARA, T. NOMURA, N. FUKUSHIMA, T. YAMAGUCHI, H. SHIMODAIRA, C. ISHIOKA ( <i>Yamagata; Sendai; Osaka; Medeshima; Akita; Ishinomaki, Japan</i> ).....	2009
Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. A. GADDUCCI, S. COSIO, F. LANDONI, A.A. LISSONI, P. ZOLA, M.E. LAUDANI, A. ARDIZZOIA, A. GAMBINO, E. SARTORI ( <i>Pisa; Milan; Turin; Lecco; Brescia, Italy</i> ) .....	2017
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events. M. KATSUTA, T. KIMURA, K. TASHIRO, M. MURAKAMI, K. HATA, T. YANAGISAWA, H. ONUMA, T. YAMAMOTO, S. SUGAYA, Y. WATANABE, Y. NOBEYAMA, S. EGAWA, A. ASAHINA ( <i>Tokyo; Shizuoka; Kanagawa, Japan</i> )...	2023
A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer. E. GLATZEL, E.M. WERNER, S. BOHNET, D. RADES ( <i>Lübeck, Germany</i> ).....	2029
CD133(+)/HIF-1 $\alpha$ (-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer. Y. TACHIKAWA, K. KAWAI, K. OZAKI, H. NOZAWA, K. SASAKI, K. MURONO, S. EMOTO, J. KISHIKAWA, Y. YOKOYAMA, S. ABE, Y. NAGAI, H. ANZAI, H. SONODA, S. ISHIHARA ( <i>Tokyo, Japan</i> ).....	2033

Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer. M. FUJIWARA, R. FUJIWARA, T. URASAKI, T. OGUCHI, Y. KOMAI, N. NUMAO, S. YAMAMOTO, J. YONESE, T. YUASA ( <i>Tokyo, Japan</i> ) .....	2045
Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy. M. UCHIDA, S. MURATA, H. MORIKAWA, H. YONEMITSU, S. ISHIDA, K. SUETSUGU, T. TSUJI, H. WATANABE, T. KAWASHIRI, K. KATO, K. HOSOHATA, T. MIYAMOTO, N. EGASHIRA, T. NAKAMURA, K. AKASHI, I. IEIRI ( <i>Osaka; Kyoto; Fukuoka, Japan</i> ) .....	2053
The Significance of CD109 Expression in Oropharyngeal Squamous Cell Carcinoma. S. TSUTSUMI, K. MOMIYAMA, M. ICHINOE, T. KATO, S. MOGI, S. MIYAMOTO, Y. MURAKUMO, T. YAMASHITA ( <i>Sagamihara, Japan</i> ) .....	2061
Elevated Preoperative DUPAN-2 Level Predicts Locoregional Recurrence After Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma. A. SASAKI, S. INOKUCHI, S. TSUTSUMI, T. FUTSUKAICHI, T. TERASHI, M. IKEBE, T. BANDO, T. UTSUNOMIYA ( <i>Oita, Japan</i> ).....	2071
Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence. M. TANAKA, S.-I. YAMASHITA, Y. YOSHINAGA, Y. ENOMOTO, Y. NOHARA, S. ONO, K. NABESHIMA, A. IWASAKI, T. SATO ( <i>Fukuoka; Chikushino, Japan</i> ).....	2079
Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients. Y. SADAKA, M. SODA, A. HORI, Y. MIYAHARA, Y. OIDA, Y. NISHIGAKI, E. TOMITA, T. MIZUI, K. KITAICHI ( <i>Gifu, Japan</i> ).....	2087
Clinical Outcomes of Radiotherapy in Elderly and Younger Patients With T4 Esophageal Cancer: A Retrospective Single-center Analysis. Y. TAKAKUSAGI, K. KANO, S. SHIMA, K. TSUCHIDA, N. MIZOGUCHI, H. KATOH, T. KAMADA, R. TANIUCHI, M. IINO, T. AOSHIKA, S. SAITO, D. YOSHIDA ( <i>Kanagawa; Saitama, Japan</i> ) ...	2095
Influence of the Coronavirus Disease 2019 Vaccine on Drug Therapy for Urological Cancer. S. KAWAGUCHI, K. IZUMI, S. KADOMOTO, H. IWAMOTO, H. YAEGASHI, M. IJIMA, T. NOHARA, K. SHIGEHARA, Y. KADONO, A. MIZOKAMI ( <i>Kanazawa, Japan</i> ) .....	2105
Predictors of Lateral Pelvic Lymph Node Metastasis in Advanced Low Rectal Cancer Treated With Neoadjuvant Chemotherapy. T. ISHIZAKI, K. KATSUMATA, M. ENOMOTO, J. MAZAKI, R. UDO, T. TAGO, K. KASAHARA, H. KUWABARA, Y. NAGAKAWA, A. TSUCHIDA ( <i>Tokyo, Japan</i> ).....	2113
Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. M. FUJIWARA, R. FUJIWARA, T. OGUCHI, Y. KOMAI, N. NUMAO, S. YAMAMOTO, J. YONESE, T. YUASA ( <i>Tokyo, Japan</i> ) .....	2123
Significance of Altered Fatty Acid Transporter Expressions in Uterine Cervical Cancer and Its Precursor Lesions. J. AN, H.E. OH, H. KIM, J.-H. LEE, E.S. LEE, Y.-S. KIM, J.-W. CHOI ( <i>Seoul; Ansan, Republic of Korea</i> ).....	2131
Clavicle Pro Humero Reconstruction for Malignant Tumor of the Proximal Humerus in Children and Adults. H. KINOSHITA, H. KAMODA, Y. HAGIWARA, T. ISHII, S. OHTORI, T. YONEMOTO ( <i>Chiba, Japan</i> ) .....	2139
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring <i>EGFR</i> Mutations. C.-H. CHEN, J.W.-C. CHANG, C.-F. CHANG, C.-Y. HUANG, C.-T. YANG, C.-H.S. KUO, Y.-F. FANG, P.-C. HSU, C.-E. WU ( <i>Taoyuan, Taiwan, ROC</i> ).....	2145
Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy. H.L. PARK, B. YANG, J.E. SHIN, J.-Y. KIM, J.Y. SHIN, E. SHIN, S. NOH, J.H. KIM ( <i>Seoul, Republic of Korea</i> ).....	2159

Treatment Outcomes in Neuroendocrine Prostate Cancer. H. IWAMOTO, R. NAKAGAWA, T. MAKINO, S. KADOMOTO, H. YAEGASHI, T. NOHARA, K. SHIGEHARA, K. IZUMI, Y. KADONO, A. MIZOKAMI (Kanazawa, Japan) .....	2167
The Significance of Surgical Intervention for Metasynchronous Liver Metastasis in Gastric Cancer: A Single-centre Analysis. T. HANAKI, T. SUNAGUCHI, K. GOTO, M. MORIMOTO, Y. MURAKAMI, Y. SHISHIDO, K. MIYATANI, K. KIHARA, T. MATSUNAGA, M. YAMAMOTO, N. TOKUYASU, T. SAKAMOTO, T. HASEGAWA, Y. FUJIWARA (Yonago, Japan) .....	2177
Tumor Size Significantly Affects Prognosis in Pathological T3a Renal Cell Carcinoma. G.-S. LAI, J.-R. LI, S.-S. WANG, C.-S. CHEN, C.-K. YANG, S.-C. HUNG, C.-L. CHENG, Y.-C. OU, K.-Y. CHIU (Taichung; Nantou, Taiwan, ROC).....	2185
Abstracts of the Joint International Symposia “Vitamin D in Prevention and Therapy” and “Biologic Effects of Light”, 4-6 May, 2022 (Homburg/Saar, Germany) .....	2193
Corrigendum.....	2223

## Number 5, May

### Reviews

Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions. T. SURSAL, J.S. RONECKER, A.J. DICPINIGAITIS, A.L. MOHAN, M.E. TOBIAS, C.D. GANDHI, M. JHANWAR-UNIYAL (Valhalla, NY, USA).....	2225
Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC. M. BASSANELLI, S. RAMELLA, M. ZEULI, A. CERIBELLI (Rome; Rieti, Italy).....	2241
Exosomal Functional Cargoes from Liquid Biopsy of Gastric Cancer: A Systematic Review of Studies With Potential Clinical Relevance. E. VIRGILIO, F. MONTALI, A. ANNICCHIARICO, C. SALVEMINI, M. BALDINU, E. GIARNIERI, M. MONTAGNINI, S. VILLANI, A. PROIETTI, R. D’URSO, R. COSTI (Parma; Fidenza; Rome, Italy).....	2249
The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer. C. ACHILLA, T. PAPAVERAMIDIS, L. ANGELIS, A. CHATZIKYRIAKIDOU (Thessaloniki, Greece).....	2261

### Experimental Studies

The <i>MDM2</i> and <i>CDKN2A</i> Copy-number-variation Influence the <i>TP53</i> -signature-score in Wild-type <i>TP53</i> Luminal Type Breast Cancer. M. HAN, S. YAMAGUCHI, M. ONISHI, T. FUJII, M. HOSOYA, X. WEN, H. KIDO, S. KATO (Tokyo, Japan) .....	2277
Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer. R. KLIMAITE, M. KAZOKAITE, A. KONDROTIENE, D. DAUKSIENE, R. VERKAUSKIENE, B. ZILAITIENE, A. DAUKSA (Kaunas, Lithuania) .....	2289
Dimethyl Fumarate Induces Apoptosis <i>via</i> Inhibiting NF- $\kappa$ B and STAT3 Signaling in Adult T-cell Leukemia/Lymphoma Cells. T. MAETA, T. SATO, K. ASANO, S. ITO (Iwate, Japan) .....	2301
Pathological Significance and Prognostic Role of <i>WWC1</i> in Upper Urinary Tract Urothelial Cancer. H. KURATA, K. MITSUNARI, T. KONDO, M. MASATO, H. ITO, Y. MUKAE, Y. NAKAMURA, T. MATSUO, K. OHBA, Y. MOCHIZUKI, H. SAKAI, Y. MIYATA (Nagasaki, Japan) .....	2311

Expression of <i>ENO1</i> Is Up-regulated in Low-grade Glioma and Positively Correlated With Meningioma Grade. D.T.D. DINH, S. KUHL, L. GÖRTZ, R. GOLDBRUNNER, M. TIMMER (Cologne, Germany) .....	2319
ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors. R.E. FRIEDRICH, L.K.N. NÖRNBERG, C. HAGEL (Hamburg; Gießen, Germany) .....	2327
Guanylate-binding Protein 2 Is Associated With Poor Survival and Malignancy in Clear-cell Renal Cell Carcinoma. Q. LIU, R.M. HOFFMAN, J. SONG, S. MIAO, J. ZHANG, D. DING, D. WANG (Chongqing; Zhengzhou, PR China; San Diego; La Jolla, CA, USA).....	2341
Investigating miRNA-related Pathways Contributing to Kidney Cancer Pathogenesis. P. YOUSEF, R. IBRAHIM, C. BOULOS, Z. KHATAB, M. PASIC, A. KRIZOVA (Toronto, ON, Canada) .....	2355
Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an <i>In Vitro</i> Model of Colorectal Carcinoma. G. PETRAKIS, T. MANTSO, M.I. KOUKOURAKIS, M.I. PANAYIOTIDIS, S. BOTAITIS (Chania; Alexandroupolis, Greece; Newcastle Upon Tyne, UK; Nicosia, Cyprus) .....	2363
Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan. M.-H. WU, C.-H. CHEN, C.-P. CHEN, T.-L. HUANG, T.-C. YUEH, Z.-H. WANG, C.-W. TSAI, J.-S. PEI, M.-C. MONG, Y.-C. YANG, D.-T. BAU, W.-S. CHANG (Taichung; Taipei; Taoyuan, Taiwan, ROC) .....	2375
Tumor-infiltrating ICOS <sup>+</sup> Effector Regulatory T-Cells in Oral Squamous Cell Carcinoma as a Promising Biomarker for Prognosis and ‘Hot’ Tumor. H. KAJIKAWA, M. HIRATA, M. HARUNA, A. UEYAMA, K. HIROSE, A. KAWASHIMA, K. IWAHORI, K. MATSUNAGA, S. TOYOSAWA, N. UZAWA, H. WADA (Suita; Toyonaka, Japan) .....	2383
Optimal Organ for Patient-derived Xenograft Model in Pancreatic Cancer and Microenvironment that Contributes to Success. S. EGUCHI, K. KIMURA, K. KAGEYAMA, N. TANI, R. TANAKA, K. NISHIO, H. SHINKAWA, G. OHIRA, R. AMANO, S. TANAKA, A. YAMAMOTO, S. TAKEMURA, M. YASHIRO, S. KUBO (Osaka, Japan).....	2395
The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases. C. DOLL, C. STEFFEN, B. BECK-BROICHSITTER, M. RICHTER, K. NEUMANN, A. POHRT, P. LOHNEIS, A. LEHMANN, M. HEILAND, C. STROMBERGER, A. COORDES, K. JOHRENS, J.-D. RAGUSE (Berlin; Stuttgart; Cologne; Dresden; Münster, Germany) .....	2405
Copenhagen Rats Display Dominantly Inherited Yet Non-uniform Resistance to Spontaneous, Radiation-induced, and Chemically-induced Mammary Carcinogenesis. M. NISHIMURA, T. IMAOKA, K. DAINO, Y. NISHIMURA, T. KOKUBO, M. TAKABATAKE, S. KAKINUMA, Y. SHIMADA (Chiba; Tokyo; Aomori, Japan) .....	2415
The Effect of Asparagus Extract on Pancreatic Cancer: An Intriguing Surprise. H. XIAO, Z. DENG, J.T. HOUGH, X. CHEN, Z. ZHU, J. LEE, A. DOMINGUEZ, T. SHI, J. SCHMIDT, Q. BAI, M.R. WAKEFIELD, Y. FANG (Chenzhou; Shenzhen, PR China; Des Moines, IA; Columbia, MO, USA) .....	2425
Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance. Y. OH, J.-S. LEE, J.S. LEE, J.H. PARK, H.S. KIM, S. YOON (Suwon, Republic of Korea).....	2433
Expression of LncRNAs in HPV-induced Carcinogenesis and Cancer Cachexia: A Study in K14-HPV16 Mice. T.R. DIAS, J.M.O. SANTOS, D. ESTÊVÃO, N.R. COSTA, V.F. MESTRE, B. MEDEIROS-FONSECA, M.M.S.M. BASTOS, P.A. OLIVEIRA, R.M.G. DA COSTA, R. MEDEIROS (Porto; Vila Real, Portugal; São Luís, Brazil) .....	2443



Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer. H. SONODA, C. KITAMURA, K. KANO, H. ANZAI, Y. NAGAI, S. ABE, Y. YOKOYAMA, H. ISHII, J. KISHIKAWA, K. MURONO, S. EMOTO, K. SASAKI, K. KAWAI, H. NOZAWA, J. AOKI, S. ISHIHARA ( <i>Tokyo, Japan</i> ) .....	2461
First Human Cell Experiments With FLASH Carbon Ions. M. TASHIRO, Y. YOSHIDA, T. OIKE, M. NAKAO, K. YUSA, Y. HIROTA, T. OHNO ( <i>Gunma, Japan</i> ) .....	2469
Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy. C.-H. HSIEH, C.-T. YEH, Y.-H. HUANG, M.-W. LAI ( <i>Taoyuan, Taiwan, ROC</i> ).....	2479
Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells. T.-S. HUANG, J.-J. LEE, S.-Y. HUANG, S.-P. CHENG ( <i>Taipei; New Taipei City, Taiwan, ROC</i> ).....	2487
Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib. C.-J. YANG, M.-H. WU, J.-J. TSAI, F.-T. HSU, T.-C. HSIA, K.-C. LIU, Y.-C. KUO ( <i>Changhua; Yilan; Taipei; New Taipei City; Taichung; Hsinchu, Taiwan, ROC</i> ) .....	2495
<i>Clinical Studies</i>	
Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis – A Prospective Three-year Study. S.S. TUOHINEN, T. SKYTÄ, H. HUHTALA, V. VIRTANEN, P.-L. KELLOKUMPU-LEHTINEN, P. RAATIKAINEN ( <i>Helsinki; Tampere, Finland</i> ) .....	2507
A Higher Mean Heart Radiation Dose Induces Higher Frequency of Multiple Cardiac Changes. S.S. TUOHINEN, H. AULA, T. SKYTÄ, H. HUHTALA, K. KESKI-PUKKILA, K. NIKUS, V. VIRTANEN, P.-L. KELLOKUMPU-LEHTINEN, P. RAATIKAINEN ( <i>Helsinki; Tampere; Seinäjoki, Finland</i> ) .....	2519
Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes. S. KUNTE, J. SHARETT, W. WEI, C. NASR, B. PRENDES, E. LAMARRE, J. KU, R.R. LORENZ, J. SCHARPF, B.B. BURKEY, A. SHAH, N. JOSHI, J.L. GEIGER ( <i>Cleveland, OH; Spokane, WA; Chicago, IL, USA</i> ) .....	2531
Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer. M. ASP, S. MALANDER, J. BENGTSSON, H. SARTOR, P. KANNISTO ( <i>Lund, Sweden</i> ).....	2541
Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer. P. REINIKAINEN, M. KAPANEN, T. LUUKKAALA, P.-L. KELLOKUMPU-LEHTINEN ( <i>Tampere, Finland</i> ) .....	2553
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease. Y. KUBOTA, Q. HAN, C. HOZUMI, N. MASAKI, J. YAMAMOTO, Y. AOKI, T. TSUNODA, R.M. HOFFMAN ( <i>San Diego, CA, USA; Tokyo; Narita, Japan</i> ) .....	2567
Surgical Indications for Huge Hepatocellular Carcinoma. T. KUMAMOTO, R. MATSUYAMA, K. TAKEDA, Y. SAWADA, K. SAHARA, D. MORIOKA, S.-C. LUO, Y. YABUSHITA, Y. HOMMA, I. ENDO ( <i>Yokohama, Japan; Taichung, Taiwan, ROC</i> ) .....	2573
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for <i>EGFR</i> -mutated Non-small Cell Lung Cancer. T. SHIOZAWA, T. NUMATA, T. TAMURA, T. ENDO, T. KABURAGI, Y. YAMAMOTO, H. YAMADA, N. KIKUCHI, K. SAITO, M. INAGAKI, K. KURISHIMA, Y. FUNAYAMA, K. MIYAZAKI, N. KOYAMA, K. FURUKAWA, H. NAKAMURA, S. KIKUCHI, H. ICHIMURA, Y. SATO, I. SEKINE, H. SATOH, N. HIZAWA ( <i>Tsukuba; Mito; Kasama; Hitachi; Hitachinaka; Tsuchiura; Ryugasaki; Saitama; Ami, Japan</i> ).....	2583
Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study. M. TAKEMURA, K. IKEMURA, T. YOSHINAMI, Y. TOYOZUMI, T. SHINTANI, M. UEDA, K. SHIMAZU, M. OKUDA ( <i>Suita, Japan</i> ) .....	2591

p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening. M. MAGKANA, P. MENTZELOPOULOU, E. MAGKANA, A. PAMPANOS, N. VRACHNIS, E. KALAFATI, G. DASKALAKIS, E. DOMALI, N. THOMAKOS, A. RODOLAKIS, N.P. ANAGNOU, K.I. PAPPA ( <i>Athens, Greece</i> ) .....	2599
Posterior-Anterior Cephalometric Study of Neurofibromatosis Type 1 Patients With Facial Plexiform Neurofibroma: Analysis of Skeletal Symmetry Concerning Midfacial and Skull Base Reference Points (Zygomatic Arch, Mastoid, and Juga). R.E. FRIEDRICH, G. CHRIST, H.A. SCHEUER ( <i>Hamburg, Germany</i> ) .....	2607
Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer. S. SATO, Y. MIKAYAMA, M. SHIOZAWA, S. NUKADA, K. IGUCHI, H. OKAMOTO, T. KOHMURA, K. KAZAMA, K. TANAKA, T. OSHIMA, Y. RINO ( <i>Yokohama, Japan</i> ) .....	2625
Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer. S. TATE, K. NISHIKIMI, A. MATSUOKA, S. OTSUKA, M. SHOZU ( <i>Chiba, Japan</i> ) ....	2637
Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma. T. FURUKAWA, M. TAKAMATSU, Y. INOUE, T. OKAMOTO, T. MIE, Y. YAMADA, T. TAKEDA, A. KASUGA, M. MATSUYAMA, T. SASAKI, M. OZAKA, A. OBA, H. ITO, Y. ONO, T. SATO, Y. TAKAHASHI, A. SAIURA, N. SASAHIRA ( <i>Tokyo, Japan</i> ) .....	2645
Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers. B. WARWAS, F. CREMERS, K. GERULL, A. LEICHTLE, K.L. BRUCHHAGE, S.G. HAKIM, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	2657
Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma. M.H. WANG, W. ROA, K. WACHOWICZ, A. YAHYA, A. MURTHA, J. AMANIE, J. CHAINEY, H. QUON, S. GHOSH, S. PATEL ( <i>Edmonton; Calgary, Canada</i> ).....	2665
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. H. TANIOKA, K. SHIMADA, A. TSUJI, M. KOCHI, H.M. KIM, T. TAKAHASHI, T. DENDA, A. TAKAGANE, T. WATANABE, M. KOTAKA, M. NAKAMURA, Y. SUNAKAWA, M. TAKEUCHI, W. ICHIKAWA, M. FUJII ( <i>Kurashiki; Tokyo; Kida; Itami; Gifu; Chiba; Hakodate; Himeji; Kobe; Matsumoto; Kawasaki; Yokohama, Japan</i> ).....	2675
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial. K. CHIN, D. TAKAHARI, R. KAWABATA, H. HOSAKA, S. SAITOU, T. SHIRAISHI, H. YABUSAKI, M. GOTO, M. NAKAMURA, H. IMAMURA, Y. SHINDO, F. NAGASHIMA, W. ICHIKAWA, T. SAOTOME, W. YAMAMOTO, N. ISHIZUKA, K. YAMAGUCHI ( <i>Tokyo; Osaka; Gunma; Aomori; Ehime; Niigata; Osaka; Nagano; Akita; Yokohama; Chiba, Japan</i> ).....	2683
Association Between PD-L1 and Histatin1, 3 Expression in Advanced Head and Neck Squamous Cell Carcinoma. W. WONGPANUWICH, S. YODSANGA, R. CHAISUPARAT, P. AMORNPHIMOLTHAM ( <i>Bangkok, Thailand</i> ).....	2689
Repeated Stereotactic Body Radiotherapy for Lung Malignancies: Toxicity Can Be Reduced by Sparing Lung Irradiation. S. WATANABE, H. YAMAZAKI, T. KIMOTO, G. SUZUKI, K. YAMADA ( <i>Kyoto, Japan</i> ) .....	2701
The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment. T. AOYAMA, M. JU, K. KOMORI, H. TAMAGAWA, A. TAMAGAWA, Y. MAEZAWA, I. HASHIMOTO, K. KANO, K. HARA, H. CHO, K. SEGAMI, D. MACHIDA, M. NAKAZONO, T. OSHIMA, N. YUKAWA, Y. RINO ( <i>Yokohama; Tokyo, Japan</i> ).....	2711
Usefulness of Surgical Staging of Gastric Cancer in Neoadjuvant Chemotherapy Candidates: A Single-center Retrospective Study. K. KOMORI, K. KANO, T. YAMADA, H. WATANABE, K. TAKAHASHI, Y. MAEZAWA, H. FUJIKAWA, M. NUMATA, T. AOYAMA, H. TAMAGAWA, N. YUKAWA, Y. RINO, M. MASUDA, T. OGATA, T. OSHIMA ( <i>Yokohama, Japan</i> ) .....	2719



Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma. S. SHIROTAKE, Y. MIYAMA, Y. BABA, H. TAJIMA, Y. OKADA, K. NAKAZAWA, Y. USAMI, M. YASUDA, D. IGARASHI, G. KANEKO, K. KANAO, M. OYAMA, K. NISHIMOTO ( <i>Hidaka, Japan</i> ).....	2727
Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System. M. KASHIWAGI, T. SHIMIZU, R. KAWAI, T. KAWASHIRI, Y. UESAWA, M. UCHIDA ( <i>Kyotanabe; Kobe; Fukuoka; Kiyose, Japan</i> ) .....	2737
Diversified Effects of Bile Contamination, Postoperative Infections, and Antimicrobial Resistance Level on the Oncologic Prognosis After Pancreatoduodenectomy for Ductal Adenocarcinoma. L. GIANOTTI, K.C. HONSELMANN, M. ANGRISANI, F. GAVAZZI, T. KECK, U. WELLNER, L. BOLM, N. PETRUCH, G. CAPRETTI, G. NAPPO, D.P. BERNASCONI, M. SANDINI, A. ZERBI ( <i>Monza; Rozzano; Siena, Italy; Luebeck, Germany</i> ).....	2743
High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma. Y. CHUNG, S. KIM, H.-S. KIM, S.-I. DO ( <i>Seoul, Republic of Korea</i> ).....	2753
Impact of Infectious Complications on Survival and Recurrence of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study. H. TAMAGAWA, T. AOYAMA, M. NUMATA, K. KAZAMA, Y. ATSUMI, K. IGUCHI, M. JU, S. SAWAZAKI, S. SATO, K. KANO, T. OHSHIMA, T. YAMADA, T. GODAI, A. HIGUCHI, H. SAEKI, N. YUKAWA, Y. RINO ( <i>Yokohama; Fujisawa, Japan</i> ) .....	2763
Handgrip Strength Predicts Poorly the Surgical Outcome or Length of Hospitalization in Patients With Surgically Operated Oral Cancer. J. SUOJANEN, S. KAINULAINEN, L. TARVAINEN, J. TORNWALL, T. WILKMAN ( <i>Lahti; Helsinki, Finland</i> ) .....	2771
Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma. T. KATO, T. OSHIKIRI, H. GOTO, R. SAWADA, H. HARADA, N. URAKAWA, H. HASEGAWA, S. KANAJI, K. YAMASHITA, T. MATSUDA, Y. KAKEJI ( <i>Hyogo, Japan</i> ) .....	2775
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study. K. OKAMOTO, I. NINOMIYA, H. SAITO, M. SHIMADA, T. YAMAGUCHI, S. TERAJ, H. MORIYAMA, J. KINOSHITA, K. NAKAMURA, N. INAKI ( <i>Kanazawa, Japan</i> ).....	2783
Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma. M. EMI, Y. HMAI, T. YOSHIKAWA, R. HIROHATA, M. OSAWA, M. OKADA, Y. MURAKAMI, I. NISHIBUCHI ( <i>Hiroshima, Japan</i> ) .....	2791
Prognostic Value of the Regional Lymph Node Station in Pancreatic Neuroendocrine Tumor. K. TAKAGI, Y. UMEDA, R. YOSHIDA, K. YOSHIDA, T. FUJI, K. KUMANO, K. YASUI, T. YAGI, T. FUJIWARA ( <i>Okayama, Japan</i> ).....	2797
Corrigendum.....	2803

## Number 6, June

### Reviews

Adverse Events in Placebo Arms of Cancer Trials. J.E. WOLFF, B.J. WOLFF, M.M. THIELEN, H. HAUCH ( <i>North Chicago; Chicago, IL, USA; Hesse, Germany</i> ) .....	2805
The Role of Toll-like Receptors in Esophageal Cancer. S. DAVAKIS, A. KAPELOUZOU, T. LIAKAKOS, M. MPOURA, D. STERGIOU, S. SAKELLARIOU, A. CHARALABOPOULOS ( <i>Athens, Greece</i> ).....	2813

*Experimental Studies*

Cell Dissociation Enzymes Affect Annexin V/Flow-Cytometric Apoptotic Assay Outcomes After miRNA-based Transient Transfection. C.M. GOBIN, J.N. MENEFEFEE, C.C. LATTIMORE, A. DOTY, K.M. FREDENBURG (*Gainesville, FL, USA*) ..... 2819

Altered mRNA Expression Due to Rectal Perforation in a Porcine Model – A Pilot Study. I. OIKONOMAKIS, D. BRODIN, T.M. HÖRER, P. SKOOG, J. SEILITZ, K.F. NILSSON, A.D. MEEHAN, K. JANSSON (*Örebro; Stockholm; Gothenburg, Sweden*) ..... 2827

Isoprenylated Coumarin Exhibits Anti-proliferative Effects in Pancreatic Cancer Cells Under Nutrient Starvation by Inhibiting Autophagy. R. ZHOU, E. KUSAKA, Y. WANG, J. ZHANG, A. WEBB, D. CARRICO-MONIZ (*Wellesley, MA, USA*) ..... 2835

Preparation of Micelles Encapsulating Doxorubicin and Their Anticancer Effect in Combination With Tranilast in 3D Spheroids and *In Vivo*. T. NII, K. YOSHIKAWA, I. TAKEUCHI, K. MAKINO (*Fukuoka; Noda; Togane, Japan*) ..... 2847

Effect of Eribulin on Angiogenesis and the Expression of Endothelial Adhesion Molecules. A. ABBONA, M. PACCAGNELLA, S. ASTIGIANO, S. MARTINI, N. DENARO, F. RUATTA, O. BARBIERI, M. MERLANO, O. GARRONE (*Cuneo; Genova; Candiolo; Milan, Italy*) ..... 2859

PTPN3 Could Be a Therapeutic Target of Pancreatic Cancer. H. ONISHI, N. IWAMOTO, K. SAKANASHI, S. KOGA, Y. OYAMA, K. YANAI, K. NAKAMURA, S. NAGAI, A. FUJIMURA, K. NAKAYAMA, K. OZONO, A. YAMASAKI (*Fukuoka, Japan*) ..... 2869

Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma. K. ITO, H. ISHIDA, F. FUJISHIMA, Y. NAKAMURA, T. KONNO, K. ISE, S. HATA, Y. OZAWA, Y. TANIYAMA, T. KAMEI, H. SASANO (*Sendai, Japan*) ..... 2875

Feasibility of Gastric Tumor Xenograft (GTX)-derived Cell Lines for Individualized Anti-cancer Drug Screening. S.E. OH, M.Y. OH, S.M. KIM, S.Y. KIM, J.Y. AN, J.H. LEE, T.S. SOHN, J.M. BAE, M.-G. CHOI (*Seoul; Seongnam, Republic of Korea*) ..... 2883

DNMT1 Expression and DNA Methylation in Intraductal Papillary Neoplasms of the Bile Duct. R. DOI, Y. FUKUMURA, R. LU, K. HIRABAYASHI, Y. KINOWAKI, Y. NAKANUMA, Y. KANAI, J. NAKAHODO, N. SASAHARA, T. SAITO, T. YAO (*Tokyo; Kanagawa; Fukui, Japan*) ..... 2893

Mangosteen Inhibits Growth and Survival of Cervical Cancer Cells. N.T. GIVENS, L. ZHAO, Z. ZHU, M. LEQUIO, H. XIAO, B.D. JOHNSON, Q. BAI, M.R. WAKEFIELD, Y. FANG (*Des Moines, IA; Columbia, MO, USA; Hefei, PR China*) ..... 2903

Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance *via* Inhibition of RAF Dimerization in PLX4032-resistant Melanoma. M. POUDEL, G. KIM, P.Y. BHATTARAI, S. SHIN, S.-O. ZARAEI, C.-H. OH, H.S. CHOI (*Gwangju; Seoul, Republic of Korea*) ..... 2911

LXR $\beta$  Activation Inhibits the Proliferation of Small-cell Lung Cancer Cells by Depleting Cellular Cholesterol. K. KASHIWAGI, H. SATO-YAZAWA, J. ISHII, K. KOHNO, I. TATSUTA, T. MIYAZAWA, M. TAKAGI, H. CHIBA, T. YAZAWA (*Mibu; Itakura-machi; Fukushima, Japan*) ..... 2923

Reactivation of p53 by RITA Induces Apoptosis in Human Oral Squamous Cell Carcinoma Cells. M. ENDO, T. NISHIOKA, K. NUMAZAKI, H. HASEGAWA, T. TAKAHASHI, S. SUGAWARA, H. TADA (*Sendai; Fukushima, Japan*) ..... 2931

*Clinical Studies*

Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre. R. SHAMAVONIAN, E. CHENG, J.B. KARPES, S. BARAT, N. AHMADI, D.L. MORRIS (*Kogarah; Sydney, NSW, Australia*) ..... 2939

Recurrent Mandibular Giant Cell Lesion in Neurofibromatosis Type 1: Second Hit Mutation on the *NF1* Gene in the Osseous Lesion. R.E. FRIEDRICH, A.M. LUEBKE, U. SCHÜLLER, C. HAGEL, F.K. KOHLRUSCH, I. WIELAND, M. ZENKER (*Hamburg; Magdeburg, Germany*) ..... 2945

Proton Beam Therapy in Elderly Patients With cT1-3N0M0 Non-small Cell Lung Cancer. M. NAKAMURA, H. ISHIKAWA, K. OHNISHI, K. BABA, T. SAITO, T. SUMIYA, M. MURAKAMI, Y. HIROSHIMA, K. NAKAI, M. MIZUMOTO, T. OKUMURA, H. SAKURAI (*Tsukuba; Chiba; Narita, Japan*) ..... 2953

Does the Use of BioZorb® Result in Smaller Breast Seroma Volume? Z.A. YEHA, J. YOON, M. SAYAN, S. KUMAR, L. HATHOUT, M. KOWZUN, L. POTDEVIN, M. GEORGE, B.G. HAFPTY, N. OHRI (*New Brunswick, NJ; Boston, MA, USA*) ..... 2961

Predictive Performance of Prospectively Applied ISUP and Fuhrman Grade in Nonmetastatic Renal Cell Carcinoma. K.F. GALTUNG, P.M. LAURITZEN, E. BACO, R.E. BERG, A.M. NAAS, E. RUD (*Oslo, Norway*) ..... 2967

Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer. E. BOOKA, H. KIKUCHI, R. HANEDA, W. SONEDA, S. KAWATA, T. MURAKAMI, T. MATSUMOTO, Y. HIRAMATSU, H. TAKEUCHI (*Shizuoka, Japan*) ..... 2977

Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System. Y. HIROSHIMA, Y. TAMAKI, T. SAWADA, T. ISHIDA, K. YASUE, K. SHINODA, T. SAITO, T. KABURAGI, M. KIYOSHIMA, T. OKUMURA, H. SAKURAI (*Ibaraki; Chiba, Japan*) ..... 2989

Early Versus Late Postoperative Radiotherapy in Patients With Prostate Cancer: Results of a Single-centre Retrospective Study. F. PASQUALETTI, E. CALISTRI, T. FUENTES, A. SAINATO, B. MANFREDI, R. MORGANTI, L. GALLI, C. MERCINELLI, E. SAMMARCO, D. BALDACCINI, G. CORAGGIO, M. PANICHI, P.A. ERBA, F. PAIAR (*Pisa; Milan, Italy; Creteil, France; Barcelona, Spain*) ..... 2997

Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study. D. MUSIO, M. DE VINCENTIIS, P. D'URSO, A. MUSACCHIO, V. MAIURI, L. ZACCARO, M. RALLI, C. MARCHETTI, R. TURCHETTA, V. TOMBOLINI, F. DE FELICE (*Rome, Italy*) ..... 3003

Detection Rate of <sup>68</sup>Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer. P. PEPE, L. PEPE, S. COSENTINO, M. IPPOLITO, M. PENNISI, F. FRAGGETTA (*Catania, Italy*) ..... 3011

Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer. T. OYAMA, Y. SHIMOJI, T. NAKASONE, Y. ARAKAKI, Y. TAIRA, T. NAKAMOTO, W. KUDAKA, Y. AOKI (*Okinawa, Japan*) ..... 3017

Risk Stratification of Postoperative Pneumonia in Patients Undergoing Subtotal Esophagectomy for Esophageal Cancer. K. TAKAHASHI, K. NISHIKAWA, Y. TANISHIMA, Y. ISHIKAWA, T. KUROGOCHI, M. YUDA, Y. TANAKA, A. MATSUMOTO, F. YANO, K. ETO (*Tokyo, Japan*) ..... 3023

Large Tumor Size and High Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis After Pneumonectomy or Sleeve Lobectomy in Patients With Non-small-cell Lung Cancer. T. TSUKIOKA, O. IZUMI, H. KOMATSU, H. INOUE, R. ITO, S. SUZUKI, N. NISHIYAMA (*Osaka, Japan*) ..... 3029

The First Prognostic Tool to Estimate the Risk of Late Grade $\geq 3$ Xerostomia in Patients Irradiated for Head-and-Neck Cancer. D. RADES, B. WARWAS, F. CREMERS, K. GERULL, R. PRIES, A. LEICHTLE, K.L. BRUCHHAGE, S.G. HAKIM, S.E. SCHILD ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	3035
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease. N. FUJIMOTO, A. MINATO, T. IGAWA, T. HIROSHIGE, W. OBARA, A. FUKUDA, Y. NAGATA, Y. MIZUSHIMA, I. TOMISAKI, K. HARADA ( <i>Kitakyushu; Kurume; Morioka; Yukuhashi; Fukutsu, Japan</i> ) .....	3041
The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience. M. HIDAKA, T. HARA, A. SOYAMA, R. SASAKI, H. MATSUSHIMA, T. TANAKA, T. HAMADA, H. IMAMURA, T. ADACHI, K. KANETAKA, H. MIYAAKI, S. OKANO, S. EGUCHI ( <i>Nagasaki, Japan</i> ) .....	3049
Preservation of Split Renal Function After Laparoscopic and Robot-assisted Partial Nephrectomy. K. OHBA, T. MATSUO, K. MITSUNARI, Y. NAKAMURA, H. NAKANISHI, Y. MOCHIZUKI, Y. MIYATA ( <i>Nagasaki, Japan</i> ) .....	3055
Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer. C. NIEDER, S.G. AANES, E.C. HAUKLAND ( <i>Bodø; Tromsø; Stavanger, Norway</i> ) ....	3061
The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC). S. TULYTE, D. CHARACIEJUS, R. MATUZEVICIENE, A. JANIULIONIENE, M. RADZEVICIUS, T. ZVIRBLIS, A. SILEIKIS ( <i>Vilnius, Lithuania</i> ) .....	3067
Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis. S. ROSENKAIMER, T. SIEBURG, L. WINTER, A. MAVRATZAS, W.-K. HOFMANN, R.-D. HOFHEINZ, I. AKIN, D. DUERSCHMIED, A. HOHNECK ( <i>Mannheim, Germany</i> ) .....	3075
Improvement of Sleep Disorders During a Course of Radiotherapy for Breast Cancer – Final Results of the Prospective Interventional RADIO-SLEEP Trial. D. RADES, C.A. NARVAEZ, L. DZIGGEL, L. SPLETTSTÖSSER, S. JANSSEN, D. OLBRICH, S.E. SCHILD, S. TVILSTED, T.W. KJAER ( <i>Lübeck, Germany; Scottsdale, AZ, USA; Køge; Roskilde, Denmark</i> ) .....	3085
Utility of Drain Fluid Culture and Gram Stain in Early Intervention for Occult Anastomotic Leakage in Colorectal Cancer. T. TOMINAGA, T. NONAKA, S. OYAMA, Y. TAKAMURA, S. HASHIMOTO, T. SHIRAIISHI, T. SAWAI, T. NAGAYASU ( <i>Nagasaki, Japan</i> ) .....	3091
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis. T. KAMIJIMA, H. YAEGASHI, A. MIZOKAMI, K. NAKAJIMA, H. MATSUYAMA, T. ICHIKAWA, K. NISHIMOTO, S. TAKAHASHI, H. SHIINA, H. HORIKOSHI, K. HASHINE, Y. SUGIYAMA, T. MIYAO, M. KAMIYAMA, K. HARADA, A. ITO, H. ENOKIDA ( <i>Kanazawa; Ube; Chiba; Saitama; Tokyo; Shimane; Ota; Matsuyama; Kumamoto; Maebashi; Yamanashi; Kobe; Yahaba; Kagoshima, Japan</i> ) .....	3099
Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database. J. SATO, M. UCHIDA, H. WAKABAYASHI, T. SHIMIZU ( <i>Nasushiobara; Kyotanabe; Kobe, Japan</i> ) .....	3109
Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy. A. UNO, S. YAMAMOTO, H. IIHARA, H. FUJII, C. MAKITA, Y. HAYASAKI, Y. UEDA, M. ITO, M. TAKENAKA, T. KUMANO, M. MORI, M. YASUE, H. KATO-HAYASHI, R. KOBAYASHI, K.-I. MORISHIGE, M. MATSUO, H. HAYASHI, A. SUZUKI ( <i>Gifu, Japan</i> ) .....	3117
Difference in the Overall Survival Between Malignant Central Airway Obstruction Patients Treated by Transbronchial Microwave Ablation and Stent Placement: A Single-institution Retrospective Study. K. KASHIWABARA, S. FUJII, S. TSUMURA, K. SAKAMOTO ( <i>Kumamoto, Japan</i> ) .....	3125

Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. H. MATSUSHIMA, T. ADACHI, M. HIDAKA, M. YAMASHITA, T. HAMADA, S. FUKUI, T. TANAKA, H. IMAMURA, K. YOSHINO, T. KUGIYAMA, A. KITASATO, T. HARA, A. SOYAMA, K. KOBAYASHI, Y. SUMIDA, T. KUROKI, S. EGUCHI ( <i>Nagasaki; Sasebo; Omura, Japan</i> ) ...	3133
Compartment-specific Clinical Outcomes in Patients With Soft Tissue Sarcomas of the Thigh. S. MORINAGA, A. TAKEUCHI, N. YAMAMOTO, K. HAYASHI, S. MIWA, K. IGARASHI, H. YONEZAWA, Y. ASANO, S. SAITO, T. NOJIMA, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ) .....	3143
Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment. H. TACHIBANA, T. INAKAWA, Y. NEMOTO, H. ISHIHARA, H. FUKUDA, K. YOSHIDA, J. IIZUKA, Y. HASHIMOTO, K. TANABE, T. KONDO, T. TAKAGI ( <i>Saitama; Tokyo, Japan</i> ).....	3151
Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes. R. NAKAMURA, S. YONEYAMA, R. TOBITA, S. KURIHARA, T. HATORI, T. NUMATA, K. OTA, H. YANAI, T. ENDO, Y. INADOME, H. SATOH, Y. INAGE ( <i>Ibarakimachi; Mito, Japan</i> ) .....	3159
The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma. S. MATSUI, Y. YAMAMOTO, Y. OKAMURA, T. ITO, R. ASHIDA, K. OHGI, M. YAMADA, S. OTSUKA, K. UESAKA, T. SUGIURA ( <i>Shizuoka; Kyoto; Aichi, Japan</i> ).....	3169
Preoperative S-1 Therapy for Head and Neck Carcinoma During the Waiting Period Before Surgery. T. MATSUKI, C. FUSHIMI, S. MIYAMOTO, H. TAKAHASHI, T. MASUBUCHI, Y. TADA, K. MIURA, S.-E. KAMATA, K. KANO, S. TSUTSUMI, K. MOMIYAMA, T. YAMASHITA ( <i>Sagamihara; Tokyo; Yokohama, Japan</i> ) .....	3177
Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method. Y. SAITO, Y. TAKEKUMA, M. KOBAYASHI, N. SHINAGAWA, T. NOGUCHI, S. TAKEUCHI, Y. SHIMIZU, I. KINOSHITA, H. DOSAKA-AKITA, M. SUGAWARA ( <i>Sapporo, Japan</i> ) .....	3185
Adjuvant Concurrent Chemoradiotherapy Versus Adjuvant Chemotherapy Only in Locally Advanced Non-small-cell Lung Cancer With Involved Microscopic Resection Margin: A Population-based Cohort Study. C.-Y. TU, H.-J. CHEN, T.-C. HSIA, H.-Y. FANG, C.-C. LI, C.-R. CHIEN ( <i>Taichung, Taiwan, ROC</i> ).....	3195
Contralateral Interhemispheric Transfalcine Approach for Supratentorial Extraventricular Ependymoma Resection. M. BALDONCINI, G. FERINI, G.E. UMANA, B. CHAURASIA, M.E. DEMICHELIS, J.F. VILLALONGA, P. PALMISCIANO, P. AMICO, S. LUZZI, D.O. PIPOLO, A. CAMPERO ( <i>Buenos Aires; Tucumán, Argentina; Viagrande; Catania; Ragusa; Pavia, Italy; Birgunj, Nepal</i> ) .....	3203
Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection. K. MATSUMURA, K. YAMAMURA, E. ODA, S. AKAHOSHI, T. ISHIKO, T. MIYATA, H. MIYAMOTO, T. MOTOHARA, A. SASAO, Y. KOMOHARA, H. KAWANO, T. BEPPU ( <i>Yamaga; Kumamoto; Tamana, Japan</i> ) .....	3209
Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours. D. BOLLER, K.T. DOEPFNER, A. DE LAURENTIIS, A.S. GUERREIRO, M. MARINOV, T. SHALABY, P. DEPLEGGE, A. ROBSON, N. SAGHIR, M. HAYAKAWA, H. KAIZAWA, T. KOIZUMI, T. OHISHI, S. FATTET, O. DELATTRE, A. SCHWERI-OLAC, K. HÖLAND, M.A. GROTZER, K. FREI, O. SPERTINI, M.D. WATERFIELD, A. ARCARO ( <i>Zurich; Bern; Lausanne, Switzerland; Berkshire; London, UK; Tsukuba, Japan; Paris, France</i> ) .....	3217
Corrigenda .....	3231



**Number 7, July**

*Reviews*

- Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical *In Vivo* Models of Esophageal Squamous Cell Cancer. U.H. WEIDLE, A. NOPORA (*Penzberg, Germany*) ..... 3233
- Intradural Extramedullary Spinal Metastases from Non-neurogenic Primary Tumors: A Systematic Review. P. PALMISCIANO, A.L. CHEN, M. SHARMA, O. BIN-ALAMER, G. FERINI, G.E. UMANA, S.G. AOUN, A.S. HAIDER (*Cincinnati, OH; Dallas; Houston, TX; Louisville, KY; Pittsburgh, PA, USA; Viagrande; Catania, Italy*)..... 3251
- Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art. E. DIMAKAKOS, G. GOMATOU, M. CATALANO, D.-M. OLINIC, A.C. SPYROPOULOS, A. FALANGA, A. MARAVEYAS, A. LIEW, S. SCHULMAN, J. BELCH, G. GEROTZIAFAS, P. MARSCHANG, B. COSMI, J. SPAAK, K. SYRIGOS (*Athens, Greece; Milan; Bergamo; Bolzano; Bologna, Italy; Cluj-Napoca, Romania; Hempstead; New York, NY, USA; Cottingham; Hull; Dundee, UK; Galway, Ireland; Hamilton, ON, Canada; Paris, France; Stockholm, Sweden*) ..... 3261
- Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets. N.O. SHAM, L. ZHAO, Z. ZHU, T.M. ROY, H. XIAO, Q. BAI, M.R. WAKEFIELD, Y. FANG (*Des Moines, IA; Columbia, MO, USA; Hefei, PR China*) ..... 3275
- Postoperative Pancreatic Fistula: Is Minimally Invasive Surgery Better than Open? A Systematic Review and Meta-analysis. N. PETRUCCIANI, A. CROVETTO, F. DE FELICE, M. PACE, D. GIULITTI, M. YUSEF, G. NIGRI, S. VALABREGA, R. KASSIR, F. D'ANGELO, T. DEBS, G. RAMACCIATO, P. AURELLO (*Rome, Italy; Nice; Saint Denis, France*) ..... 3285

*Experimental Studies*

- High Expression of *p62* and *ALDH1A3* Is Associated With Poor Prognosis in Luminal B Breast Cancer. A. OZAKI, H. MOTOMURA, S. TAMORI, C. ONAGA, Y. NAGASHIMA, M. KOTORI, C. MATSUDA, A. MATSUDA, N. MOCHIZUKI, T. SATO, Y. HARA, K. SATO, Y. MIYAGI, Y. NAGASHIMA, T. HANAWA, Y. HARADA, Y. XIONG, K. SASAKI, S. OHNO, K. AKIMOTO (*Chiba; Kanagawa; Tokyo, Japan*)..... 3299
- Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells. T. HIRAIDE, Y. MORITA, M. HORIKAWA, E. SUGIYAMA, T. SATO, T. KAHYO, S. FURUHASHI, M. TAKEDA, H. KIKUCHI, Y. HIRAMATSU, T. SAKAGUCHI, H. KONNO, M. SETOU, H. TAKEUCHI (*Hamamatsu; Hiroshima; Shizuoka; Iwata, Japan*) ..... 3313
- PI3K/Akt and Wnt/ $\beta$ -catenin Signaling Cross-regulate NF- $\kappa$ B Signaling in TNF- $\alpha$ -induced Human Lgr5<sup>+</sup> Intestinal Stem Cells. X. ZHAO, B. MA, H. ZHU, J. BAI, L. LIU, X. LI, J. CAI, B. WANG, L. WANG, Y. PANG, H. ZHANG, Y. YANG, N. LI, M. CHEN (*Xianyang; Xi'an, PR China; Baltimore, MD, USA*) ..... 3325
- Comparative Analysis of the Antitumor Immune Profiles of Paired Radiotherapy-naive and Radiotherapy-treated Cervical Cancer Tissues. A. IMAMURA, T. OIKE, H. SATO, Y. YOSHIMOTO, K. ANDO, T. OHNO (*Maebashi; Fukushima, Japan*) ..... 3341
- The Role of Inflammation-associated microRNA-4257 as a Promoter of Malignancy in Colorectal Cancer. S. KATAOKA, T. ARITA, H. KONISHI, Y. YAMAMOTO, R. SHIBATA, T. YAMAMOTO, J. SHIBAMOTO, H. FURUKE, K. TAKABATAKE, W. TAKAKI, J. KIUCHI, H. SHIMIZU, S. KOMATSU, A. SHIOZAKI, Y. KURIU, E. OTSUJI (*Kyoto, Japan*) ..... 3349
- SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study. T. KAJIYAMA, S. SERADA, M. FUJIMOTO, T. OHKAWARA, M. KOMORI, M. HYODO, T. NAKA (*Nankoku; Yahaba, Japan*) ..... 3361



Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis. C. NAKAYAMA, K. TANOUE, T. IDICHI, H. SHIMOMURA, Y. KITA, Y. HOZAKA, Y. SHINDEN, D. MATSUSHITA, A. NAKAJO, T. ARIGAMI, Y. MATAKI, H. KURAHARA, T. OHTSUKA ( <i>Kagoshima, Japan</i> ).....	3373
Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese. M.-F. WU, L.-H. CHEN, N.-Y. HSIA, Y.-C. SHEN, T.-C. SHEN, Z.-H. WANG, Y.-C. YANG, Y.-C. WANG, W.-S. CHANG, T.-C. HSIA, D.-T. BAU, C.-W. TSAI ( <i>Taichung; Taoyuan, Taiwan, ROC</i> ) .....	3381
Chlorogenic Acid Inhibition of Esophageal Squamous Cell Carcinoma Metastasis via EGFR/p-Akt/Snail Signaling Pathways. Y.-K. CHEN, N.T.M. NGOC, H.-W. CHANG, Y.-F. SU, C.-H. CHEN, Y.-G. GOAN, J.Y.-F. CHEN, C.-W. TUNG, T.-C. HOUR ( <i>Pingtung; Kaohsiung; Zhunan, Taiwan, ROC</i> ) .....	3389
Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression. L. HUBER, R. BIRK, M. KNUETTEL, N. ROTTER, C. ADERHOLD, C. SCHERL, A. LAMMERT, F. JUNGBAUER, B. KRAMER ( <i>Mannheim; Marburg, Germany</i> ) .....	3403
Valproic Acid Enhances Radiosensitization via DNA Double-strand Breaks for Boronophenylalanine-mediated Neutron Capture Therapy in Melanoma Cells. Z.-Y. LAI, D.-Y. LI, C.-Y. HUANG, K.-C. TUNG, C.-C. YANG, H.-M. LIU, F.-I. CHOU, Y.-J. CHUANG ( <i>Hsinchu; Taoyuan City; Taipei, Taiwan, ROC</i> ) .....	3413
Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells. Y.-C. SHEN, H.-J. SHIH, C.-C. LIN, S.-H. HUANG, S.-C. WU, C.-H. HSIAO, S.-C. CHIU, D.-Y. CHO, C.-P. CHANG, Y. PAN, P.-H. SHIH ( <i>Changhua; Taipei; Taichung; Kaohsiung, Taiwan, ROC</i> ).....	3427
The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1. D.S. LEE, S. LEE, C. KIM, D. KIM, K.-P. KIM, C. YOO ( <i>Seoul, Republic of Korea</i> ).....	3435
Up-regulation of CPNE1 Appears to Enhance Cancer Progression In HER2-positive and Luminal A Breast Cancer Cells. H.Y. CHOI, H.J. LEE, K.M. MOON, D.K. MOON, S. LEE, H. PARK, J. HONG, M.J. PARK, D.K. WOO, J.C. YOO ( <i>Jinju; Daejeon; Seoul, Republic of Korea</i> ) .....	3445
Antibody-immunotoxin Conjugate Using FcBP-mediated Photoconjugation to Treat Cancer. K.-H. KIM, J. PARK, J.-O. KIM, H.-J. KO, S.G. PARK ( <i>Suwon; Seongnam, Republic of Korea</i> ).....	3453
Enhanced Tumoricidal Immune Responses by Transarterial Chemotherapy Using Novel Nanocomplexes in a Rat Liver Cancer Model. B.-Y. KANG, S.M. KIM, W. HUR, P.R. ROH, J.W. HAN, P.S. SUNG, E. TAK, W.J. KIM, L. JIN, H.J. CHUN, S.K. YOON ( <i>Seoul; Chungbuk; Pohang, Republic of Korea</i> ).....	3463
Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition. Y.J. KIM, S.-E. HONG, S.-K. JANG, K.S. PARK, C.-H. KIM, I.-C. PARK, H.-O. JIN ( <i>Seoul, Republic of Korea</i> ) .....	3475
Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient. M.E.M. SAEED, A.I. DRIF, T. EFFERTH ( <i>Mainz, Germany</i> ) .....	3483
Hydroxychloroquine Promotes Bcl-xL Inhibition-induced Apoptosis in BxPC-3 Human Pancreatic Cancer Cells. M.M. HOQUE, Y. IIDA, H. KOTANI, I.D. KARTIKA, M. HARADA ( <i>Shimane, Japan; Sulawesi, Indonesia</i> ) .....	3495
Comparative Proteomic Profiling of Cisplatin-resistant Nasopharyngeal Carcinoma Cell Lines: Novel Biomarkers for Improving Chemotherapy of NPC. P. PRATHAPHAN, O. REAMTONG, U. NGAOKRAJANG, T. JANVILISRI, N.M. SWAINSON, P. KIATWUTHINON ( <i>Bangkok, Thailand</i> ) .....	3507

*Clinical Studies*

Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation. J.M. HUDSON, S. SINGH, L. MILOT, C. PATEL, C. BAILEY, V. RODRIGUEZ-FREIXINOS, D. CHAN, J. HALLET, C. LAW, S. MYREHAUG (*Toronto, ON, Canada; Lyon, France; St. Leonards, NSW, Australia*) ..... 3523

Long-term Outcomes of Radiation Therapy for Prostate Cancer in Elderly Patients Aged  $\geq 75$  Years. E. NAKANISHI, T. HIRATA, K. TAMARI, F. ISOHASHI, O. SUZUKI, K. HAYASHI, Y. SEO, Y. AKINO, Y. FUMIMOTO, K. HATANO, A. KAWASHIMA, M. UEMURA, S. SHIMIZU, N. NONOMURA, K. OGAWA (*Osaka, Japan*) ..... 3529

Characterization of the Immunological Status of Hypermutated Solid Tumors in the Cancer Genome Analysis Project HOPE. Y. AKIYAMA, R. KONDOU, A. IIZUKA, H. MIYATA, C. MAEDA, A. KANEMATSU, T. ASHIZAWA, T. NAGASHIMA, K. URAKAMI, Y. SHIMODA, K. OHSHIMA, A. SHIOMI, Y. OHDE, M. TERASHIMA, K. UESAKA, Y. HIRASHIMA, Y. KIYOHARA, H. KATAGIRI, T. SUGINO, A. NOTSU, K. MORI, M. TAKAHASHI, H. KENMOTSU, K. YAMAGUCHI (*Shizuoka; Tokyo, Japan*)..... 3537

Impact of Dose-Volume Parameters of Parotid Glands on Xerostomia in Patients Irradiated for Head-and-Neck Cancer. D. RADES, B. WARWAS, F. CREMERS, K. GERULL, C. IDEL, K.L. BRUCHHAGE, S.G. HAKIM, S.E. SCHILD (*Lübeck, Germany; Scottsdale, AZ, USA*) ..... 3551

Site-specific Performance of ColonView (CV) Fecal Immunochemical Test (FIT) With Differences Between Proximal and Distal Colorectal Adenoma. M. ESKELINEN, J. MEKLIN, D.P. GUIMARAES, T. SELANDER, T. TIUSANEN, K. SYRJÄNEN, M. ESKELINEN (*Kuopio; Helsinki; Kaarina, Finland; Barretos, Brazil*) ..... 3557

Can We Predict a Higher Risk of Urothelial Bladder Cancer With a Simple Blood Test? B. WALLACE, S. DEKALO, M. KABHA, I. MINTZ, H. MATZKIN, N.J. MABJEESH (*London, ON, Canada; Tel Aviv; Beer Sheva, Israel*) ..... 3569

Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database. J. SATO, K. NAKANO, T. SHIMIZU, M. UCHIDA (*Nasushiobara; Ootawara; Kyotanabe; Kobe, Japan*) ..... 3575

Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy. H. VEYSSIÈRE, G. ALDARAZI, I. MOLNAR, X. DURANDO, N. RADOSEVIC-ROBIN (*Clermont-Ferrand, France*)..... 3583

Polyserositis as a Unique Presentation of Isolated Myeloid Sarcoma: A Case Report. P. ASAWA, U. VUSQA, K. VASHISTHA, M. TANVEER UD DIN, R. KARNA, F. CHEN, N. DUTTON, Y. SAMHOURI, S. FAZAL (*Pittsburgh, PA, USA*)..... 3595

Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure. F. DENG, M.X. KONG, J. LAI (*Providence, RI; Sacramento, CA, USA*) ..... 3601

Letemovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation. M. RICHERT-PRZYGONSKA, K. JAREMEK, R. DEBSKI, J. KONIECZEK, M. LECKA, M. DZIEDZIC, T. BOGIEL, J. STYCZYNSKI, K. CZYZEWSKI (*Bydgoszcz, Poland*) ..... 3607

Clinical Benefit of Polypectomy With Cutting Current for Colorectal Polyps: A Randomized Controlled Trial. R. KOYANAGI, M. HONDA, H. KAWAMURA, K. HAMADA, Y. HORIKAWA, Y. SHIWA, K. TECHIGAWARA, T. NAGAHASHI, T. MIYAKAWA, S. KONNO (*Fukushima; Koriyama; Utsunomiya, Japan*)..... 3613

Standardized and Feasible Laparoscopic Approach for Tumors Located in the Caudate Lobe. Y. NAKASEKO, K. FURUKAWA, K. HARUKI, S. ONDA, J. YASUDA, Y. SHIRAI, N. OKUI, K. NAKASHIMA, Y. SUZUKI, T. IKEGAMI (*Tokyo; Tochigi, Japan*) ..... 3621

Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer. S. INOUE, N. SASSA, H. KAWANISHI, Y. YUGUCHI, T. SUZUKI, J. NAGAYAMA, H. MATSUI, Y. MIYATA, Y. SOEDA, K. TOCHIGI, Y. YAMAUCHI, M. MAEDA, I. KOBAYASHI, R. HATTORI, Y. MATSUKAWA, M. KATO ( <i>Nagoya; Nagakute; Toyohashi; Yokkaichi; Komaki; Kariya, Japan</i> ) .....	3627
Impact of Amino Acids Nutrition Following Gastrectomy in Gastric Cancer Patients. S. KIKUCHI, N. TAKATA, S. KURODA, H. UMEDA, S. TANABE, N. MAEDA, K. TAKAGI, K. NOMA, Y. HASEGAWA, K. NAWACHI, S. KAGAWA, Y. UMEDA, K. SHIKATA, T. FUJIWARA ( <i>Okayama, Japan</i> ) .....	3637
Postoperative Nutrition Status of Patients With Esophago-gastric Junction Cancer With Gastric Tube or Esophago-gastric Reconstruction. K. TAKABATAKE, H. KONISHI, T. KUBOTA, A. SHIOZAKI, H. FUJIWARA, T. OHASHI, T. ARITA, H. SHIMIZU, Y. YAMAMOTO, R. MORIMURA, H. IKOMA, Y. KURIU, K. OKAMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	3645
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study. T. NAKANO, R. YASUMATSU, K. HASHIMOTO, R. KUGA, T. HONGO, H. YAMAMOTO, M. MATSUO, T. WAKASAKI, R. JIROMARU, T. MANAKO, S. TOH, M. MASUDA, M. YAMAUCHI, Y. KURATOMI, M. TAURA, T. TAKEUCHI, T. NAKAGAWA ( <i>Fukuoka; Saga; Kitakyushu, Japan</i> ) .....	3653
Impact of Macroscopic Tumour Consistency and EPIC in Low-grade Appendiceal Neoplasms With Pseudomyxoma Peritonei. E. CHENG, R. SHAMAVONIAN, J. MUI, J. KARPES, K. CHEN, N. AHMADI, D.L. MORRIS ( <i>Kogarah, NSW, Australia</i> ) .....	3665
Independent Validation of a Risk Stratification Model Predicting Survival in Patients With Metastatic Hormone-sensitive Prostate Cancer. C. NIEDER, L. STANISAVLJEVIC ( <i>Bodø; Tromsø, Norway</i> ) .....	3675
Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. A. RAJHA, P. PISO, L. HALMY, I. PANCZEL, D.-S. NEDELICUT, Z. HEROLD, A.M. SZASZ, M. ACS ( <i>Regensburg, Germany; Budapest, Hungary</i> ) .....	3681
Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment. Y. SAITO, Y. TAKEKUMA, T. TAKESHITA, T. NOGUCHI, S. TAKEUCHI, Y. SHIMIZU, I. KINOSHITA, H. DOSAKA-AKITA, M. SUGAWARA ( <i>Sapporo, Japan</i> ) .....	3693
Clinical Outcomes of Scanning Carbon-ion Radiotherapy for Soft Tissue Sarcoma of the Extremities. Y. TAKAKUSAGI, I. SERIZAWA, H. KOGE, K. KANO, S. SHIMA, K. TSUCHIDA, N. MIZOGUCHI, D. YOSHIDA, H. KATOH, T. HIRUMA, T. KAMADA ( <i>Kanagawa, Japan</i> ) .....	3701
Highly Aggressive Surgery Benefits in Patients With Advanced Ovarian Cancer. S. TATE, K. NISHIKIMI, A. MATSUOKA, S. OTSUKA, M. SHOZU ( <i>Chiba, Japan</i> ) .....	3707
Relationship Between Leukotriene Receptor Antagonists on Cancer Development in Patients With Bronchial Asthma: A Retrospective Analysis. A. MAEDA-MINAMI, M. HOSOKAWA, Y. ISHIKURA, A. ONODA, Y. KAWANO, K. NEGISHI, S. SHIMADA, T. IHARA, M. SUGAMATA, K. TAKEDA, Y. MANO ( <i>Chiba; Yamaguchi; Tohigi, Japan</i> ) .....	3717
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. M. NAKAJIMA, H. MUROI, M. KIKUCHI, T. KUBO, S. TAKISE, K. IHARA, M. NAKAGAWA, S. MORITA, T. NAKAMURA, S. YAMAGUCHI, K. KOJIMA ( <i>Mibu-machi; Nikko, Japan</i> ) .....	3725
Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study. K. NOZAWA, D. TAKATSUKA, Y. ENDO, N. HORISAWA, Y. OZAKI, A. KATAOKA, H. KOTANI, A. YOSHIMURA, M. HATTORI, M. SAWAKI, H. IWATA ( <i>Nagoya, Japan</i> ) .....	3735

Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer. K. NIGUMA, K. MAMISHIN, Y. NAITO, S. NOMURA, M. WAKABAYASHI, S. KUSUHARA, C. FUNASAKA, T. NAKAO, Y. FUKASAWA, C. KONDOH, K. HARANO, T. KOGAWA, N. MATSUBARA, A. HOSONO, T. ONISHI, T. KAWASAKI, T. MUKOHARA ( <i>Kashiwa; Tokyo, Japan</i> ).....	3743
Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens. Y. SAITO, Y. TAKEKUMA, T. TAKESHITA, M. SUGAWARA ( <i>Sapporo, Japan</i> ).....	3753
The Geriatric Nutritional Risk Index as a Prognosis Predictor in Patients With Rectal Cancer Receiving Neoadjuvant Chemotherapy. S. MINAMI, N. MIYOSHI, S. FUJINO, S. KATO, Y. SEKIDO, T. HATA, T. OGINO, H. TAKAHASHI, M. UEMURA, H. YAMAMOTO, Y. DOKI, H. EGUCHI ( <i>Suita; Osaka, Japan</i> ).....	3759

## Number 8, August

### Reviews

Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications. V. VASSILIOU, T. KATSILA, S.C. SODERGREN, D. KARDAMAKIS ( <i>Nicosia, Cyprus; Athens; Patras, Greece; Southampton, UK</i> ) .....	3767
---	------

### Experimental Studies

Tropomyosin-related Kinase B Is Potentially a Biomarker of Prognosis and Therapeutic Target for Malignant Thymic Epithelial Tumors. K. OZONO, H. ONISHI, N. IWAMOTO, K. NAKAMURA, K. MIYOSHI, M. NAKAMURA, Y. ODA ( <i>Fukuoka, Japan</i> ) .....	3779
Eriodictyol Attenuates Cholangiocarcinoma Malignancy by Regulating HMOX1 Expression: An <i>In Vitro</i> Study. J. LEE, W. SIM, S.-I. HAN, J.-H. BYEON, S.-B. JIN, N.A.A.B. MORSHIDI, Y.-Y. HONG, Y. JUNG, J.H. KIM ( <i>Jeju, Republic of Korea; San Francisco, CA, USA</i> ) .....	3789
The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan. Y.-C. WANG, Z.-H. WANG, J.-H. YEN, Y.-C. SHEN, T.-C. SHEN, W.-S. CHANG, C.-H. SU, K.-Y. CHEN, C.-M. YEN, H.-T. LEE, J.-S. YANG, D.-T. BAU, C.-W. TSAI ( <i>Taichung, Taiwan, ROC</i> ) .....	3799
STAT3 Inactivation and Induction of Apoptosis Associate With Fluoxetine-inhibited Epithelial-mesenchymal Transition and Growth of Triple-negative Breast Cancer <i>In Vivo</i> . P.-A. LIAO, P.-Y. CHU, Z.-L. TAN, F.-T. HSU, Y.-C. LEE, H.-J. WU ( <i>Taipei; New Taipei City; Taichung; Changhua; Tainan, Taiwan, ROC</i> ).....	3807
The Expression of SIRT6 Is Associated With Treatment Outcome in Elder Patients With Oral Cancer. H. YOSHII, K. SEKIHARA, Y. IDETA, S. NAKAJIMA, I. KATO, M. OKUBO-SATO, K. SUGIURA, K. MITSUDO, M. KIOI ( <i>Yokohama; Tokyo; Tsukuba, Japan</i> ) .....	3815
Magnolol Induces Apoptosis Through Extrinsic/intrinsic Pathways and Attenuates NF-κB/STAT3 Signaling in Non-small-cell Lung Cancer Cells. Y.-C. LEE, Y.-S. WENG, H.-Y. WANG, F.-T. HSU, F.-S. CHUEH, J.-Y. WU, W.-L. CHEN, J.-H. CHEN ( <i>Tainan; Taichung; Changhua; Hualien; Taipei; New Taipei City, Taiwan, ROC</i> ) .....	3825
Extracellular Vesicles from <i>EGFR T790M/L858R</i> -mutant Non-small Cell Lung Cancer Promote Cancer Progression. K. JANPIPATKUL, W. PANVONGSA, W. WORAKITCHANON, T. REUNGWETWATTANA, A. CHAIROUNGDU ( <i>Bangkok, Thailand</i> ).....	3835

### Clinical Studies

A Reappraisal of Definitive Chemoradiotherapy for Older Adults With Advanced Head and Neck Cancer. T.D. SMILE, C.A. REDDY, B. MATIA, C.W. FLEMING, C. DOMB, J.L. GEIGER, N.P. JOSHI, N.M. WOODY, D.J. CHUTE, C.C. GRIFFITH, D.J. ADELSTEIN, S.A. KOYFMAN ( <i>Cleveland, OH; Chicago, IL, USA</i> ) .....	3845
---	------

Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome. P. ASAWA, U. VUSQA, C. KHAN, Y. SAMHOURI, S. FAZAL ( <i>Pittsburgh, PA, USA</i> ) ...	3853
Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet. Y. KUBOTA, Q. HAN, K. HAMADA, Y. AOKI, N. MASAKI, K. OBARA, T. TSUNODA, R.M. HOFFMAN ( <i>San Diego, CA, USA; Tokyo, Japan</i> ) .....	3857
Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective Study. X. CHODERLOS DE LACLOS, D. FRAPPAZ, G. AHLE, C. BRONNIMANN, I. CATRY-THOMAS, A. JONCOUR, F. GHIRINGHELLI, E. VAULEON ( <i>Rennes; Lyon; Colmar; Bordeaux; Poitiers; Dijon, France</i> ).....	3863
Outcome of Scapular Ewing Sarcoma. J.B. HARGISS, J.R. LABOTT, S.E. BROIDA, P.S. ROSE, J.D. BARLOW, M.T. HOUDEK ( <i>Rochester, MN, USA</i> ) .....	3869
Clinical Significance of <i>EREG</i> Gene Expression in Gastric Cancer Tissue After Curative Surgery. H. SUEMATSU, I. HASHIMOTO, Y. HIROSHIMA, H. WATANABE, K. KANO, K. TAKAHASHI, T. AOYAMA, T. YAMADA, H. TAMAGAWA, T. OGATA, N. YUKAWA, Y. RINO, M. MASUDA, Y. MIYAGI, T. OSHIMA ( <i>Yokohama, Japan</i> ) .....	3873
Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study. G. VANNI, M. PELLICCIARO, M. MATERAZZO, O. MELAIU, B. LONGO, V. CERVELLI, O.C. BUONOMO ( <i>Rome, Italy</i> ) .....	3879
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. T. OTSU, Y. INOKAWA, H. TAKAMI, M. HAYASHI, K. KURIMOTO, N. TANAKA, H. TANAKA, D. SHIMIZU, N. HATTORI, M. KANDA, C. TANAKA, G. NAKAYAMA, Y. KODERA ( <i>Nagoya, Japan</i> ) .....	3889
MR Prediction of Malignant Switch With the Cyst Fluid's T2 Value in Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Preliminary Study. S. TAKAO, A. NISHIE, Y. USHIJIMA, Y. TAKAYAMA, K. MORITA, K. ISHIMATSU, Y. KOGA, Y. MORI, Y. AKAMINE, K. ISHIGAMI ( <i>Fukuoka; Okinawa; Tokyo, Japan</i> ).....	3895
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. K. SASAKI, Y. TSURUDA, M. SHIMONOSONO, M. NODA, Y. UCHIKADO, T. ARIGAMI, D. MATSUSHITA, S. MORI, A. NAKAJO, H. KURAHARA, T. OHTSUKA ( <i>Kagoshima, Japan</i> ).....	3905
Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors. S. KITANO, A. HONDA, N. ITOI, T. LEE ( <i>Kyoto, Japan</i> ) .....	3913
Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer. H. KAWAMURA, M. HONDA, Y. TAKANO, S. KINUTA, T. KAMIGA, S. SAJI, K. KONO ( <i>Koriyama; Aizu-Wakamatsu; Shirakawa; Fukushima, Japan</i> ) .....	3921
The Albumin–Bilirubin Score Is a Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment. M. JU, T. AOYAMA, K. KOMORI, H. TAMAGAWA, A. TAMAGAWA, Y. MAEZAWA, J. MORITA, A. ONODERA, K. ENDO, I. HASHIMOTO, K. KANO, K. HARA, H. CHO, M. NAKAZONO, K. SEGAMI, T. ISHIGURO, S. ONUMA, T. OSHIMA, N. YUKAWA, Y. RINO ( <i>Yokohama; Tokyo, Japan</i> ).....	3929
The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer. K. TAKADA, S. KASHIWAGI, R. KOUHASHI, N. IIMORI, A. YABUMOTO, W. GOTO, Y. ASANO, Y. TAUCHI, T. MORISAKI, M. SHIBUTANI, H. TANAKA, M. OHIRA ( <i>Osaka, Japan</i> ) .....	3937
Effectiveness of Porous Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma. N. IMAI, M. ISHIGAMI, Y. OIE, M. KUMAGAI, Y. INUKAI, S. YOKOYAMA, K. YAMAMOTO, T. ITO, Y. ISHIZU, T. HONDA, H. KAWASHIMA ( <i>Nagoya, Japan</i> ).....	3947



Clinical Outcome After Esophagectomy or Definitive Chemoradiotherapy in Elderly Patients (≥80 Years) With Esophageal Cancer. M. SHIMONOSONO, K. SASAKI, Y. TSURUDA, M. NODA, Y. UCHIKADO, T. ARIGAMI, D. MATSUSHITA, S. MORI, H. KURAHARA, A. NAKAJO, T. OHTSUKA ( <i>Kagoshima, Japan</i> ).....	3953
Phase II Study of a Multi-center Randomized Controlled Trial to Evaluate Oral Vitamin B12 Treatment for Vitamin B12 Deficiency After Total Gastrectomy in Gastric Cancer Patients. T. AOYAMA, Y. MAEZAWA, H. CHO, Y. SAIGUSA, J. TAMURA, K. TSUCHIDA, K. KOMORI, K. KANO, K. SEGAMI, K. HARA, K. SENUKI, Y. SUZUKI, M. YAMAKAWA, H. TAMAGAWA, T. OSHIMA, N. YUKAWA, Y. RINO ( <i>Yokohama; Tokyo, Japan</i> ) .....	3963
Metastatic SMARCB1 Deficient Skin Carcinoma With Neuroendocrine Differentiation in the Parotid Glands Clinically Mimicking Primary Salivary Gland Malignancy: Unusual Case With Diagnostic Pitfalls. F. FANG, Q. ZHANG, J.M. PINTO-CUBEROS, J. LAI ( <i>Galveston, TX; Roseville; Sacramento, CA, USA</i> ).....	3971
Primary Central Nervous System Post–transplant Lymphoproliferative Disorder Misdiagnosed as Glioblastoma: A Case Report. H. TANAKA, R. MATSUDA, M. NAKAMURA, I. NAKAGAWA, H. NAKASE ( <i>Kashihara, Japan</i> ) .....	3975
<b>PROCEEDINGS OF THE 25TH ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES.</b> 11 December, 2021 ( <i>Fukuoka, Japan</i> ) .....	3981-4188
Preface.....	3981
<i>Experimental Studies</i>	
Anti-inflammatory and Insulin Signaling Phenotype Induced by Repeated Lipopolysaccharide Stimulation in 3T3-L1 Adipocytes. K. YAMAMOTO, M. YAMASHITA, H. INAGAWA, C. KOHCHI, G.-I. SOMA ( <i>Kagawa; Niigata, Japan</i> ) .....	3983
Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner. K. YOSHIDA, K. NISHI, S. ISHIKURA, K. NAKABAYASHI, R. YAZAKI, T. OHSHIMA, M. SUENAGA, S. SHIRASAWA, T. TSUNODA ( <i>Fukuoka; Tokyo, Japan</i> ).....	3993
Significance of Intraperitoneal-free <i>KRT20</i> and <i>CEACAM6</i> mRNA Expression for Peritoneal Recurrence of Gastric Cancer. H. KAKU, K. AOYAGI, T. SUDO, Y. TANAKA, T. MINAMI, T. ISOBE, J. KIZAKI, Y. UMETANI, N. MURAKAMI, F. FUJITA, Y. AKAGI ( <i>Fukuoka, Japan</i> ) .....	4003
Experimental Exploration for Genes Related to Susceptibility and Resistance to Irinotecan. S. OGATA, T. SUDOU, F. FUJITA, T. YOSHIDA, K. KOUSHI, T. NOGUCHI, J. FUKUDA, N. OGATA, Y. NOBUKUNI, Y. AKAGI ( <i>Kurume, Japan</i> ) .....	4011
Molecular Interaction Between Boron Tracedrug UTX-51 Derivatives and Bovine Serum Albumin: Application to an Analytical Model of AGEs Destruction by Thermal Neutron Irradiation. K. OHKURA, A. TABATA, Y. UTO, H. HORI ( <i>Suzuka; Tokushima, Japan</i> ) .....	4017
Effect of Chloroquine on Doxorubicin-induced Apoptosis in A549 Cells. K. SATO, N. OTA, S. ENDO, A. NAKATA, H. YAMASHITA, R. TATSUNAMI ( <i>Sapporo, Japan</i> ).....	4025
Effect of Aspirin on G <sub>0</sub> /G <sub>1</sub> Cell Cycle Arrest and microRNA Signatures in Pancreatic Adenocarcinoma Cells. R. NAKABAYASHI, S. FUJIHARA, H. IWAMA, S. HAMAYA, T. MIZUO, M. HIRATA, K. FUJITA, T. KONO, D. NAMIMA, N. FUJITA, H. YAMANA, K. KOBAYASHI, H. KAMADA, A. MORISHITA, H. KOBARA, M. ONO, K. OKANO, T. MASAKI ( <i>Kagawa, Japan</i> ) .....	4037
Suppression of Inflammatory Cytokine Genes Expression in Vascular Endothelial Cells by Super-low Dose Lipopolysaccharide-activated Macrophages. T. HONDA, H. INAGAWA ( <i>Kanagawa; Niigata; Kagawa, Japan</i> ).....	4049
	6187



Oral Administration of Mulberry ( <i>Morus alba</i> L.) Leaf Powder Prevents the Development of Hepatocellular Carcinoma in Stelic Animal Model (STAM) Mice. K. WAKAME, K. SATO, M. KASAI, E. KIKUCHI, K. SHIMIZU, A. KUDO, K.-I. KOMATSU, A. NAKATA ( <i>Sapporo; Tokyo, Japan</i> ) .....	4055
<i>Clinical Studies</i>	
Salvage PTBD With Chemotherapy Improves Survival in Patients With Unresectable Malignant Biliary Obstruction – A Single Center Retrospective Study. D. MUROYA, H. TSURU, H. SHIMOKOBE, Y. NAGAO, Y. YOSHIMOTO, Y. WADA, K. HAYASHI, S. TANIWAKI, R. MIDORIKAWA, S. TANIWAKI, S. KOJIMA, S. ARAI, T. SHIRAHAMA, Y. GOTO, H. SAKAI, M. YOSHITOMI, T. HISAKA, Y. AKAGI, K. OKUDA ( <i>Kurume; Kitakyushu, Japan</i> ) .....	4063
CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients. A. SHIMAZAKI, M. KUBO, K. KURATA, Y. TAKAO, S. HAYASHI, Y. HARADA, H. KAWAJI, K. KANESHIRO, M. YAMADA, M. KAI, M. NAKAMURA ( <i>Fukuoka; Yamaguchi, Japan</i> ).....	4071
Tumour Budding as an Independent Prognostic Factor for Survival in Patients With Distal Bile Duct Cancer. G. NAKAYAMA, T. HISAKA, H. SAKAI, M. AKASHI, G. YUICHI, T. SATO, Y. NAITO, J. AKIBA, H. YANO, Y. AKAGI ( <i>Kurume, Japan</i> ).....	4079
Liberal Application of Portal Vein Embolization for Right Hepatectomy Against Hepatocellular Carcinoma: Strategy to Achieve Zero Mortality for a Damaged Liver. N. SHIRAHAMA, Y. GOTO, H. SAKAI, S. FUKUTOMI, M. AKASHI, T. SATO, Y. AKAGI, K. OKUDA, T. HISAKA ( <i>Kurume, Japan</i> ).....	4089
Significance of the Multi-gene Panel myRisk in Japan. S. HAYASHI, M. KUBO, S. MATSUZAKI, M. KAI, T. MORISAKI, M. YAMADA, K. KANESHIRO, Y. TAKAO, A. SHIMAZAKI, K. NAGAYOSHI, Y. MIZUUCHI, M. NAKAMURA ( <i>Fukuoka, Japan</i> ) .....	4097
Standardized Methods Using EUS-guided Fine-needle Biopsy and a Minimal Medium Creates Three Pancreatic Cancer Organoids. Y. ISHIDA, T. TSUNODA, Y. HAMADA, N. TSUCHIYA, T. KOGA, T. KITAGUCHI, K. MATSUMOTO, S. MATSUMOTO, T. SASAKI, R. NAKASHIMA, F. ISHII, M. KAJIWARA, S. SHIRASAWA, S. HASEGAWA, F. HIRAI ( <i>Fukuoka, Japan</i> ).....	4103
Cumulative Summation Analysis of Learning Curve for Robotic-assisted Hysterectomy in Patients With Gynecologic Tumors. F. YOTSUMOTO, A. SANUI, T. ITO, D. MIYAHARA, K. YOSHIKAWA, K. SHIGEKAWA, Y. NOGUCHI, S. YASUNAGA, S. MIYAMOTO ( <i>Fukuoka, Japan</i> ) .....	4111
Chitinase 3-like 1, Carcinoembryonic Antigen-related Cell Adhesion Molecule 6, and Ectopic Claudin-2 in the Carcinogenic Processes of Ulcerative Colitis. T. KINUGASA, T. TSUNODA, E. MIZOGUCHI, T. OKADA, T. SUDO, A. KAWAHARA, J. AKIBA, Y. AKAGI ( <i>Fukuoka; Kurume, Japan</i> ).....	4119
Hematogenous Dissemination of Tumor Cells in Hepatocellular Carcinoma: Comparing Anterior and Non-anterior Approach Hepatectomy. S. SASAKI, Y. NOMURA, T. SUDO, H. SAKAI, T. HISAKA, J. AKIBA, O. NAKASHIMA, H. YANO, M. KAGE, Y. AKAGI, K. OKUDA ( <i>Kurume, Japan</i> ) .....	4129
Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors. N. OGATA, U. TOH, T. SUDOU, S. OGATA, Y. TAKAO, R. SUGIHARA, H. WATANABE, S. MATUSHIMA, Y. AKAGI ( <i>Fukuoka; Saitama, Japan</i> ).....	4139
Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma. Y. NAITO, J. AKIBA, Y. KINJO, E. SADASHIMA, T. OGATA, Y. YANO, M. TANIGAWA, M. NAKAYAMA, A. KAWAHARA, Y. OKABE, H. SAKAI, T. HISAKA, Y. AKAGI, H. YANO ( <i>Kurume, Saga, Japan</i> ) .....	4145
Pancreaticoenterostomy With Seromuscular-parenchymal Anastomosis for Prevention of Postoperative Pancreatic Fistula in Distal Pancreatectomy. S. TANIWAKI, D. MUROYA, Y. WADA, K. OKUDA, H. TSURU, H. SHIMOKOUBE, Y. NAGAO, K. HAYASHI, Y. YOSHIMOTO ( <i>Kitakyushu, Japan</i> ) .....	4153

Fatty Liver Does Not Increase the Risk of Postoperative Liver Damage Following Hepatectomy. Y. NOMURA, J. AKIBA, H. YANO, Y. AKAGI, T. HISAKA ( <i>Kurume, Japan</i> ) .....	4159
Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy. Y. YOKOYAMA, M. KUBO-KANEDA, K. SUNADA, Y. TEISHIKATA, A. KITAMURA, K. OKAMOTO, K. TORIYABE, M. NII, K. YOSHIDA, E. KONDO, T. IKEDA ( <i>Mie, Japan</i> ) .....	4165
Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment. H. YOSHIOKA, T. OKUDA, T. NAKAO, M. FUJITA, J.C. TAKAHASHI ( <i>Osaka, Japan</i> ) .....	4173
Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors. R. TAKIMOTO, T. KAMIGAKI, S. OKADA, H. IBE, E. OGUMA, S. GOTO ( <i>Tokyo; Sapporo, Japan</i> ) .....	4179

## Number 9, September

### Reviews

Craniopharyngiomas Invading the Ventricular System: A Systematic Review. P. PALMISCIANO, K. YOUNG, M. OGASAWARA, O. YOUSEFI, C. OGASAWARA, G. FERINI, O. BIN-ALAMER, M. SHARMA, G.E. UMANA, K. YU, A.A. COHEN-GADOL, T.Y. EL AHMADIEH, A.S. HAIDER ( <i>Cincinnati, OH; Honolulu, HI; Berkeley, CA; Galveston; Houston, TX; Pittsburgh, PA; Louisville, KY; New York, NY; Indianapolis, IN, USA; Shiraz, Iran; Viagrande; Catania, Italy</i> ) .....	4189
Applicability of a Host-mediated <i>In Vivo/In Vitro</i> Model in Screening for the Carcinogenic Potential of Chemicals. K. SCHLATTERER, A. ESMAEILI, T. MASSA, S. APOSTOLIDIS, P. CHANDRA ( <i>Berlin; Neuruppin; Frankfurt, Germany</i> ) .....	4199
Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research. A. GADDUCCI, S. COSIO ( <i>Pisa, Italy</i> ) .....	4207
Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis. A.T. CRISTAUDO, S.B. JENNINGS, D.L. MORRIS ( <i>Kogarah; Sydney, NSW, Australia</i> ) .....	4217
Epithelial to Mesenchymal Transition in Lung Cancer: Potential EMT-Targeting Natural Product-derived Compounds. P. CHANVORACHOTE, K. PETSRI, S. THONGSOM ( <i>Bangkok, Thailand</i> ) .....	4237
Evidence of Potential Plant-derived Compounds With Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches. M. SUKPRASANSAP, P. CHANVORACHOTE ( <i>Phutthamonthon; Bangkok, Thailand</i> ) .....	4247

### Experimental Studies

Establishment of Cytotoxic and Non-cytotoxic NK-92 Cell Clones – Evaluation of Their Function as Target Cells. H. BERGMAN, E. HERMANSON, C. LINDQVIST ( <i>Turku, Finland</i> ) .....	4259
Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting ERBB4 in MCF-7 Cells. S.W. SON, S.H. HEO, S.S. OH, C.H. LEE, J.K. PARK ( <i>Chuncheon, Republic of Korea; Bethesda, MD, USA</i> ) .....	4265
Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor. M. YODA, K. SAKUMA, T. KII, A. TANAKA ( <i>Niigata, Japan</i> ) .....	4273

Effects of Mixed Nuts on Colonic Cell Proliferation and <i>Ptgs2</i> and <i>Rela</i> Gene Expression. M.Y. HONG, J. MOORE, A. NAKAGAWA, V. NUNGARAY ( <i>San Diego; Torrance, CA, USA</i> ) .....	4285
An <i>In Vivo</i> Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line. K. SAKUMA, T. KII, H. TAKAHASHI, S. SUZUKI, K. YOSHIKAWA, T. OGAWA, A. TANAKA ( <i>Niigata; Nagakute, Japan</i> ).....	4293
Verification of A New Filter for Isolation of Circulating Tumor Cells by Only Blood Filtration. K. MORITA, N. SAWABATA, S. TATSUMI, T. FUJII, T. NISHIKAWA, T. KAWAGUCHI, T. ARAKANE, Y. TOMINAGA, H. SAKAGUCHI, T. KOBAYASHI, S. HONTSU, Y. YAMAMOTO, N. FUJIOKA, N. OUJISAGESHIMA, T. ITO, C. OHBAYASHI ( <i>Kashihara; Nara; Tokyo, Japan</i> ) .....	4305
The $\gamma$ -Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Species. H. II, K. TANIGUCHI, T. YOSHIYA, Y. NOHARA, S. KAGEYAMA, A. KAWAUCHI, S. NAKATA ( <i>Kyoto; Osaka; Shiga, Japan</i> ) .....	4311
Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells. K. ASANUMA, T. NAKAMURA, K. NAKAMURA, T. HAGI, T. OKAMOTO, K. KITA, Y. MATSUYAMA, K. YOSHIDA, Y. ASANUMA, A. SUDO ( <i>Tsu; Izumo, Japan</i> ) ...	4319
The Contribution of Flap Endonuclease 1 Genotypes to Oral Cancer Risk. S.-H. PAN, W.-C. CHIEN, J.-L. HE, L.-C. SHIH, C.-L. HSU, T.-C. HSIA, Y.-C. WANG, H.-Y. TSAO, C.-W. TSAI, D.-T. BAU, W.-S. CHANG ( <i>Taichung; Changhua, Taiwan, ROC</i> ) .....	4329
Neuroectodermal Rosettes in Immature Teratomas Are Not the Counterpart of Embryonal Tumours With Multilayered Rosettes. N. MAGARIFUCHI, Y. YAMADA, Y. OISHI, K. KATO, K. TAGUCHI, Y. ODA ( <i>Fukuoka, Japan</i> ).....	4337
Aptamer-cocktail Functionalized Nano-microfluidic Chip for Enhancing Isolation and Characterization of Circulating Cancer Cells. M. LI, D. LIU, J. ZHANG, X. ZHANG, X. DOU ( <i>Huainan; Shenzhen, PR China</i> ).....	4345
Implication of IL6-positive Cancer-associated Fibroblasts in Merkel Cell Carcinoma Pathogenesis: A Possible Modulator of Immune Microenvironment. Z. ZHENG, D.S. YOO, S. LI, M. PEI, S.G. LEE, J.Y. KIM, K.Y. CHUNG, M.R. ROH ( <i>Yanji, PR China; Seoul, Republic of Korea</i> ) .....	4359
Two-Phase Deep Learning Algorithm for Detection and Differentiation of Ewing Sarcoma and Acute Osteomyelitis in Paediatric Radiographs. S CONSALVO, F. HINTERWIMMER, J. NEUMANN, M. STEINBORN, M. SALZMANN, F. SEIDL, U. LENZE, C. KNEBEL, D. RUECKERT, R.H.H. BURGKART ( <i>Munich, Germany</i> ) .....	4371
Genetic and Transcriptional Analysis of 8q24.21 Cluster in Gastric Cancer. B. SANTOS PEREIRA, F. WISNIESKI, D. QUEIROZ CALCAGNO, L. CAIRES SANTOS, C. OLIVEIRA GIGEK, E.S. CHEN, L.T. RASMUSSEN, S.L.M. PAYÃO, R. SANCHES ALMEIDA, C.A. PINTO, B.T. REAL KARIA, R. ARTIGIANI, S. DEMACHKI, P.P. ASSUMPÇÃO, L. GOMES LOURENÇO, C.H. ARASAKI, R. RODRÍGUEZ BURBANO, M. FERREIRA LEAL, M.A. CARDOSO SMITH ( <i>São Paulo; Belém, Brazil</i> ) .....	4381
The Effect of Trimetazidine on Diathermy-related Thermal Injury of the Rat Liver. S. FERENCZ, A. PALKOVICS, A. FINCSUR, A. VERECZKEI, I. TAKACS, B. NEMETH, A. PAPP ( <i>Pecs, Hungary</i> ).....	4395
Magnolol Suppresses ERK/NF- $\kappa$ B Signaling and Triggers Apoptosis Through Extrinsic/Intrinsic Pathways in Osteosarcoma. C.-H. LI, M.-C. KU, K.-C. LEE, P.-F. YUEH, F.-T. HSU, R.-F. LIN, C.-C. YANG, W.-C. WANG, J.-H. CHEN, L.-C. HSU, Y.-H. LEE ( <i>Changhua; Yilan; Taipei; Taichung; Taoyuan; New Taipei City, Taiwan, ROC</i> ) .....	4403
Irradiation Methods for Accurate Dose Delivery to Postoperative Keloid Scars With Minimal Normal Tissue Exposure Using TomoTherapy: A Phantom Study. K. OKUHATA, K. KIJIMA, K. NAKAMURA, Y. YANAGI, H. MONZEN ( <i>Osaka; Kyoto, Japan</i> ).....	4411

*Clinical Studies*

- Immunological and Genetic Characterization of Patients With Head and Neck Cancer who Developed Recurrence. K. YASUI, R. KONDOU, H. MIYATA, A. IIZUKA, T. ASHIZAWA, T. NAGASHIMA, K. OHSHIMA, K. URAKAMI, K. MURAMATSU, T. SUGINO, K. YAMAGUCHI, H. OGAWA, T. ONOE, H. HARADA, H. ASAKURA, S. MURAYAMA, T. NISHIMURA, S. GOTO, S. OKADA, T. MUKAIGAWA, S. HAMAUCHI, T. YOKOTA, Y. ONOZAWA, Y. AKIYAMA (*Shizuoka; Tokyo, Japan*) ..... 4417
- Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment. Z.L. MILAS, B. NEELANDS, S.J. TRUFAN, J. BENBOW, D. CARRIZOSA, D.S. BRICKMAN, C.H. FRENKEL, A.L. SUMRALL, S.M. SUDHAKAR, M.C. WARD (*Charlotte, NC, USA*) ..... 4429
- Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database. J. TANAKA, T. KOSEKI, M. KONDO, Y. ITO, S. YAMADA (*Toyoake, Japan*) .... 4439
- Assessing Resection Margin Status in Breast-conserving Surgery Specimens: Comparison Among Gross Evaluation, Frozen Section Analysis, and Permanent Section Diagnosis in 725 Patients With Breast Cancer. J. DO, J. CHU, J. AHN, G.E. BAE, S.H. LEE, H.-S. KIM, S.-I. DO (*Lexington, KY, USA; Seoul; Daejeon, Republic of Korea*) ..... 4453
- Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. C.-T. CHEN, C.-H. HSU, A.-L. CHENG, Y.-Y. SHAO (*Hsinchu; Taipei, Taiwan, ROC*) ..... 4461
- Surgical Strategies to Approaching the Splenic Artery in Robotic Distal Pancreatectomy. K. TAKAGI, K. KUMANO, Y. UMEDA, R. YOSHIDA, T. FUJI, K. YASUI, T. YAGI, T. FUJIWARA (*Okayama, Japan*) .... 4471
- Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. D. SANO, M. TOKUHISA, H. TAKAHASHI, T. HATANO, G. NISHIMURA, Y. ICHIKAWA, N. ORIDATE (*Yokohama, Japan*) ..... 4477
- Intraoperative Brachytherapy Combined With Adjuvant Radiotherapy Shows Equal Results in the Treatment of Leiomyosarcoma on the Extremities Compared to Adjuvant Radiotherapy Only – A Multicentric Retrospective Analysis. D. DAMMERER, A.V. BEECK, K. WABRO, K. BLOCKHUYS, J. MICHIELSEN (*Innsbruck; Krems an der Donau, Austria; Edegem, Belgium*) ..... 4485
- Crypts in Asymmetric Branching in Patients With Ulcerative Colitis in Remission. C.A. RUBIO, M. VIETH, C. LANG-SCHWARZ (*Stockholm, Sweden; Bayreuth, Germany*) ..... 4493
- Improved Outcome in Pediatric Acute Myeloid Leukemia: Progress With Hematopoietic Cell Transplantation. J. STANKIEWICZ, J. STYCZYNSKI (*Bydgoszcz, Poland*) ..... 4499
- Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series. V. DALLA VIA, A. STELMES, M. RECHER, C. ARRANTO, T. JUNKER, F. MATTEAZZI, D. HEIM, J.R. PASSWEG, M. MEDINGER, J. VAN DEN BERG (*Basel, Switzerland*) ..... 4505
- Evaluation of Sleep Disturbances in Patients With Bladder Cancer Scheduled for Local or Loco-regional Radiochemotherapy. D. RADES, S. KOPELKE, S.E. SCHILD, T.W. KJAER, S. TVILSTED, T. BARTSCHT (*Lübeck; Schwerin, Germany; Scottsdale, AZ, USA; Roskilde; Køge, Denmark*) ..... 4511
- Predicting Long-term Survival After Lung Metastasectomy in Patients With Malignant Germ-cell Tumors. M.G. STOLERIU, G. STATHOPOULOS, E. STACHER-PRIEHSE, C. KETSCHER, U. GRÜTZNER, J. FERTMANN, C. SCHNEIDER, R. HATZ, N. STROBL, G. PREISSLER (*Munich; Gauting; Stuttgart, Germany; Patras; Rio, Greece*) ..... 4517

Sleep Problems Prior to Radio-chemotherapy in Patients With Locally Advanced Cancer of the Esophagus or the Esophagogastric Junction. D. RADES, S. KOPELKE, S.E. SCHILD, S. TVILSTED, T.W. KJAER, T. BARTSCHT ( <i>Lübeck; Schwerin, Germany; Scottsdale, AZ, USA; Køge; Roskilde, Denmark</i> ).....	4529
Molecular Characteristics of Metastatic Lesions Have Superior Prognostic Impact on Endometrial Cancer. K. OKAMOTO, K. NAKAMURA, J. HARAGA, H. MASUYAMA ( <i>Okayama, Japan</i> ).....	4535
Clinical Impact of Surgical Sarcopenia on Long-term Survival. K. KOMORI, K. KANO, T. AOYAMA, K. HARA, S. NAGASAWA, M. NAKAZONO, Y. SHIMODA, Y. MAEZAWA, Y. KUMAZU, T. KAWABE, M. NUMATA, T. HAYASHI, T. YAMADA, H. TAMAGAWA, T. SATO, H. CHO, N. YUKAWA, Y. RINO, T. YOSHIKAWA, T. OGATA, T. OSHIMA ( <i>Yokohama; Tokyo, Japan</i> ).....	4545
Prognostic Value of Repeat Hepatectomy for Hepatocellular Carcinoma Patients. A. NANASHIMA, Y. TANOUE, M. HIYOSHI, N. IMAMURA, K. YANO, T. HAMADA, E. KITAMURA, K. KAI, K. TAHIRA, T. NAGAYASU ( <i>Miyazaki; Nagasaki, Japan</i> ).....	4553
Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer. C. TAN, O.M. FISHER, L. HUANG, N. ALZHRANI, W. LIAUW, D. GLENN, D.L. MORRIS ( <i>Sydney, NSW, Australia; Riyadh, Kingdom of Saudi Arabia</i> ).....	4563
Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy. K. UEDA, S. SUEKANE, H. KUROSE, N. ITO, N. OGASAWARA, T. HIROSHIGE, K. CHIKUI, K. EJIMA, K. UEMURA, M. NAKIRI, K. NISHIHARA, M. MATSUO, T. IGAWA ( <i>Kurume, Japan</i> ).....	4573
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer. H. FUJII, S. SADAKA, K. AJISAWA, N. OKUMURA, A. MAKIYAMA, H. IIHARA, I. YASUFUKU, K. OHATA, R. KOBAYASHI, Y. TANAKA, H. HAYASHI, A. SUZUKI ( <i>Gifu, Japan</i> ).....	4581
Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation. S. HATTORI, S. OKAUCHI, Y. SASATANI, G. OHARA, K. MIYAZAKI, S. SATO, T. KODAMA, T. SHIOZAWA, H. SATOH, N. HIZAWA ( <i>Mito; Ryugasaki; Tsukuba, Japan</i> ).....	4589
Detection Ability of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Clinical T Classification of Synchronous Esophageal Cancer in Pharyngeal Cancer. H. TSUZUKI, H. SUZUKI, T. TAMAKI, M. SONE, N. HANAI ( <i>Nagoya, Japan</i> ).....	4597
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study. S. TATSUKI, T. SHOJI, M. ABE, H. TOMABECHI, E. TAKATORI, Y. KAIDO, T. NAGASAWA, M. KAGABU, T. AIDA, T. BABA ( <i>Iwate; Aomori, Japan</i> ).....	4603
Impact of GLIM Defined Malnutrition on Long Term Prognosis in Patients With Gastric Cancer After Gastrectomy. R. MATSUI, N. INAKI, T. TSUJI ( <i>Ishikawa; Chiba; Kanazawa, Japan</i> ).....	4611
Clinical Outcomes of Limb-sparing Tumor Surgery With Vascular Reconstruction for Bone and Soft-tissue Tumors. Y. ASANO, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, S. MIWA, K. IGARASHI, Y. TANIGUCHI, S. MORINAGA, K. TADA, T. NOJIMA, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ).....	4619
Endocervical Adenocarcinoma: Comprehensive Histological Review and Re-classification of 123 Consecutive Cases According to the Updated World Health Organization Classification of Female Genital Tumors. Y. LEE, H. BAE, H.-S. KIM ( <i>Seoul, Republic of Korea</i> ).....	4627
First-ever Clinical Experience With Magnetic Resonance-based Lattice Radiotherapy for Treating Bulky Gynecological Tumors. G. FERINI, V. VALENTI, A. VIOLA, G.E. UMANA, S.I. ILLARI, S. PARISI, A. PONTORIERO, S. PERGOLIZZI ( <i>Viagrande; Catania; Messina, Italy</i> ).....	4641



Pheochromocytoma Turned Malignant During Pregnancy in a Patient With Neurofibromatosis Type I - A Case Report and Systematic Review of the Current Literature. C. ZEITLER, L. FUDERER, K. SCHMITZ, R. ARORA, D. DAMMERER (*Innsbruck; Krems, Austria*) ..... 4647

Corrigendum ..... 4657

**Number 10, October**

*Reviews*

Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists. A. GADDUCCI, S. COSIO, P.V. LIPPOLIS (*Pisa, Italy*) ..... 4659

Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. A. AVALLONE, S. BIMONTE, C. CARDONE, M. CASCELLA, A. CUOMO (*Naples, Italy*)..... 4667

*Experimental Studies*

Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15. K. FURUKAWA, J. LING, Y. SUN, Y. LU, J. FU, R. MARUKUCHI, P.J. CHIAO (*Houston, TX, USA; Tokyo, Japan*) ..... 4679

Microtumor Spheroids Provide a Model for Studying. Molecules Involved in Vascular Organization: An Illustrative Study for VE-cadherin. P. DEMBÉLÉ, O. GARNIER, D.K. MARTIN, I. VILGRAIN (*Grenoble, France*) ..... 4689

PRKRIP1, a Splicing Complex Factor, Is a Marker of Poor Prognosis in Colorectal Cancer. Y. OZATO, T. MASUDA, Y. KOBAYASHI, S. TAKAO, Y. HISAMATU, T. TOSHIMA, Y. YONEMURA, M. UEMURA, H. EGUCHI, Y. DOKI, M. MORI, K. MIMORI (*Beppu; Suita; Isehara, Japan*) ..... 4701

Long-chain Non-coding RNA MIR4435-2HG Expression Correlates With Size of Intestinal Polyps in Children and With Metastasis of Colon Cancer. D. ZHU, P. GUO, X.Y. JIN, R. ZHANG, G. JI, Z. YANG, R.M. HOFFMAN, W. SHENG (*Nanjing; Xinjiang, PR China; San Diego, CA, USA*) ..... 4707

Micro RNA miR-1303 Promotion of Proliferation, Migration and Invasion of Human Liver Cancer Cells Is Enhanced by Low Talin 1 (TLN1) Expression. J. HUANG, Q. XI, J. XIONG, H. PENG, H. YANG, Y. SUN, R.M. HOFFMAN (*Hefei, PR China; San Diego, CA, USA*) ..... 4715

CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells. Y. MITOBE, Y. NAKAGAWA-SAITO, K. TOGASHI, S. SUZUKI, A. SUGAI, K.-I. MATSUDA, Y. SONODA, C. KITANAKA, M. OKADA (*Yamagata, Japan*) ..... 4727

β-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines. M. MUGURUMA, M. ASAOKA, S. TERAOKA, K. MIYAHARA, T. KAWATE, T. ISHIKAWA (*Tokyo, Japan*) ..... 4735

The CGRP Receptor Antagonist MK0974 Induces EVI1<sup>high</sup> AML Cell Apoptosis by Disrupting ERK Signaling. A. SUEKANE, T. ICHIKAWA, Y. SAITO, S. NAKAHATA, K. MORISHITA (*Miyazaki; Tokyo; Kagoshima, Japan*) ..... 4743

Kruppel-like Factor 2 Inhibits Proliferation in Renal Angiomyolipoma via IL-6/JAK/STAT3 Signaling Pathway. C.-Y. LIU, T.-H. CHANG, C.-H. HSIEH, Y.-H. CHANG, J.S.-T. PANG, C.-K. CHUANG (*New Taipei City; Taoyuan, Taiwan, ROC*) ..... 4753



The Complex Composition of Trans-resveratrol, Quercetin, Vitamin E and Selenium Inhibits the Growth of Colorectal Carcinoma. J. CZAPLA, A. DRZYZGA, S. MATUSZCZAK, E. PILNY, T. CICHON, K. STOJECKI, R. SMOLARCZYK ( <i>Gliwice; Wroclaw, Poland</i> ).....	4763
<i>Clinical Studies</i>	
Retrospective Analysis of Treatment Pathways in Patients With BRAF <sup>V600E</sup> -mutant Metastatic Colorectal Carcinoma – MORSE <sup>CRC</sup> . A. GERGER, W. EISTERER, S. FUXIUS, S. BASTIAN, D. KOEBERLE, M. WELSLAU, D.A. SANOYAN, C. MAAS, J. UHLIG, K. FENCHEL, R. GREIL, E. VON DER HEYDE, G.R. AGOCS, R. WEIDE, M. SCHWAGER, F. REICHENBACH, D.P. MODEST, R. FRITSCH ( <i>Graz; Klagenfurt; Salzburg, Austria; Heidelberg; Aschaffenburg; Halberstadt; Naunhof; Saalfeld; Hannover; Koblenz; Berlin; Freiburg, Germany; Chur; Bern; Zurich; Fribourg, Switzerland</i> ).....	4773
Surgical Administration of Indocyanine Green in Hepatectomy for Improved Bile Leakage Detection. T. HANAKI, K. GOTO, M. MORIMOTO, Y. MURAKAMI, T. MATSUNAGA, M. YAMAMOTO, N. TOKUYASU, T. SAKAMOTO, T. HASEGAWA, Y. FUJIWARA ( <i>Tottori, Japan</i> ).....	4787
Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors. P.J.J. DAMEN, K.P.M. SUIJKERBUIJK, A.S.R. VAN LINDERT, W.S.C. EPPINGA, S.Y. EL SHAROUNI, J.J.C. VERHOEFF ( <i>Utrecht, the Netherlands</i> ).....	4795
Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy. Y. TAKAYAMA, J. YANO, R. SEIKE, S. MISHIMA, H. SHODA ( <i>Hiroshima, Japan</i> ) .....	4805
Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor. H. OZAWA, T. HIGUCHI, Y. FUJIMOTO, A. BUN, R. FUKUI, H. KANAOKA, M. NAGAHASHI, K. KITAJIMA, K. YAMAKADO, Y. MIYOSHI ( <i>Nishinomiya, Japan</i> ).....	4813
Tumor Load Matters – the Peritoneal Cancer Index in Patients With High-grade Serous Ovarian Cancer. E. EGGER, F. MERKER, D.J. RALSER, M. CONDIC, M. MARINOVA, M. MUDERS, M. STOPE, A. MUSTEA ( <i>Bonn, Germany</i> ) .....	4825
Outcomes and Side Effects of Preoperative Chemoradiotherapy for Locally Advanced Upper Rectal Cancer. S. CHOMICKI, S. CHAPET, M. DRIFA, M. OUAISSI, P. BOURLIER, K. DEBBI, G. LOGANADANE, G. CALAIS ( <i>Créteil; Tours; Chambray les Tours, France</i> ) .....	4833
Relationship Between Fat Mass Indices and Postoperative Complications After Laparoscopic Gastrectomy in Patients With Gastric Cancer: A Propensity Score Matching Analysis. R. MATSUI, N. INAKI, T. TSUJI, T. FUKUNAGA ( <i>Kanazawa; Urayasu; Tokyo, Japan</i> ).....	4841
Intraoperative Holographic Guidance Using Virtual Reality and Mixed Reality Technology During Laparoscopic Colorectal Cancer Surgery. S. RYU, T. KITAGAWA, K. GOTO, A. OKAMOTO, R. MARUKUCHI, K. HARA, R. ITO, Y. NAKABAYASHI ( <i>Kawaguchi, Japan</i> ).....	4849
Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. J.-R. LI, S.-S. WANG, C.-S. CHEN, C.-K. YANG, K. LU, C.-L. CHENG, S.-C. HUNG, S.-Y. CHEN, C.Y. HSU, K.-Y. CHIU ( <i>Taichung; Nantou, Taiwan, ROC</i> ).....	4857
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors. H. KANAOKA, M. NAGAHASHI, Y. ATAKE, A. HATTORI, A. BUN, R. FUKUI, H. OZAWA, Y. FUJIMOTO, T. HIGUCHI, K. NATORI, M. IMAMURA, K. MURASE, Y. TAKATSUKA, Y. MIYOSHI ( <i>Nishinomiya, Japan</i> ) .....	4867
Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter. T. MORI, A. FURUKAWA, T. BILAL, A. UEDA, H. BANDO, T. MASUDA, F. ARAI, S. MATSUSAKA ( <i>Tsukuba; Tokyo, Japan</i> ) .....	4879

Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy. S. KISE, Y. ARAKAKI, W. KUDAKA, T. ARIGA, N. KINJO, H. KOHATU, Y. AOKI ( <i>Okinawa, Japan</i> ) .....	4887
Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib. Y. FUJIMOTO, T. NAMISAKI, S. TAKEDA, K. MURATA, M. ENOMOTO, H. TAKAYA, Y. TSUJI, Y. FUJINAGA, Y. SAWADA, N. NISHIMURA, K. KITAGAWA, K. KAJI, T. INOUE, H. KAWARATANI, K. MORIYA, T. AKAHANE, A. MITORO, H. YOSHIJI ( <i>Nara, Japan</i> ) .....	4895
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. T. OKADA, T. MATSUKI, C. FUSHIMI, I. OKAMOTO, H. SATO, T. KONDO, K. TOKASHIKI, T. ITO, T. MASUBUCHI, Y. TADA, K. MIURA, K. HANYU, G. OMURA, H. TAKAHASHI, T. YAMASHITA, N. ORIDATE, K. TSUKAHARA ( <i>Tokyo; Sagami-hara; Yokohama, Japan</i> ) .....	4907
Awake Breast Conservative Surgery: A Strategy to Shorten Surgical Waiting Lists During and Post COVID-19 Emergency. G. VANNI, M. PELLICCIARO, M. MATERAZZO, J. CASPI, M. CHIOCCHI, F. TACCONI, A. NOCE, G. NICOLAI, I. PORTARENA, C. BUONOMO, D. MARIO, O.C. BUONOMO ( <i>Rome, Italy</i> ).....	4913
Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer. Y. MATSUI, T. YAMADA, K. MORIMOTO, Y. KATAYAMA, O. HIRANUMA, S. SHIOTSU, N. TAMIYA, T. TAKEDA, Y. MORIMOTO, M. IWASAKU, S. TOKUDA, K. TAKAYAMA ( <i>Kyoto; Shiga, Japan</i> ).....	4921
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer. M. SAKAI, M. SOHDA, S. UCHIDA, A. YAMAGUCHI, T. WATANABE, H. SAITO, Y. UBUKATA, N. NAKAZAWA, K. KURIYAMA, A. SANO, H. OGAWA, T. YOKOBORI, S.-E. NODA, T. OHNO, K. SHIRABE, H. SAEKI ( <i>Gunma, Japan</i> ) .....	4929
Comparison of Survival Outcomes Based on Pre-treatment Pleural Effusion in Advanced Epithelial Ovarian Cancer. J. LEE, D.G. HONG ( <i>Daegu, Republic of Korea</i> ).....	4937
Prognostic Significance of Clinical Factors Including <i>BRCA</i> Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer. J.Y. KIM, H. PARK, D.W. LEE, M.J. KIM, J.E. SHIN, K.E. LEE, H.N. LEE ( <i>Seoul, Republic of Korea</i> ) .....	4945
Clinicopathological Characteristics of Advanced Epstein–Barr Virus-associated Gastric Cancer Highlighting Aberrant p53 Expression. H. JANG, A.N. SEO, M. KIM ( <i>Seoul; Daegu, Republic of Korea</i> ) .....	4955
Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study. M. UTSUMI, M. INAGAKI, K. KITADA, N. TOKUNAGA, M. KONDO, K. YUNOKI, Y. SAKURAI, R. HAMANO, H. MIYASOU, Y. TSUNEMITSU, S. OTSUKA ( <i>Fukuyama, Japan</i> ).....	4963
The Effect and Tolerability of Second-line Chemotherapy Are Associated With Disease Control by Nivolumab Chemotherapy in Patients With Gastric Cancer. H. MATSUOKA, T. MIZUNO, M. SAKAI, K. SUZUKI, A. SERIZAWA, M. NAKAUCHI, T. TANAKA, S. SHIBASAKI, T. HAYASHI, K. SUDA ( <i>Toyoake; Nagoya, Japan</i> ).....	4973
Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel. K. OKABE, N. TERADA, T. SHIRAKAWA, C. ONIZUKA, T. KIMURA, Y. YAMASHITA, I. OTUKA, T. UENO, M. NAGANO, H. TAKAMORI, S. MUKAI, T. KAMOTO ( <i>Sapporo; Miyazaki; Nichinan; Nobeoka; Miyakonojo, Japan</i> ).....	4981
Combined Inflammation and Nutrition Factors Reinforce the Prognostic Prediction for Stage III Colorectal Cancer Patients. S. KATO, N. MIYOSHI, S. FUJINO, S. MINAMI, C. MATSUDA, M. YASUI, M. OHUE, Y. SEKIDO, T. HATA, T. OGINO, H. TAKAHASHI, M. UEMURA, H. YAMAMOTO, Y. DOKI, H. EGUCHI ( <i>Osaka, Japan</i> ) .....	4989

Long-term Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. K. NAGATA, R. SASAKI, S. IWATSU, M. FUKUSHIMA, M. HARAGUCHI, S. YAMAMICHI, S. MIUMA, H. MIYAAKI, N. TAURA, T. YAMAZAKI, K. NAKAO ( <i>Nagasaki, Japan</i> ) .....	5001
<b>PROCEEDINGS OF THE JOINT INTERNATIONAL SYMPOSIA “Vitamin D in Prevention and Therapy” and “Biologic Effects of Light”</b> . May 04-06, 2022 ( <i>Homburg/Saar, Germany</i> ) .....	5009-5106
<i>Reviews</i>	
An Appraisal to Address Health Consequences of Vitamin D Deficiency With Food Fortification and Supplements: Time to Act! J. REICHRATH, W. MÁRZ, F.R. DE GRUIJL, R. VIETH, W.B. GRANT, A.T. SLOMINSKI, M.F. HOLICK, T. VOGT, S. PILZ ( <i>Homburg; Heidelberg; Mannheim, Germany; Graz, Austria; Leiden, the Netherlands; Toronto, ON, Canada; San Francisco, CA; Birmingham, AL; Boston, MA, USA</i> ).....	5009
Counteracting Side-effects of Photodynamic Therapy for Actinic Keratoses. H.C. WULF, I.M. HEERFORDT ( <i>Copenhagen, Denmark</i> ) .....	5017
Cutaneous Melanoma: Sheep in Wolves Clothing? F.R. DE GRUIJL, B.K. ARMSTRONG ( <i>Leiden, the Netherlands; Perth, WA, Australia</i> ).....	5021
Critique of Public Health Guidance for Vitamin D and Sun Exposure in the Context of Cancer and COVID-19. R. VIETH ( <i>Toronto, ON, Canada</i> ) .....	5027
Photosynthesis in Plants and Algae. D.-P. HÄDER ( <i>Möhrendorf, Germany</i> ) .....	5035
<i>Experimental Studies</i>	
A Novel Immunomodulatory Mechanism by Which Vitamin D Influences Folate Receptor 3 Expression to Reduce COVID-19 Severity. R.J. LU, P. SHIRVANI, M.F. HOLICK ( <i>Boston, MA, USA</i> ) .....	5043
Cross-talk of Aryl Hydrocarbon Receptor (AHR)- and Vitamin D Receptor (VDR)-signaling in Human Keratinocytes. C. CHRISTOFI, L. LAMNIS, A. STARK, H. PALM, K. RÖMER, T. VOGT, J. REICHRATH ( <i>Homburg, Germany</i> ) .....	5049
Quantification of Urinary Thymidine Dimers in Volunteers After Ultraviolet Radiation Using a New UPLC-MS/MS-based Method. C.M. LERCHE, P.A. PHILIPSEN, S. HERMANSSON, J. HEYDENREICH, H.C. WULF ( <i>Copenhagen, Denmark; Solna, Sweden</i> ).....	5069
Synthesis of <sup>13</sup> C Labeled Vitamin D Metabolites for Their Use in LC-MS/MS: Valuable Tools for Cancer Research and Other Applications. L. KATTNER, E. RAUCH ( <i>Saarbruecken, Germany</i> ).....	5077
High Oral Vitamin D <sub>3</sub> Intake Does Not Protect Against UVR-induced Squamous Cell Carcinoma in Mice. C.M. LERCHE, F.E. PINTO, P.A. PHILIPSEN, E.S. BECH, J. JAKOBSEN, M. HAEDERSDAL, H.C. WULF ( <i>Copenhagen; Kongens Lyngby, Denmark</i> ).....	5083
Mosquitoes Exposed to Sunlight in Florida Are Capable of Making Vitamin D <sub>3</sub> . M.F. HOLICK, P.K. STODDARD ( <i>Boston, MA; Miami, FL, USA</i> ).....	5091
<i>Clinical Studies</i>	
Evaluation of 14-day Concentration-time Curves of Vitamin D <sub>3</sub> and 25-Hydroxyvitamin D <sub>3</sub> in Healthy Adults With Varying Body Mass Index. N. CHAROENNGAM, P.M. MUELLER, M.F. HOLICK ( <i>Boston; Cambridge, MA, USA; Bangkok, Thailand; Bubendorf, Switzerland</i> ) .....	5095
Ultra-low Ultraviolet Radiation in Office Lighting Can Moderate Seasonal Vitamin D Cycle: A Pilot Study. A.R. WEBB, B.M.I. VAN DER ZANDE, R.C. KIFT, H. O’NEIL, N.X. LIN, D. WRIGHT ( <i>Manchester; Sunderland; Newcastle upon Tyne, UK; Eindhoven, the Netherlands</i> ).....	5101

<b>ABSTRACTS OF THE 32nd ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO). 6-8 October 2022 (Florence, Italy) .....</b>	<b>5107-5164</b>
Corrigendum .....	5165

**Number 11, November**

*Reviews*

Clinical Impact of Nutrition and Inflammation Assessment Tools in Gastric Cancer Treatment. T. AOYAMA, K. HARA, K. KAZAMA, Y. MAEZAWA ( <i>Yokohama; Kanagawa; Tokyo, Japan</i> ) .....	5167
Management of Resistant Post-transplant Lymphoproliferative Disorder: CAR-T Is a New Option. J. STYCZYNSKI, J. SADLOK, T. STYCZYNSKI, A. MARJANSKA, M. RICHERT-PRZYGONSKA ( <i>Bydgoszcz, Poland</i> ) .....	5181

*Experimental Studies*

Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ER $\beta$ Agonists. V. SCHMITZ, G. BAUERSCHMITZ, J. GALLWAS, C. GRÜNDKER ( <i>Göttingen, Germany</i> ) .....	5187
Candidate Oncogenes, <i>ARHGAP4</i> , <i>NOS3</i> , and <i>OR51B5</i> , for the Development of Scirrhus-type Gastric Cancer. T. SERA, T. SAKUMA, K. MARUO, G. TSUJIO, Y. YAMAMOTO, A. SUGIMOTO, S. KUSHIYAMA, S. TOGANO, K. KURODA, H. KASASHIMA, M. OHIRA, K. MAEDA ( <i>Osaka, Japan</i> ) .....	5195
Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment. T. SASAKI, K. SHIGETA, S. KITAHARA, Y. SUZUKI, S. MATSUI, R. SEISHIMA, K. OKABAYASHI, D.G. DUDA, Y. KITAGAWA ( <i>Tokyo; Sendai, Japan; Boston, MA, USA</i> ).....	5205
Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model. N. MASAKI, Q. HAN, C. SAMONTE, N.F. WU, C. HOZUMI, J. WU, K. OBARA, Y. KUBOTA, Y. AOKI, M. BOUVET, R.M. HOFFMAN ( <i>San Diego, CA; Cambridge, MA, USA; Tokyo; Narita, Japan</i> ) .....	5217
High Expression of <i>CD58</i> and <i>ALDH1A3</i> Predicts a Poor Prognosis in Basal-like Breast Cancer. Y. XIONG, H. MOTOMURA, S. TAMORI, A. OZAKI, C. ONAGA, Y. HARA, K. SATO, K. TAHATA, Y. HARADA, K. SASAKI, Y.-W. ZHENG, S. OHNO, K. AKIMOTO ( <i>Chiba; Tokyo, Japan; Jiangsu, PR China</i> ) .....	5223
Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Y. AKIYAMA, T. ASHIZAWA, A. IIZUKA, T. ANDO, Y. ISHIKAWA, R. KONDOU, H. MIYATA, C. MAEDA, A. KANEMATSU, T. SUGINO, K. YAMAGUCHI ( <i>Shizuoka; Yokohama, Japan</i> ) .....	5233
Luminophore Chemistry for Detection of Urinary Bladder Cancer – Comparison to Cytology and Urinary Rapid Tests (BTA stat <sup>®</sup> , NMP22 <sup>®</sup> BladderChek <sup>®</sup> and UBC <sup>®</sup> Rapid Test). T.H. ECKE, M. SCISLOWSKI, N. HASSAN, M. SAURA, S. HALLMANN, S. KOCH, S. VUOLLE, M. MALAKOUTIKHAH, K. KOPRA, H. HÄRMÄ ( <i>Bad Saarow; Berlin; Brandenburg, Germany; Turku, Finland</i> ) .....	5249
Loss of Heterozygosity of <i>BRCA1/2</i> as a Predictive Marker for Talazoparib Response. A.G. MIZRAHI, H. HAMAD, A. GUGENHEIM, B. NISMAN, A. KUZNETZ, I.B. DAVID, Y. GELFEND, S. COHEN, A. ZICK, K. SHEVA, H. NECHUSHTAN, T. PERETZ, A. MEIROVITZ ( <i>Jerusalem; Be'er Sheva, Israel</i> ) .....	5257
Pan-Aurora Kinase Inhibitor Danusertib Induces Apoptosis of Epstein–Barr Virus-transformed B-Cells Through Caspase and Endoplasmic Reticulum Stress Signaling. J.S. KIM, D.Y. HUR ( <i>Busan, Republic of Korea</i> ) .....	5265

The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma Susceptibility. T.-C. YUEH, H.-Y. TSAO, W.-C. CHIEN, C.-W. TSAI, J.-S. PEI, M.-H. WU, C.-P. CHEN, C.-C. CHEN, Z.-H. WANG, M.-C. MONG, Y.-C. YANG, Y.-C. HUNG, D.-T. BAU, W.-S. CHANG ( <i>Taichung; Taipei; Changhua; Taoyuan, Taiwan, ROC</i> ) .....	5275
Significant Contribution of Interleukin-18 Genotypes to Childhood Acute Lymphocytic Leukemia Risk in Taiwanese. C.-C. CHEN, H.-E. TZENG, C.-C. KUO, S.N.S. LIM, P.-C. HSU, Y.-N. HSU, Y.-T. CHIN, W.-S. CHANG, C.-H. WANG, C.-W. TSAI, J.-S. PEI, D.-T. BAU ( <i>Taoyuan; Taichung; Taipei, Taiwan, ROC</i> ) .....	5283
Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer <i>In Silico</i> Analysis. P.G. GONÇALVES, R.M. REIS, L.T. BIDINOTTO ( <i>Barretos; Botucatu, SP, Brazil; Braga; Guimarães, Portugal</i> ) .....	5291
Impact of Knowledge-based Plan Model Improvement on Plan Complexity and Deliverability in VMAT For Prostate Cancer: A Multi-institutional Study. M. TAMURA, Y. UEDA, J.-I. FUKUNAGA, T. KAMIMA, Y. SHIMIZU, Y. MURAKI, K. KUBO, K. NAKAMATSU, M. HOSONO, H. MONZEN ( <i>Osaka; Fukuoka; Tokyo; Shizuoka, Japan</i> ) .....	5305
Establishment and Characterisation of Human Clear Cell Sarcoma and Malignant Melanoma Cell Lines. M. ISHIGURO, T. FUKUSHIGE, H. IWASAKI, M. HAMASAKI ( <i>Fukuoka, Japan</i> ) .....	5315
Changes in Serum Trace Element Concentrations Before and After Surgery in Resectable Breast Cancer. E. TAKAHASHI, K. IMAI, M. FUKUYAMA, K. TERATA, H. NANJO, K. ISHIYAMA, Y. HIROSHIMA, M. YATSUYANAGI, C. KUDO, A. MORISHITA, A. WAKITA, S. TAKASHIMA, Y. SATO, K. NOMURA, Y. MINAMIYA ( <i>Akita, Japan</i> ) .....	5323
Role of Matrix Metalloproteinase-2 Genotypes in Taiwanese Patients With Colorectal Cancer. T.-C. YUEH, Y.-C. HUNG, H.-T. LEE, M.-D. YANG, Z.-H. WANG, Y.-C. YANG, T.-W. KE, J.-S. PEI, C.-W. TSAI, D.-T. BAU, W.-S. CHANG ( <i>Taichung; Taipei; Taoyuan, Taiwan, ROC</i> ) .....	5335
Engulfment and Cell Motility 1 (ELMO1) Regulates Tumor Cell Behavior and Predicts Prognosis in Colorectal Cancer. Y.-L. PARK, S.-B. CHO, S.-Y. PARK, H.-H. OH, E. MYUNG, C.-M. IM, S. SON, S. KIM, S.-Y. CHO, M.-W. CHUNG, J.-Y. HONG, K.-H. KIM, D.-S. MYUNG, W.-S. LEE, D. PARK, Y.-E. JOO ( <i>Gwangju, Republic of Korea</i> ) .....	5343
Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer. R. SHOJI, H. TSUCHIE, H. NAGASAWA, M. HONGO, Y. KASUKAWA, K. NOZAKA, D. KUDO, H. SAITO, K. ABE, S. IGARASHI, S. HARATA, F. KASAMA, N. MIYAKOSHI ( <i>Akita, Japan</i> ) .....	5357
The Activity of Vitamin C Against Ovarian Cancer Cells Is Enhanced by Hyperthermia. A. BIENKOWSKA-TOKARCZYK, A. MANDA-HANDZLIK, K. GAWRYCHOWSKI, U. DEMKOW, M. MAŁECKI ( <i>Warsaw, Poland</i> ) .....	5365
15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes. S.-H. KIM, S.E. SONG, H. BAIK, D.Y. HUR, M.S. KANG, K.B. BAE ( <i>Busan, Republic of Korea</i> ) .....	5385
Effects of Cyclooxygenase-2 in Canine Melanoma-derived Extracellular Vesicles on Tumor Microenvironment <i>In Vitro</i> . N.-H. KIM, J.-H. AN, J.-H. LEE, S.-M. PARK, K.-B. KIM, T.-H. KIM, Y.-I. OH, K.-W. SEO, H.-Y. YOUN ( <i>Seoul; Chuncheon-si; Daegu, Republic of Korea</i> ) .....	5397
Determination of Clonogenic Radiosensitivity of HeLa Cells in Early and Late G <sub>1</sub> Phases. K. TOHYAMA, A. KAIDA, M. MIURA ( <i>Tokyo, Japan</i> ) .....	5407



*Clinical Studies*

- Prognostic Role of *Porphyromonas gingivalis* Gingipain Rgp and Matrix Metalloproteinase 9 in Oropharyngeal Squamous Cell Carcinoma. A.K. KYLMÄ, T. SORSA, L. JOUHI, H.K. MUSTONEN, H. MOHAMED, R. RANDÉN-BRADY, A. MÄKITIE, T. ATULA, J. HAGSTRÖM, C. HAGLUND (*Helsinki; Turku, Finland; Huddinge; Stockholm, Sweden; Al Bayda, Libya*) ..... 5415
- Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis. K. KOCH, L. OSSWALD, I. MILLER, K. BRAITSCH, K. GÖTZE, F. BASSERMANN, P. HERHAUS, M. VERBEEK (*Munich, Germany*) ..... 5431
- Vascularized and Non-vascularized Fibula Grafts in Tumour Reconstruction: Single Centre Experience With Mid to Long-term Results. S.M. GORSKI, C. DONG, U. LENZE, M. HAUG, A.H. KRIEG (*Basel, Switzerland*) ..... 5443
- Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies. K. KING, R. RAUCH, S. ROY, O. MENYOK, K. TATEBE, B. TAJUDEEN, P. PAPAGIANNOPOULOS, P.S. BATRA, M. BHAYANI, S. AL KHUDARI, K. STENSON, M.J. JELINEK, M.J. FIDLER, N. JOSHI (*Chicago, IL, USA*) ..... 5449
- Effect of Palliative Care Decision on Use of Hospital Services in Pancreatic Cancer Patients: A Retrospective Study. S. MIINALAINEN, A. RISSANEN, R.-L. LESKELA, T. SAARTO, O. HIRVONEN, A. ANTTONEN (*Turku; Helsinki, Finland*) ..... 5457
- Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study. S. TAKEDA, T. NAMISAKI, Y. TSUJI, Y. FUJIMOTO, K. MURATA, M. ENOMOTO, Y. FUJINAGA, N. NISHIMURA, K. KITAGAWA, H. TAKAYA, K. KAJI, T. INOUE, H. KAWARATANI, T. AKAHANE, A. MITORO, H. YOSHIJI (*Kashihara, Japan*) ..... 5465
- Molecular Characteristics and Immunogenomic Profiling of Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma in a 68-year-old Patient. G. HUANG, L.N. HOWARD, E. ALONSOZANA, D. SILL, D. BOSE, J. LAI (*Clarksville; Baltimore, MD; Sacramento, CA, USA*) ..... 5475
- Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. S. KOMATSU, Y. YANO, M. KIDO, K. KURAMITSU, H. GON, K. FUKUSHIMA, T. URADE, S. SO, A. YAMAMOTO, T. GOTO, H. YANAGIMOTO, H. TOYAMA, Y. UEDA, Y. KODAMA, T. FUKUMOTO (*Kobe, Japan*) ..... 5479
- PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics. A. MEIROVITZ, L. BAIDER, T. PERETZ, S. STEPHANOS, V. BARAK (*Jerusalem, Israel; Ulm, Germany*) ..... 5487
- Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases. K. TAKEDA, Y. KIKUCHI, Y. SAWADA, T. KUMAMOTO, J. WATANABE, C. KUNISKI, T. MISUMI, I. ENDO (*Yokohama, Japan*) ..... 5497
- Surgery, Limb Edema and Health-related Quality of Life: A Prospective Follow-up Study on Patients With Cutaneous Malignant Melanoma. P. HEINO, P. MYLLÄRI, T. JAHKOLA, M.-L. LUOMA, P. RÄSÄNEN, R.P. ROINE (*Helsinki; Kuopio, Finland*) ..... 5507
- Interleukin-18 (IL-18) Cytokine Serum Concentrations Correlate With Pain Scores and the Number of Analgesic Doses Following Surgery. M. ESKELINEN, I. SAIMANEN, T. SELANDER, A. HOLOPAINEN, S. ASPINEN, E. HÄMÄLÄINEN, M. ESKELINEN (*Kuopio, Finland*) ..... 5521
- Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour – A Methodological Assessment Study. C.M. BRINCH, N. AGGERHOLM-PEDERSEN, T.S. POULSEN, W. SKOVRIDER-RUMINSKI, P. DE HEER, L. PENNINGA, A. KRARUP-HANSEN, E. HOGDALL (*Herlev; Aarhus; Copenhagen, Denmark*) ..... 5527



Neoadjuvant Therapy for Patients With Non-small Cell Lung Cancer Complicated With Chest Wall Invasion. K. SATO, S. NAKAMURA, Y. KADOMATSU, H. UENO, T. KATO, N. OZEKI, K. FUKUMOTO, T.F. CHEN-YOSHIKAWA ( <i>Nagoya, Japan</i> ).....	5539
Association Between a High Gene Expression Variant of Chymase and Increased Risk for Basal Cell Carcinoma. S. CHARALAMPIDOU, I. GINTONI, D. AVGOUSTIDIS, V. PAPAKOSTA, D. VLACHAKIS, S. VASSILIOU, C. YAPIJAKIS ( <i>Athens, Greece</i> ) .....	5547
Clinical Significance of Early Recurrence After Curative Resection of Colorectal Cancer. N. YAMAUCHI, T. MATSUDA, R. SAWAD, H. HASEGAWA, K. YAMASHITA, H. HARADA, N. URAKAWA, H. GOTO, S. KANAJI, T. OSHIKIRI, Y. KAKEJI ( <i>Kobe, Japan</i> ) .....	5553
Distress Scores During a Course of Radiotherapy: A Pilot Study. C. DELIKANLI, S. JANSSEN, D. KEIL, S. TVILSTED, S.E. SCHILD, D. RADES ( <i>Lübeck; Hannover, Germany; Køge, Denmark; Scottsdale, AZ, USA</i> ) .....	5561
Prognostic Significance of the Nodal Ratio and Number of Positive Nodes in Patients With Squamous Cell Carcinomas of the Head and Neck. I. REUTER, H.-H. MÜLLER, S. WIEGAND ( <i>Marburg; Münster; Leipzig, Germany</i> ) .....	5567
The Significance of Staging Laparoscopy in Detection of Radiologically Occult Peritoneal Carcinomatosis in Gastric Cancer With Gastric Outlet Obstruction: Consideration of The Optimal Treatment Approach. M. KOMATSU, T. KINOSHITA, E. AKIMOTO, M. YOSHIDA, D. TERAJIMA, H. NAGATA, T. HABU, T. OKAYAMA, Y. TAKABE, J. HARADA, M. YAMAGUCHI, M. YURA ( <i>Kashiwa; Tokyo, Japan</i> ).....	5571
Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients. A. PANUNZIO, S. TAPPERO, C.C. GARCIA, M. PICCINELLI, F. BARLETTA, R.-B. INCESU, Z. TIAN, A. TAFURI, D. TILKI, A. BRIGANTI, O. DE COBELLI, F.K.H. CHUN, C. TERRONE, F. SAAD, S.F. SHARIAT, I. BOURDEAU, M.A. CERRUTO, A. ANTONELLI, P.I. KARAKIEWICZ ( <i>Verona; Genoa; Milan, Italy; Montreal, QC, Canada; Frankfurt am Main; Hamburg, Germany; Istanbul, Turkey; Vienna, Austria; New York, NY; Dallas, TX, USA; Amman, Jordan</i> ) .....	5579
Neoadjuvant Modified Short-course Radiotherapy for Stage IV Rectal Cancer. H. DOI, M. FUJIWARA, N. BEPPU, H. YOKOYAMA, S. HARUI, A. SUGIHARA, H. YANAGI, Y. HISHIKAWA, N. YAMANAKA, N. KAMIKONYA ( <i>Nishinomiya; Osaka-Sayama, Japan</i> ) .....	5587
Detection of Recurrence After Primary Treatment for Oropharyngeal Carcinoma. F. LANDSTRÖM, J. REIZENSTEIN, S. KRISTIANSSON ( <i>Örebro, Sweden</i> ) .....	5597
Clinicopathological Characterization of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. H.YO. WOO, S.W. CHAE, S.-I. DO, K. NA ( <i>Seoul, Republic of Korea</i> ).....	5601
Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy. P.-H. SU, C.-C. HSU, S.-W. HSUEH, C.-Y. HUNG, K.-Y. YEH, H.-M. WANG, C.-H. LU, Y.-C. LIN, J.T.-C. CHANG, W.-C. CHOU ( <i>Keelung; Taoyuan; Taipei; Chiayi, Taiwan, ROC</i> ) .....	5609
Thyroglobulin Levels as a Predictor of Papillary Cancer Recurrence After Thyroid Lobectomy. J.-S. CHO, H.K. KIM ( <i>Gwangju, Republic of Korea</i> ).....	5619
A Survival Score for Very Elderly Patients With Brain Metastases Assigned to Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy. D. RADES, C. DELIKANLI, O. BLANCK, S.E. SCHILD, S. JANSSEN ( <i>Lübeck; Kiel; Hannover, Germany; Scottsdale, AZ, USA</i> ) .....	5629

The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer. T. AOYAMA, Y. MAEZAWA, K. HARA, M. JU, K. KOMORI, H. TAMAGAWA, A. TAMAGAWA, K. KAZAMA, S. SAWAZAKI, I. HASHIMOTO, K. KANO, H. CHO, J. MORITA, K. SEGAMI, T. ISHIGURO, T. SATO, T. OSHIMA, N. YUKAWA, Y. RINO ( <i>Yokohama; Tokyo, Japan</i> ) .....	5635
Gustave Roussy Immune Score for Predicting Postoperative Complications and Non-cancer Death in Elderly Patients With Colon Cancer. T. TOMINAGA, T. NONAKA, S. OYAMA, Y. TAKAMURA, S. HASHIMOTO, T. SHIRAISHI, T. SAWAI, T. NAGAYASU ( <i>Nagasaki, Japan</i> ) .....	5643
Evaluating Neoadjuvant Chemotherapy for Lower Esophageal Squamous Cell Carcinoma by Measuring Esophageal Wall Thickness. H. SATO, K. NISHIKAWA, T. HAMAKAWA, C. KUSUNOKI, M. MIYAKE, A. MIYAMOTO, T. KATO, M. MANO, K. TAKAMI, M. HIRAO ( <i>Suita; Sakai; Osaka; Izumisano, Japan</i> ) .....	5655
Vater Papilla-preserving Strategy for Advanced Hepatocellular Carcinoma With Excessive Bile Duct Tumor Thrombus. K. YAMAMURA, T. BEPPU, K. INOUE, K. MATSUMURA, E. ODA, Y. NAGAYAMA, T. MOTOHARA, H. MIYAMOTO, Y. KOMOHARA, H. OKABE, T. MIYATA, T. ISIKO ( <i>Kumamoto, Japan</i> ) .....	5663
Corrigenda .....	5671

## Number 12, December

### Review

Phase I CAR-T Clinical Trials Review. S. BULSARA, M. WU, T. WANG ( <i>Houston, TX, USA</i> ) .....	5673
--	------

### Experimental Studies

<i>In Vitro</i> Anticancer Activity of the Light Stable Zinc Isotope ( <sup>64</sup> Zn) Compounds. P. NOVAK, A. BALAKIN, M. TEMNIK ( <i>North Miami Beach, FL, USA</i> ) .....	5685
The Prognostic Value of Plasma Small Extracellular Vesicles' Phenotype in Patients With Gastrointestinal Stromal Tumor. C.M. BRINCH, E. HOGDALL, P. DE HEER, L. PENNINGA, R. BÆK, M.M. JORGENSEN, B.E. ENGELMANN, P.B. ROSSEN, H.J. MORTENSEN, A. KRARUP-HANSEN, N. AGGERHOLM-PEDERSEN ( <i>Herlev; Copenhagen; Aalborg; Aarhus, Denmark</i> ) .....	5699
GPX4 Regulates Tumor Cell Proliferation <i>via</i> Suppressing Ferroptosis and Exhibits Prognostic Significance in Gastric Cancer. K. SUGEZAWA, M. MORIMOTO, M. YAMAMOTO, Y. MATSUMI, Y. NAKAYAMA, K. HARA, C. UEJIMA, K. KIHARA, T. MATSUNAGA, N. TOKUYASU, T. SAKAMOTO, Y. UMEKITA, Y. FUJIWARA ( <i>Yonago, Japan</i> ) .....	5719
The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer. A. PARTYNSKA, A. PIOTROWSKA, K. PAWELCZYK, A. RZETCHONEK, K. RATAJCZAK-WIELGOMAS, M. PODHORSKA-OKOLOW, P. DZIEGIEL ( <i>Wroclaw, Poland</i> ) .....	5731
Intracellular C3 Modulates EMT <i>via</i> the Akt/Smad Pathway in Pancreatic Cancer Cells. R. SUZUKI, T. TAKAGI, M. SUGIMOTO, Y. SATO, H. IRIE, Y. YOMOGIDA, H. OHIRA ( <i>Fukushima, Japan</i> ) .....	5743
Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma. Y. MORISHITA, K. TAKENOUCI, S. SAKASHITA, K. MATSUURA, R. HAYASHI, T. NAKATSURA ( <i>Kashiwa, Japan</i> ).....	5751
Endosomal Localization of RacGAP Protein ARHGAP22 Regulates its GAP Activity in Human Melanoma Cells. M. MORI, K. SAITO, A. SEKINE, R. HASEBE, Y. OHTA ( <i>Kanagawa, Japan</i> ) .....	5763
COX-2 Acts as a Key Mediator of Trifluoperazine-induced Cell Death in U87MG Glioma Cells. J. PARK, J.Y. JEONG, S.S. KANG ( <i>Jinju, Republic of Korea</i> ) .....	5773

Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer. M. KOIZUMI, S. SATO, M. YOSHIHARA, Y. NAKAMURA, H. TERAU, Y. OKUBO, K. WASHIMI, E. YOSHIOKA, T. YOKOSE, T. KISHIDA, N. KOSHIKAWA, Y. MIYAGI ( <i>Yokohama; Tokyo, Japan</i> ) .....	5783
Genetic Predisposition to Male Breast Cancer: A Case Series. A. APESSOS, K. AGIANNITOPOULOS, G. PEPE, G.N. TSAOUSIS, P. PITTA, C. BILI, L. FLORENTIN, E. SALOUSTROS, E. KAMPLETSAS, D. TRYFONOPOULOS, N. TSOUKALAS, E. BOURNAKIS, F. ZAGOURI, A. KOTSAKIS, A. KOUMARIANOU, I. KORANTZIS, I. BOUKOVINAS, G. LYPAS, G. FOUNTZILAS, V. MICHALAKI, S. XYNOGALOS, H. LINARDOU, E. PAPADOPOULOU, G. NASIOULAS, V. GEORGOULIAS ( <i>Athens; Larissa; Ioannina; Heraklion; Thessaloniki; Piraeus, Greece; Limassol, Cyprus</i> ) .....	5795
Hypoxia Increases the Proliferative and Metastatic Ability of Canine Mammary Tumor Cells <i>via</i> Up-regulation of TSG-6. T.-H. KIM, J.-H. LEE, J.-H. AN, B.-G. KO, K.-B. KIM, H.-Y. YOUN ( <i>Seoul; Chuncheon-si, Republic of Korea</i> ) .....	5803
<i>Clinical Studies</i>	
Disparities in Time to Treatment for Breast Cancer. K. SUKNIAM, A.A. KASBI, M.A. ASHARY, K. POPP, K. ATTWOOD, A. GEORGE, E. GABRIEL ( <i>Suwanee, GA; Jacksonville, FL; Buffalo, NY, USA</i> ).....	5813
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction. Y. KUBOTA, Q. HAN, N. MASAKI, C. HOZUMI, K. HAMADA, Y. AOKI, K. OBARA, T. TSUNODA, R.M. HOFFMAN ( <i>San Diego, CA, USA; Tokyo; Narita, Japan</i> ).....	5819
Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years. N. STEINER, P. SCHOBBER, W. WILLENBACHER, B. KIRCHER, E. GUNSILIUS, D. WOLF, D. NACHBAUR ( <i>Innsbruck, Austria</i> ) .....	5825
Significance of Zinc Replacement Therapy After Pancreaticoduodenectomy. C. TAKISHITA, Y. NAGAKAWA, H. OSAKABE, N. NAKAGAWA, Y. MITSUKA, J. MAZAKI, K. IWASAKI, T. ISHIZAKI, S. KOZONO ( <i>Tokyo, Japan</i> ) .....	5833
Evaluation of the Diagnostic Potential of Circulating MicroRNAs <i>miR-1</i> and <i>miR-21</i> in Patients With Ovarian Cancer. D.J. RALSER, M. CONDIC, E. EGGER, D. KOENSGEN, A. MUSTEA, M.B. STOPE ( <i>Bonn, Germany</i> ) .....	5839
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study. A. BEIGE, F. GHIRINGHELLI, J. LECUELLE, C. TRUNTZER, G. TRUC, J. VINCENT, W. FARAH, F. BORSOTTI, I. MAZILU, S.M. ILIE ( <i>Dijon, France</i> ) .....	5847
Predicting Overall Survival Using Machine Learning Algorithms in Oral Cavity Squamous Cell Carcinoma. J.Y. TAN, J. ADEOYE, P. THOMSON, D. SHARMA, P. RAMAMURTHY, S.-W. CHOI ( <i>Hong Kong, SAR; Queensland, Australia</i> ).....	5859
Detection of “Incidentalomas” on Brain and Body <sup>68</sup> Ga-DOTATOC-PET Scans: A Retrospective Study and Case Illustration. G.E. UMANA, G. FERINI, M.M. HARIKAR, T. VENKATARAM, R. COSTANZO, G. SCALIA, P. PALMISCIANO, L. BRUNASSO, F. PAOLINI, A. SCIORTINO, R. MAUGERI, A. CREA, F. BARONE, F. INSERRA, V. DA ROS, G. CUTTONE, G. CORSALE, C. CRISTAUDO, S. COSENTINO, M.G. SABINI, M. IPPOLITO ( <i>Catania; Viagrande; Palermo; Rome, Italy</i> ) .....	5867
A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer. C.H. LIM, Y.W. KOH, S.H. HYUN, S.J. LEE ( <i>Seoul; Suwon, Republic of Korea</i> ) .....	5875

Clinical Significance of <i>SEC11A</i> Expression in Patients With Locally Advanced Gastric Cancer. H. SUEMATSU, K. SAKAMAKI, N. OUE, Y. HIROSHIMA, Y. KIMURA, S. ONUMA, I. HASHIMOTO, S. NAGASAWA, T. AOYAMA, T. YAMADA, H. TAMAGAWA, T. OGATA, Y. RINO, M. MASUDA, W. YASUI, Y. MIYAGI, T. OSHIMA ( <i>Yokohama; Hiroshima, Japan</i> ).....	5885
Further Study on Field Cancerization in the Human Colon. C.A. RUBIO, C. LANG-SCHWARZ, M. VIETH ( <i>Stockholm, Sweden; Bayreuth, Germany</i> ).....	5891
Fibroblast Activation Protein and Tertiary Lymphoid Structure in Colorectal Cancer Recurrence. S. HAYASE, N. MIYOSHI, S. FUJINO, M. YASUI, M. OHUE, S. MINAMI, S. KATO, A. NAGAE, Y. SEKIDO, T. HATA, A. HAMABE, T. OGINO, H. TAKAHASHI, M. UEMURA, H. YAMAMOTO, Y. DOKI, H. EGUCHI ( <i>Osaka, Japan</i> ) .....	5897
Simultaneously Integrated Boost Affects Survival in Locally Advanced p16-Negative Oropharyngeal Squamous Cell Carcinoma. F. DE FELICE, D. MUSIO, M. SERPONE, G. VAVALLE, C. MARCHETTI, V. TOMBOLINI ( <i>Rome, Italy</i> ) .....	5909
Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database. J. SATO, T. EREN, S. MURATA, T. SHIMIZU, M. UCHIDA ( <i>Nasushiobara; Ootawara; Kyotanabe; Kobe, Japan</i> ).....	5917
Low Expression of <i>SNAI1</i> in Lymph Node Metastasis Indicates Delayed Recurrence of Colonic Cancer. S. LIM, K. KAWAI, H. NOZAWA, K. SASAKI, K. MURONO, S. EMOTO, Y. YOKOYAMA, H. MATSUZAKI, Y. NAGAI, S. ABE, Y. YOSHIOKA, T. SHINAGAWA, H. SONODA, S. ISHIHARA ( <i>Tokyo, Japan</i> ).....	5927
Limited Oncological Benefits of Laparoscopic Total Gastrectomy With Splenectomy for Patients With Type 4 or Large Type 3 Gastric Cancer. M. SAKAGUCHI, H. HOSOGI, S. HISAMORI, Y. KINJO, S. KANAYA, K. OBAMA ( <i>Osaka; Kyoto; Himeji, Japan</i> ) .....	5937
Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer. K. SUZUKI, S. SASADA, Y. KIMURA, A. EMI, T. KADOYA, M. OKADA ( <i>Hiroshima, Japan</i> ) .....	5945
Clinical Outcome and Risk Factors of Chronic Radiation Proctitis Following Pelvic Radiation Therapy. C.-M. IM, I.-J. CHO, H.-J. YU, B. HAN, H.-H. OH, Y.-J. SEO, K.-H. KIM, D.-S. MYUNG, S.-B. CHO, W.-S. LEE, T.-K. NAM, Y.-E. JOO ( <i>Gwangju, Republic of Korea</i> ).....	5951
Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC. K. SHIMOMURA, T. YAMAGUCHI, Y. OYA, K. UCHIDA, K. MUROTANI ( <i>Nagoya; Kurume; Toyoake, Japan</i> ).....	5961
Impact of Osteopenia on Pancreatic Fistula in Patients Undergoing Pancreaticoduodenectomy. T. YAMANAKA, N. HARIMOTO, R. MURANUSHI, K. HOSHINO, K. HAGIWARA, N. ISHII, M. TSUKAGOSHI, K. WATANABE, K. ARAKI, K. SHIRABE ( <i>Gunma, Japan</i> ).....	5971
Detailed Surgical Techniques and Short-term Clinical Outcomes of Sleeve Lobectomy for Locally Advanced Right Lower Lobe Lung Cancer. T. TSUKIOKA, N. IZUMI, H. KOMATSU, H. INOUE, R. ITO, S. SUZUKI, N. NISHIYAMA ( <i>Osaka, Japan</i> ).....	5977
Impact of Abdominal Aortic Calcification After Major Hepatobiliary Pancreatic Surgery: A Retrospective Cohort Study. Y. IMAOKA, M. OHIRA, K. SATO, K. IMAOKA, T. BEKKI, R. NAKANO, S. KURODA, H. TAHARA, K. IDE, T. KOBAYASHI, Y. TANAKA, H. OHDAN ( <i>Hiroshima, Japan</i> ) .....	5983
Definitive Radiotherapy Using Electron Beam and Intensity-modulated Radiotherapy for Unresectable Angiosarcoma of the Scalp. N. OKANO, H. YUMISAKI, S. SAITO, N. KUBO, K. OKADA, H. KAWAMURA, M. YASUDA, T. OHNO ( <i>Gunma, Japan</i> ) .....	5991

Modified Geriatric Nutrition Risk Index as a Prognostic Predictor for Unresectable/Recurrent Esophageal Cancer. K. KOUZU, H. TSUJIMOTO, N. UEHATA, Y. ISHIBASHI, Y. KISHI, H. UENO ( <i>Tokorozawa, Japan</i> ).....	5999
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study. K. TAJIRI, Y. TOKIMITSU, K. KAWAI, Y. MOTOFUJI, E. SHINNO, Y. KASHII, N. MURAISHI, A. MURAYAMA, Y. HAYASHI, M. MINEMURA, T. TAKAHARA, Y. SHIMIZU, I. YASUDA ( <i>Toyama; Nanto; Imizu, Japan</i> ) .....	6007
Prognostic Nutrition Index as an Indicator of Therapeutic Response to Lenvatinib Therapy in Hepatocellular Carcinoma. M. SHIBANO, K. TAKAHASHI, M. TAKAHASHI, S. UCHIDA-KOBAYASHI, N. KAWADA, Y. NAKAMURA, T. OTORI, K. NAGAYAMA ( <i>Osaka, Japan</i> ) .....	6019
Risk of Abemaciclib-induced Liver Injury in Hormone Receptor–positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis. A. TANIGUCHI, N. KITAKA, H. KANAOKA, S. NAKAJIMA, Y. OYAMA, Y. SETO, A. SOMA, H. KUSAMA, N. WATANABE, S. MATSUI, M. NISHIO, F. FUJISAWA, T. NAKAYAMA ( <i>Osaka, Japan</i> ) .....	6027
Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. Y. HAMAI, M. EMI, Y. IBUKI, T. KUROKAWA, T. YOSHIKAWA, M. OHSAWA, R. HIROHATA, N. KITASAKI, M. OKADA ( <i>Hiroshima, Japan</i> ).....	6037
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer. T. KUSAKA, K. SHIGA, K. KATAGIRI, D. SAITO, S.-I. OIKAWA, A. IKEDA, K. TSUCHIDA, J. MIYAGUCHI, Y. OHASHI, H. ARIGA, K. TANNO ( <i>Yahaba, Japan</i> ).....	6047
Association of ABC and RENAL Scoring Systems With Morbidity in Partial Nephrectomy. M.E. JIMÉNEZ ROMERO, I.B. GONZÁLEZ, M.A. SÁNCHEZ HURTADO, J.C. RODRÍGUEZ BOCANEGRA, J.D. SANTOTORIBIO ( <i>Cádiz; Cáceres, Spain</i> ) .....	6057
First-Line Gemcitabine, Nab-Paclitaxel, and Oxaliplatin Chemotherapy With Itraconazole in Patients With Metastatic Pancreatic Cancer: A Single Institution Experience. M. SAWASAKI, H. TSUBAMOTO, A. SUGIHARA, S. IKUTA, Y. SAKAI, Y. OSAKI, T. SONODA ( <i>Nishinomiya, Japan</i> ) .....	6063
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer. T. INAGAKI, M. SATO, M. KIN, K. OTSUKA, M. MURAKAMI, M. KOGO ( <i>Tokyo, Japan</i> ).....	6071
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis. J.H. YI, S.J. KIM, J.-O. LEE, G.-W. LEE, J.-Y. KWAK, H.-S. EOM, J.-C. JO, Y.S. CHOI, S.Y. OH, W.S. KIM ( <i>Seoul; Seongnam; Jinju; Jeonju; Goyang; Ulsan; Suwon; Busan, Republic of Korea</i> ).....	6083
Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors. J.H. PARK, H.S. LEE, J.W. CHOI, S.D. LIM, H.K. KOH, K.R. CHO, J. CHO, Y.-C. KOH, S.Y. YOON ( <i>Seoul, Republic of Korea</i> ) .....	6091
Safety and Efficacy of Palliative Radiotherapy (25 Gy × 5 Fractions) for Symptomatic Pelvic Tumors. T. AOSHIKA, T. ABE, M. IINO, S. SAITO, Y. RYUNO, T. OHTA, M. IGARI, R. HIRAI, Y. KUMAZAKI, S.-E. NODA, S. KATO ( <i>Saitama, Japan</i> ) .....	6099
A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma. S. MOTOYAMA, M. HOSAKA, T. KAMEI, M. UENO, M. WATANABE, Y. OHKURA, S. MINE, S. TANABE, T. TOYOKAWA, A. WAKITA, K. NISHIKAWA, I. NINOMIYA, K. FUJITA, M. KANDA, M. HIRAI, M. HOSHI, S.-W. CHIU, M. TAKATA, T. YAMAGUCHI, M. MIURA ( <i>Akita; Sendai; Tokyo; Okayama; Osaka; Kanazawa; Kyoto, Japan</i> ).....	6105



Overall Survival of Small-cell Lung Cancer Patients With Malignant Central Airway Obstruction Who Received Chemotherapy Without Undergoing Transbronchial Interventions: A Single-institution Retrospective Study. K. KASHIWABARA, S. FUJII, S. TSUMURA, K. SAKAMOTO ( <i>Kumamoto, Japan</i> ) .....	6113
Unusual Findings in a Patient With Carney Complex due to a Novel <i>PRKARIA</i> Mutation. R.E. FRIEDRICH, M. ZENKER ( <i>Hamburg; Magdeburg, Germany</i> ) .....	6121
Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery. S. SEO, E. HATANO, M. KANAI, K. OGAWA, Y. TAKADA, S. KOBAYASHI, H. EGUCHI, H. NAGANO, T. IOKA ( <i>Kyoto; Osaka; Ehime; Ube, Japan</i> ) .....	6127
Corrigenda .....	6135
Index .....	6137

## Subject Index

(Figures refer to page numbers)

- 14-3-3 sigma protein, gastric cancer, cell proliferation, tumor progression, metastasis, prognostic factor, 519
- 15-PGDH, colon cancer, metastasis, PGE2, epithelial-to-mesenchymal transition, 5385
- <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography, breast cancer, endocrine therapy, CDK4/6 inhibitor, predictive factor, 4813
- 2-5 cm, soft-tissue tumor, malignancy, MRI, needle biopsy, unplanned excision, 1555
- 25 Gy/5 fr, palliative radiotherapy, pelvic tumors, 6099
- 1,25-dihydroxyvitamin D<sub>3</sub>, squamous cell carcinoma, keratinocytes, 1, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- 25-hydroxyvitamin D, vitamin D, pharmacokinetics, clinical trial, intestinal absorption, 5095
- 25-hydroxyvitamin D serum concentration, vitamin D deficiency, food fortification, supplementation, vitamin D status, review, 5009
- 25-hydroxyvitamin D<sub>3</sub>, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- 25-hydroxyvitamin D<sub>3</sub>, vitamin D, d-vitamin, cholecalciferol, UVR, hairless mice, 5083
- 25(OH)2D, COVID-19, sARS-CoV-2, vitamin D, 1,25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, vitamin D response element, VDRE, review, 5043
- 25(OH)D, COVID-19, sARS-CoV-2, vitamin D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- 25(OH)D, ultraviolet Radiation, vitamin D, winter, cross-over trial, office lighting, 5101
- 3D cell culture, osteoblasts, bisphosphonates, PRP, PRF, 1295
- 3D culture, TNBC,  $\beta$ -tubulin isoform, docetaxel, spheroid, morphology, 4735
- 3D floating culture, cancer spheroid, KRAS, low-toxic, context-independent, 3993
- 5-fluorouracil, colorectal cancer, thymidine phosphorylase, inhibitor of methylation, 837
- 5-fluorouracil, esophageal squamous cell carcinoma, docetaxel, cisplatin, neoadjuvant chemoradiotherapy, 3905
- 5-fluorouracil, hyperthermia, colorectal carcinoma, cancer therapeutics, capecitabine, bevacizumab, cetuximab, 2363
- 5% glucose, gemcitabine, vascular pain, saline, lyophilized formulation, liquid formulation, 343
- <sup>68</sup>Ga-DOTATOC, gamma-knife radiosurgery, incidentaloma, meningioma, neuroendocrine tumor, PET/CT scan, 5867
- <sup>68</sup>Ga-PSMA PET/CT, prostate cancer, bone scan, pCa staging, 1495
- <sup>68</sup>Ga-PSMA PET/CT, prostate cancer, mpMRI, targeted prostate biopsy, 3011
- 8-oxo-deoxyguanosine, mixed nuts, pistachios, colon cell proliferation, cyclooxygenase 2, 4285
- 8-oxo-deoxyguanosine, mixed nuts, pistachios, colon cell proliferation, cyclooxygenase 2, 4285
- 8q24.21, gastric cancer, gene expression, CNV, 4381
- <sup>90</sup>Y-microspheres, rabbit models, loco-regional therapy, 827
- 9p, *in silico* analysis, TCGA, prognostic value, gene expression, 9p22.1 locus, 5291
- 9p22.1 locus, *in silico* analysis, TCGA, prognostic value, gene expression, 9p, 5291
- A-enolase, glioma, meningioma, ENO1, glioblastoma, MBP1, 2319
- A $\beta$ T cell therapy, immune-cell therapy, adjuvant therapy, solid tumor, dendritic cell vaccine, 4179
- B-actin, papillary thyroid carcinoma, circulating cell-free DNA, cfDNA integrity index, GAPDH, 2289
- B-tubulin isoform, TNBC, docetaxel, 3D culture, spheroid, morphology, 4735
- $\Gamma$ -glutamylcyclotransferase, antisense, lung cancer, AMPK, cyclin-dependent kinase inhibitor, reactive oxygen species, 1221
- $\gamma$ -glutamylcyclotransferase, n-acetylcysteine, reactive oxygen species, cyclin-dependent kinase inhibitors, pro-GA, breast cancer, 4311
- $\Gamma\delta$ T cells, adoptive immunotherapy (AIT), zoledronate, ZAK cells, pancreatic cancer, 1181
- A20/TNFAIP3, triple-negative breast cancer (TNBC), cell division cycle 20 (Cdc20), cASP1/Caspase-1, inflammation, metastasis, inflammation inhibitors, 681
- A549 cells, chloroquine, doxorubicin, autophagy, apoptosis, oxidative stress, caspase, extracellular-signal-regulated kinase, 4025
- ABCA1, liver X receptors, small-cell lung cancer, cholesterol metabolism, T0901317, 2923
- Abdominal aortic calcification, comprehensive complication index, complications, HBP surgery, risk factors, 5983
- Abemaciclib, aromatase inhibitor, breast cancer, liver injury, risk factor, 6027
- Abemaciclib, ER+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, palbociclib, 1099
- Abiraterone acetate, docetaxel, enzalutamide, CRPC, sequential treatment, 2123
- Abiraterone, docetaxel, enzalutamide, metastatic castration-resistant prostate cancer, 4857
- Abiraterone, PSA decline, sequential therapy, enzalutamide, CRPC, 3041

- Ablation, intrahepatic cholangiocarcinoma, multidisciplinary treatment, systemic chemotherapy, 3209
- Abscopal effect, checkpoint inhibitors, radiotherapy, oligoprogression, volumetric assessment, 4795
- Abscopal effect, chemoimmunotherapy, brain metastasis, non-small cell lung cancer, radiotherapy, 4805
- Absolute lymphocyte count, advanced breast cancer, CDK4/6 inhibitor, peripheral blood biomarker, prognostic factor, 4867
- Absolute lymphocyte count, eribulin, progression-free survival, advanced or metastatic breast cancer, tumor immunology, 939
- ACC, adrenocortical carcinoma, hispanics, race, 5579
- Accelerated hyperfractionated radiotherapy, rectal cancer, preoperative radiotherapy, neoadjuvant radiotherapy, short-course radiotherapy, capecitabine, S-1, chemotherapy, radiotherapy, 5587
- Acellular dermal matrix, breast reconstruction, pre-pectoral, semi-smooth implant, nano-textured, 1013
- Acetyl plumbagin, breast cancer, drug resistance, cholesterol, tamoxifen, 565
- Acetylation, HDAC6, cholangiocarcinoma, GRP78, ACY-1215, 471
- Acridine orange, metastasis, breast cancer, zoledronate, 5357
- Actin cytoskeleton, melanoma, leukemia, cancer cell migration, rhoGTPase, rac, rhoGAP, rab11, recycling endosome, 5763
- Actinic keratosis, adverse events, photodynamic therapy, protoporphyrin IX, skin, review, 5017
- Activator protein-1, BRAF V600E, PLX4032, imidazothiazole, chemoresistance, melanoma, 2911
- Activity of aldehyde dehydrogenase, near-infrared turn-on fluorescence probe, C5S-A, breast cancer, stem cells, 1199
- Acute leukemia, p13KC2 $\beta$ , pharmacological inhibition, cell proliferation, migration, brain tumours, neuroendocrine tumours, 3217
- Acute myeloid leukemia, children, therapeutic era, survival, 4499
- Acute side-effects, prostate cancer radiotherapy, quality of life, stereotactic body radiotherapy, rectal displacement device, 2553
- ACY-1215, HDAC6, cholangiocarcinoma, GRP78, acetylation, 471
- Adaptive boost planning, bioZorb<sup>®</sup> marker, tumor bed boost volume, 2961
- Adenocarcinoma of the esophagogastric junction, esophageal cancer, radio-chemotherapy, sleep problems, prevalence, risk factors, 4529
- Adenocarcinoma, annexin A10, lung cancer, spiral array, 1289
- Adenocarcinoma, colorectal, appendiceal, peritonectomy, carcinoembryonic antigen, review, 4217
- Adenocarcinoma, esophageal cancer, squamous cell carcinoma, toll-like receptors, microbiome, review, 2813
- Adenocarcinoma, esophagogastric cancer, recurrence, lymph node metastasis, 1051
- Adenocarcinoma, lung transplant, lung cancer, idiopathic pulmonary fibrosis, 1157
- Adenocarcinoma, non-small cell carcinoma, chemotherapy, radiotherapy, chest wall, 5539
- Adenovirus death protein, adenovirus vector, progeny virus, cytopathic effect, 1719
- Adhesion molecules, eribulin, tGF- $\beta$ , endMT, neo-angiogenesis, 2859
- Adipocyte, anti-inflammation, insulin signal, lipopolysaccharide, type 2 diabetes, 3983
- Adipocytes, bladder cancer, EPHA2, cancer recurrence, biomarker, machine learning, 5783
- Adjuvant chemotherapy, adjuvant concurrent chemoradiotherapy, propensity score, resection margin, 3195
- Adjuvant chemotherapy, cisplatin, capecitabine, gastric cancer, metastasis, 2009
- Adjuvant chemotherapy, invasive IPMC, poorly differentiated adenocarcinoma, lymph node metastasis, tubular type, 2645
- Adjuvant chemotherapy, rectal cancer, neoadjuvant chemotherapy, prognosis, 1527
- Adjuvant chemotherapy, relative dose intensity, pancreatic ductal adenocarcinoma, S-1, overall survival, 3133
- Adjuvant chemotherapy, resection, colorectal cancer liver metastases, recurrence, overall survival, 5497
- Adjuvant concurrent chemoradiotherapy, adjuvant chemotherapy, propensity score, resection margin, 3195
- Adjuvant radiation therapy, locoregional radiotherapy, breast cancer, toxicity, side-effects, 923
- Adjuvant radiotherapy, breast cancer, sleep disorders, prospective trial, patient reported outcomes, 3085
- Adjuvant radiotherapy, prostate cancer, biochemical recurrent prostate cancer, radiotherapy timing, salvage radiotherapy, 2997
- Adjuvant radiotherapy, squamous cell carcinoma, oral cancer, pN1, survival, metastatic lymphadenopathy, neck dissection, postoperative radiotherapy, 97
- Adjuvant therapy, gemcitabine, pancreatic cancer, positive peritoneal lavage cytology, postoperative chemotherapy, S-1, 893
- Adjuvant therapy, immune-cell therapy, solid tumor,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4179
- Adjuvant therapy, oral squamous cell carcinoma, prognostic factors, p16, HPV, 2405
- ADME evaluation, small chemical compound library, *in silico* screening, ELISA for inhibition of PD-1/PD-L1 binding, mHC-dKO NOG mouse, 5233
- Adoptive immunotherapy (AIT), zoledronate, ZAK cells,  $\gamma\delta$ T cells, pancreatic cancer, 1181
- Adoptive T cell therapy, multiple myeloma, dendritic cells, cytotoxic T cells, B cell maturation antigen, 1785
- Adrenocortical carcinoma, ACC, hispanics, race, 5579
- Adult T-cell, dimethyl fumarate, NF- $\kappa$ B, STAT3, c-IAP2, leukemia, lymphoma, 2301

- Advanced breast cancer, CDK4/6 inhibitor, peripheral blood biomarker, absolute lymphocyte count, prognostic factor, 4867
- Advanced breast cancer, everolimus, first line, safety, effectiveness, 1031
- Advanced cancer, nivolumab, immunotherapy, checkpoint inhibitors, PD-1/PDL-1, CTLA-4, 1433
- Advanced colorectal cancer, checkpoint-with-forkhead-and-ring-finger-domains (CHFR), dNA-promoter methylation, irinotecan, histoculture drug response assay (HDRA), clinical correlation, biomarker, 697
- Advanced gastric cancer, epstein–Barr virus, gastric carcinoma with lymphoid stroma, p53, 4955
- Advanced hepatocellular carcinoma, liver resection, conversion surgery, lenvatinib, 3049
- Advanced hepatocellular carcinoma, maintenance chemotherapy, sorafenib, very high risk of recurrence, 6127
- Advanced low rectal cancer, predictors, lateral pelvic lymph node metastasis, size criterion, magnetic resonance imaging, 2113
- Advanced or metastatic breast cancer, eribulin, absolute lymphocyte count, progression-free survival, tumor immunology, 939
- Advanced ovarian cancer, cardiophrenic lymph nodes, lymphadenectomy, review, 13
- Advanced ovarian cancer, complete surgery, primary debulking surgery, predictive index value, peritoneal cancer index, 115
- Advanced ovarian cancer, PCI, CT, complete cytoreductive surgery, overall survival, 2541
- Advanced urothelial carcinoma, platinum-based chemotherapy pembrolizumab, real-world clinical practice, 1571
- Adverse drug event, COVID-19 vaccine, cancer, anticancer agent, urology, 2105
- Adverse drug event, ovarian neoplasms, bevacizumab, chemotherapy, gastrointestinal perforation, 4165
- Adverse event, granulocyte colony-stimulating factor, esophageal cancer, bone marrow suppression, chemotherapy, 2783
- Adverse event, head and neck squamous cell carcinoma, S-1, preoperative chemotherapy, surgical case, 3177
- Adverse events, actinic keratosis, photodynamic therapy, protoporphyrin IX, skin, review, 5017
- Adverse events, biomarker, chemotherapy, hepatocellular carcinoma, intestinal permeability, 4895
- Adverse events, biomarker, chemotherapy, hepatocellular carcinoma, intestinal permeability, 5465
- Adverse events, breast cancer, endocrine therapy, aromatase inhibitors, side effects, community pharmacy services, community pharmacists, health knowledge, educational intervention, review, 661
- Adverse events, chemotherapy, medication guidance sheet, non-Hodgkin's lymphoma, ESHAP±R therapy, 2053
- Adverse events, lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, Child–Pugh, progression-free survival, objective response, 173
- Adverse events, meta-analysis, systematic review, asthenia, fatigue, placebo, cancer, oncology, randomized trials, CTCAE, review, 45
- Adverse events, meta-analysis, systematic review, placebo, cancer, oncology, randomized trials, CTCAE, medDRA, review, 2805
- Aedes aegypti* mosquitoes, vitamin D, mosquitoes, *Drosophila melanogaster*, migratory birds, bats, vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 5091
- Aerobic exercise, cachexia, resistance exercise, inflammation, colon cancer, colon-26, muscle fiber type, 397
- Afatinib, lung cancer, osimertinib, T790M, *EGFR* mutation, 2145
- Afatinib, lung neoplasms, epidermal growth factor receptor, prognosis, 1615
- Aged, robotic surgical procedure, laparoscopy, laparotomy, endometrial neoplasm, survival, 75
- AGK-BRAF* gene fusion, myoepithelial carcinoma, mEK-inhibitor, cobimetinib, next generation sequencing, NGS, 373
- AHR, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- AKT, amentoflavone, lenvatinib, ERK, hepatocellular carcinoma, 2495
- Albumin-bilirubin grade, hepatocellular carcinoma, atezolizumab plus bevacizumab, lenvatinib, treatment sequence, 1403
- Albumin, bilirubin, gastric cancer, survival, 3929
- Albumin, NSCLC, lung cancer, PD-L1, inflammation, CRP, haemoglobin, NLR, 1563
- Alcohol drinking, colorectal cancer, genotype, *MMP2*, metastasis, polymorphism, Taiwan, 5335
- ALDH1, breast cancer, CD58, prognostic marker, cancer stem cell, basal-like, luminal, 5223
- Alectinib, lung toxicity, japanese adverse drug event report database, time to onset, 3109
- Algae, photosynthesis, plants, photosynthetic bacteria, cyanobacteria, chlorophyll, electron transport chain, aTPase, calvin cycle, 5035
- Allogeneic transplantation, letermovir prophylaxis, CMV reactivation, 5431
- Allogeneic, multiple myeloma, autologous, stem cell transplantation, overall survival, progression-free survival, non-relapse mortality, relapse incidence, 5825
- Allogenic hematopoietic cell transplantation, case series, fludarabine, primary immunodeficiency, treosulfan, 4505
- Alpha fetoprotein, atezolizumab plus bevacizumab, hepatocellular carcinoma, ramucirumab, post-treatment, 1905

- Alpha-tocopheryl succinate, chemotherapy, apoptosis, oxidative stress, 547
- Amentoflavone, lenvatinib, AKT, ERK, hepatocellular carcinoma, 2495
- AML, CGRP, RAMP1, CRLR, EVI1, 4743
- Amlodipine, hepatitis C virus, ritonavir, CYP3A4, calcium channel blockers, peripheral edema, 2087
- Amphiphilic polymers, polyphosphoesters, drug delivery, drug carriers, doxorubicin, 1801
- AMPK, eupatilin, glucose uptake, cell cycle arrest, tap73, 483
- AMPK,  $\gamma$ -glutamylcyclotransferase, antisense, lung cancer, cyclin-dependent kinase inhibitor, reactive oxygen species, 1221
- AMPs, immune checkpoint inhibitors, histatin, HNSCC, 2689
- Ampulla of Vater carcinoma, carcinoembryonic antigen, carbohydrate antigen 19-9, 3169
- Analgesic doses, cholelithiasis, surgery, IL-18, NRS pain score, 5521
- Anaplastic ependymoma, chemotherapy, refractory, 3863
- Anastomotic leakage, colorectal surgery, gene expression analysis, microarray, 2827
- Androgen receptor axis targeted agent, bone metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, overall survival, 1465
- Androgen receptor-targeted agents, prostate cancer, bone metastases, vintage hormone therapy, 3099
- Androgen-deprivation therapy, prostate cancer, hormone-sensitive, survival, prostate-specific antigen, 1107
- Aneuploidy, cytogenetic analysis, chromosome aberrations, cancer, risk assessment, medical workers, 1059
- Angiosarcoma, chemoradiation, unresectable, scalp, intensity-modulated radiotherapy, 5991
- Angiotensin 2, skin cancer, basal cell carcinoma, renin angiotensin system, chymase, *CMAI* gene, G1903A, rs1800875, 5547
- Annexin A10, gastric cancer, oncology, GI cancer, chemoresistance, 1707
- Annexin A10, lung cancer, adenocarcinoma, spiral array, 1289
- Annexin V, transient transfection, dissociative enzymes, miRNA, flow cytometry, trypsin, 2819
- Anterior approach, hepatocellular carcinoma, liver resection, circulating tumor cell, hanging maneuver, 4129
- Anterior wall, vertical location, lymph node metastasis, gastric cancer, 237
- Anti-angiogenic drug, colorectal carcinoma therapy, plant derived polyphenols, trans-resveratrol, quercetin, vitamin E, selenium, dogs, 4763
- Anti-cancer, snail mucus, apoptosis, TNBC, chemotherapy, 845
- Anti-CLIC1 antibodies, clear cell renal cell carcinoma (cc-RCC), cornea rabbit model, chick embryo chorioallantoic membrane model, 1313
- Anti-*EGFR* mAb, colorectal cancer, chemotherapy, liquid biopsy, 2625
- Anti-fibrotic drug, micelles, pH-responsive, three-dimensional cell culture, tumor microenvironment, tumor-bearing mice, 2847
- Anti-inflammation, adipocyte, insulin signal, lipopolysaccharide, type 2 diabetes, 3983
- Anti-PD-1 therapy, hepatocellular carcinoma, STAT3 inhibition, CD8<sup>+</sup> T cell infiltration, tumor microenvironment, immunosuppression, 5205
- Antibiotic resistance, pancreatic adenocarcinoma, infection, overall survival, bacteriobilia, surgery, 2743
- Antibiotics, proton pump inhibitors, urothelial carcinoma, gut microbiota, pembrolizumab, immune checkpoint inhibitors, 1629
- Anticancer activity, vitamin C, hyperthermia, ovarian cancer, 5365
- Anticancer agent, COVID-19 vaccine, cancer, adverse drug event, urology, 2105
- Anticancer drug sensitivity trial, paclitaxel, cetuximab, bortezomib, nuclear factor-kappa B, 4273
- Anticancer drug, ocular adverse reactions, Japanese Adverse Drug Event Report, JADER, safety signal, pharmacovigilance database, 4439
- Anticancer effect, zinc, light isotope, stable isotope, cytotoxicity, apoptosis, 5685
- Anticancer, lung cancer, cancer stem cell, plant-derived compounds, review, 4247
- Antiproliferative activity, linear furocoumarin, psoralen, HL60 cells, structure and activity relationship, 1777
- Antisense,  $\gamma$ -glutamylcyclotransferase, lung cancer, AMPK, cyclin-dependent kinase inhibitor, reactive oxygen species, 1221
- Apalutamide, cutaneous adverse event, drug eruption, prostate cancer, body weight, maculopapular eruption, 2023
- Apoptosis, aurora kinase inhibitor, cell-cycle arrest, endoplasmic reticulum stress, epstein-Barr virus-transformed B-cells, 5265
- Apoptosis, azoxystrobin, cancer, p53, 1307
- Apoptosis, cancer-associated fibroblasts, bcl-xL, mcl-1, IL-6, colorectal cancer, STAT3, 1277
- Apoptosis, chemotherapy, alpha-tocopheryl succinate, oxidative stress, 547
- Apoptosis, chloroquine, doxorubicin, A549 cells, autophagy, oxidative stress, caspase, extracellular-signal-regulated kinase, 4025
- Apoptosis, estrogen receptor  $\beta$ , silibinin, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, cardiomyocytes, doxorubicin, autophagy, 767
- Apoptosis, fluoxetine, triple-negative breast cancer, STAT3, epithelial-to-mesenchymal transition, 3807
- Apoptosis, magnolol, ERK, NF- $\kappa$ B, osteosarcoma, 4403
- Apoptosis, mangosteen, cervical cancer, proliferation, 2903
- Apoptosis, *N-Trans-p-coumaroyl*tyramine, nSAIDs, ER stress, potentiation, breast cancer cells, 1833



- Apoptosis, olaparib, epstein-Barr virus nuclear antigen-1, EBNA-1, ataxia telangiectasia and Rad3 related kinase, ATR, gastric cancer cell, 555
- Apoptosis, oral squamous cell carcinoma, RITA, p53, *MDM2*, 2931
- Apoptosis, pancreatic cancer, nateglinide, NO, nitrated compound, 1313
- Apoptosis, snail mucus, anti-cancer, TNBC, chemotherapy, 845
- Apoptosis, zinc, light isotope, stable isotope, anticancer effect, cytotoxicity, 5685
- Appendiceal, colorectal, peritonectomy, adenocarcinoma, carcinoembryonic antigen, review, 4217
- Appendiceal, second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001
- Appendicular skeletal metastases, tumor growth speed, pathological fracture, impending fracture, prophylactic surgery, 229
- Arginase 1, cancer immunology, colorectal cancer, CD15, multiplex fluorescent labeling, 459
- Arms, carboplatin desensitization, ovarian cancer, hypersensitivity reactions, criteria for discontinuation, erythema, 1091
- Aromatase inhibitor, abemaciclib, breast cancer, liver injury, risk factor, 6027
- Aromatase inhibitors, breast cancer, endocrine therapy, side effects, adverse events, community pharmacy services, community pharmacists, health knowledge, educational intervention, review, 661
- Aromatase inhibitors, breast cancer, osteoporosis, minodronate, bisphosphonate, 4139
- Artery resection, pancreas neck cancer, artery reconstruction, indocyanine green fluorescence imaging, 217
- Artificial intelligence, ewing sarcoma, osteomyelitis, tumor detection, early diagnosis, deep learning, transfer learning, 4371
- Artificial intelligence, metastasis, prognosis, radiation oncologists, palliative care, 1397
- Aryl hydrocarbon receptor, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- Asparagus* extract, cancer, mDAPanc-28, pancreatic cancer, P21, P53, FAS, CDK4, 2425
- Aspirin, pancreatic cancer, cell cycle, microRNA, 4037
- Asthenia, meta-analysis, systematic review, adverse events, fatigue, placebo, cancer, oncology, randomized trials, CTCAE, review, 45
- Asymmetric branching, colon biopsies, crypts, ulcerative colitis, remission, 4493
- Ataxia telangiectasia and Rad3 related kinase, olaparib, apoptosis, Epstein-Barr virus nuclear antigen-1, EBNA-1, ATR, gastric cancer cell, 555
- Atezolizumab plus bevacizumab, alpha fetoprotein, hepatocellular carcinoma, ramucirumab, post-treatment, 1905
- Atezolizumab plus bevacizumab, hepatocellular carcinoma, albumin-bilirubin grade, lenvatinib, treatment sequence, 1403
- Atezolizumab plus bevacizumab, hepatocellular carcinoma, lenvatinib, rechallenge, 5479
- ATPase, photosynthesis, plants, algae, photosynthetic bacteria, cyanobacteria, chlorophyll, electron transport chain, calvin cycle, 5035
- ATR, olaparib, apoptosis, epstein-Barr virus nuclear antigen-1, EBNA-1, ataxia telangiectasia and Rad3 related kinase, gastric cancer cell, 555
- Atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Atrophic gastritis, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- ATRX loss, *MGMT*, methylation status, hypermethylation, low methylation, glioblastoma, temozolomide chemotherapy, wild-type *IDH*, glioblastoma, 335
- Aurora kinase inhibitor, cell-cycle arrest, apoptosis, endoplasmic reticulum stress, epstein-Barr virus-transformed B-cells, 5265
- Austria, chemotherapy, targeted therapy, Germany, Switzerland, treatment reality, disease characteristics, 4773
- Autoimmune, atrophic gastritis, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Autologous, multiple myeloma, allogeneic, stem cell transplantation, overall survival, progression-free survival, non-relapse mortality, relapse incidence, 5825
- Automatic measurement, tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs), imaging analysis software, digital pathology, project HOPE, 419
- Autophagy, chloroquine, doxorubicin, A549 cells, apoptosis, oxidative stress, caspase, extracellular-signal-regulated kinase, 4025
- Autophagy, DYRK1A protein, DYRK1B protein, protein kinases, endoplasmic reticulum stress, colorectal cancer, 589
- Autophagy, estrogen receptor  $\beta$ , silibinin, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, cardiomyocytes, doxorubicin, apoptosis, 767
- Autophagy, novel anti-pancreatic cancer agent, coumarin derivative, selective cytotoxicity, 2835

- Awake breast surgery, breast cancer, surgical waiting list, COVID-19 strategies, 4913
- Awake craniotomy, language function, brain metastasis, intraoperative electrical stimulation mapping, subcortical metastasis, 1641
- Awake surgery, motor function, brain metastasis, intraoperative electrical stimulation mapping, subcortical metastasis, precentral gyrus, 1151
- Axillary reverse mapping, breast cancer, axillary surgery, indocyanine green, 3879
- Axillary surgery, breast cancer, axillary reverse mapping, indocyanine green, 3879
- AXL, immunotherapy, KIT, MET, papillary renal cell carcinoma, *VEGFR*, 3151
- Axonal growth, calcitonin gene-related peptide, dorsal root ganglion neurons, nerve growth factor, spinal metastasis, 581
- Azoxystrobin, cancer, apoptosis, p53, 1307
- B cell maturation antigen, multiple myeloma, adoptive T cell therapy, dendritic cells, cytotoxic T cells, 1785
- B lymphocytes, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, T cells, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- Bacteriobilia, pancreatic adenocarcinoma, infection, antibiotic resistance, overall survival, surgery, 2743
- Barcelona Clinic Liver Cancer Stage C, hepatocellular carcinoma, sorafenib, transarterial chemoembolization, national Health Insurance, reimbursement criteria, 4461
- Basal cell carcinoma, skin cancer, renin angiotensin system, chymase, *CMA1* gene, G1903A, rs1800875, angiotensin 2, 5547
- Basal-like, breast cancer, CD58, prognostic marker, cancer stem cell, ALDH1, luminal, 5223
- Bats, vitamin D, mosquitoes, *Aedes aegypti* mosquitoes, *Drosophila melanogaster*, migratory birds, vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 5091
- BAX and *BCL2* silencing, SK-N-SH cells, casiopeína IIIa, mPTP, cRISPR/Cas9, ca2+ retention capacity, 885
- Bcl-xL, cancer-associated fibroblasts, mcl-1, IL-6, colorectal cancer, apoptosis, STAT3, 1277
- BCRP, ko143, combinatorial treatment, p-glycoprotein, drug resistance, temozolomide, 723
- BCS, faxitron, intra operative mammography, radiography, 1925
- BDNF, thymic carcinoma, thymoma, trkB, therapeutic target, 3779
- Bendamustine, rituximab, mantle cell lymphoma, 6083
- Bendamustine, skin damage, Japanese Adverse Drug Reaction Reporting Database, time to onset, 2737
- Benign gynecological tumor, robot-assisted hysterectomy, cumulative summation analysis, learning curve, endometrial cancer, 4111
- Bevacizumab, adverse drug event, ovarian neoplasms, chemotherapy, gastrointestinal perforation, 4165
- Bevacizumab, brain metastasis, salvage chemotherapy, ovarian cancer, survival, 2637
- Bevacizumab, glioblastoma, relapsed, refractory, 6091
- Bevacizumab, hyperthermia, colorectal carcinoma, cancer therapeutics, 5-fluorouracil, capecitabine, cetuximab, 2363
- Bevacizumab, recurrent glioblastoma, fotemustine, second line cytotoxic, 5847
- Bevacizumab, S-1, irinotecan, SIRB, cetuximab, second-line treatment, 2675
- Bile duct cancer, budding phenomenon, eMT-induced transcription factors, 4079
- Bile duct cancer, p38 MAPK, *TP53*, tumour repopulation, exosomes, 745
- Bile duct tumor thrombus, hepatocellular carcinoma, vater papilla-preserving strategy, liver resection, 5663
- Biliary fistula, indocyanine green, liver surgery, navigation surgery, fluorescence imaging, 4787
- Bilirubin, albumin, gastric cancer, survival, 3929
- Bio-engineered drug carrier, milk extracellular vesicles, *EGFR* expressing tumor, GE11 peptide, drug delivery system, 857
- Bioanalysis, CPD, cyclobutane pyrimidine dimer, DNA damage, thymidine dimer, LC-MS/MS, urine, 5069
- Biochemical recurrent prostate cancer, prostate cancer, radiotherapy timing, adjuvant radiotherapy, salvage radiotherapy, 2997
- Bioinformatics, copine 1, renal cell carcinoma, immunohistochemistry, prognostic marker, 355
- Biomarker, advanced colorectal cancer, checkpoint-with-forkhead-and-ring-finger-domains (CHFR), dNA-promoter methylation, irinotecan, histoculture drug response assay (HDRA), clinical correlation, 697
- Biomarker, adverse events, chemotherapy, hepatocellular carcinoma, intestinal permeability, 4895
- Biomarker, adverse events, chemotherapy, hepatocellular carcinoma, intestinal permeability, 5465
- Biomarker, bladder cancer, EPHA2, cancer recurrence, adipocytes, machine learning, 5783
- Biomarker, esophageal squamous cell carcinoma, platelet-to-lymphocyte ratio, 2775
- Biomarker, gut microbiome, lung adenocarcinoma, never-smokers, 1589
- Biomarker, melanoma, EB13, tumor microenvironment, 511
- Biomarker, sIL-2R, metastases prediction, uveal melanoma, 1447
- Biomarker, small cell lung cancer, MUC1, CD147, circulating tumor cells, 429
- Biomarker, small extracellular vesicles, gastrointestinal stromal tumor, EV array, 5699
- Biomarker, tumor marker, head and neck cancer, tumor recurrence, 137
- Biomarkers, prognosis, overall survival, systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, 1911

- Biopsy, breast cancer, smoking, ductal carcinoma *in situ*, invasive ductal carcinoma, 311
- Biopsy, breast, ultrasonography, vacuum, neoplasms, 2159
- BioZorb<sup>®</sup> marker, tumor bed boost volume, adaptive boost planning, 2961
- Biphasic cytology, intrahepatic cholangiocarcinoma, cholangioblastic variant, liver, inhibin A, *NIPBL-NACCI* fusion gene, 5475
- Bisphosphonate, aromatase inhibitors, breast cancer, osteoporosis, minodronate, 4139
- Bisphosphonates, 3D cell culture, osteoblasts, PRP, PRF, 1295
- Bivariate model, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Bladder cancer, dicycloplatin capsules, recurrence, remission, tolerable side effects, 1339
- Bladder cancer, EPHA2, cancer recurrence, biomarker, adipocytes, machine learning, 5783
- Bladder cancer, luminometric method, chelates, urine-based diagnostics, 5249
- Bladder cancer, NFIA, NFIB, urothelial carcinoma, muscle-invasive bladder cancer, 493
- Bladder cancer, sleep disturbances, irradiation, frequency, risk factors, 4511
- Blood coagulation-related gene, macrophages, monocytes, vascular endothelial cell, inflammatory cytokine gene, lipopolysaccharide, 4049
- Blood transfusion, robotic surgical procedure, hemoglobin, hysterectomy, endometrial neoplasm, cost analysis, 1893
- Blood, COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, gene expression, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- BMI-1, polycomb protein, mucinous ovarian carcinoma, chemoresistance, cancer stem cell, 1739
- Body weight, cutaneous adverse event, drug eruption, apalutamide, prostate cancer, maculopapular eruption, 2023
- Bone and soft-tissue sarcoma, carbon-ion radiotherapy, head and neck tumor, 1439
- Bone marrow suppression, granulocyte colony-stimulating factor, esophageal cancer, chemotherapy, adverse event, 2783
- Bone metastases, palliative radiation therapy, radiotherapy, brain metastases, prognostic model, comorbidity, 1477
- Bone metastases, prostate cancer, androgen receptor-targeted agents, vintage hormone therapy, 3099
- Bone metastatic castration-resistant prostate cancer, androgen receptor axis targeted agent, docetaxel, cabazitaxel, overall survival, 1465
- Bone sarcoma, fibula, limb-sparing procedure, vascularized bone graft, non-vascularized fibula, 5443
- Bone sarcoma, SEER program, neoplasm grading, hand, treatment outcome, orthopedic surgery, 1635
- Bone scan, prostate cancer, <sup>68</sup>Ga-PSMA PET/CT, pCa staging, 1495
- Bone tumor, limb-sparing tumor surgery, vascular reconstruction, extremity, soft tissue tumor, 4619
- Bone, neurofibromatosis type 1, plexiform neurofibroma, cephalometry, symmetry, facial skeleton, 2607
- Boron neutron capture therapy, COVID-19, salvage maxillectomy, recurrent oral cancer, nasoseptal flap, 1653
- Boron tracedrugs, molecular design, UTX-51, BSA, 4017
- Bortezomib, anticancer drug sensitivity trial, paclitaxel, cetuximab, nuclear factor-kappa B, 4273
- Bortezomib, osteosarcoma, everolimus, synergistic effect, compound library, 4319
- Bortezomib, polyphenol, PC12, SH-SY5Y, NGF, overlay method, neurotoxicity, tumor-specificity, cell cycle, chlorogenic acid, caffeic acid, 781
- Bowel obstruction, fibromatosis, mesenteric tumor, 381
- Brachytherapy, leiomyosarcoma, radiotherapy, soft-tissue sarcoma, extremity, multicentric analysis, 4485
- Brachytherapy, oral cancer, radiotherapy, reirradiation, complication, 293
- BRAF V600E, PLX4032, imidazothiazole, chemoresistance, activator protein-1, melanoma, 2911
- Brain metastases, brain tumor, fractionation, gamma knife radiosurgery, hypofractionated radiosurgery, meningioma, 1851
- Brain metastases, palliative radiation therapy, radiotherapy, bone metastases, prognostic model, comorbidity, 1477
- Brain metastases, very elderly patients, radiosurgery, fractionated stereotactic radiotherapy, survival score, 5629
- Brain metastasis, bevacizumab, salvage chemotherapy, ovarian cancer, survival, 2637
- Brain metastasis, chemoimmunotherapy, non-small cell lung cancer, radiotherapy, abscopal effect, 4805
- Brain metastasis, language function, awake craniotomy, intraoperative electrical stimulation mapping, subcortical metastasis, 1641
- Brain metastasis, motor function, awake surgery, intraoperative electrical stimulation mapping, subcortical metastasis, precentral gyrus, 1151
- Brain metastasis, thymic carcinoma, cerebellar metastasis, stereotactic radiotherapy, 1169
- Brain tumor, brain metastases, fractionation, gamma knife radiosurgery, hypofractionated radiosurgery, meningioma, 1851
- Brain tumors, gliomas, temozolomide, radiation therapy, diffusion tensor imaging, 329
- Brain tumours, p13KC2 $\beta$ , pharmacological inhibition, cell proliferation, migration, acute leukemia, neuroendocrine tumours, 3217
- Brain, central nervous system, lymphoma, 5601
- BRCA mutation, epithelial ovarian cancer, survival, 4945

- BRCA* mutation, pARPi, heterozygosity, talazoparib, predictive marker, 5257
- Breast cancer cells, *N-Trans-p-coumaroyl*tyramine, nSAIDs, ER stress, apoptosis, potentiation, 1833
- Breast cancer cells, three-dimensional model, endothelial cells, *in vivo* mimicking, 4689
- Breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Breast cancer recurrence, CHIP, DNA methylation, ER, 759
- Breast cancer, <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography, endocrine therapy, CDK4/6 inhibitor, predictive factor, 4813
- Breast cancer, abemaciclib, aromatase inhibitor, liver injury, risk factor, 6027
- Breast cancer, acridine orange, metastasis, zoledronate, 5357
- Breast cancer, adjuvant radiation therapy, py, locoregional radiotherapy, toxicity, side-effects, 923
- Breast cancer, adjuvant radiotherapy, sleep disorders, prospective trial, patient reported outcomes, 3085
- Breast cancer, aromatase inhibitors, osteoporosis, minodronate, bisphosphonate, 4139
- Breast cancer, awake breast surgery, surgical waiting list, COVID-19 strategies, 4913
- Breast cancer, axillary reverse mapping, axillary surgery, indocyanine green, 3879
- Breast cancer, breast-conserving surgery, gross evaluation, frozen section analysis, permanent section diagnosis, 4453
- Breast cancer, cardio-oncology, global longitudinal strain, toxic cardiomyopathy, treatment-related side effects, 3075
- Breast cancer, CD58, prognostic marker, cancer stem cell, ALDH1, basal-like, luminal, 5223
- Breast cancer, chemotherapy, febrile neutropenia, filgrastim, secondary prophylactic G-CSF, 5945
- Breast cancer, circulating tumor cells, circulating tumor cell cluster, 4879
- Breast cancer, copy number variant, cyclin D1, circulating tumor DNA, 4071
- Breast cancer, disparity, inequality, treatment, 5813
- Breast cancer, drug resistance, cholesterol, tamoxifen, acetyl plumbagin, 565
- Breast cancer, DYRK2, TERT, prognostic factor, 2079
- Breast cancer, endocrine therapy, aromatase inhibitors, side effects, adverse events, community pharmacy services, community pharmacists, health knowledge, educational intervention, review, 661
- Breast cancer, etoposide, microRNA, miRNA-205-5p, spheroid, ERBB4, 4265
- Breast cancer, G protein-coupled estrogen receptor 1 (GPER1), invasion, selective ER $\beta$  agonists, tamoxifen resistance, 5187
- Breast cancer, genotype, interleukin-8, polymorphism, Taiwan, 3799
- Breast cancer, heredity, strain difference, susceptibility, gene-environmental interaction, 2415
- Breast cancer, immunoadjuvant molecules, pathological complete response, neoadjuvant chemotherapy, LAG-3, TIM-3, OX-40, 125
- Breast cancer, immunohistochemistry, prognosis, 279
- Breast cancer, near-infrared turn-on fluorescence probe, C5S-A, activity of aldehyde dehydrogenase, stem cells, 1199
- Breast cancer, radiotherapy, cardiac biomarkers, ECG, echocardiography, 2519
- Breast cancer, radiotherapy, myocardial imaging, cyclic variation of the integrated backscatter, speckle tracking echocardiography, global longitudinal strain, 2507
- Breast cancer, serum, trace element, surgery, ICP-MS, 5323
- Breast cancer, smoking, ductal carcinoma *in situ*, invasive ductal carcinoma, biopsy, 311
- Breast cancer, smoking, hormone receptor, endocrine therapy, cigarette, 3937
- Breast cancer, thyroid hormones, carcinoma *in situ*, multifocal/multicentric tumors, lymphovascular invasion, proliferation, prognosis, 253
- Breast cancer, *TP53*, *MDM2*, *CDKN2A*, copy number alteration, 2277
- Breast cancer, tumor interstitial fluid, cytokine, clinical research methods, 1327
- Breast cancer, tumor-infiltrating lymphocytes, neoadjuvant chemotherapy, fibrotic foci, prognostic marker, 1421
- Breast cancer,  $\gamma$ -glutamylcyclotransferase, n-acetylcysteine, reactive oxygen species, cyclin-dependent kinase inhibitors, pro-GA, 4311
- Breast osteosarcoma, PDOX, nude mice, combination therapy, methioninase, rapamycin, efficacy, synergy, Hoffman effect, 5217
- Breast reconstruction, pre-pectoral, semi-smooth implant, nano-textured, acellular dermal matrix, 1013
- Breast-conserving surgery, breast cancer, gross evaluation, frozen section analysis, permanent section diagnosis, 4453
- Breast, biopsy, ultrasonography, vacuum, neoplasms, 2159
- Breast, carcinoma, hypofractionation, mastectomy, segmental, radiotherapy, 53
- Breast, carcinoma, mastectomy, segmental, radiotherapy, 93
- Breast, receptor-interacting serine/threonine-protein kinase 3, immunohistochemistry, triple-negative breast carcinoma, prognosis, 2753
- Bronchoplasty, sleeve lobectomy, right lower lobe lung cancer, 5977
- Bruton's tyrosine kinase inhibitor, primary central nervous system lymphoma, tirabrutinib, 4173
- BSA, molecular design, UTX-51, boron tracedrugs, 4017



- Buccal mucosa, programmed cell death 1 antibody, low-dose topical administration, immune-related adverse events, oral cancer cell line, programmed cell death 1-ligand 1, 4293
- Budding phenomenon, bile duct cancer, eMT-induced transcription factors, 4079
- C-IAP2, dimethyl fumarate, NF- $\kappa$ B, STAT3, adult T-cell, leukemia, lymphoma, 2301
- C-reactive protein, esophageal cancer, lymph node metastasis, genetic polymorphism, endoscopic resection, 6105
- C-reactive protein, geriatric nutrition risk index, esophageal cancer, prognostic factor, nutrition, 5999
- C-reactive protein, pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, NLR, lactate dehydrogenase, LDH, CRP, immune checkpoint inhibitor, predictive factor, 2045
- C19MC, neuroepithelium, immature teratoma, ETMR, LIN28A, 4337
- C5S-A, near-infrared turn-on fluorescence probe, activity of aldehyde dehydrogenase, breast cancer, stem cells, 1199
- CA-125, ovarian cancer, chemotherapy, clinical outcomes, overall survival, progression-free survival, platinum-free interval, platinum resistance, 349
- CA125, ovarian cancer, screening, ultrasound, microRNA, *TP53* clonal variants, review, 4207
- CA125, pegylated liposomal doxorubicin, platinum refractory/resistant, recurrent ovarian cancer, 3017
- CA19-9, pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, supplement, combination therapy, stable disease, methionine addiction, Hoffman effect, 2567
- Ca<sup>2+</sup> retention capacity, *BAX* and *BCL2* silencing, SK-N-SH cells, casiopeína IIIia, mPMP, CRISPR/Cas9, 885
- Cabazitaxel, bone metastatic castration-resistant prostate cancer, androgen receptor axis targeted agent, docetaxel, overall survival, 1465
- Cachexia, resistance exercise, aerobic exercise, inflammation, colon cancer, colon-26, muscle fiber type, 397
- Caffeic acid, polyphenol, PC12, SH-SY5Y, NGF, overlay method, neurotoxicity, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, 781
- Calcitonin gene-related peptide, axonal growth, dorsal root ganglion neurons, nerve growth factor, spinal metastasis, 581
- Calcium channel blockers, hepatitis C virus, ritonavir, CYP3A4, amlodipine, peripheral edema, 2087
- Calvin cycle, photosynthesis, plants, algae, photosynthetic bacteria, cyanobacteria, chlorophyll, electron transport chain, aTPase, 5035
- Cancer antigen, head and neck cancer, oral cancer, human leukocyte antigen class I, cancer vaccines, T cell therapy, 5751
- Cancer cachexia, HPV, K14-HPV16, muscle wasting, lncRNAs, 2443
- Cancer cell migration, melanoma, leukemia, rhoGTPase, rac, rhoGAP, rab11, recycling endosome, actin cytoskeleton, 5763
- Cancer cell, circulating tumor cell, liquid biopsy, microfluidic chip cell sorter, multistep sorting, PD-L1, 407
- Cancer immunology, colorectal cancer, arginase 1, CD15, multiplex fluorescent labeling, 459
- Cancer microenvironment, cancer-associated fibroblasts, scirrhous-type gastric cancer, dipeptidyl peptidase-4, proliferation, 501
- Cancer prevention, vitamin D metabolites, LC-MS/MS assay development, vitamin D synthesis, 5077
- Cancer recurrence, bladder cancer, EPHA2, biomarker, adipocytes, machine learning, 5783
- Cancer spheroid, KRAS, 3D floating culture, low-toxic, context-independent, 3993
- Cancer stem cell, breast cancer, CD58, prognostic marker, ALDH1, basal-like, luminal, 5223
- Cancer stem cell, lung cancer, anticancer, plant-derived compounds, review, 4247
- Cancer stem cell, polycomb protein, BMI-1, mucinous ovarian carcinoma, chemoresistance, 1739
- Cancer surgery, cutaneous malignant melanoma, health-related quality of life, limb edema, limb lymphedema, extremity lymphedema, 5507
- Cancer therapeutics, hyperthermia, colorectal carcinoma, 5-fluorouracil, capecitabine, bevacizumab, cetuximab, 2363
- Cancer treatment, radiotherapy, distress levels, elderly patients, pilot study, 5561
- Cancer unknown primary, neuroendocrine, gene expression profiling, RT-PCR, 1381
- Cancer vaccines, head and neck cancer, oral cancer, cancer antigen, human leukocyte antigen class I, T cell therapy, 5751
- Cancer-associated fibroblasts, bcl-xL, mcl-1, IL-6, colorectal cancer, apoptosis, STAT3, 1277
- Cancer-associated fibroblasts, Merkel cell carcinoma, tumor infiltrating lymphocytes, 4359
- Cancer-associated fibroblasts, ovarian cancer, stromal cells, mesenchymal stem cells, normal ovary, 1729
- Cancer-associated fibroblasts, scirrhous-type gastric cancer, dipeptidyl peptidase-4, proliferation, cancer microenvironment, 501
- Cancer, *Asparagus* extract, mDAPanc-28, pancreatic cancer, P21, P53, FAS, CDK4, 2425
- Cancer, azoxystrobin, apoptosis, p53, 1307
- Cancer, Chinese hamster ovary cell, chemotherapy, drug resistance, genetic mutation, irinotecan, 4011
- Cancer, COVID-19 vaccine, anticancer agent, adverse drug event, urology, 2105
- Cancer, cytogenetic analysis, chromosome aberrations, aneuploidy, risk assessment, medical workers, 1059
- Cancer, esophagus, neoadjuvant therapy, PET, surgery, survival, 6037



- Cancer, FLASH, ultra-high dose rate, radiation, carbon ions, fibroblast, 2469
- Cancer, meta-analysis, systematic review, adverse events, asthenia, fatigue, placebo, oncology, randomized trials, CTCAE, review, 45
- Cancer, meta-analysis, systematic review, adverse events, placebo, oncology, randomized trials, CTCAE, medDRA, review, 2805
- Cancer, methionine addiction, Hoffman effect, methionine restriction, methioninase, clinical treatment, review, 641
- Cancer, radiation, proctitis, pelvis, 5951
- Cancer, sacral, chordoma, survival, population, SEER, 929
- Cancer, UV exposure, diabetes mellitus, melanoma, cardiovascular disease, mortality, review, 1671
- Cancer, x-chromosome, x-linked, polymorphism, gender dimorphism, review, 2261
- Canine mammary gland tumors, cell cycle, hIF1 $\alpha$ , metastasis, siRNA, TSG-6, 5803
- Capecitabine, cisplatin, gastric cancer, adjuvant chemotherapy, metastasis, 2009
- Capecitabine, gastric cancer, elderly, oxaliplatin, chemotherapy, phase 2 trial, 2683
- Capecitabine, hand-foot syndrome, prevention strategies, proton pump inhibitors, 2591
- Capecitabine, hyperthermia, colorectal carcinoma, cancer therapeutics, 5-fluorouracil, bevacizumab, cetuximab, 2363
- Capecitabine, rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, neoadjuvant radiotherapy, short-course radiotherapy, S-1, chemotherapy, radiotherapy, 5587
- CAR T-cell therapy, ICANS, steroid refractory, intrathecal chemotherapy, potential treatment, 3853
- CAR-T, lymphoproliferative disorder, transplantation, EBV, PTLN, review, 5181
- CAR-T, phase I, clinical trial, study design, dose escalation, reporting, review, 5673
- Carbohydrate antigen 19-9, ampulla of Vater carcinoma, carcinoembryonic antigen, 3169
- Carbon ions, FLASH, ultra-high dose rate, radiation, cancer, fibroblast, 2469
- Carbon-ion radiotherapy, bone and soft-tissue sarcoma, head and neck tumor, 1439
- Carboplatin desensitization, ovarian cancer, hypersensitivity reactions, criteria for discontinuation, erythema, arms, 1091
- Carboplatin/paclitaxel, esophageal cancer, geriatric oncology, trimodality therapy, platinum/5-fluorouracil, 59
- Carcinoembryonic antigen, ampulla of Vater carcinoma, carbohydrate antigen 19-9, 3169
- Carcinoembryonic antigen, colorectal, appendiceal, peritonectomy, adenocarcinoma, review, 421
- Carcinogens, host-mediated *in vivo/in vitro* assay, tumorigenic potential, review, 4199
- Carcinoma *in situ*, breast cancer, thyroid hormones, multifocal/multicentric tumors, lymphovascular invasion, proliferation, prognosis, 253
- Carcinoma, breast, hypofractionation, mastectomy, segmental, radiotherapy, 53
- Carcinoma, breast, mastectomy, segmental, radiotherapy, 93
- Carcinoma, renal cell, multivariate analysis, neoplasm grading, nephrectomy, prognosis, 2967
- Cardiac biomarkers, breast cancer, radiotherapy, ECG, echocardiography, 2519
- Cardio-oncology, global longitudinal strain, toxic cardiomyopathy, treatment-related side effects, breast cancer, 3075
- Cardiomyocytes, estrogen receptor  $\beta$ , silibinin, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, doxorubicin, apoptosis, autophagy, 767
- Cardiophrenic lymph nodes, advanced ovarian cancer, lymphadenectomy, review, 13
- Cardiovascular disease, UV exposure, diabetes mellitus, cancer, melanoma, mortality, review, 1671
- Carney complex, fibroma, myxoma, neurofibroma, melanoma, cerebello-pontine angle, PRKAR1A, 6121
- Carotid body tumor, surgical resection, feeding arteries, preoperative embolization, review, 645
- Case series, allogenic hematopoietic cell transplantation, fludarabine, primary immunodeficiency, treosulfan, 4505
- Casiopeína IIIa, *BAX* and *BCL2* silencing, SK-N-SH cells, mPTP, cRISPR/Cas9, Ca<sup>2+</sup> retention capacity, 885
- CASP1/Caspase-1, triple-negative breast cancer (TNBC), A20/TNFAIP3, cell division cycle 20 (Cdc20), inflammation, metastasis, inflammation inhibitors, 681
- Caspase, chloroquine, doxorubicin, A549 cells, autophagy, apoptosis, oxidative stress, extracellular-signal-regulated kinase, 4025
- Castration resistant prostate cancer, ethinylestradiol, ra-223, prostate-specific antigen, 1065
- Castration-resistant prostate cancer, radium-223, 4981
- Cauda equina, intradural metastases, spine oncology, spine metastases, systematic review, 1661
- CD109, oropharyngeal squamous cell carcinoma, prognosis, 2061
- CD11b, collapsin response mediator protein 4 (CRMP4), DPYSL3, CD163, M2 macrophage, myeloid-derived suppressor cell (MDSC), 791
- CD133, hIF-1 $\alpha$ , cD133(+)/HIF-1 $\alpha$ (-), chemoradiotherapy, rectal cancer, 2033
- CD133(+)/HIF-1 $\alpha$ (-), CD133, hIF-1 $\alpha$ , chemoradiotherapy, rectal cancer, 2033
- CD147, small cell lung cancer, biomarker, MUC1, circulating tumor cells, 429
- CD15, cancer immunology, colorectal cancer, arginase 1, multiplex fluorescent labeling, 459

- CD163, collapsin response mediator protein 4 (CRMP4), DPYSL3, M2 macrophage, cD11b, myeloid-derived suppressor cell (MDSC), 791
- CD36, cervical cancer, human papilloma virus, FATP4, 2131
- CD58, breast cancer, prognostic marker, cancer stem cell, ALDH1, basal-like, luminal, 5223
- CD8<sup>+</sup> T cell infiltration, hepatocellular carcinoma, STAT3 inhibition, anti-PD-1 therapy, tumor microenvironment, immunosuppression, 5205
- CDK4, *Asparagus* extract, cancer, mDAPanc-28, pancreatic cancer, P21, P53, FAS, 2425
- CDK4/6 inhibitor resistance, ER+/HER2- metastatic breast cancer, palbociclib, abemaciclib, 1099
- CDK4/6 inhibitor, advanced breast cancer, peripheral blood biomarker, absolute lymphocyte count, prognostic factor, 4867
- CDK4/6 inhibitor, breast cancer, <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography, endocrine therapy, predictive factor, 4813
- CDK4/6 inhibitor, everolimus, metastatic hormone receptor-positive breast cancer, 3913
- CDKN2A*, *TP53*, *MDM2*, breast cancer, copy number alteration, 2277
- CEACAM6*, colitis-associated cancer, ulcerative colitis, CHI3L1, CLND<sub>2</sub>, 4119
- CEACAM6*, gastric cancer, peritoneal recurrence, *KRT20*, peritoneal lavage fluid, 4003
- Cell culture, circulating tumor cells, filter, immunostaining, gene mutation analysis, 4305
- Cell culture, clear cell sarcoma, subungual melanoma, cell line, 5315
- Cell cycle arrest, eupatilin, AMPK, glucose uptake, tap73, 483
- Cell cycle, canine mammary gland tumors, hIF1 $\alpha$ , metastasis, siRNA, TSG-6, 5803
- Cell cycle, hepatocellular carcinoma, lenvatinib resistance, cisplatin, microRNA, 1263
- Cell cycle, pancreatic cancer, aspirin, microRNA, 4037
- Cell cycle, polyphenol, PC12, SH-SY5Y, NGF, overlay method, neurotoxicity, tumor-specificity, bortezomib, chlorogenic acid, caffeic acid, 781
- Cell cycle, radiosensitivity, fucci, G1 phase, G2 arrest, DNA damage repair, 5407
- Cell division cycle 20 (Cdc20), triple-negative breast cancer (TNBC), A20/TNFAIP3, cASP1/Caspase-1, inflammation, metastasis, inflammation inhibitors, 681
- Cell line, clear cell sarcoma, subungual melanoma, cell culture, 5315
- Cell proliferation, gastric cancer, 14-3-3 sigma protein, tumor progression, metastasis, prognostic factor, 519
- Cell proliferation, p13KC2 $\beta$ , pharmacological inhibition, migration, acute leukemia, brain tumours, neuroendocrine tumours, 3217
- Cell-cycle arrest, aurora kinase inhibitor, apoptosis, endoplasmic reticulum stress, Epstein–Barr virus-transformed B-cells, 5265
- Cellular proliferation, non-B non-C hepatocellular carcinoma, tumor size, ki-67, 449
- Central giant cell granuloma, neurofibromatosis type 1, plexiform neurofibroma, rASopathy, root resorption, 2945
- Central nervous system, lymphoma, brain, 5601
- Cephalometry, neurofibromatosis type 1, plexiform neurofibroma, symmetry, bone, facial skeleton, 2607
- Cerebellar metastasis, brain metastasis, thymic carcinoma, stereotactic radiotherapy, 1169
- Cerebello-pontine angle, carney complex, fibroma, myxoma, neurofibroma, melanoma, PRKAR1A, 6121
- Cerebral ventricles, craniopharyngioma, intraventricular tumor, neuro-oncology, skull base, systematic review, 4189
- Cervical cancer, HPV, p16/Ki-67 dual-stained cytology, triage, CIN2, CIN3, HSIL, screening, risk stratification, pap test, 2599
- Cervical cancer, human papilloma virus, FATP4, CD36, 2131
- Cervical cancer, mangosteen, proliferation, apoptosis, 2903
- Cervical cancer, nausea, vomiting, radiotherapy, cisplatin, 3117
- Cervical lymph node metastasis, tongue cancer, squamous cell carcinoma, ultrasonography, doppler, 287
- Cervical swab, ovarian cancer, pap test, liquid Pap specimen, review, 1
- Cervical tumor, SMILE, stratified mucin-producing intraepithelial tumor, pathology, robotic, 1175
- Cervix, endocervical adenocarcinoma, human papillomavirus, world Health Organization Classification, 4627
- Cetuximab, anticancer drug sensitivity trial, paclitaxel, bortezomib, nuclear factor-kappa B, 4273
- Cetuximab, hyperthermia, colorectal carcinoma, cancer therapeutics, 5-fluorouracil, capecitabine, bevacizumab, 2363
- Cetuximab, S-1, irinotecan, bevacizumab, SIRB, second-line treatment, 2675
- CfDNA integrity index, papillary thyroid carcinoma, circulating cell-free DNA, GAPDH,  $\beta$ -actin, 2289
- CfDNA, LDH, VEGF, PD-L1, tumour-burden, 801
- CGRP, RAMP1, CRLR, AML, EVI1, 4743
- CH223191, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- Checkpoint inhibitors, nivolumab, advanced cancer, immunotherapy, PD-1/PDL-1, CTLA-4, 1433
- Checkpoint inhibitors, radiotherapy, oligoprogression, abscopal effect, volumetric assessment, 4795
- Checkpoint-with-forkhead-and-ring-finger-domains (CHFR), advanced colorectal cancer, dNA-promoter methylation, irinotecan, histoculture drug response assay (HDRA), clinical correlation, biomarker, 697

- Chelates, luminometric method, bladder cancer, urine-based diagnostics, 5249
- Chemo-radiotherapy, esophageal cancer, elderly, esophagectomy, 3953
- Chemoinmunotherapy, brain metastasis, non-small cell lung cancer, radiotherapy, abscopal effect, 4805
- Chemoradiation, angiosarcoma, unresectable, scalp, intensity-modulated radiotherapy, 5991
- Chemoradiotherapy, CD133, HIF-1 $\alpha$ , cD133(+)/HIF-1 $\alpha$ (-), rectal cancer, 2033
- Chemoradiotherapy, conventional fractionated radiotherapy, neoadjuvant long course, population-based, radiotherapy dose escalation, locally advanced rectal cancer, 1143
- Chemoradiotherapy, esophageal neoplasms, survival, 4929
- Chemoradiotherapy, head and neck cancer, glottic carcinoma, radiotherapy, laryngeal preservation, elective nodal irradiation, 205
- Chemoradiotherapy, head and neck, radiotherapy, older adults, 3845
- Chemoradiotherapy, mallampati score, head and neck cancer, trismus, restricted mouth opening, outcome, 5609
- Chemoradiotherapy, superficial esophageal carcinoma, endoscopic resection, esophagectomy, 2791
- Chemoresistance, annexin A10, gastric cancer, oncology, GI cancer, 1707
- Chemoresistance, BRAF V600E, PLX4032, imidazothiazole, activator protein-1, melanoma, 2911
- Chemoresistance, polycomb protein, BMI-1, mucinous ovarian carcinoma, cancer stem cell, 1739
- Chemotherapy regimen, concurrent chemoradiotherapy, recurrence, 1073
- Chemotherapy-induced peripheral neuropathy, pain management, target therapy, immunotherapy, 4667
- Chemotherapy, adverse drug event, ovarian neoplasms, bevacizumab, gastrointestinal perforation, 4165
- Chemotherapy, adverse events, biomarker, hepatocellular carcinoma, intestinal permeability, 4895
- Chemotherapy, adverse events, biomarker, hepatocellular carcinoma, intestinal permeability, 5465
- Chemotherapy, alpha-tocopheryl succinate, apoptosis, oxidative stress, 547
- Chemotherapy, breast cancer, febrile neutropenia, filgrastim, secondary prophylactic G-CSF, 5945
- Chemotherapy, Chinese hamster ovary cell, cancer, drug resistance, genetic mutation, irinotecan, 4011
- Chemotherapy, circulating tumor cells, drug resistance, sorafenib, *ex vivo* culture, 2479
- Chemotherapy, colorectal cancer, liquid biopsy, anti-EGFR mAb, 2625
- Chemotherapy, esophageal squamous cell carcinoma, prognostic factor, no residual tumor, 195
- Chemotherapy, gastric cancer, elderly, oxaliplatin, capecitabine, phase 2 trial, 2683
- Chemotherapy, granulocyte colony-stimulating factor, esophageal cancer, bone marrow suppression, adverse event, 2783
- Chemotherapy, homologous recombination, PARP inhibitors, epithelial ovarian cancer, recurrence, 2017
- Chemotherapy, medication guidance sheet, adverse events, non-Hodgkin's lymphoma, ESHAP $\pm$ R therapy, 2053
- Chemotherapy, metastatic pancreatic cancer, first-line, itraconazole, 6063
- Chemotherapy, non-small cell carcinoma, adenocarcinoma, radiotherapy, chest wall, 5539
- Chemotherapy, NSCLC, lung cancer, nivolumab, overall survival, pemetrexed, taxanes, vinorelbine, 1987
- Chemotherapy, ovarian cancer, clinical outcomes, overall survival, progression-free survival, platinum-free interval, platinum resistance, CA-125, 349
- Chemotherapy, ovarian cancer, platinum-resistant recurrence, platinum rechallenge therapy, 4603
- Chemotherapy, ovarian cancer, platinum-resistant recurrence, platinum rechallenge therapy, 4603
- Chemotherapy, ovarian cancer, pleural effusion, overall survival, progression-free survival, 4937
- Chemotherapy, PCNSL, elderly, CMT, radiation, 1867
- Chemotherapy, rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, neoadjuvant radiotherapy, short-course radiotherapy, capecitabine, S-1, radiotherapy, 5587
- Chemotherapy, refractory, anaplastic ependymoma, 3863
- Chemotherapy, snail mucus, anti-cancer, apoptosis, TNBC, 845
- Chemotherapy, targeted therapy, germany, austria, switzerland, treatment reality, disease characteristics, 4773
- Chest wall, non-small cell carcinoma, adenocarcinoma, chemotherapy, radiotherapy, 5539
- CHI3L1, colitis-associated cancer, ulcerative colitis, CEACAM6, CLND<sub>2</sub>, 4119
- Chick embryo chorioallantoic membrane model, anti-CLIC1 antibodies, clear cell renal cell carcinoma (cc-RCC), cornea rabbit model, 1313
- Child-Pugh, lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, adverse events, progression-free survival, objective response, 173
- Childhood ALL, genotype, IL-18, polymorphism, Taiwan, 5283
- Children, acute myeloid leukemia, therapeutic era, survival, 4499
- Chinese hamster ovary cell, cancer, chemotherapy, drug resistance, genetic mutation, irinotecan, 4011
- CHIP, breast cancer recurrence, DNA methylation, ER, 759
- Chloride intracellular channel 1, immunohistochemistry, lung adenocarcinoma, spiral array, 271
- Chlorogenic acid, polyphenol, PC12, SH-SY5Y, NGF, overlay method, neurotoxicity, tumor-specificity, bortezomib, cell cycle, caffeic acid, 781

- Chlorophyll, photosynthesis, plants, algae, photosynthetic bacteria, cyanobacteria, electron transport chain, aTPase, calvin cycle, 5035
- Chloroquine, doxorubicin, A549 cells, autophagy, apoptosis, oxidative stress, caspase, extracellular-signal-regulated kinase, 4025
- Cholangioblastic variant, intrahepatic cholangiocarcinoma, biphasic cytology, liver, inhibin A, *NIPBL-NACCI* fusion gene, 5475
- Cholangiocarcinoma, eriodictyol, HMOX1, FAK, viability, 3789
- Cholangiocarcinoma, HDAC6, GRP78, acetylation, ACY-1215, 471
- Cholecalciferol, vitamin D, d-vitamin, UVR, hairless mice, 25-hydroxyvitamin D<sub>3</sub>, 5083
- Cholelithiasis, surgery, IL-18, NRS pain score, analgesic doses, 5521
- Cholesterol metabolism, liver X receptors, small-cell lung cancer, ABCA1, T0901317, 2923
- Cholesterol, breast cancer, drug resistance, tamoxifen, acetyl plumbagin, 565
- Chordoma, sacral, survival, population, SEER, cancer, 929
- Chorioallantoic membrane, MCF-7, mesenchymal stem cells, vascular plexus, vasculogenesis, 877
- Chromosome aberrations, cytogenetic analysis, aneuploidy, cancer, risk assessment, medical workers, 1059
- Chymase, skin cancer, basal cell carcinoma, renin angiotensin system, *CMA1* gene, G1903A, rs1800875, angiotensin 2, 5547
- Cigarette, breast cancer, smoking, hormone receptor, endocrine therapy, 3937
- CIN2, HPV, cervical cancer, p16/Ki-67 dual-stained cytology, triage, CIN3, HSIL, screening, risk stratification, pap test, 2599
- Circadian rhythm, fructose-containing western diet, hypertension, nonalcoholic fatty liver disease, obesity, physical exercise, 609
- Circulating cell-free DNA, papillary thyroid carcinoma, cfDNA integrity index, GAPDH,  $\beta$ -actin, 2289
- Circulating tumor cell cluster, circulating tumor cells, breast cancer, 4879
- Circulating tumor cell, cancer cell, liquid biopsy, microfluidic chip cell sorter, multistep sorting, PD-L1, 407
- Circulating tumor cell, hepatocellular carcinoma, liver resection, anterior approach, hanging maneuver, 4129
- Circulating tumor cells, circulating tumor cell cluster, breast cancer, 4879
- Circulating tumor cells, drug resistance, chemotherapy, sorafenib, *ex vivo* culture, 2479
- Circulating tumor cells, filter, immunostaining, cell culture, gene mutation analysis, 4305
- Circulating tumor cells, microfluidic, epithelial mesenchymal transition, phenotype profile analysis, 4345
- Circulating tumor cells, small cell lung cancer, biomarker, MUC1, CD147, 429
- Circulating tumor DNA, copy number variant, cyclin D1, breast cancer, 4071
- Circulating tumour DNA, gastrointestinal stromal tumour, next-generation sequencing, 5527
- Cisplatin, capecitabine, gastric cancer, adjuvant chemotherapy, metastasis, 2009
- Cisplatin, esophageal squamous cell carcinoma, docetaxel, 5-fluorouracil, neoadjuvant chemoradiotherapy, 3905
- Cisplatin, head and neck cancer, hearing loss, radiotherapy, concomitant treatment, toxicity, cochlea, constraints, dose, 3003
- Cisplatin, head and neck cancer, radiotherapy, HPV, SIB, IMRT, toxicity, 5909
- Cisplatin, hepatocellular carcinoma, lenvatinib resistance, cell cycle, microRNA, 1263
- Cisplatin, HIPEC duration, intraperitoneal chemotherapy, cytoreductive surgery, 1019
- Cisplatin, nausea, vomiting, radiotherapy, cervical cancer, 3117
- Cisplatin, nephrotoxicity, short hydration, oral rehydration solution (ORS), risk factor, 3185
- Cisplatin, ovarian cancer, primary debulking surgery, interval debulking surgery, hyperthermic intraperitoneal chemotherapy, review, 4659
- CJ14939, JAK/STAT, JAK inhibitor, oxaliplatin, colorectal cancer, 1813
- Classification, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, 1247
- Clavicle pro humero reconstruction, malignant bone tumor, non-union, sarcoma, 2139
- Clear cell renal cell carcinoma (cc-RCC), anti-CLIC1 antibodies, cornea rabbit model, chick embryo chorioallantoic membrane model, 1313
- Clear cell sarcoma, subungual melanoma, cell line, cell culture, 5315
- Clear-cell renal cell carcinoma, guanylate-binding protein 2, expression, prognostic biomarker, 2341
- Clinical correlation, advanced colorectal cancer, checkpoint-with-forkhead-and-ring-finger-domains (CHFR), dNA-promoter methylation, irinotecan, histoculture drug response assay (HDRA), biomarker, 697
- Clinical desire, pressurized intraperitoneal aerosol chemotherapy, peritoneal metastasis, survey, prerequisite, cost, 363
- Clinical outcome, low rectal cancer, neoadjuvant chemoradiotherapy, rectal surgery, intersphincteric resection, enhanced recovery after surgery, ERAS, 1949
- Clinical outcomes, ovarian cancer, chemotherapy, overall survival, progression-free survival, platinum-free interval, platinum resistance, CA-125, 349
- Clinical research methods, tumor interstitial fluid, breast cancer, cytokine, 1327



- Clinical study, high-dose methotrexate (HD-MTX), hepatic dysfunction, osteosarcoma, 1043
- Clinical T classification, positron emission tomography-computed tomography, synchronous esophageal cancer, pharyngeal squamous cell carcinoma, detectability, 4597
- Clinical treatment, cancer, methionine addiction, Hoffman effect, methionine restriction, methioninase, review, 641
- Clinical trial study design, recommended daily intake, RDA, evidence-based medicine, public health, primary disease prevention, COVID-19, evolution, primate biology, vitamin D toxicity, review, 5027
- Clinical trial, CAR-T, phase I, study design, dose escalation, reporting, review, 5673
- Clinical trial, vitamin D, 25-hydroxyvitamin D, pharmacokinetics, intestinal absorption, 5095
- CLND2, colitis-associated cancer, ulcerative colitis, CHI3L1, *CEACAM6*, 4119
- CMAI* gene, skin cancer, basal cell carcinoma, renin angiotensin system, chymase, G1903A, rs1800875, angiotensin 2, 5547
- CMT, PCNSL, elderly, chemotherapy, radiation, 1867
- CMV reactivation, letermovir prophylaxis, allogeneic transplantation, 5431
- CNV, gastric cancer, gene expression, 8q24.21, 4381
- Co-treatment, jak2, pacritinib, p-gp, drug resistance, 2433
- Cobimetinib, *AGK-BRAF* gene fusion, myoepithelial carcinoma, mEK-inhibitor, next generation sequencing, NGS, 373
- Cochlea, head and neck cancer, hearing loss, cisplatin, radiotherapy, concomitant treatment, toxicity, constraints, dose, 3003
- Colitis-associated cancer, ulcerative colitis, CHI3L1, *CEACAM6*, CLND2, 4119
- Collapsin response mediator protein 4 (CRMP4), DPYSL3, CD163, M2 macrophage, cD11b, myeloid-derived suppressor cell (MDSC), 791
- Colon biopsies, crypts, asymmetric branching, ulcerative colitis, remission, 449
- Colon cancer, cachexia, resistance exercise, aerobic exercise, inflammation, colon-26, muscle fiber type, 397
- Colon cancer, elderly patients, gRIm score, non-cancer-specific survival, postoperative complication, 5643
- Colon cancer, epithelial-mesenchymal transition, lymph node metastasis, SNAI1, SNAI1, 5927
- Colon cancer, long chain non-coding RNA, MIR4435-2HG, colon polyps, 4707
- Colon cancer, metastasis, PGE2, 15-PGDH, epithelial-to-mesenchymal transition, 5385
- Colon cancer, pentoxifylline (PTX), tumor markers, cytokines, 5487
- Colon cell proliferation, mixed nuts, pistachios, 8-oxo-deoxyguanosine, cyclooxygenase 2, 4285
- Colon polyps, long chain non-coding RNA, MIR4435-2HG, colon cancer, 4707
- Colon-26, cachexia, resistance exercise, aerobic exercise, inflammation, colon cancer, muscle fiber type, 397
- Colon, field cancerization, nondysplastic crypts, crypt branching, tubular adenomas, 5891
- Colorectal cancer liver metastases, adjuvant chemotherapy, resection, recurrence, overall survival, 5497
- Colorectal cancer patients, elderly, postoperative complications, protective factors, risk factors, 1123
- Colorectal cancer screening, fecal immunochemical test, FIT, ROC, proximal colon, distal colon, 1879
- Colorectal cancer, alcohol drinking, genotype, *MMP2*, metastasis, polymorphism, Taiwan, 5335
- Colorectal cancer, cancer immunology, arginase 1, CD15, multiplex fluorescent labeling, 459
- Colorectal cancer, cancer-associated fibroblasts, bcl-xL, mcl-1, IL-6, apoptosis, STAT3, 1277
- Colorectal cancer, chemotherapy, liquid biopsy, anti-*EGFR* mAb, 2625
- Colorectal cancer, DYRK1A protein, DYRK1B protein, protein kinases, endoplasmic reticulum stress, autophagy, 589
- Colorectal cancer, early recurrence, late recurrence, 5553
- Colorectal cancer, fibroblast activation protein, tertiary lymphoid structures, 5897
- Colorectal cancer, genotype, *MTRR*, polymorphism, Taiwan, 2375
- Colorectal cancer, JAK/STAT, CJ14939, JAK inhibitor, oxaliplatin, 1813
- Colorectal cancer, laparoscopic surgery, mixed reality, navigation, virtual reality, 4849
- Colorectal cancer, microwave ablation, radiofrequency ablation, pulmonary metastasis, 4563
- Colorectal cancer, postoperative infectious complication, long-term survival, 2763
- Colorectal cancer, pRKR-interacting protein 1, prognostic biomarker, 4701
- Colorectal cancer, stage III, nutrition, prognostic score, 4989
- Colorectal cancer, thymidine phosphorylase, 5-fluorouracil, inhibitor of methylation, 837
- Colorectal cancers, H19, LINC00675, plasma markers, lncRNA, 1301
- Colorectal carcinoma therapy, anti-angiogenic drug, plant derived polyphenols, trans-resveratrol, quercetin, vitamin E, selenium, dogs, 4763
- Colorectal carcinoma, hyperthermia, cancer therapeutics, 5-fluorouracil, capecitabine, bevacizumab, cetuximab, 2363
- Colorectal liver metastases, fluorouracil plus leucovorin, microwave ablation, systemic chemotherapy, 1645
- Colorectal liver metastasis, lymphocyte-to-C-reactive protein ratio, prognosis, overall survival, tumour, 4963
- Colorectal liver metastasis, prognostic factor, lymph node metastasis, N factor, TNM classification, 1997
- Colorectal neoplasm, ELMO1, oncogenic phenotype, prognosis, tumor progression, 5343



- Colorectal neoplasms, tumor marker, observational study, survival analysis, 3921
- Colorectal surgery, anastomotic leakage, gene expression analysis, microarray, 2827
- Colorectal surgery, gastric surgery, spirometry, postoperative complication, COVID-19, 1623
- Colorectal surgery, rectal cancer, low anastomoses, laparoscopic surgery, radiotherapy, indocyanine green, 211
- Colorectal, appendiceal, peritonectomy, adenocarcinoma, carcinoembryonic antigen, review, 4217
- Colorectal, second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, completeness of cytoreduction, peritoneal cancer index, 1001
- Colorectal, transumbilical incision, laparoscopic, surgical site infection, hernia, 1115
- Colorectal, trimetazidine, liver, thermic damage, rat model, 4395
- Combination therapy, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, Hoffman protocol, complete response, 5819
- Combination therapy, breast osteosarcoma, PDOX, nude mice, methioninase, rapamycin, efficacy, synergy, Hoffman effect, 5217
- Combination therapy, osteosarcoma, nude mice, PDOX, methionine addiction, Hoffman effect, methioninase, methotrexate, resistance, efficacy, 731
- Combination therapy, pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, supplement, stable disease, CA19-9, methionine addiction, Hoffman effect, 2567
- Combinatorial treatment, ko143, p-glycoprotein, BCRP, drug resistance, temozolomide, 723
- Community pharmacy services, breast cancer, endocrine therapy, aromatase inhibitors, side effects, adverse events, community pharmacists, health knowledge, educational intervention, review, 661
- Comorbidity, palliative radiation therapy, radiotherapy, bone metastases, brain metastases, prognostic model, 1477
- Compartment, soft tissue sarcoma, thigh, 3143
- Complement C3, pancreatic ductal adenocarcinoma, metastasis, epithelial-to-mesenchymal transition, 5743
- Complement C3a receptor, pancreatic adenocarcinoma, metastasis, complement C3a, epithelial-to-mesenchymal transition, 1207
- Complement C3a, pancreatic adenocarcinoma, metastasis, complement C3a receptor, epithelial-to-mesenchymal transition, 1207
- Complete cytoreductive surgery, advanced ovarian cancer, PCI, CT, overall survival, 2541
- Complete response, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, 5819
- Complete surgery, advanced ovarian cancer, primary debulking surgery, predictive index value, peritoneal cancer index, 115
- Completeness of cytoreduction, second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, colorectal, peritoneal cancer index, 1001
- Complication, oral cancer, radiotherapy, brachytherapy, reirradiation, 293
- Complications, abdominal aortic calcification, comprehensive complication index, HBP surgery, risk factors, 5983
- Compound library, osteosarcoma, bortezomib, everolimus, synergistic effect, 4319
- Comprehensive complication index, abdominal aortic calcification, complications, HBP surgery, risk factors, 5983
- Concomitant treatment, head and neck cancer, hearing loss, cisplatin, radiotherapy, toxicity, cochlea, constraints, dose, 3003
- Concurrent chemoradiotherapy, chemotherapy regimen, recurrence, 1073
- Concurrent chemoradiotherapy, malignant central airway obstruction, small-cell lung cancer, extraluminal obstruction, stent placement, 6113
- Concurrent chemoradiotherapy, squamous cell carcinoma of the cervix, sarcopenia, PMI, SMI, 4887
- Concurrent chemoradiotherapy, squamous cell carcinoma, head and neck, prognostic factor, TPF, 6047
- Confocal, gallbladder cancer, microscopy, endomicroscopy diagnosis, malignancy, 67
- Constraints, head and neck cancer, hearing loss, cisplatin, radiotherapy, concomitant treatment, toxicity, cochlea, dose, 3003
- Context-independent, cancer spheroid, KRAS, 3D floating culture, low-toxic, 3993
- Contralateral interhemispheric approach, extraventricular ependymoma, supratentorial ependymoma, 3203
- Conventional fractionated radiotherapy, neoadjuvant long course, chemoradiotherapy, population-based, radiotherapy dose escalation, locally advanced rectal cancer, 1143
- Conversion hepatectomy, surgery, hepatocellular carcinoma, lenvatinib, molecular therapy, review, 35
- Conversion surgery, advanced hepatocellular carcinoma, liver resection, lenvatinib, 3049
- Conversion surgery, gastric cancer, prognosis, 1541
- Copine 1, renal cell carcinoma, immunohistochemistry, prognostic marker, bioinformatics, 355
- Copy number alteration, *TP53*, *MDM2*, *CDKN2A*, breast Cancer, 2277

- Copy number variant, cyclin D1, circulating tumor DNA, breast cancer, 4071
- Copy-number deletions, lymphoid malignancies, platinum, gene-expression analysis, 1821
- Cornea rabbit model, anti-CLIC1 antibodies, clear cell renal cell carcinoma (cc-RCC), chick embryo chorioallantoic membrane model, 1313
- Corpus, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Corticosteroids, immunotherapy, non-small cell lung cancer, immune-related adverse events, 5961
- Cost analysis, robotic surgical procedure, hemoglobin, blood transfusion, hysterectomy, endometrial neoplasm, 1893
- Cost, pressurized intraperitoneal aerosol chemotherapy, peritoneal metastasis, survey, clinical desire, prerequisite, 363
- Coumarin derivative, novel anti-pancreatic cancer agent, selective cytotoxicity, autophagy, 2835
- COVID-19 strategies, breast cancer, awake breast surgery, surgical waiting list, 4913
- COVID-19 vaccine, cancer, anticancer agent, adverse drug event, urology, 2105
- COVID-19, boron neutron capture therapy, salvage maxillectomy, recurrent oral cancer, nasoseptal flap, 1653
- COVID-19, colorectal surgery, gastric surgery, spirometry, postoperative complication, 1623
- COVID-19, recommended daily intake, RDA, clinical trial study design, evidence-based medicine, public health, primary disease prevention, evolution, primate biology, vitamin D toxicity, review, 5027
- COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- Cowden syndrome, minimally invasive follicular thyroid carcinoma, *PTEN* gene mutation, *PTEN* hamartoma tumor syndrome, *RECQL4* gene, germline mutation, surveillance, 1481
- COX-2, glioblastoma multiforme, trifluoperazine, pPAR $\gamma$ , 5773
- CPD, cyclobutane pyrimidine dimer, DNA damage, thymidine dimer, LC-MS/MS, urine, bioanalysis, 5069
- CPS, nivolumab, PD-L1, recurrent/metastatic head and neck cancer, TPS, 1547
- Craniopharyngioma, cerebral ventricles, intraventricular tumor, neuro-oncology, skull base, systematic review, 4189
- Cribriform adenocarcinoma of salivary glands, salivary gland tumor, polymorphous adenocarcinoma, polymorphous low-grade adenocarcinoma, PRKD1, molecular diagnostics, 1455
- CRISPR/Cas9, *BAX* and *BCL2* silencing, SK-N-SH cells, casiopeína IIIa, mPTP, Ca<sup>2+</sup> retention capacity, 885
- Criteria for discontinuation, carboplatin desensitization, ovarian cancer, hypersensitivity reactions, erythema, arms, 1091
- CRLR, CGRP, RAMP1, AML, EVI1, 4743
- Crohn's disease, crypt branching, histopathology, 1919
- Cross-over trial, ultraviolet Radiation, vitamin D, 25(OH)D, winter, office lighting, 5101
- CRP, NSCLC, lung cancer, PD-L1, inflammation, albumin, haemoglobin, NLR, 1563
- CRP, pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, NLR, lactate dehydrogenase, LDH, c-reactive protein, immune checkpoint inhibitor, predictive factor, 2045
- CRPC, abiraterone acetate, docetaxel, enzalutamide, sequential treatment, 2123
- CRPC, PSA decline, sequential therapy, enzalutamide, abiraterone, 3041
- Crypt branching, crohn's disease, histopathology, 1919
- Crypt branching, field cancerization, colon, nondysplastic crypts, tubular adenomas, 5891
- Crypt branching, ulcerative colitis, histopathology, 147
- Crypts, colon biopsies, asymmetric branching, ulcerative colitis, remission, 4493
- CT, advanced ovarian cancer, PCI, complete cytoreductive surgery, overall survival, 2541
- CTCAE, meta-analysis, systematic review, adverse events, asthenia, fatigue, placebo, cancer, oncology, randomized trials, review, 45
- CTCAE, meta-analysis, systematic review, adverse events, placebo, cancer, oncology, randomized trials, medDRA, review, 2805
- CTLA-4, nivolumab, advanced cancer, immunotherapy, checkpoint inhibitors, PD-1/PDL-1, 1433
- Cumulative summation analysis, robot-assisted hysterectomy, learning curve, endometrial cancer, benign gynecological tumor, 4111
- Curative surgery, esophageal cancer, systemic inflammation score, prognostic factor, 2711
- Customized bolus, delivery accuracy, normal tissue exposure, ear keloid, tomoTherapy, 4411
- Cutaneous adverse event, drug eruption, apalutamide, prostate cancer, body weight, maculopapular eruption, 2023
- Cutaneous malignant melanoma, health-related quality of life, limb edema, limb lymphedema, extremity lymphedema, cancer surgery, 5507
- Cutaneous squamous cell carcinoma, SMARCB1 gene, parotid gland, metastasis, 3971
- Cyanobacteria, photosynthesis, plants, algae, photosynthetic bacteria, chlorophyll, electron transport chain, aTPase, calvin cycle, 5035
- CyberKnife, stereotactic ablative body radiotherapy, SABR, SBRT, lung cancer, 321
- Cyclic variation of the integrated backscatter, radiotherapy, breast cancer, myocardial imaging, speckle tracking echocardiography, global longitudinal strain, 2507
- Cyclin D1, copy number variant, circulating tumor DNA, breast cancer, 4071

- Cyclin-dependent kinase inhibitor,  $\gamma$ -glutamylcyclotransferase, antisense, lung cancer, AMPK, reactive oxygen species, 1221
- Cyclin-dependent kinase inhibitors,  $\gamma$ -glutamylcyclotransferase, n-acetylcysteine, reactive oxygen species, pro-GA, breast cancer, 4311
- Cyclobutane pyrimidine dimer, CPD, DNA damage, thymidine dimer, LC-MS/MS, urine, bioanalysis, 5069
- Cyclooxygenase 2, mixed nuts, pistachios, colon cell proliferation, 8-oxo-deoxyguanosine, 4285
- Cyclooxygenase-2, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, vitamin D receptor, VDR, CYP24A1, 5049
- Cyclophosphamide, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- CYP24A1, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, 5049
- CYP3A4, hepatitis C virus, ritonavir, calcium channel blockers, amlodipine, peripheral edema, 2087
- Cytochrome P450 1A1, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- Cytogenetic analysis, chromosome aberrations, aneuploidy, cancer, risk assessment, medical workers, 1059
- Cytokine, tumor interstitial fluid, breast cancer, clinical research methods, 1327
- Cytokines, colon cancer, pentoxifylline (PTX), tumor markers, 5487
- Cytopathic effect, adenovirus vector, adenovirus death protein, progeny virus, 1719
- Cytoreduction, ovarian cancer, surgery, ultra-radical, lactate, length of stay, 1979
- Cytoreduction, peritoneal cancer index, high grade ovarian cancer, surgical complexity, 4825
- Cytoreductive nephrectomy, renal cell carcinoma, nivolumab plus ipilimumab, 2727
- Cytoreductive surgery, HIPEC duration, intraperitoneal chemotherapy, cisplatin, 1019
- Cytoreductive surgery, malignant peritoneal mesothelioma, HIPEC, outcomes, survival, 2939
- Cytoreductive surgery, second-look surgery, stoma-reversal, peritonectomy, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001
- Cytotoxic T cells, multiple myeloma, adoptive T cell therapy, dendritic cells, B cell maturation antigen, 1785
- Cytotoxic T cells, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, NK cells, nKT-like cells, T regulatory cells, 3067
- Cytotoxicity, zinc, light isotope, stable isotope, anticancer effect, apoptosis, 5685
- D-vitamin, vitamin D, cholecalciferol, UVR, hairless mice, 25-hydroxyvitamin D<sub>3</sub>, 5083
- Daoy, medulloblastoma, immunotherapy, gemcitabine, rapamycin, lipopolysaccharide, 1697
- Death receptor 6, glioma, low-grade glioma, prognosis, survival, tumor necrosis factor receptor 21, 1237
- Deep learning, artificial intelligence, ewing sarcoma, osteomyelitis, tumor detection, early diagnosis, transfer learning, 4371
- Deficiency, vitamin B12, oral treatment, total gastrectomy, gastric cancer, randomized controlled trial, 3963
- Delivery accuracy, knowledge-based treatment planning, VMAT, plan complexity, prostate cancer, 5305
- Delivery accuracy, normal tissue exposure, ear keloid, customized bolus, tomoTherapy, 4411
- Dendritic cell vaccine, immune-cell therapy, adjuvant therapy, solid tumor,  $\alpha\beta$ T cell therapy, 4179
- Dendritic cells, multiple myeloma, adoptive T cell therapy, cytotoxic T cells, B cell maturation antigen, 1785
- Dermatofibrosarcoma protuberans, fibrosarcoma, presentation, 105
- Detectability, positron emission tomography-computed tomography, synchronous esophageal cancer, pharyngeal squamous cell carcinoma, clinical T classification, 4597
- Diabetes mellitus, glucose metabolism disorder, mouth neoplasms, maxillofacial surgery, epidemiology, 1899
- Diabetes mellitus, UV exposure, cancer, melanoma, cardiovascular disease, mortality, review, 1671
- Diabetes, oral cancer, public health, smoking, impaired fasting glycemia, 109
- Diabetic cancer patients, immunotherapy, immune checkpoint inhibitor, nivolumab, metformin, safety, 1487
- Diagnostic accuracy, gastroPanel<sup>®</sup>, meta-analysis, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Diagnostic biomarker, miRNA, ovarian cancer, *miR-1*, *miR-21*, 5839
- Dicycloplatin capsules, bladder cancer, recurrence, remission, tolerable side effects, 1339
- Differentiated thyroid cancer, lobectomy, risk factors, recurrence, thyroglobulin, 5619

- Diffuse large B-cell lymphoma, estrogen receptor  $\beta$ , silibinin, non-Hodgkin lymphoma, cardiomyocytes, doxorubicin, apoptosis, autophagy, 767
- Diffuse plexiform neurofibroma, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, classification, 1247
- Diffuse plexiform neurofibroma, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, NRG1, ki-67, 2327
- Diffusion tensor imaging, gliomas, brain tumors, temozolomide, radiation therapy, 329
- Digital pathology, tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs), automatic measurement, imaging analysis software, project HOPE, 419
- Dimethyl fumarate, NF- $\kappa$ B, STAT3, c-IAP2, adult T-cell, leukemia, lymphoma, 2301
- Dipeptidyl peptidase-4, cancer-associated fibroblasts, scirrhous-type gastric cancer, proliferation, cancer microenvironment, 501
- Discontinuation of treatment, radiotherapy, lung cancer, risk factors, prognostic instrument, 1973
- Discontinuation, gastrointestinal stromal tumours, tyrosine kinase inhibitors, imatinib, qualitative research, side-effects, psycho-social, hope, 955
- Discontinuation, immune checkpoint inhibitor, survival, non-small-cell lung cancer, driver gene mutation, 4589
- Disease characteristics, chemotherapy, targeted therapy, germany, austria, switzerland, treatment reality, 4773
- Disease control, nivolumab, tolerability, progressive disease, immune-related adverse events, 4973
- Disparities, head and neck cancer, survivorship care plans, hypothyroidism, radiation, thyroid stimulating hormone, 4429
- Disparity, breast cancer, inequality, treatment, 5813
- Dissociative enzymes, annexin V, transient transfection, miRNA, flow cytometry, trypsin, 2819
- Distal colon, fecal immunochemical test, FIT, colorectal cancer screening, ROC, proximal colon, 1879
- Distal pancreatectomy, laparoscopic, pancreatic cancer, radical antegrade modular pancreatosplenectomy, robotic, review, 653
- Distal pancreatectomy, postoperative pancreatic fistula (POPF), pancreaticoenterostomy, 4153
- Distal pancreatectomy, robot, surgical approach, splenic artery, pancreatic cancer, 4471
- Distress levels, cancer treatment, radiotherapy, elderly patients, pilot study, 5561
- DNA damage repair, cell cycle, radiosensitivity, fucci, G1 phase, G2 arrest, 5407
- DNA damage, CPD, cyclobutane pyrimidine dimer, thymidine dimer, LC-MS/MS, urine, bioanalysis, 5069
- DNA methylation, breast cancer recurrence, CHIP, ER, 759
- DNA methylation, exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-lncRNA, exo-circRNA, exo-DNA, gastric juice, review, 2249
- DNA methylation, intraductal papillary neoplasm type 1, intraductal papillary neoplasm type 2, DNMT1, multiple gene expression analysis, 2893
- DNA-promoter methylation, advanced colorectal cancer, checkpoint-with-forkhead-and-ring-finger-domains (CHFR), irinotecan, histoculture drug response assay (HDRA), clinical correlation, biomarker, 697
- DNMT1, intraductal papillary neoplasm type 1, intraductal papillary neoplasm type 2, DNA methylation, multiple gene expression analysis, 2893
- Docetaxel, abiraterone acetate, enzalutamide, CRPC, sequential treatment, 2123
- Docetaxel, abiraterone, enzalutamide, metastatic castration-resistant prostate cancer, 4857
- Docetaxel, bone metastatic castration-resistant prostate cancer, androgen receptor axis targeted agent, cabazitaxel, overall survival, 1465
- Docetaxel, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, combination therapy, Hoffman protocol, complete response, 5819
- Docetaxel, esophageal squamous cell carcinoma, cisplatin, 5-fluorouracil, neoadjuvant chemoradiotherapy, 3905
- Docetaxel, radiotherapy, prostate cancer, quality of life, 87
- Docetaxel, TNBC,  $\beta$ -tubulin isoform, 3D culture, spheroid, morphology, 4735
- Dog, endothelial cell, macrophage, melanoma, tumor microenvironment, 5397
- Dogs, colorectal carcinoma therapy, anti-angiogenic drug, plant derived polyphenols, trans-resveratrol, quercetin, vitamin E, selenium, 4763
- Doppler, tongue cancer, squamous cell carcinoma, ultrasonography, cervical lymph node metastasis, 287
- Dorsal root ganglion neurons, axonal growth, calcitonin gene-related peptide, nerve growth factor, spinal metastasis, 581
- Dose escalation, CAR-T, phase I, clinical trial, study design, reporting, review, 5673
- Dose, head and neck cancer, hearing loss, cisplatin, radiotherapy, concomitant treatment, toxicity, cochlea, constraints, 3003
- Doxorubicin, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Doxorubicin, chloroquine, A549 cells, autophagy, apoptosis, oxidative stress, caspase, extracellular-signal-regulated kinase, 4025



- Doxorubicin, estrogen receptor  $\beta$ , silibinin, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, cardiomyocytes, apoptosis, autophagy, 767
- Doxorubicin, polyphosphoesters, amphiphilic polymers, drug delivery, drug carriers, 1801
- DPYSL3, collapsin response mediator protein 4 (CRMP4), CD163, M2 macrophage, cD11b, myeloid-derived suppressor cell (MDSC), 791
- Drain fluid culture, gram stain, occult anastomotic leakage, 3091
- Driver gene mutation, discontinuation, immune checkpoint inhibitor, survival, non-small-cell lung cancer, 4589
- Drosophila melanogaster*, vitamin D, mosquitoes, *aedes aegypti* mosquitoes, migratory birds, bats, vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 5091
- Drug carriers, polyphosphoesters, amphiphilic polymers, drug delivery, doxorubicin, 1801
- Drug delivery system, milk extracellular vesicles, *EGFR* expressing tumor, GE11 peptide, bio-engineered drug carrier, 857
- Drug delivery, polyphosphoesters, amphiphilic polymers, drug carriers, doxorubicin, 1801
- Drug discovery, pancreatic cancer, patient-derived orthotopic xenograft (PDOX), NOG mouse, nude mouse red fluorescent protein (RFP), lymph-node metastasis, intravital imaging, personalized therapy, 739
- Drug eruption, cutaneous adverse event, apalutamide, prostate cancer, body weight, maculopapular eruption, 2023
- Drug repositioning, repurposing, MDMX, HDMX, 4727
- Drug resistance, breast cancer, cholesterol, tamoxifen, acetyl plumbagin, 565
- Drug resistance, Chinese hamster ovary cell, cancer, chemotherapy, genetic mutation, irinotecan, 4011
- Drug resistance, circulating tumor cells, chemotherapy, sorafenib, *ex vivo* culture, 2479
- Drug resistance, jak2, pacritinib, co-treatment, p-gp, 2433
- Drug resistance, ko143, combinatorial treatment, p-glycoprotein, BCRP, temozolomide, 723
- Drug screening, gastric tumor xenograft-derived cell line, patient-derived xenograft, gastric cancer, high-throughput screening, 2883
- DsDNA, ovarian cancer, tumor marker, nETs, h3Cit-DNA, 965
- Ductal carcinoma *in situ*, breast cancer, smoking, invasive ductal carcinoma, biopsy, 311
- DUPAN-2, pancreatic cancer, recurrence pattern, locoregional recurrence, pancreatectomy, 2071
- DYRK1A protein, DYRK1B protein, protein kinases, endoplasmic reticulum stress, autophagy, colorectal cancer, 589
- DYRK2, breast cancer, TERT, prognostic factor, 2079
- Ear keloid, delivery accuracy, normal tissue exposure, customized bolus, tomoTherapy, 4411
- Early diagnosis, artificial intelligence, ewing sarcoma, osteomyelitis, tumor detection, deep learning, transfer learning, 4371
- Early recurrence, colorectal cancer, late recurrence, 5553
- EBI3, melanoma, biomarker, tumor microenvironment, 511
- EBNA-1, olaparib, apoptosis, Epstein-Barr virus nuclear antigen-1, ataxia telangiectasia and Rad3 related kinase, ATR, gastric cancer cell, 555
- EBV, lymphoproliferative disorder, transplantation, PTLD, CAR-T, review, 5181
- ECG, breast cancer, radiotherapy, cardiac biomarkers, echocardiography, 2519
- Echocardiography, breast cancer, radiotherapy, cardiac biomarkers, ECG, 2519
- Educational intervention, breast cancer, endocrine therapy, aromatase inhibitors, side effects, adverse events, community pharmacy services, community pharmacists, health knowledge, review, 661
- Effect size, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, review, 1679
- Effectiveness, advanced breast cancer, everolimus, first line, safety, 1031
- Effectiveness, everolimus, pancreatic neuroendocrine tumors, progression-free survival, real-world study, tolerability, 1941
- Efficacy, breast osteosarcoma, PDOX, nude mice, combination therapy, methioninase, rapamycin, synergy, Hoffman effect, 5217
- Efficacy, osteosarcoma, nude mice, PDOX, methionine addiction, Hoffman effect, methioninase, methotrexate, resistance, combination therapy, 731
- EGFR* expressing tumor, milk extracellular vesicles, GE11 peptide, drug delivery system, bio-engineered drug carrier, 857
- EGFR* mutation, lung cancer, afatinib, osimertinib, T790M, 2145
- EGFR* mutation, lung cancer, osimertinib, PD-L1, 2583
- EGFR* mutations, non-small cell lung cancer, targeted therapies, epigenetic therapy, 441
- EGFR-TKI* resistance, extracellular vesicles, NSCLC, t790M/L858R-mutation, 3835
- Elderly patients, cancer treatment, radiotherapy, distress levels, pilot study, 5561
- Elderly patients, colon cancer, gRIIm score, non-cancer-specific survival, postoperative complication, 5643
- Elderly patients, proton beam therapy, non-small cell lung cancer, 2953
- Elderly, colorectal cancer patients, postoperative complications, protective factors, risk factors, 1123
- Elderly, esophageal cancer, esophagectomy, chemo-radiotherapy, 3953



- Elderly, gastric cancer, oxaliplatin, capecitabine, chemotherapy, phase 2 trial, 2683
- Elderly, PCNSL, CMT, chemotherapy, radiation, 1867
- Elderly, radiotherapy, esophageal cancer, T4, 2095
- Elective nodal irradiation, head and neck cancer, glottic carcinoma, radiotherapy, chemoradiotherapy, laryngeal preservation, 205
- Electron transport chain, photosynthesis, plants, algae, photosynthetic bacteria, cyanobacteria, chlorophyll, ATPase, calvin cycle, 5035
- ELISA for inhibition of PD-1/PD-L1 binding, small chemical compound library, *in silico* screening, mHC-dKO NOG mouse, ADME evaluation, 5233
- ELMO1, oncogenic phenotype, prognosis, tumor progression, colorectal neoplasm, 5343
- EMT-induced transcription factors, bile duct cancer, budding phenomenon, 4079
- End-of-life care, pancreatic cancer, palliative care, service use, place of death, 5457
- EndMT, eribulin, tGF- $\beta$ , neo-angiogenesis, adhesion molecules, 2859
- Endocervical adenocarcinoma, cervix, human papillomavirus, world Health Organization Classification, 4627
- Endocrine therapy, breast cancer,  $^{18}\text{F}$ -fluorodeoxyglucose-positron emission tomography, CDK4/6 inhibitor, predictive factor, 4813
- Endocrine therapy, breast cancer, aromatase inhibitors, side effects, adverse events, community pharmacy services, community pharmacists, health knowledge, educational intervention, review, 661
- Endocrine therapy, breast cancer, smoking, hormone receptor, cigarette, 3937
- Endometrial cancer, lymph node metastasis, p53, MMR deficiency, heterogeneity, 4535
- Endometrial cancer, robot-assisted hysterectomy, cumulative summation analysis, learning curve, benign gynecological tumor, 4111
- Endometrial neoplasm, robotic surgical procedure, hemoglobin, blood transfusion, hysterectomy, cost analysis, 1893
- Endometrial neoplasm, robotic surgical procedure, laparoscopy, laparotomy, aged, survival, 75
- Endometrium cancer, PD-L1, PD-1, immune checkpoint, prognostic factor, targeted therapy, 1367
- Endomicroscopy diagnosis, gallbladder cancer, microscopy, confocal, malignancy, 67
- Endoplasmic reticulum stress, aurora kinase inhibitor, cell-cycle arrest, apoptosis, Epstein-Barr virus-transformed B-cells, 5265
- Endoplasmic reticulum stress, DYRK1A protein, DYRK1B protein, protein kinases, autophagy, colorectal cancer, 589
- Endoscopic resection, esophageal cancer, lymph node metastasis, c-reactive protein, genetic polymorphism, 6105
- Endoscopic resection, superficial esophageal carcinoma, esophagectomy, chemoradiotherapy, 2791
- Endothelial cell, dog, macrophage, melanoma, tumor microenvironment, 5397
- Endothelial cells, three-dimensional model, breast cancer cells, *in vivo* mimicking, 4689
- Engraftment rate, patient-derived xenograft, pancreatic ductal adenocarcinoma, microenvironment, vascular endothelial cells, 2395
- Enhanced recovery after surgery, low rectal cancer, neoadjuvant chemoradiotherapy, rectal surgery, intersphincteric resection, ERAS, clinical outcome, 1949
- ENO1, glioma, meningioma,  $\alpha$ -enolase, glioblastoma, MBP1, 2319
- Enzalutamide, abiraterone acetate, docetaxel, CRPC, sequential treatment, 2123
- Enzalutamide, abiraterone, docetaxel, metastatic castration-resistant prostate cancer, 4857
- Enzalutamide, PSA decline, sequential therapy, abiraterone, CRPC, 3041
- EPHA2, bladder cancer, cancer recurrence, biomarker, adipocytes, machine learning, 5783
- Epidemiology, diabetes mellitus, glucose metabolism disorder, mouth neoplasms, maxillofacial surgery, 1899
- Epidermal growth factor receptor, lung neoplasms, afatinib, prognosis, 1615
- Epidermal growth factor receptor, non-small-cell lung cancer, osimertinib, pemetrexed, polo-like kinase 1, 709
- Epigenetic therapy, non-small cell lung cancer, *EGFR* mutations, targeted therapies, 441
- Epiregulin, EREG, gastric cancer, 3873
- Epithelial mesenchymal transition, circulating tumor cells, microfluidic, phenotype profile analysis, 4345
- Epithelial ovarian cancer, *BRCA* mutation, survival, 4945
- Epithelial ovarian cancer, homologous recombination, PARP inhibitors, chemotherapy, recurrence, 2017
- Epithelial to mesenchymal transition, lung cancer, potential compounds targeting EMT, review, 4237
- Epithelial-mesenchymal transition, tumor microenvironment (TME), tumor-infiltrating lymphocytes, human papillomavirus, *TP53* mutation-TGF- $\beta$ 1-PAX7 pathway, 4417
- Epithelial-to-mesenchymal transition, colon cancer, metastasis, PGE2, 15-PGDH, 5385
- Epithelial-to-mesenchymal transition, fluoxetine, triple-negative breast cancer, STAT3, apoptosis, 3807
- Epithelial-to-mesenchymal transition, pancreatic adenocarcinoma, metastasis, complement C3a, complement C3a receptor, 1207
- Epithelial-to-mesenchymal transition, pancreatic ductal adenocarcinoma, metastasis, complement C3, 5743
- Epithelial-mesenchymal transition, colon cancer, lymph node metastasis, SNAI1, SNAIL, 5927
- Epstein-Barr virus nuclear antigen-1, olaparib, apoptosis, EBNA-1, ataxia telangiectasia and Rad3 related kinase, ATR, gastric cancer cell, 555

- Epstein-Barr virus, post-transplant lymphoproliferative disorders, primary central nervous lymphoma, glioblastoma, 3975
- Epstein-Barr virus-transformed B-cells, aurora kinase inhibitor, cell-cycle arrest, apoptosis, endoplasmic reticulum stress, 5265
- Epstein-Barr virus, advanced gastric cancer, gastric carcinoma with lymphoid stroma, p53, 4955
- ER stress, *N-Trans-p-coumaroyltyramine*, nSAIDs, apoptosis, potentiation, breast cancer cells, 1833
- ER, breast cancer recurrence, CHIP, DNA methylation, 759
- ER+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, palbociclib, abemaciclib, 1099
- ERAS, low rectal cancer, neoadjuvant chemoradiotherapy, rectal surgery, intersphincteric resection, enhanced recovery after surgery, clinical outcome, 1949
- ERBB2, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB3, NRG1, ki-67, 2327
- ERBB4, etoposide, microRNA, miRNA-205-5p, breast cancer, spheroid, 4265
- EREG, epiregulin, gastric cancer, 3873
- Eribulin, absolute lymphocyte count, progression-free survival, advanced or metastatic breast cancer, tumor immunology, 939
- Eribulin, tGF- $\beta$ , endMT, neo-angiogenesis, adhesion molecules, 2859
- Eriodictyol, HMOX1, FAK, viability, cholangiocarcinoma, 3789
- ERK, amentoflavone, lenvatinib, AKT, hepatocellular carcinoma, 2495
- ERK, magnolol, NF- $\kappa$ B, osteosarcoma, apoptosis, 4403
- ERK2 (MAPK1), sarcomatoid renal cell carcinoma, POLR2A, RUNX2, micro-RNA378a-3p, 811
- Erythema, carboplatin desensitization, ovarian cancer, hypersensitivity reactions, criteria for discontinuation, arms, 1091
- ESHAP $\pm$ R therapy, chemotherapy, medication guidance sheet, adverse events, non-Hodgkin's lymphoma, 2053
- Esophageal cancer, adenocarcinoma of the esophagogastric junction, radio-chemotherapy, sleep problems, prevalence, risk factors, 4529
- Esophageal cancer, adenocarcinoma, squamous cell carcinoma, toll-like receptors, microbiome, review, 2813
- Esophageal cancer, elderly, esophagectomy, chemo-radiotherapy, 3953
- Esophageal cancer, esophageal wall thickness, tumor location, neoadjuvant chemotherapy, 5655
- Esophageal cancer, geriatric nutrition risk index, prognostic factor, nutrition, c-reactive protein, 5999
- Esophageal cancer, geriatric oncology, trimodality therapy, platinum/5-fluouracil, carboplatin/paclitaxel, 59
- Esophageal cancer, granulocyte colony-stimulating factor, bone marrow suppression, chemotherapy, adverse event, 2783
- Esophageal cancer, lymph node metastasis, c-reactive protein, genetic polymorphism, endoscopic resection, 6105
- Esophageal cancer, neoadjuvant chemotherapy, febrile neutropenia, predictive factors, pegfilgrastim, neutrophil count, 6071
- Esophageal cancer, radiotherapy, T4, elderly, 2095
- Esophageal cancer, synchronous other primary cancer, metachronous other primary cancer, 5635
- Esophageal cancer, systemic inflammation score, curative surgery, prognostic factor, 2711
- Esophageal cancer, transhiatal esophagectomy, transcervical mediastinoscopy, minimally invasive surgery, robotic-assisted surgery, review, 675
- Esophageal neoplasms, chemoradiotherapy, survival, 4929
- Esophageal squamous cell carcinoma, biomarker, platelet-to-lymphocyte ratio, 2775
- Esophageal squamous cell carcinoma, chemotherapy, prognostic factor, no residual tumor, 195
- Esophageal squamous cell carcinoma, docetaxel, cisplatin, 5-fluorouracil, neoadjuvant chemoradiotherapy, 3905
- Esophageal squamous cell carcinoma, neutrophil-to-lymphocyte ratio, immune checkpoint inhibitor, gastric/gastroesophageal adenocarcinoma, 2977
- Esophageal wall thickness, esophageal cancer, tumor location, neoadjuvant chemotherapy, 5655
- Esophagectomy, esophageal cancer, elderly, chemo-radiotherapy, 3953
- Esophagectomy, postoperative pneumonia, recurrent laryngeal nerve palsy, forced expiratory volume, 3023
- Esophagectomy, superficial esophageal carcinoma, endoscopic resection, chemoradiotherapy, 2791
- Esophagogastric cancer, adenocarcinoma, recurrence, lymph node metastasis, 1051
- Esophagus, cancer, neoadjuvant therapy, PET, surgery, survival, 6037
- Esophagus, murine double minute 2, nutlin-3, p53, p73, 2875
- Estrogen receptor  $\beta$ , silibinin, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, cardiomyocytes, doxorubicin, apoptosis, autophagy, 767
- Ethinylestradiol, ra-223, castration resistant prostate cancer, prostate-specific antigen, 1065
- ETMR, neuroepithelium, immature teratoma, C19MC, LIN28A, 4337
- Etoposide, microRNA, miRNA-205-5p, breast cancer, spheroid, ERBB4, 4265
- Eupatilin, AMPK, glucose uptake, cell cycle arrest, tap73, 483
- EUS-FNB, pancreatic cancer, organoid, 4103
- EV array, small extracellular vesicles, gastrointestinal stromal tumor, biomarker, 5699
- Everolimus, advanced breast cancer, first line, safety, effectiveness, 1031

- Everolimus, CDK4/6 inhibitor, metastatic hormone receptor-positive breast cancer, 3913
- Everolimus, effectiveness, pancreatic neuroendocrine tumors, progression-free survival, real-world study, tolerability, 1941
- Everolimus, osteosarcoma, bortezomib, synergistic effect, compound library, 4319
- EVII, CGRP, RAMP1, CRLR, AML, 4743
- Evidence-based medicine, recommended daily intake, RDA, clinical trial study design, public health, primary disease prevention, COVID-19, evolution, primate biology, vitamin D toxicity, review, 5027
- Evolution, recommended daily intake, RDA, clinical trial study design, evidence-based medicine, public health, primary disease prevention, COVID-19, primate biology, vitamin D toxicity, review, 5027
- Ewing sarcoma, artificial intelligence, osteomyelitis, tumor detection, early diagnosis, deep learning, transfer learning, 4371
- Ewing sarcoma, hand, wrist, finger, 1377
- Ewing sarcoma, scapula, shoulder girdle, limb salvage, 3869
- Ex vivo* culture, circulating tumor cells, drug resistance, chemotherapy, sorafenib, 2479
- Exo-circRNA, exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-lncRNA, exo-DNA, DNA methylation, gastric juice, review, 2249
- Exo-DNA, exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-lncRNA, exo-circRNA, DNA methylation, gastric juice, review, 2249
- Exo-lncRNA, exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-circRNA, exo-DNA, DNA methylation, gastric juice, review, 2249
- Exo-miR, exosomes, extracellular vesicles, gastric cancer, exo-lncRNA, exo-circRNA, exo-DNA, DNA methylation, gastric juice, review, 2249
- Exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-lncRNA, exo-circRNA, exo-DNA, DNA methylation, gastric juice, review, 2249
- Exosomes, p38 MAPK, *TP53*, tumour repopulation, bile duct cancer, 745
- Expression, guanylate-binding protein 2, clear-cell renal cell carcinoma, prognostic biomarker, 2341
- Extracellular vesicles, exosomes, gastric cancer, exo-miR, exo-lncRNA, exo-circRNA, exo-DNA, DNA methylation, gastric juice, review, 2249
- Extracellular vesicles, NSCLC, *EGFR-TKI* resistance, t790M/L858R-mutation, 3835
- Extracellular vesicles, pancreatic ductal adenocarcinoma (PDAC), integrin  $\alpha 6$  (ITGA6), splice variant, 1763
- Extracellular-signal-regulated kinase, chloroquine, doxorubicin, A549 cells, autophagy, apoptosis, oxidative stress, caspase, 4025
- Extraluminal obstruction, malignant central airway obstruction, small-cell lung cancer, stent placement, concurrent chemoradiotherapy, 6113
- Extraventricular ependymoma, contralateral interhemispheric approach, supratentorial ependymoma, 3203
- Extremity lymphedema, cutaneous malignant melanoma, health-related quality of life, limb edema, limb lymphedema, cancer surgery, 5507
- Extremity, leiomyosarcoma, brachytherapy, radiotherapy, soft-tissue sarcoma, multicentric analysis, 4485
- Extremity, limb-sparing tumor surgery, vascular reconstruction, bone tumor, soft tissue tumor, 4619
- Eye preservation, uveal melanoma, intensity-modulated radiotherapy, stereotactic body radiotherapy, 1965
- Facial skeleton, neurofibromatosis type 1, plexiform neurofibroma, cephalometry, symmetry, bone, 2607
- FAK, eriodictyol, HMOX1, viability, cholangiocarcinoma, 3789
- FAS, *Asparagus* extract, cancer, mDAPanc-28, pancreatic cancer, P21, P53, CDK4, 2425
- Fatigue, meta-analysis, systematic review, adverse events, asthenia, placebo, cancer, oncology, randomized trials, CTCAE, review, 45
- FATP4, cervical cancer, human papilloma virus, CD36, 2131
- Faxitron, intra operative mammography, radiography, BCS, 1925
- Febrile neutropenia, breast cancer, chemotherapy, filgrastim, secondary prophylactic G-CSF, 5945
- Febrile neutropenia, esophageal cancer, neoadjuvant chemotherapy, predictive factors, pegfilgrastim, neutrophil count, 6071
- Fecal immunochemical test, FIT, colorectal cancer screening, ROC, proximal colon, distal colon, 1879
- Feeding arteries, carotid body tumor, surgical resection, preoperative embolization, review, 645
- FEN1, genotype, oral cancer, polymorphism, Taiwan, 4329
- Ferroptosis, GPX4, gastric cancer, reactive oxygen species, 5719
- Fibroblast activation protein, colorectal cancer, tertiary lymphoid structures, 5897
- Fibroblast, FLASH, ultra-high dose rate, radiation, carbon ions, cancer, 2469
- Fibroma, carney complex, myxoma, neurofibroma, melanoma, cerebello-pontine angle, PRKAR1A, 6121
- Fibromatosis, bowel obstruction, mesenteric tumor, 381
- Fibrosarcoma, dermatofibrosarcoma protuberans, presentation, 105
- Fibrotic foci, tumor-infiltrating lymphocytes, neoadjuvant chemotherapy, breast cancer, prognostic marker, 1421
- Fibula, bone sarcoma, limb-sparing procedure, vascularized bone graft, non-vascularized fibula, 5443
- Field cancerization, colon, nondysplastic crypts, crypt branching, tubular adenomas, 5891
- Filgrastim, breast cancer, chemotherapy, febrile neutropenia, secondary prophylactic G-CSF, 5945
- Filter, circulating tumor cells, immunostaining, cell culture, gene mutation analysis, 4305

- Finger, Ewing sarcoma, hand, wrist, 1377
- First line, advanced breast cancer, everolimus, safety, effectiveness, 1031
- First-line therapy, prostate cancer, metastatic castration-sensitive prostate cancer, mCSPC, PSA response, 165
- First-line therapy, renal cell carcinoma, immuno-oncology combination therapy, molecular targeted therapy, 4573
- First-line, metastatic pancreatic cancer, chemotherapy, itraconazole, 6063
- FIT, fecal immunochemical test, colorectal cancer screening, ROC, proximal colon, distal colon, 1879
- FLASH, ultra-high dose rate, radiation, carbon ions, cancer, fibroblast, 2469
- Flow cytometry, annexin V, transient transfection, dissociative enzymes, miRNA, trypsin, 2819
- Flow cytometry, oral squamous cell carcinoma, immune checkpoint, tumor-infiltrating lymphocytes, regulatory T-lymphocytes, 2383
- Fludarabine, allogenic hematopoietic cell transplantation, case series, primary immunodeficiency, treosulfan, 4505
- Fluorescence imaging, indocyanine green, biliary fistula, liver surgery, navigation surgery, 4787
- Fluorescence-guided surgery, indocyanine green, ICG, radiofrequency ablation, liver tumors, local recurrence, salvage hepatectomy, tumor margins, R0 resection, 1345
- Fluorouracil plus leucovorin, colorectal liver metastases, microwave ablation, systemic chemotherapy, 1645
- Fluoxetine, triple-negative breast cancer, STAT3, apoptosis, epithelial-to-mesenchymal transition, 3807
- FOLFIRINOX, pancreatic cancer, second-line chemotherapy, nal-IRI, peripheral neuropathy, pegfilgrastim, 3889
- FOLFIRINOX, pancreatic cancer, stage IV, oral recombinant methioninase, supplement, combination therapy, stable disease, CA 19-9, methionine addiction, Hoffman effect, 2567
- Food fortification, vitamin D deficiency, supplementation, vitamin D status, 25-hydroxyvitamin D serum concentration, review, 5009
- Forced expiratory volume, esophagectomy, postoperative pneumonia, recurrent laryngeal nerve palsy, 3023
- Forest plot, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Fotemustine, recurrent glioblastoma, bevacizumab, second line cytotoxic, 5847
- Fractionated stereotactic radiotherapy, very elderly patients, brain metastases, radiosurgery, survival score, 5629
- Fractionation, brain tumor, brain metastases, gamma knife radiosurgery, hypofractionated radiosurgery, meningioma, 1851
- Frail patients, metastatic colorectal cancer, XELOX therapy, oxaliplatin, 1859
- Frequency, sleep disturbances, bladder cancer, irradiation, risk factors, 4511
- Frozen section analysis, breast cancer, breast-conserving surgery, gross evaluation, permanent section diagnosis, 4453
- Fructose-containing western diet, hypertension, nonalcoholic fatty liver disease, obesity, physical exercise, circadian rhythm, 609
- Fucci, cell cycle, radiosensitivity, G1 phase, G2 arrest, DNA damage repair, 5407
- Functional outcomes, intramedullary nail, metastatic disease, pathologic fracture, 919
- G protein-coupled estrogen receptor 1 (GPER1), breast cancer, invasion, selective ER $\beta$  agonists, tamoxifen resistance, 5187
- G1 phase, cell cycle, radiosensitivity, fucci, G2 arrest, DNA damage repair, 5407
- G1903A, skin cancer, basal cell carcinoma, renin angiotensin system, chymase, *CMA1* gene, rs1800875, angiotensin 2, 5547
- G2 arrest, cell cycle, radiosensitivity, fucci, G1 phase, DNA damage repair, 5407
- Gadoxetic acid, neuroendocrine tumor, liver, MRI, 911
- Galectin-3, SREBP1, thyroid cancer, 2487
- Gallbladder cancer, laparoscopic whole-layer cholecystectomy, laparoscopic gallbladder bed resection, radical cholecystectomy, 903
- Gallbladder cancer, microscopy, confocal, endomicroscopy diagnosis, malignancy, 67
- Gamma knife radiosurgery, brain tumor, brain metastases, fractionation, hypofractionated radiosurgery, meningioma, 1851
- Gamma-knife radiosurgery, <sup>68</sup>Ga-DOTATOC, incidentaloma, meningioma, neuroendocrine tumor, PET/CT scan, 5867
- GAPDH, papillary thyroid carcinoma, circulating cell-free DNA, cfDNA integrity index,  $\beta$ -actin, 2289
- Gastric cancer cell, olaparib, apoptosis, epstein-Barr virus nuclear antigen-1, EBNA-1, ataxia telangiectasia and Rad3 related kinase, ATR, 555
- Gastric cancer, 14-3-3 sigma protein, cell proliferation, tumor progression, metastasis, prognostic factor, 519
- Gastric cancer, albumin, bilirubin, survival, 3929
- Gastric cancer, annexin A10, oncology, GI cancer, chemoresistance, 1707
- Gastric cancer, cisplatin, capecitabine, adjuvant chemotherapy, metastasis, 2009
- Gastric cancer, conversion surgery, prognosis, 1541
- Gastric cancer, elderly, oxaliplatin, capecitabine, chemotherapy, phase 2 trial, 2683
- Gastric cancer, EREG, epiregulin, 3873
- Gastric cancer, exosomes, extracellular vesicles, exo-miR, exo-lncRNA, exo-circRNA, exo-DNA, DNA methylation, gastric juice, review, 2249
- Gastric cancer, gastric outlet obstruction, laparoscopic gastrojejunostomy, staging laparoscopy, 5571



- Gastric cancer, gastric tumor xenograft-derived cell line, patient-derived xenograft, drug screening, high-throughput screening, 2883
- Gastric cancer, gene expression, CNV, 8q24.21, 4381
- Gastric cancer, genotype, *MMP-2*, polymorphism, Taiwan, 1749
- Gastric cancer, GPX4, ferroptosis, reactive oxygen species, 5719
- Gastric cancer, intramuscular adipose tissue content, obesity, postoperative complication, visceral fat, 4841
- Gastric cancer, malnutrition, overall survival, postoperative complication, prognosis, 4611
- Gastric cancer, metachronous liver metastasis, liver resection, review, 25
- Gastric cancer, metasynchronous liver metastasis, hepatectomy, 2177
- Gastric cancer, nivolumab, immune-related adverse events, survival, 1535
- Gastric cancer, nutritional assessment, inflammation assessment, review, 5167
- Gastric cancer, peritoneal recurrence, *KRT20*, *CEACAM6*, peritoneal lavage fluid, 4003
- Gastric cancer, ramucirumab, paclitaxel, nab-paclitaxel, prognosis, 1599
- Gastric cancer, SEC11A, SPC18, 5885
- Gastric cancer, surgical diagnosis, neoadjuvant chemotherapy, 2719
- Gastric cancer, surgical sarcopenia, long-term survival, 4545
- Gastric cancer, vertical location, anterior wall, lymph node metastasis, 237
- Gastric cancer, vitamin B12, oral treatment, deficiency, total gastrectomy, randomized controlled trial, 3963
- Gastric carcinoma with lymphoid stroma, Epstein–Barr virus, advanced gastric cancer, p53, 4955
- Gastric juice, exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-lncRNA, exo-circRNA, exo-DNA, DNA methylation, review, 2249
- Gastric neoplasms, paclitaxel, peripheral neuropathy, survival, 4581
- Gastric outlet obstruction, gastric cancer, laparoscopic gastrojejunostomy, staging laparoscopy, 5571
- Gastric surgery, colorectal surgery, spirometry, postoperative complication, COVID-19, 1623
- Gastric tumor xenograft-derived cell line, patient-derived xenograft, gastric cancer, drug screening, high-throughput screening, 2883
- Gastric/ gastroesophageal adenocarcinoma, neutrophil-to-lymphocyte ratio, immune checkpoint inhibitor, esophageal squamous cell carcinoma, 2977
- Gastrin-17, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Gastrointestinal perforation, adverse drug event, ovarian neoplasms, bevacizumab, chemotherapy, 4165
- Gastrointestinal stromal tumor, small extracellular vesicles, biomarker, EV array, 5699
- Gastrointestinal stromal tumour, circulating tumour DNA, next-generation sequencing, 5527
- Gastrointestinal stromal tumours, tyrosine kinase inhibitors, imatinib, discontinuation, qualitative research, side-effects, psycho-social, hope, 955
- GastroPanel<sup>®</sup>, atrophic gastritis, autoimmune, serological biomarker panel, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- GastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- GE11 peptide, milk extracellular vesicles, *EGFR* expressing tumor, drug delivery system, bio-engineered drug carrier, 857
- Gemcitabine, adjuvant therapy, pancreatic cancer, positive peritoneal lavage cytology, postoperative chemotherapy, S-1, 893
- Gemcitabine, medulloblastoma, daoy, immunotherapy, rapamycin, lipopolysaccharide, 1697
- Gemcitabine, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, B lymphocytes, T cells, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- Gemcitabine, recombinant thrombomodulin, GPR15, pancreatic cancer, 4679
- Gemcitabine, vascular pain, 5% glucose, saline, lyophilized formulation, liquid formulation, 343
- Gender dimorphism, x-chromosome, x-linked, polymorphism, cancer, review, 2261
- Gene expression analysis, colorectal surgery, anastomotic leakage, microarray, 2827
- Gene expression profiling, cancer unknown primary, neuroendocrine, RT-PCR, 1381
- Gene expression, COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- Gene expression, gastric cancer, CNV, 8q24.21, 4381
- Gene expression, *in silico* analysis, TCGA, prognostic value, 9p, 9p22.1 locus, 5291
- Gene fusion, glioma, targeted therapy, next-generation sequencing, molecular genetics, 1933
- Gene mutation analysis, circulating tumor cells, filter, immunostaining, cell culture, 4305
- Gene-expression analysis, lymphoid malignancies, platinum, copy-number deletions, 1821
- Gene–environmental interaction, breast cancer, heredity, strain difference, susceptibility, 2415



- Genetic medicine, hereditary cancer, genetic testing, multigene panel testing, risk reduction, 4097
- Genetic mutation, chinese hamster ovary cell, cancer, chemotherapy, drug resistance, irinotecan, 4011
- Genetic polymorphism, esophageal cancer, lymph node metastasis, c-reactive protein, endoscopic resection, 6105
- Genetic predisposition, male breast cancer, next generation sequencing, multigene analysis, 5795
- Genetic testing, hereditary cancer, genetic medicine, multigene panel testing, risk reduction, 4097
- Genotype, alcohol drinking, colorectal cancer, *MMP2*, metastasis, polymorphism, Taiwan, 5335
- Genotype, breast cancer, interleukin-8, polymorphism, Taiwan, 3799
- Genotype, childhood ALL, IL-18, polymorphism, Taiwan, 5283
- Genotype, colorectal cancer, *MTRR*, polymorphism, Taiwan, 2375
- Genotype, FEN1, oral cancer, polymorphism, Taiwan, 4329
- Genotype, gastric cancer, *MMP-2*, polymorphism, Taiwan, 1749
- Genotype, hepatocellular carcinoma, *MMP-7*, polymorphism, HCC, Taiwan, 5275
- Genotype, interleukin-8, lung cancer, polymorphism, Taiwan, 1229
- Geriatric nutrition risk index, esophageal cancer, prognostic factor, nutrition, c-reactive protein, 5999
- Geriatric oncology, esophageal cancer, trimodality therapy, platinum/5-fluoracil, carboplatin/paclitaxel, 59
- Germ tumors, lung metastases, risk score, 4517
- Germany, chemotherapy, targeted therapy, Austria, Switzerland, treatment reality, disease characteristics, 4773
- Germline mutation, minimally invasive follicular thyroid carcinoma, *PTEN* gene mutation, cowden syndrome, *PTEN* hamartoma tumor syndrome, *RECQL4* gene, surveillance, 1481
- GI cancer, annexin A10, gastric cancer, oncology, chemoresistance, 1707
- Gingipain, oropharyngeal squamous cell carcinoma, OPSCC, human papillomavirus, *Porphyromonas gingivalis*, rgp, matrix metalloproteinase, survival analysis, 5415
- Glioblastoma multiforme, trifluoperazine, COX-2, pPAR $\gamma$ , 5773
- Glioblastoma, glioma, meningioma, ENO1,  $\alpha$ -enolase, MBP1, 2319
- Glioblastoma, *MGMT*, methylation status, ATRX loss, hypermethylation, low methylation, glioblastoma, temozolomide chemotherapy, wild-type *IDH*, 335
- Glioblastoma, post-transplant lymphoproliferative disorders, Epstein-Barr virus, primary central nervous lymphoma, 3975
- Glioblastoma, prospective study, predictive biomarker, high-grade glioma, magnetic resonance spectroscopic imaging, 2665
- Glioblastoma, relapsed, refractory, bevacizumab, 6091
- Glioma, death receptor 6, low-grade glioma, prognosis, survival, tumor necrosis factor receptor 21, 1237
- Glioma, gene fusion, targeted therapy, next-generation sequencing, molecular genetics, 1933
- Glioma, meningioma, ENO1,  $\alpha$ -enolase, glioblastoma, MBP1, 2319
- Glioma, pineal region glioma, pineal region tumors, systematic review, 1189
- Gliomas, brain tumors, temozolomide, radiation therapy, diffusion tensor imaging, 329
- Global longitudinal strain, cardio-oncology, toxic cardiomyopathy, treatment-related side effects, breast cancer, 3075
- Global longitudinal strain, radiotherapy, breast cancer, myocardial imaging, cyclic variation of the integrated backscatter, speckle tracking echocardiography, 2507
- Glottic carcinoma, head and neck cancer, radiotherapy, chemoradiotherapy, laryngeal preservation, elective nodal irradiation, 205
- Glucose metabolism disorder, diabetes mellitus, mouth neoplasms, maxillofacial surgery, epidemiology, 1899
- Glucose uptake, eupatilin, AMPK, cell cycle arrest, tap73, 483
- GPR15, recombinant thrombomodulin, gemcitabine, pancreatic cancer, 4679
- GPX4, ferroptosis, gastric cancer, reactive oxygen species, 5719
- Gram stain, drain fluid culture, occult anastomotic leakage, 3091
- Granulocyte colony-stimulating factor, esophageal cancer, bone marrow suppression, chemotherapy, adverse event, 2783
- GRIm score, colon cancer, elderly patients, non-cancer-specific survival, postoperative complication, 5643
- Gross evaluation, breast cancer, breast-conserving surgery, frozen section analysis, permanent section diagnosis, 4453
- GRP78, HDAC6, cholangiocarcinoma, acetylation, ACY-1215, 471
- Guanylate-binding protein 2, expression, clear-cell renal cell carcinoma, prognostic biomarker, 2341
- Gut microbiome, biomarker, lung adenocarcinoma, never-smokers, 1589
- Gut microbiota, proton pump inhibitors, urothelial carcinoma, pembrolizumab, immune checkpoint inhibitors, antibiotics, 1629
- Gynecological cancer, magnetic resonance imaging, lattice radiotherapy, spatially fractionated radiation therapy, inoperable bulky tumors, palliative care, palliative radiotherapy, 4641
- H19, colorectal cancers, LINC00675, plasma markers, lncRNA, 1301
- H3Cit-DNA, ovarian cancer, tumor marker, nETs, dsDNA, 965
- Haemoglobin, NSCLC, lung cancer, PD-L1, inflammation, CRP, albumin, NLR, 1563

- Hairless mice, vitamin D, d-vitamin, cholecalciferol, UVR, 25-hydroxyvitamin D<sub>3</sub>, 5083
- Hand grip force, hand grip strength, head and neck cancer, oral cancer, microvascular reconstruction, 2771
- Hand grip strength, hand grip force, head and neck cancer, oral cancer, microvascular reconstruction, 2771
- Hand-foot syndrome, capecitabine, prevention strategies, proton pump inhibitors, 2591
- Hand, bone sarcoma, SEER program, neoplasm grading, treatment outcome, orthopedic surgery, 1635
- Hand, Ewing sarcoma, wrist, finger, 1377
- Hanging maneuver, hepatocellular carcinoma, liver resection, anterior approach, circulating tumor cell, 4129
- HBP surgery, abdominal aortic calcification, comprehensive complication index, complications, risk factors, 5983
- HCC, genotype, hepatocellular carcinoma, *MMP-7*, polymorphism, Taiwan, 5275
- HDAC6, cholangiocarcinoma, GRP78, acetylation, ACY-1215, 471
- HDMX, drug repositioning, repurposing, MDMX, 4727
- Head and neck cancer, cisplatin, radiotherapy, HPV, SIB, IMRT, toxicity, 5909
- Head and neck cancer, glottic carcinoma, radiotherapy, chemoradiotherapy, laryngeal preservation, elective nodal irradiation, 205
- Head and neck cancer, hand grip force, hand grip strength, oral cancer, microvascular reconstruction, 2771
- Head and neck cancer, hearing loss, cisplatin, radiotherapy, concomitant treatment, toxicity, cochlea, constraints, dose, 3003
- Head and neck cancer, mallampati score, chemoradiotherapy, trismus, restricted mouth opening, outcome, 5609
- Head and neck cancer, nodal ratio, positive nodes, lymph nodes, 5567
- Head and neck cancer, oral cancer, cancer antigen, human leukocyte antigen class I, cancer vaccines, T cell therapy, 5751
- Head and neck cancer, radiotherapy, intensity modulated radiation therapy, hypofractionation, toxicity, 1845
- Head and neck cancer, salivary gland carcinoma, PD-1 inhibitor, PD-L1, mismatch repair protein, 981
- Head and neck cancer, survivorship care plans, hypothyroidism, radiation, thyroid stimulating hormone, disparities, 4429
- Head and neck cancer, tumor marker, biomarker, tumor recurrence, 137
- Head and neck neoplasms, thyroid cancer, neoplasms, second primary, radiotherapy, SEER program, 1359
- Head and neck squamous cell carcinoma, S-1, preoperative chemotherapy, surgical case, adverse event, 3177
- Head and neck tumor, bone and soft-tissue sarcoma, carbon-ion radiotherapy, 1439
- Head and neck, chemoradiotherapy, radiotherapy, older adults, 3845
- Head and neck, concurrent chemoradiotherapy, squamous cell carcinoma, prognostic factor, TPF, 6047
- Head and neck, nivolumab, squamous cell carcinoma, platinum-refractory, platinum-sensitive, 4907
- Head and neck, recurrent/metastatic squamous cell carcinoma, programmed cell death protein 1, pembrolizumab, 4475
- Head and neck, recurrent/metastatic squamous cell carcinoma, programmed cell death protein 1, pembrolizumab, 4477
- Head and neck, squamous cell carcinoma, nivolumab, 1607
- Head-and-neck cancer, radiotherapy, late xerostomia, prognostic tool, treatment planning, 3035
- Head-and-neck cancer, radiotherapy, radio-chemotherapy, xerostomia, risk factors, 2657
- Health knowledge, breast cancer, endocrine therapy, aromatase inhibitors, side effects, adverse events, community pharmacy services, community pharmacists, educational intervention, review, 661
- Health-related quality of life, cutaneous malignant melanoma, limb edema, limb lymphedema, extremity lymphedema, cancer surgery, 5507
- Hearing loss, head and neck cancer, cisplatin, radiotherapy, concomitant treatment, toxicity, cochlea, constraints, dose, 3003
- Heat shock proteins family (HSP), *Helicobacter pylori*, human gastric adenocarcinoma AGS cells, iTRAQ proteomic, ingenuity pathway analysis (IPA), 531
- Heated intraperitoneal chemotherapy, second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, peritoneal carcinomatosis, appendiceal, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001
- Helicobacter pylori*, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Helicobacter pylori*, human gastric adenocarcinoma AGS cells, heat shock proteins family (HSP), iTRAQ proteomic, ingenuity pathway analysis (IPA), 531
- Hemoglobin, robotic surgical procedure, blood transfusion, hysterectomy, endometrial neoplasm, cost analysis, 1893
- Hemostasis, interventional radiology, pancreatic resection, pseudoaneurysm, surgery, 1579
- Hepatectomy, gastric cancer, metasynchronous liver metastasis, 2177
- Hepatectomy, non-alcoholic fatty liver disease, liver steatosis, hepatitis, steatohepatitis, 4159
- Hepatectomy, surgical site infection, ring drape, unused sterile instruments, 1007
- Hepatic dysfunction, high-dose methotrexate (HD-MTX), osteosarcoma, clinical study, 1043
- Hepatitis C virus, ritonavir, CYP3A4, calcium channel blockers, amlodipine, peripheral edema, 2087
- Hepatitis, non-alcoholic fatty liver disease, hepatectomy, liver steatosis, steatohepatitis, 4159

- Hepatocellular carcinoma, adverse events, biomarker, chemotherapy, intestinal permeability, 4895
- Hepatocellular carcinoma, adverse events, biomarker, chemotherapy, intestinal permeability, 5465
- Hepatocellular carcinoma, alpha fetoprotein, atezolizumab plus bevacizumab, ramucirumab, post-treatment, 1905
- Hepatocellular carcinoma, amentoflavone, lenvatinib, AKT, ERK, 2495
- Hepatocellular carcinoma, atezolizumab plus bevacizumab, albumin-bilirubin grade, lenvatinib, treatment sequence, 1403
- Hepatocellular carcinoma, bile duct tumor thrombus, vater papilla-preserving strategy, liver resection, 5663
- Hepatocellular carcinoma, conversion hepatectomy, surgery, lenvatinib, molecular therapy, review, 35
- Hepatocellular carcinoma, genotype, *MMP-7*, polymorphism, HCC, Taiwan, 5275
- Hepatocellular carcinoma, lenvatinib resistance, cisplatin, cell cycle, microRNA, 1263
- Hepatocellular carcinoma, lenvatinib, atezolizumab plus bevacizumab, rechallenge, 5479
- Hepatocellular carcinoma, lenvatinib, prognostic nutrition index, therapeutic response, 6019
- Hepatocellular carcinoma, lenvatinib, tyrosine kinase inhibitor, Child-Pugh, adverse events, progression-free survival, objective response, 173
- Hepatocellular carcinoma, liver resection, anterior approach, circulating tumor cell, hanging maneuver, 4129
- Hepatocellular carcinoma, liver resection, mortality, recurrence, surgery, 2573
- Hepatocellular carcinoma, liver transplantation, recurrence, lenvatinib, 1161
- Hepatocellular carcinoma, mALBI grade, prognostic factor, stereotactic body radiotherapy, 5001
- Hepatocellular carcinoma, metformin, radiotherapy, neutron, radiosensitizer, xenograft, 867
- Hepatocellular carcinoma, mulberry, stelic animal model, high-fat diet, streptozotocin, nonalcoholic hepatitis, nonalcoholic fatty liver disease, 4055
- Hepatocellular carcinoma, portal vein embolization, postoperative liver failure, right hepatectomy, mortality, 4089
- Hepatocellular carcinoma, prognosis, m2BPGi, sustained viral response, 245
- Hepatocellular carcinoma, recurrent patients, repeat hepatectomy, prognosis, 4553
- Hepatocellular carcinoma, sorafenib, barcelona Clinic Liver Cancer Stage C, transarterial chemoembolization, national Health Insurance, reimbursement criteria, 4461
- Hepatocellular carcinoma, STAT3 inhibition, anti-PD-1 therapy, CD8<sup>+</sup> T cell infiltration, tumor microenvironment, immunosuppression, 5205
- Hepatocellular carcinoma, tyrosine kinase inhibitor, lenvatinib, sorafenib, post-progression survival, sequential therapy, 6007
- Hereditary cancer, genetic medicine, genetic testing, multigene panel testing, risk reduction, 4097
- Heredity, breast cancer, strain difference, susceptibility, gene-environmental interaction, 2415
- Hernia, transumbilical incision, laparoscopic, surgical site infection, colorectal, 1115
- Heterogeneity, endometrial cancer, lymph node metastasis, p53, MMR deficiency, 4535
- Heterogeneity, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, publication bias, effect size, review, 1679
- Heterozygosity, pARPi, *BRCA* mutation, talazoparib, predictive marker, 5257
- Hierarchical summary ROC, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- HIF-1 $\alpha$ , CD133, cD133(+)/HIF-1 $\alpha$ (-), chemoradiotherapy, rectal cancer, 2033
- HIF1 $\alpha$ , canine mammary gland tumors, cell cycle, metastasis, siRNA, TSG-6, 5803
- High grade ovarian cancer, peritoneal cancer index, cytoreduction, surgical complexity, 4825
- High-dose methotrexate (HD-MTX), hepatic dysfunction, osteosarcoma, clinical study, 1043
- High-fat diet, mulberry, stelic animal model, streptozotocin, nonalcoholic hepatitis, nonalcoholic fatty liver disease, hepatocellular carcinoma, 4055
- High-grade glioma, prospective study, predictive biomarker, glioblastoma, magnetic resonance spectroscopic imaging, 2665
- High-throughput screening, gastric tumor xenograft-derived cell line, patient-derived xenograft, gastric cancer, drug screening, 2883
- HIPEC duration, intraperitoneal chemotherapy, cisplatin, cytoreductive surgery, 1019
- HIPEC, malignant peritoneal mesothelioma, cytoreductive surgery, outcomes, survival, 2939
- Hispanics, adrenocortical carcinoma, ACC, race, 5579
- Histatin, immune checkpoint inhibitors, HNSCC, aMPs, 2689
- Histoculture drug response assay (HDRA), advanced colorectal cancer, checkpoint-with-forkhead-and-ring-finger-domains (CHFR), dNA-promoter methylation, irinotecan, clinical correlation, biomarker, 697
- Histopathology, crypt branching, crohn's disease, 1919
- Histopathology, crypt branching, ulcerative colitis, 147
- HL60 cells, linear furocoumarin, psoralen, antiproliferative activity, structure and activity relationship, 1777
- HMOX1, eriodictyol, FAK, viability, cholangiocarcinoma, 3789
- HNSCC, immune checkpoint inhibitors, histatin, aMPs, 2689

- Hoffman effect, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Hoffman effect, breast osteosarcoma, PDOX, nude mice, combination therapy, methioninase, rapamycin, efficacy, synergy, 5217
- Hoffman effect, cancer, methionine addiction, methionine restriction, methioninase, clinical treatment, review, 641
- Hoffman effect, osteosarcoma, nude mice, PDOX, methionine addiction, methioninase, methotrexate, resistance, combination therapy, efficacy, 731
- Hoffman effect, pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, supplement, combination therapy, stable disease, CA19-9, methionine addiction, 2567
- Hoffman effect, rectal cancer, patient, stable disease, methionine addiction, methionine restriction, oral recombinant methioninase, low-methionine diet, 3857
- Hoffman protocol, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, complete response, 5819
- Homologous recombination, PARP inhibitors, chemotherapy, epithelial ovarian cancer, recurrence, 2017
- Hope, gastrointestinal stromal tumours, tyrosine kinase inhibitors, imatinib, discontinuation, qualitative research, side-effects, psycho-social, 955
- Hormone receptor, breast cancer, smoking, endocrine therapy, cigarette, 3937
- Hormone-sensitive, prostate cancer, androgen-deprivation therapy, survival, prostate-specific antigen, 1107
- Host-mediated *in vivo/in vitro* assay, carcinogens, tumorigenic potential, review, 4199
- Host-mediated *in vivo/in vitro* assay, carcinogens, tumorigenic potential, review, 4199
- Hp IgG antibody, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, parietal cell antibody, intrinsic factor antibody, 1517
- HPV, cervical cancer, p16/Ki-67 dual-stained cytology, triage, CIN2, CIN3, HSIL, screening, risk stratification, pap test, 2599
- HPV, head and neck cancer, cisplatin, radiotherapy, SIB, IMRT, toxicity, 5909
- HPV, K14-HPV16, cancer cachexia, muscle wasting, lncRNAs, 2443
- HPV, oral squamous cell carcinoma, prognostic factors, p16, adjuvant therapy, 2405
- HSIL, HPV, cervical cancer, p16/Ki-67 dual-stained cytology, triage, CIN2, CIN3, screening, risk stratification, pap test, 2599
- Human gastric adenocarcinoma AGS cells, *Helicobacter pylori*, heat shock proteins family (HSP), iTRAQ proteomic, ingenuity pathway analysis (IPA), 531
- Human leukocyte antigen class I, head and neck cancer, oral cancer, cancer antigen, cancer vaccines, T cell therapy, 5751
- Human papilloma virus, cervical cancer, FATP4, CD36, 2131
- Human papillomavirus, cervix, endocervical adenocarcinoma, world Health Organization Classification, 4627
- Human papillomavirus, oropharyngeal squamous cell carcinoma, OPSCC, *Porphyromonas gingivalis*, gingipain, rgp, matrix metalloproteinase, survival analysis, 5415
- Human papillomavirus, tumor microenvironment (TME), epithelial-mesenchymal transition, tumor-infiltrating lymphocytes, TP53 mutation-TGF- $\beta$ 1-PAX7 pathway, 4417
- Hypermethylation, MGMT, methylation status, ATRX loss, low methylation, glioblastoma, temozolomide chemotherapy, wild-type IDH, glioblastoma, 335
- Hypersensitivity reactions, carboplatin desensitization, ovarian cancer, criteria for discontinuation, erythema, arms, 1091
- Hypertension, fructose-containing western diet, nonalcoholic fatty liver disease, obesity, physical exercise, circadian rhythm, 609
- Hyperthermia, colorectal carcinoma, cancer therapeutics, 5-fluorouracil, capecitabine, bevacizumab, cetuximab, 2363
- Hyperthermia, vitamin C, ovarian cancer, anticancer activity, 5365
- Hyperthermic intraperitoneal chemotherapy, ovarian cancer, primary debulking surgery, interval debulking surgery, cisplatin, review, 4659
- Hypofractionated radiosurgery, brain tumor, brain metastases, fractionation, gamma knife radiosurgery, meningioma, 1851
- Hypofractionation, breast, carcinoma, mastectomy, segmental, radiotherapy, 53
- Hypofractionation, head and neck cancer, radiotherapy, intensity modulated radiation therapy, toxicity, 1845
- Hypothyroidism, head and neck cancer, survivorship care plans, radiation, thyroid stimulating hormone, disparities, 4429
- Hysterectomy, robotic surgical procedure, hemoglobin, blood transfusion, endometrial neoplasm, cost analysis, 1893
- ICANS, steroid refractory, intrathecal chemotherapy, CAR T-cell therapy, potential treatment, 3853
- ICG, indocyanine green, fluorescence-guided surgery, radiofrequency ablation, liver tumors, local recurrence, salvage hepatectomy, tumor margins, R0 resection, 1345
- ICP-MS, serum, trace element, breast cancer, surgery, 5323
- Idiopathic pulmonary fibrosis, lung transplant, lung cancer, adenocarcinoma, 1157
- IL-18, childhood ALL, genotype, polymorphism, Taiwan, 5283
- IL-18, cholelithiasis, surgery, NRS pain score, analgesic doses, 5521



- IL-6, cancer-associated fibroblasts, bcl-xL, mcl-1, colorectal cancer, apoptosis, STAT3, 1277
- IL-6, Kruppel-like factor 2, renal angiomyolipomas, JAK, STAT3, 4753
- Imaging analysis software, tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs), automatic measurement, digital pathology, project HOPE, 419
- Imatinib, gastrointestinal stromal tumours, tyrosine kinase inhibitors, discontinuation, qualitative research, side-effects, psycho-social, hope, 955
- Imidazothiazole, BRAF V600E, PLX4032, chemoresistance, activator protein-1, melanoma, 2911
- Immature teratoma, neuroepithelium, ETMR, C19MC, LIN28A, 4337
- Immune cells, kindlin-3, prostate cancer, tumor growth, xenograft model, 1217
- Immune checkpoint inhibitor, discontinuation, survival, non-small-cell lung cancer, driver gene mutation, 4589
- Immune checkpoint inhibitor, immunotherapy, nivolumab, metformin, safety, diabetic cancer patients, 1487
- Immune checkpoint inhibitor, neutrophil-to-lymphocyte ratio, esophageal squamous cell carcinoma, gastric/gastroesophageal adenocarcinoma, 2977
- Immune checkpoint inhibitor, non-clear cell renal cell carcinoma, 973
- Immune checkpoint inhibitor, non-small cell lung cancer, malignant melanoma, kidney cancer, systemic therapy, 3061
- Immune checkpoint inhibitor, pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, NLR, lactate dehydrogenase, LDH, c-reactive protein, CRP, predictive factor, 2045
- Immune checkpoint inhibitors, histatin, HNSCC, aMPs, 2689
- Immune checkpoint inhibitors, proton pump inhibitors, urothelial carcinoma, gut microbiota, pembrolizumab, antibiotics, 1629
- Immune checkpoint, endometrium cancer, PD-L1, PD-1, prognostic factor, targeted therapy, 1367
- Immune checkpoint, oral squamous cell carcinoma, tumor-infiltrating lymphocytes, flow cytometry, regulatory T-lymphocytes, 2383
- Immune-cell therapy, adjuvant therapy, solid tumor,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4179
- Immune-related adverse events, gastric cancer, nivolumab, survival, 1535
- Immune-related adverse events, immunotherapy, non-small cell lung cancer, corticosteroids, 5961
- Immune-related adverse events, nivolumab, tolerability, disease control, progressive disease, 4973
- Immune-related adverse events, programmed cell death 1 antibody, low-dose topical administration, buccal mucosa, oral cancer cell line, programmed cell death 1-ligand 1, 4293
- Immuno-oncology combination therapy, renal cell carcinoma, molecular targeted therapy, first-line therapy, 4573
- Immunoadjuvant molecules, breast cancer, pathological complete response, neoadjuvant chemotherapy, LAG-3, TIM-3, OX-40, 125
- Immunohistochemistry, breast cancer, prognosis, 279
- Immunohistochemistry, breast, receptor-interacting serine/threonine-protein kinase 3, triple-negative breast carcinoma, prognosis, 2753
- Immunohistochemistry, chloride intracellular channel 1, lung adenocarcinoma, spiral array, 271
- Immunohistochemistry, copine 1, renal cell carcinoma, prognostic marker, bioinformatics, 355
- Immunohistochemistry, pancreas, pancreatic ductal adenocarcinoma, sulphite oxidase, 4145
- Immunostaining, circulating tumor cells, filter, cell culture, gene mutation analysis, 4305
- Immunosuppression, hepatocellular carcinoma, STAT3 inhibition, anti-PD-1 therapy, CD8<sup>+</sup> T cell infiltration, tumor microenvironment, 5205
- Immunotherapy, AXL, KIT, MET, papillary renal cell carcinoma, VEGFR, 3151
- Immunotherapy, chemotherapy-induced peripheral neuropathy, pain management, target therapy, 4667
- Immunotherapy, immune checkpoint inhibitor, nivolumab, metformin, safety, diabetic cancer patients, 1487
- Immunotherapy, medulloblastoma, daoy, gemcitabine, rapamycin, lipopolysaccharide, 1697
- Immunotherapy, nivolumab, advanced cancer, checkpoint inhibitors, PD-1/PDL-1, CTLA-4, 1433
- Immunotherapy, non-small cell lung cancer, immune-related adverse events, corticosteroids, 5961
- Immunotherapy, radiotherapy, NSCLC, SABR, SBRT, review, 2241
- Impaired fasting glycemia, diabetes, oral cancer, public health, smoking, 109
- Impending fracture, appendicular skeletal metastases, tumor growth speed, pathological fracture, prophylactic surgery, 229
- IMRT, head and neck cancer, cisplatin, radiotherapy, HPV, SIB, toxicity, 5909
- In silico* analysis, TCGA, prognostic value, gene expression, 9p, 9p22.1 locus, 5291
- In silico* screening, small chemical compound library, ELISA for inhibition of PD-1/PD-L1 binding, mHC-dKO NOG mouse, ADME evaluation, 5233
- In vivo* mimicking, three-dimensional model, breast cancer cells, endothelial cells, 4689
- Incidence, melanoma, trends, mortality, overdiagnosis, sunburn, review, 5021
- Incidentaloma, <sup>68</sup>Ga-DOTATOC, gamma-knife radiosurgery, meningioma, neuroendocrine tumor, PET/CT scan, 5867
- Indocyanine green fluorescence imaging, pancreas neck cancer, artery resection, artery reconstruction, 217
- Indocyanine green, biliary fistula, liver surgery, navigation surgery, fluorescence imaging, 4787



- Indocyanine green, breast cancer, axillary reverse mapping, axillary surgery, 3879
- Indocyanine green, ICG, fluorescence-guided surgery, radiofrequency ablation, liver tumors, local recurrence, salvage hepatectomy, tumor margins, R0 resection, 1345
- Indocyanine green, rectal cancer, colorectal surgery, low anastomoses, laparoscopic surgery, radiotherapy, 211
- Inequality, breast cancer, disparity, treatment, 5813
- Infection, pancreatic adenocarcinoma, antibiotic resistance, overall survival, bacteriobilia, surgery, 2743
- Inferior vena cava, renal carcinoma, tumor thrombus, surgical reconstruction, 1351
- Inflammation assessment, nutritional assessment, gastric cancer, review, 5167
- Inflammation inhibitors, triple-negative breast cancer (TNBC), A20/TNFAIP3, cell division cycle 20 (Cdc20), cASP1/Caspase-1, inflammation, metastasis, 681
- Inflammation, cachexia, resistance exercise, aerobic exercise, colon cancer, colon-26, muscle fiber type, 397
- Inflammation, NSCLC, lung cancer, PD-L1, CRP, albumin, haemoglobin, NLR, 1563
- Inflammation, triple-negative breast cancer (TNBC), A20/TNFAIP3, cell division cycle 20 (Cdc20), cASP1/Caspase-1, metastasis, inflammation inhibitors, 681
- Inflammatory cytokine gene, macrophages, monocytes, vascular endothelial cell, blood coagulation-related gene, lipopolysaccharide, 4049
- Ingenuity pathway analysis (IPA), *Helicobacter pylori*, human gastric adenocarcinoma AGS cells, heat shock proteins family (HSP), iTRAQ proteomic, 531
- Inhibin A, intrahepatic cholangiocarcinoma, cholangioblastic variant, biphasic cytology, liver, *NIPBL-NACCI* fusion gene, 5475
- Inhibitor of methylation, colorectal cancer, thymidine phosphorylase, 5-fluorouracil, 837
- Inoperable bulky tumors, magnetic resonance imaging, lattice radiotherapy, spatially fractionated radiation therapy, gynecological cancer, palliative care, palliative radiotherapy, 4641
- Insulin signal, adipocyte, anti-inflammation, lipopolysaccharide, type 2 diabetes, 3983
- Integrin  $\alpha 6$  (ITGA6), pancreatic ductal adenocarcinoma (PDAC), splice variant, extracellular vesicles, 1763
- Intensity modulated radiation therapy, head and neck cancer, radiotherapy, hypofractionation, toxicity, 1845
- Intensity-modulated radiotherapy, angiosarcoma, chemoradiation, unresectable, scalp, 5991
- Intensity-modulated radiotherapy, uveal melanoma, stereotactic body radiotherapy, eye preservation, 1965
- Interleukin-8, breast cancer, genotype, polymorphism, Taiwan, 3799
- Interleukin-8, genotype, lung cancer, polymorphism, Taiwan, 1229
- Interpretability, oral cavity cancer, machine learning, sHapley values, prognosis, 5859
- Intersphincteric resection, low rectal cancer, neoadjuvant chemoradiotherapy, rectal surgery, enhanced recovery after surgery, ERAS, clinical outcome, 1949
- Interstitial lung disease, paclitaxel, nab-paclitaxel, relapsed tumor, small cell lung cancer, 4921
- Interval debulking surgery, ovarian cancer, primary debulking surgery, hyperthermic intraperitoneal chemotherapy, cisplatin, review, 4659
- Interval debulking surgery, recurrence of ovarian cancer, primary debulking surgery, progression-free survival, metastasis, 2003
- Interventional radiology, hemostasis, pancreatic resection, pseudoaneurysm, surgery, 1579
- Intestinal absorption, vitamin D, 25-hydroxyvitamin D, pharmacokinetics, clinical trial, 5095
- Intestinal permeability, adverse events, biomarker, chemotherapy, hepatocellular carcinoma, 4895
- Intestinal permeability, adverse events, biomarker, chemotherapy, hepatocellular carcinoma, 5465
- Intra operative mammography, faxitron, radiography, BCS, 1925
- Intractable cancer, scirrhus gastric cancer, proliferation, oncogenes, molecular target, 5195
- Intraductal papillary neoplasm type 1, intraductal papillary neoplasm type 2, DNMT1, DNA methylation, multiple gene expression analysis, 2893
- Intraductal papillary neoplasm type 2, intraductal papillary neoplasm type 1, DNMT1, DNA methylation, multiple gene expression analysis, 2893
- Intradural metastases, cauda equina, spine oncology, spine metastases, systematic review, 1661
- Intrahepatic cholangiocarcinoma, cholangioblastic variant, biphasic cytology, liver, inhibin A, *NIPBL-NACCI* fusion gene, 5475
- Intrahepatic cholangiocarcinoma, multidisciplinary treatment, ablation, systemic chemotherapy, 3209
- Intramedullary nail, metastatic disease, pathologic fracture, functional outcomes, 919
- Intramuscular adipose tissue content, gastric cancer, obesity, postoperative complication, visceral fat, 4841
- Intraoperative electrical stimulation mapping, language function, awake craniotomy, brain metastasis, subcortical metastasis, 1641
- Intraoperative electrical stimulation mapping, motor function, awake surgery, brain metastasis, subcortical metastasis, precentral gyrus, 1151
- Intraperitoneal chemotherapy, HIPEC duration, cisplatin, cytoreductive surgery, 1019
- Intrathecal chemotherapy, ICANS, steroid refractory, CAR T-cell therapy, potential treatment, 3853
- Intraventricular tumor, cerebral ventricles, craniopharyngioma, neuro-oncology, skull base, systematic review, 4189

- Intravital imaging, pancreatic cancer, patient-derived orthotopic xenograft (PDOX), NOG mouse, nude mouse red fluorescent protein (RFP), lymph-node metastasis, personalized therapy, drug discovery, 739
- Intrinsic factor antibody, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, 1517
- Invasion, breast cancer, G protein-coupled estrogen receptor 1 (GPER1), selective ER $\beta$  agonists, tamoxifen resistance, 5187
- Invasion, liver cancer, microRNA-1303, TLN1, proliferation, migration, 4715
- Invasion, PTPN3, pancreatic cancer, proliferation, MAPK, 2869
- Invasive ductal carcinoma, breast cancer, smoking, ductal carcinoma *in situ*, biopsy, 311
- Invasive IPMC, adjuvant chemotherapy, poorly differentiated adenocarcinoma, lymph node metastasis, tubular type, 2645
- Invasive lobular carcinoma, breast cancer patient, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Invasive papillary cholangiocarcinoma, preclinical model, patient-derived xenograft, 599
- Irinotecan, advanced colorectal cancer, checkpoint-with-forkhead-and-ring-finger-domains (CHFR), dNA-promoter methylation, histoculture drug response assay (HDRA), clinical correlation, biomarker, 697
- Irinotecan, chinese hamster ovary cell, cancer, chemotherapy, drug resistance, genetic mutation, 4011
- Irinotecan, S-1, bevacizumab, SIRB, cetuximab, second-line treatment, 2675
- Irradiation, sleep disturbances, bladder cancer, frequency, risk factors, 4511
- Itraconazole, metastatic pancreatic cancer, chemotherapy, first-line, 6063
- ITRAQ proteomic, *Helicobacter pylori*, human gastric adenocarcinoma AGS cells, heat shock proteins family (HSP), ingenuity pathway analysis (IPA), 531
- JADER, anticancer drug, ocular adverse reactions, japanese Adverse Drug Event Report, safety signal, pharmacovigilance database, 4439
- JAK inhibitor, JAK/STAT, CJ14939, oxaliplatin, colorectal cancer, 1813
- JAK, Kruppel-like factor 2, renal angiomyolipomas, IL-6, STAT3, 4753
- JAK/STAT, CJ14939, JAK inhibitor, oxaliplatin, colorectal cancer, 1813
- Jak2, pacritinib, co-treatment, p-gp, drug resistance, 2433
- Japanese adverse drug event report database, alectinib, lung toxicity, time to onset, 3109
- Japanese Adverse Drug Event Report, anticancer drug, ocular adverse reactions, JADER, safety signal, pharmacovigilance database, 4439
- Japanese Adverse Drug Reaction Reporting Database, bendamustine, skin damage, time to onset, 2737
- Japanese Adverse Drug Reaction Reporting database, lenalidomide, lung toxicity, signal, time to onset, 5917
- Jaundice, pancreatic intraepithelial neoplasia, pancreatic carcinoma, platelet, lymphocyte, platelet/lymphocyte ratio, sarcopenia, 1413
- K14-HPV16, HPV, cancer cachexia, muscle wasting, lncRNAs, 2443
- K562, natural killer cells, lysis, NK-92, pBMCs, 4259
- KAT6A, lysine acetyltransferase, non-small cell lung cancer, 5731
- Keratinocytes, squamous cell carcinoma, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- Ki-67, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, NRG1, 2327
- Ki-67, non-B non-C hepatocellular carcinoma, cellular proliferation, tumor size, 449
- KIBRA, WWC1, tumor growth, matrix metalloproteinases, predictive marker, upper urinary tract cancer, 2311
- Kidney cancer, non-small cell lung cancer, malignant melanoma, systemic therapy, immune checkpoint inhibitor, 3061
- Kidney, renal cell carcinoma, SBRT, SABR, review, 667
- Kindlin-3, immune cells, prostate cancer, tumor growth, xenograft model, 1217
- KIT, AXL, immunotherapy, MET, papillary renal cell carcinoma, *VEGFR*, 3151
- Knowledge-based treatment planning, VMAT, plan complexity, delivery accuracy, prostate cancer, 5305
- Ko143, combinatorial treatment, p-glycoprotein, BCRP, drug resistance, temozolomide, 723
- KRAS, cancer spheroid, 3D floating culture, low-toxic, context-independent, 3993
- KRT20*, gastric cancer, peritoneal recurrence, *CEACAM6*, peritoneal lavage fluid, 4003
- Kruppel-like factor 2, renal angiomyolipomas, IL-6, JAK, STAT3, 4753
- Lactate dehydrogenase, pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, NLR, LDH, c-reactive protein, CRP, immune checkpoint inhibitor, predictive factor, 2045
- Lactate, ovarian cancer, surgery, cytoreduction, ultra-radical, length of stay, 1979

- LAG-3, immunoadjuvant molecules, breast cancer, pathological complete response, neoadjuvant chemotherapy, TIM-3, OX-40, 125
- Language function, awake craniotomy, brain metastasis, intraoperative electrical stimulation mapping, subcortical metastasis, 1641
- Laparoscopic gallbladder bed resection, gallbladder cancer, laparoscopic whole-layer cholecystectomy, radical cholecystectomy, 903
- Laparoscopic gastrojejunostomy, gastric cancer, gastric outlet obstruction, staging laparoscopy, 5571
- Laparoscopic partial nephrectomy, renal function, parenchymal suture, robot-assisted partial nephrectomy, 3055
- Laparoscopic surgery, colorectal cancer, mixed reality, navigation, virtual reality, 4849
- Laparoscopic surgery, rectal cancer, colorectal surgery, low anastomoses, radiotherapy, indocyanine green, 211
- Laparoscopic surgery, type 4 gastric cancer, splenectomy, 5937
- Laparoscopic whole-layer cholecystectomy, gallbladder cancer, laparoscopic gallbladder bed resection, radical cholecystectomy, 903
- Laparoscopic, distal pancreatectomy, pancreatic cancer, radical antegrade modular pancreatosplenectomy, robotic, review, 653
- Laparoscopic, transumbilical incision, surgical site infection, colorectal, hernia, 1115
- Laparoscopy, robotic surgical procedure, laparotomy, endometrial neoplasm, aged, survival, 75
- Laryngeal preservation, head and neck cancer, glottic carcinoma, radiotherapy, chemoradiotherapy, elective nodal irradiation, 205
- Late recurrence, colorectal cancer, early recurrence, 5553
- Late xerostomia, head-and-neck cancer, radiotherapy, prognostic tool, treatment planning, 3035
- Lateral pelvic lymph node metastasis, predictors, advanced low rectal cancer, size criterion, magnetic resonance imaging, 2113
- Lattice radiotherapy, magnetic resonance imaging, spatially fractionated radiation therapy, gynecological cancer, inoperable bulky tumors, palliative care, palliative radiotherapy, 4641
- LC-MS/MS assay development, cancer prevention, vitamin D metabolites, vitamin D synthesis, 5077
- LC-MS/MS, CPD, cyclobutane pyrimidine dimer, DNA damage, thymidine dimer, urine, bioanalysis, 5069
- LDH, cfDNA, VEGF, PD-L1, tumour-burden, 801
- LDH, pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, NLR, lactate dehydrogenase, c-reactive protein, CRP, immune checkpoint inhibitor, predictive factor, 2045
- Learning curve, robot-assisted hysterectomy, cumulative summation analysis, endometrial cancer, benign gynecological tumor, 4111
- Leiomyosarcoma, brachytherapy, radiotherapy, soft-tissue sarcoma, extremity, multicentric analysis, 4485
- Lenalidomide, lung toxicity, japanese Adverse Drug Reaction Reporting database, signal, time to onset, 5917
- Length of stay, ovarian cancer, surgery, cytoreduction, ultra-radical, lactate, 1979
- Lenvatinib resistance, hepatocellular carcinoma, cisplatin, cell cycle, microRNA, 1263
- Lenvatinib, advanced hepatocellular carcinoma, liver resection, conversion surgery, 3049
- Lenvatinib, amentoflavone, AKT, ERK, hepatocellular carcinoma, 2495
- Lenvatinib, conversion hepatectomy, surgery, hepatocellular carcinoma, molecular therapy, review, 35
- Lenvatinib, hepatocellular carcinoma, atezolizumab plus bevacizumab, albumin-bilirubin grade, treatment sequence, 1403
- Lenvatinib, hepatocellular carcinoma, atezolizumab plus bevacizumab, rechallenge, 5479
- Lenvatinib, hepatocellular carcinoma, liver transplantation, recurrence, 1161
- Lenvatinib, hepatocellular carcinoma, tyrosine kinase inhibitor, sorafenib, post-progression survival, sequential therapy, 6007
- Lenvatinib, prognostic nutrition index, hepatocellular carcinoma, therapeutic response, 6019
- Lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, Child–Pugh, adverse events, progression-free survival, objective response, 173
- Leptomeningeal metastases, radiotherapy, spine metastases, spine surgery, spine tumors, systematic review, 619
- Letermovir prophylaxis, CMV reactivation, allogeneic transplantation, 5431
- Leukaemia, TYRO3, TAM family, small interfering RNA, 1757
- Leukemia, dimethyl fumarate, NF- $\kappa$ B, STAT3, c-IAP2, adult T-cell, lymphoma, 2301
- Leukemia, melanoma, cancer cell migration, rhoGTPase, rac, rhoGAP, rab11, recycling endosome, actin cytoskeleton, 5763
- Light isotope, zinc, stable isotope, anticancer effect, cytotoxicity, apoptosis, 5685
- Limb edema, cutaneous malignant melanoma, health-related quality of life, limb lymphedema, extremity lymphedema, cancer surgery, 5507
- Limb lymphedema, cutaneous malignant melanoma, health-related quality of life, limb edema, extremity lymphedema, cancer surgery, 5507
- Limb salvage, Ewing sarcoma, scapula, shoulder girdle, 3869
- Limb-sparing procedure, bone sarcoma, fibula, vascularized bone graft, non-vascularized fibula, 5443
- Limb-sparing tumor surgery, vascular reconstruction, extremity, bone tumor, soft tissue tumor, 4619
- LIN28A, neuroepithelium, immature teratoma, ETMR, C19MC, 4337
- LINC00675, colorectal cancers, H19, plasma markers, lncRNA, 1301

- Linear furocoumarin, psoralen, antiproliferative activity, HL60 cells, structure and activity relationship, 1777
- Lipopolysaccharide, adipocyte, anti-inflammation, insulin signal, type 2 diabetes, 3983
- Lipopolysaccharide, macrophages, monocytes, vascular endothelial cell, inflammatory cytokine gene, blood coagulation-related gene, 4049
- Lipopolysaccharide, medulloblastoma, daoy, immunotherapy, gemcitabine, rapamycin, 1697
- Liquid biopsy, cancer cell, circulating tumor cell, microfluidic chip cell sorter, multistep sorting, PD-L1, 407
- Liquid biopsy, colorectal cancer, chemotherapy, anti-EGFR mAb, 2625
- Liquid formulation, gemcitabine, vascular pain, 5% glucose, saline, lyophilized formulation, 343
- Liquid Pap specimen, ovarian cancer, pap test, cervical swab, review, 1
- Liver cancer, microRNA-1303, TLN1, proliferation, migration, invasion, 4715
- Liver injury, abemaciclib, aromatase inhibitor, breast cancer, risk factor, 6027
- Liver metastasis, neuroendocrine prostate cancer, small cell carcinoma, somatostatin receptor scintigraphy, prostate cancer, 2167
- Liver resection, advanced hepatocellular carcinoma, conversion surgery, lenvatinib, 3049
- Liver resection, gastric cancer, metachronous liver metastasis, review, 25
- Liver resection, hepatocellular carcinoma, anterior approach, circulating tumor cell, hanging maneuver, 4129
- Liver resection, hepatocellular carcinoma, bile duct tumor thrombus, vater papilla-preserving strategy, 5663
- Liver resection, hepatocellular carcinoma, mortality, recurrence, surgery, 2573
- Liver steatosis, non-alcoholic fatty liver disease, hepatectomy, hepatitis, steatohepatitis, 4159
- Liver surgery, indocyanine green, biliary fistula, navigation surgery, fluorescence imaging, 4787
- Liver transplantation, hepatocellular carcinoma, recurrence, lenvatinib, 1161
- Liver tumors, indocyanine green, ICG, fluorescence-guided surgery, radiofrequency ablation, local recurrence, salvage hepatectomy, tumor margins, R0 resection, 1345
- Liver X receptors, small-cell lung cancer, cholesterol metabolism, ABCA1, T0901317, 2923
- Liver, intrahepatic cholangiocarcinoma, cholangioblastic variant, biphasic cytology, inhibin A, *NIPBL-NACCI* fusion gene, 5475
- Liver, neuroendocrine tumor, gadoxetic acid, MRI, 911
- Liver, trimetazidine, thermic damage, rat model, colorectal, 4395
- LncRNA, colorectal cancers, H19, LINC00675, plasma markers, 1301
- LncRNAs, HPV, K14-HPV16, cancer cachexia, muscle wasting, 2443
- Lobectomy, differentiated thyroid cancer, risk factors, recurrence, thyroglobulin, 5619
- Local recurrence, indocyanine green, ICG, fluorescence-guided surgery, radiofrequency ablation, liver tumors, salvage hepatectomy, tumor margins, R0 resection, 1345
- Local recurrence, upper rectal cancer, neoadjuvant chemoradiotherapy, side effects, surgical complications, 4833
- Locally advanced rectal cancer, conventional fractionated radiotherapy, neoadjuvant long course, chemoradiotherapy, population-based, radiotherapy dose escalation, 1143
- Loco-regional therapy, rabbit models, <sup>90</sup>Y-microspheres, 827
- Locoregional radiotherapy, adjuvant radiation therapy, breast cancer, toxicity, side-effects, 923
- Locoregional recurrence, DUPAN-2, pancreatic cancer, recurrence pattern, pancreatectomy, 2071
- Long chain non-coding RNA, MIR4435-2HG, colon polyps, colon cancer, 4707
- Long-term survival, colorectal cancer, postoperative infectious complication, 2763
- Long-term survival, gastric cancer, surgical sarcopenia, 4545
- Low anastomoses, rectal cancer, colorectal surgery, laparoscopic surgery, radiotherapy, indocyanine green, 211
- Low methylation, *MGMT*, methylation status, *ATRX* loss, hypermethylation, glioblastoma, temozolomide chemotherapy, wild-type *IDH*, glioblastoma, 335
- Low rectal cancer, neoadjuvant chemoradiotherapy, rectal surgery, intersphincteric resection, enhanced recovery after surgery, ERAS, clinical outcome, 1949
- Low-dose topical administration, programmed cell death 1 antibody, immune-related adverse events, buccal mucosa, oral cancer cell line, programmed cell death 1-ligand 1, 4293
- Low-grade glioma, death receptor 6, glioma, prognosis, survival, tumor necrosis factor receptor 21, 1237
- Low-methionine diet, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Low-methionine diet, rectal cancer, patient, stable disease, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, 3857
- Low-toxic, cancer spheroid, KRAS, 3D floating culture, context-independent, 3993
- Luminal, breast cancer, CD58, prognostic marker, cancer stem cell, ALDH1, basal-like, 5223
- Luminometric method, chelates, bladder cancer, urine-based diagnostics, 5249
- Lung adenocarcinoma, biomarker, gut microbiome, never-smokers, 1589



- Lung adenocarcinoma, chloride intracellular channel 1, immunohistochemistry, spiral array, 271
- Lung adenocarcinoma, TNM staging, surgical resection, recurrence, 1137
- Lung cancer, afatinib, osimertinib, T790M, *EGFR* mutation, 2145
- Lung cancer, annexin A10, adenocarcinoma, spiral array, 1289
- Lung cancer, cancer stem cell, anticancer, plant-derived compounds, review, 4247
- Lung cancer, *EGFR* mutation, osimertinib, PD-L1, 2583
- Lung cancer, epithelial to mesenchymal transition, potential compounds targeting EMT, review, 4237
- Lung cancer, genotype, interleukin-8, polymorphism, Taiwan, 1229
- Lung cancer, lung metastasis, stereotactic body radiotherapy, syncTraX, real-time tumor tracking system, RTRT, radiotherapy, 2989
- Lung cancer, lung transplant, idiopathic pulmonary fibrosis, adenocarcinoma, 1157
- Lung cancer, NSCLC, nivolumab, chemotherapy, overall survival, pemetrexed, taxanes, vinorelbine, 1987
- Lung cancer, NSCLC, PD-L1, inflammation, CRP, albumin, haemoglobin, NLR, 1563
- Lung cancer, radiotherapy, discontinuation of treatment, risk factors, prognostic instrument, 1973
- Lung cancer, radiotherapy, pneumonitis, risk factors, prognostic tool, 2029
- Lung cancer, stereotactic ablative body radiotherapy, SABR, SBRT, cyberKnife, 321
- Lung cancer,  $\gamma$ -glutamylcyclotransferase, antisense, AMPK, cyclin-dependent kinase inhibitor, reactive oxygen species, 1221
- Lung metastases, germ tumors, risk score, 4517
- Lung metastasis, lung cancer, stereotactic body radiotherapy, syncTraX, real-time tumor tracking system, RTRT, radiotherapy, 2989
- Lung neoplasms, epidermal growth factor receptor, afatinib, prognosis, 1615
- Lung toxicity, alectinib, japanese adverse drug event report database, time to onset, 3109
- Lung toxicity, lenalidomide, japanese Adverse Drug Reaction Reporting database, signal, time to onset, 5917
- Lung transplant, lung cancer, idiopathic pulmonary fibrosis, adenocarcinoma, 1157
- Lymph node dissection, pancreatic neuroendocrine tumor, outcome, 2797
- Lymph node metastasis, adjuvant chemotherapy, invasive IPMC, poorly differentiated adenocarcinoma, tubular type, 2645
- Lymph node metastasis, colorectal liver metastasis, prognostic factor, N factor, TNM classification, 1997
- Lymph node metastasis, endometrial cancer, p53, MMR deficiency, heterogeneity, 4535
- Lymph node metastasis, epithelial–mesenchymal transition, colon cancer, SNAIL1, SNAIL, 5927
- Lymph node metastasis, esophageal cancer, c-reactive protein, genetic polymorphism, endoscopic resection, 6105
- Lymph node metastasis, esophagogastric cancer, adenocarcinoma, recurrence, 1051
- Lymph node metastasis, vertical location, anterior wall, gastric cancer, 237
- Lymph nodes, nodal ratio, positive nodes, head and neck cancer, 5567
- Lymph-node metastasis, pancreatic cancer, patient-derived orthotopic xenograft (PDOX), NOG mouse, nude mouse red fluorescent protein (RFP), intravital imaging, personalized therapy, drug discovery, 739
- Lymphadenectomy, cardiophrenic lymph nodes, advanced ovarian cancer, review, 13
- Lymphocyte-to-C-reactive protein ratio, colorectal liver metastasis, prognosis, overall survival, tumour, 4963
- Lymphocyte, pancreatic intraepithelial neoplasia, pancreatic carcinoma, platelet, platelet/lymphocyte ratio, sarcopenia, jaundice, 1413
- Lymphoid malignancies, platinum, gene-expression analysis, copy-number deletions, 1821
- Lymphoma, central nervous system, brain, 5601
- Lymphoma, dimethyl fumarate, NF- $\kappa$ B, STAT3, c-IAP2, adult T-cell, leukemia, 2301
- Lymphoproliferative disorder, transplantation, EBV, PTLD, CAR-T, review, 5181
- Lymphovascular invasion, breast cancer, thyroid hormones, carcinoma *in situ*, multifocal/multicentric tumors, proliferation, prognosis, 253
- Lyophilized formulation, gemcitabine, vascular pain, 5% glucose, saline, liquid formulation, 343
- Lysine acetyltransferase, KAT6A, non-small cell lung cancer, 5731
- Lysis, natural killer cells, NK-92, K562, pBMCs, 4259
- Lysophosphatidylserine, ulcerative colitis-associated colorectal cancer, lysophospholipids, lysophosphatidylinositol, 2461
- Lysophospholipids, ulcerative colitis-associated colorectal cancer, lysophosphatidylinositol, lysophosphatidylserine, 2461
- M2 macrophage, collapsin response mediator protein 4 (CRMP4), DPYSL3, CD163, cD11b, myeloid-derived suppressor cell (MDSC), 791
- M2BPGi, prognosis, hepatocellular carcinoma, sustained viral response, 245
- Machine learning, bladder cancer, EPHA2, cancer recurrence, biomarker, adipocytes, 5783
- Machine learning, non-small cell lung cancer, PET/CT, PD-L1, texture analysis, 5875
- Machine learning, oral cavity cancer, interpretability, sHapley values, prognosis, 5859



- Macrophage, dog, endothelial cell, melanoma, tumor microenvironment, 5397
- Macrophages, monocytes, vascular endothelial cell, inflammatory cytokine gene, blood coagulation-related gene, lipopolysaccharide, 4049
- Maculopapular eruption, cutaneous adverse event, drug eruption, apalutamide, prostate cancer, body weight, 2023
- Magnetic resonance imaging, lattice radiotherapy, spatially fractionated radiation therapy, gynecological cancer, inoperable bulky tumors, palliative care, palliative radiotherapy, 4641
- Magnetic resonance imaging, predictors, lateral pelvic lymph node metastasis, advanced low rectal cancer, size criterion, 2113
- Magnetic resonance spectroscopic imaging, prospective study, predictive biomarker, high-grade glioma, glioblastoma, 2665
- Magnolol, ERK, NF- $\kappa$ B, osteosarcoma, apoptosis, 4403
- Magnolol, non-small-cell lung cancer, signal transducer and activator of transcription 3, STAT3, nuclear factor kappa B, NF- $\kappa$ B, 3825
- Maintenance chemotherapy, sorafenib, advanced hepatocellular carcinoma, very high risk of recurrence, 6127
- MALBI grade, hepatocellular carcinoma, prognostic factor, stereotactic body radiotherapy, 5001
- Male breast cancer, next generation sequencing, genetic predisposition, multigene analysis, 5795
- Malignancy, gallbladder cancer, microscopy, confocal, endomicroscopy diagnosis, 67
- Malignancy, soft-tissue tumor, 2-5 cm, MRI, needle biopsy, unplanned excision, 1555
- Malignant biliary obstruction, PTBD, 4063
- Malignant bone tumor, clavicle pro humero reconstruction, non-union, sarcoma, 2139
- Malignant central airway obstruction, small-cell lung cancer, extraluminal obstruction, stent placement, concurrent chemoradiotherapy, 6113
- Malignant melanoma, non-small cell lung cancer, kidney cancer, systemic therapy, immune checkpoint inhibitor, 3061
- Malignant peripheral nerve sheath tumor, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, ERBB2, ERBB3, NRG1, ki-67, 2327
- Malignant peritoneal mesothelioma, cytoreductive surgery, HIPEC, outcomes, survival, 2939
- Mallampati score, head and neck cancer, chemoradiotherapy, trismus, restricted mouth opening, outcome, 5609
- Malnutrition, gastric cancer, overall survival, postoperative complication, prognosis, 4611
- Mangosteen, cervical cancer, proliferation, apoptosis, 2903
- Mantle cell lymphoma, bendamustine, rituximab, 6083
- MAPK, PTPN3, pancreatic cancer, proliferation, invasion, 2869
- Masseter muscle, oesophageal cancer, prognosis, psoas muscle, sarcopenia, 301
- Mastectomy, breast, carcinoma, hypofractionation, segmental, radiotherapy, 53
- Mastectomy, breast, carcinoma, segmental, radiotherapy, 93
- Matrix metalloproteinase, oropharyngeal squamous cell carcinoma, OPSCC, human papillomavirus, *Porphyromonas gingivalis*, gingipain, rgp, survival analysis, 5415
- Matrix metalloproteinases, WWC1, KIBRA, tumor growth, predictive marker, upper urinary tract cancer, 2311
- Maxillofacial surgery, diabetes mellitus, glucose metabolism disorder, mouth neoplasms, epidemiology, 1899
- MBP1, glioma, meningioma, ENO1,  $\alpha$ -enolase, glioblastoma, 2319
- MCF-7, chorioallantoic membrane, mesenchymal stem cells, vascular plexus, vasculogenesis, 877
- Mcl-1, cancer-associated fibroblasts, bcl-xL, IL-6, colorectal cancer, apoptosis, STAT3, 1277
- MCSPC, prostate cancer, metastatic castration-sensitive prostate cancer, PSA response, first-line therapy, 165
- MDAPanc-28, *Asparagus* extract, cancer, pancreatic cancer, P21, P53, FAS, CDK4, 2425
- MDM2*, oral squamous cell carcinoma, RITA, apoptosis, p53, 2931
- MDM2*, *TP53*, *CDKN2A*, breast Cancer, copy number alteration, 2277
- MDMX, drug repositioning, repurposing, HDMX, 4727
- MedDRA, meta-analysis, systematic review, adverse events, placebo, cancer, oncology, randomized trials, CTCAE, review, 2805
- Medical workers, cytogenetic analysis, chromosome aberrations, aneuploidy, cancer, risk assessment, 1059
- Medication guidance sheet, chemotherapy, adverse events, non-Hodgkin's lymphoma, ESHAP $\pm$ R therapy, 2053
- Medulloblastoma, daoy, immunotherapy, gemcitabine, rapamycin, lipopolysaccharide, 1697
- Medulloblastoma, wnt, SHH, non-Wnt/non-SHH, review, 2225
- MEK-inhibitor, *AGK-BRAF* gene fusion, myoepithelial carcinoma, cobimetinib, next generation sequencing, NGS, 373
- Melanoma, BRAF V600E, PLX4032, imidazothiazole, chemoresistance, activator protein-1, 2911
- Melanoma, carney complex, fibroma, myxoma, neurofibroma, cerebello-pontine angle, PRKAR1A, 6121
- Melanoma, dog, endothelial cell, macrophage, tumor microenvironment, 5397
- Melanoma, EBI3, biomarker, tumor microenvironment, 511
- Melanoma, leukemia, cancer cell migration, rhoGTPase, rac, rhoGAP, rab11, recycling endosome, actin cytoskeleton, 5763
- Melanoma, trends, incidence, mortality, overdiagnosis, sunburn, review, 5021
- Melanoma, UV exposure, diabetes mellitus, cancer, cardiovascular disease, mortality, review, 1671
- Melphalan, multiple myeloma, OCT3, *SLC22A3*, oral mucositis, 385

- Meningioma, <sup>68</sup>Ga-DOTATOC, gamma-knife radiosurgery, incidentaloma, neuroendocrine tumor, PET/CT scan, 5867
- Meningioma, brain tumor, brain metastases, fractionation, gamma knife radiosurgery, hypofractionated radiosurgery, 1851
- Meningioma, glioma, ENO1,  $\alpha$ -enolase, glioblastoma, MBP1, 2319
- Merkel cell carcinoma, tumor infiltrating lymphocytes, cancer-associated fibroblasts, 4359
- Mesenchymal stem cells, cancer-associated fibroblasts, ovarian cancer, stromal cells, normal ovary, 1729
- Mesenchymal stem cells, chorioallantoic membrane, MCF-7, vascular plexus, vasculogenesis, 877
- Mesenteric tumor, bowel obstruction, fibromatosis, 381
- MET, AXL, immunotherapy, KIT, papillary renal cell carcinoma, *VEGFR*, 3151
- Meta regression, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Meta-analysis, gastroPanel<sup>®</sup>, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Meta-analysis, systematic review, adverse events, asthenia, fatigue, placebo, cancer, oncology, randomized trials, CTCAE, review, 45
- Meta-analysis, systematic review, adverse events, placebo, cancer, oncology, randomized trials, CTCAE, medDRA, review, 2805
- Metachronous liver metastasis, gastric cancer, liver resection, review, 25
- Metachronous other primary cancer, synchronous other primary cancer, esophageal cancer, 5635
- Metastases prediction, sIL-2R, biomarker, uveal melanoma, 1447
- Metastasis, acridine orange, breast cancer, zoledronate, 5357
- Metastasis, alcohol drinking, colorectal cancer, genotype, *MMP2*, polymorphism, Taiwan, 5335
- Metastasis, breast cancer patient, invasive lobular carcinoma, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Metastasis, canine mammary gland tumors, cell cycle, hIF1 $\alpha$ , siRNA, TSG-6, 5803
- Metastasis, cisplatin, capecitabine, gastric cancer, adjuvant chemotherapy, 2009
- Metastasis, colon cancer, PGE2, 15-PGDH, epithelial-to-mesenchymal transition, 5385
- Metastasis, gastric cancer, 14-3-3 sigma protein, cell proliferation, tumor progression, prognostic factor, 519
- Metastasis, osteosarcoma, neutrophil count, platelet-lymphocyte ratio, 1081
- Metastasis, pancreatic adenocarcinoma, complement C3a, complement C3a receptor, epithelial-to-mesenchymal transition, 1207
- Metastasis, pancreatic ductal adenocarcinoma, complement C3, epithelial-to-mesenchymal transition, 5743
- Metastasis, prognosis, radiation oncologists, palliative care, artificial intelligence, 1397
- Metastasis, recurrence of ovarian cancer, primary debulking surgery, interval debulking surgery, progression-free survival, 2003
- Metastasis, SMARCB1 gene, cutaneous squamous cell carcinoma, parotid gland, 3971
- Metastasis, triple-negative breast cancer (TNBC), A20/TNFAIP3, cell division cycle 20 (Cdc20), cASP1/Caspase-1, inflammation, inflammation inhibitors, 681
- Metastasis; oxaliplatin, rectal cancer, survival, pCR, radiotherapy, total neoadjuvant therapy, 991
- Metastatic castration-resistant prostate cancer, abiraterone, docetaxel, enzalutamide, 4857
- Metastatic castration-sensitive prostate cancer, prostate cancer, mCSPC, PSA response, first-line therapy, 165
- Metastatic colorectal cancer, XELOX therapy, oxaliplatin, frail patients, 1859
- Metastatic disease, intramedullary nail, pathologic fracture, functional outcomes, 919
- Metastatic hormone receptor-positive breast cancer, everolimus, CDK4/6 inhibitor, 3913
- Metastatic lymphadenopathy, squamous cell carcinoma, oral cancer, pN1, survival, adjuvant radiotherapy, neck dissection, postoperative radiotherapy, 97
- Metastatic pancreatic cancer, chemotherapy, first-line, itraconazole, 6063
- Metastatic urothelial carcinoma, radiotherapy, quality of life, review, 3767
- Metasynchronous liver metastasis, gastric cancer, hepatectomy, 2177
- Metformin, hepatocellular carcinoma, radiotherapy, neutron, radiosensitizer, xenograft, 867
- Metformin, immunotherapy, immune checkpoint inhibitor, nivolumab, safety, diabetic cancer patients, 1487
- Methioninase, breast osteosarcoma, PDOX, nude mice, combination therapy, rapamycin, efficacy, synergy, Hoffman effect, 5217
- Methioninase, cancer, methionine addiction, Hoffman effect, methionine restriction, clinical treatment, review, 641
- Methioninase, osteosarcoma, nude mice, PDOX, methionine addiction, Hoffman effect, methotrexate, resistance, combination therapy, efficacy, 731

- Methionine addiction, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Methionine addiction, cancer, Hoffman effect, methionine restriction, methioninase, clinical treatment, review, 641
- Methionine addiction, osteosarcoma, nude mice, PDOX, Hoffman effect, methioninase, methotrexate, resistance, combination therapy, efficacy, 731
- Methionine addiction, pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, supplement, combination therapy, stable disease, CA19-9, Hoffman effect, 2567
- Methionine addiction, rectal cancer, patient, stable disease, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, 3857
- Methionine PET, breast cancer patient, invasive lobular carcinoma, metastasis, METPET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Methionine restriction, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Methionine restriction, cancer, methionine addiction, Hoffman effect, methioninase, clinical treatment, review, 641
- Methionine restriction, rectal cancer, patient, stable disease, methionine addiction, Hoffman effect, oral recombinant methioninase, low-methionine diet, 3857
- Methotrexate, osteosarcoma, nude mice, PDOX, methionine addiction, Hoffman effect, methioninase, resistance, combination therapy, efficacy, 731
- Methylation status, *MGMT*, *ATRX* loss, hypermethylation, low methylation, glioblastoma, temozolomide chemotherapy, wild-type *IDH*, glioblastoma, 335
- METPET, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- MFOLFIRINOX, pancreatic ductal adenocarcinoma, PDAC, surgery, gemcitabine, B lymphocytes, T cells, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- MGMT*, methylation status, *ATRX* loss, hypermethylation, low methylation, glioblastoma, temozolomide chemotherapy, wild-type *IDH*, glioblastoma, 335
- MHC-dKO NOG mouse, small chemical compound library, *in silico* screening, ELISA for inhibition of PD-1/PD-L1 binding, ADME evaluation, 5233
- Micelles, pH-responsive, three-dimensional cell culture, tumor microenvironment, anti-fibrotic drug, tumor-bearing mice, 2847
- Micro-RNA378a-3p, sarcomatoid renal cell carcinoma, *POLR2A*, *RUNX2*, *ERK2* (*MAPK1*), 811
- Microarray, colorectal surgery, anastomotic leakage, gene expression analysis, 2827
- Microbiome, esophageal cancer, adenocarcinoma, squamous cell carcinoma, toll-like receptors, review, 2813
- Microenvironment, patient-derived xenograft, pancreatic ductal adenocarcinoma, vascular endothelial cells, engraftment rate, 2395
- Microfluidic chip cell sorter, cancer cell, circulating tumor cell, liquid biopsy, multistep sorting, PD-L1, 407
- Microfluidic, circulating tumor cells, epithelial mesenchymal transition, phenotype profile analysis, 4345
- MicroRNA-1303, liver cancer, *TLN1*, proliferation, migration, invasion, 4715
- MicroRNA, etoposide, miRNA-205-5p, breast cancer, spheroid, *ERBB4*, 4265
- MicroRNA, hepatocellular carcinoma, lenvatinib resistance, cisplatin, cell cycle, 1263
- MicroRNA, ovarian cancer, screening, CA125, ultrasound, *TP53* clonal variants, review, 4207
- MicroRNA, pancreatic cancer, aspirin, cell cycle, 4037
- Microscopy, gallbladder cancer, confocal, endomicroscopy diagnosis, malignancy, 67
- Microvascular reconstruction, hand grip force, hand grip strength, head and neck cancer, oral cancer, 2771
- Microwave ablation, colorectal liver metastases, fluorouracil plus leucovorin, systemic chemotherapy, 1645
- Microwave ablation, radiofrequency ablation, pulmonary metastasis, colorectal cancer, 4563
- Microwave ablation, radiofrequency ablation, pulmonary metastasis, colorectal cancer, 4563
- Migration, liver cancer, microRNA-1303, *TLN1*, proliferation, invasion, 4715
- Migration, pI3KC2 $\beta$ , pharmacological inhibition, cell proliferation, acute leukemia, brain tumours, neuroendocrine tumours, 3217
- Migratory birds, vitamin D, mosquitoes, *Aedes aegypti* mosquitoes, *Drosophila melanogaster*, bats, vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 5091
- Milk extracellular vesicles, *EGFR* expressing tumor, GE11 peptide, drug delivery system, bio-engineered drug carrier, 857
- Minimally invasive follicular thyroid carcinoma, *PTEN* gene mutation, cowden syndrome, *PTEN* hamartoma tumor syndrome, *RECQL4* gene, germline mutation, surveillance, 1481

- Minimally invasive surgery, esophageal cancer, transhiatal esophagectomy, transcervical mediastinoscopy, robotic-assisted surgery, review, 675
- Minodronate, aromatase inhibitors, breast cancer, osteoporosis, bisphosphonate, 4139
- miR-1*, diagnostic biomarker, miRNA, ovarian cancer, *miR-21*, 5839
- MIR4435-2HG, long chain non-coding RNA, colon polyps, colon cancer, 4707
- MiRNA-205-5p, etoposide, microRNA, breast cancer, spheroid, ERBB4, 4265
- MiRNA, annexin V, transient transfection, dissociative enzymes, flow cytometry, trypsin, 2819
- MiRNA, diagnostic biomarker, ovarian cancer, *miR-1*, *miR-21*, 5839
- MiRNA, renal cell carcinoma, transcription factor, tissue expression, prognostic markers, 2355
- Mismatch repair protein, head and neck cancer, salivary gland carcinoma, PD-1 inhibitor, PD-L1, 981
- Mixed nuts, pistachios, colon cell proliferation, 8-oxo-deoxyguanosine, cyclooxygenase 2, 4285
- Mixed reality, colorectal cancer, laparoscopic surgery, navigation, virtual reality, 4849
- MMP-2*, gastric cancer, genotype, polymorphism, Taiwan, 1749
- MMP-7*, genotype, hepatocellular carcinoma, polymorphism, HCC, Taiwan, 5275
- MMP2*, alcohol drinking, colorectal cancer, genotype, metastasis, polymorphism, Taiwan, 5335
- MMR deficiency, endometrial cancer, lymph node metastasis, p53, heterogeneity, 4535
- Moderate sedation, transbronchial microwave ablation, stent placement, post anticancer therapy, 3125
- Molecular design, UTX-51, BSA, boron tracedrugs, 4017
- Molecular diagnostics, salivary gland tumor, polymorphous adenocarcinoma, polymorphous low-grade adenocarcinoma, PRKD1, cribriform adenocarcinoma of salivary glands, 1455
- Molecular genetics, glioma, gene fusion, targeted therapy, next-generation sequencing, 1933
- Molecular target, scirrhous gastric cancer, intractable cancer, proliferation, oncogenes, 5195
- Molecular targeted therapy, renal cell carcinoma, immunology combination therapy, first-line therapy, 4573
- Molecular therapy, conversion hepatectomy, surgery, hepatocellular carcinoma, lenvatinib, review, 35
- Monocytes, macrophages, vascular endothelial cell, inflammatory cytokine gene, blood coagulation-related gene, lipopolysaccharide, 4049
- Morphology, TNBC,  $\beta$ -tubulin isoform, docetaxel, 3D culture, spheroid, 4735
- Mortality, hepatocellular carcinoma, liver resection, recurrence, surgery, 2573
- Mortality, melanoma, trends, incidence, overdiagnosis, sunburn, review, 5021
- Mortality, portal vein embolization, postoperative liver failure, hepatocellular carcinoma, right hepatectomy, 4089
- Mortality, UV exposure, diabetes mellitus, cancer, melanoma, cardiovascular disease, review, 1671
- Mosquitoes, vitamin D, *aedes aegypti* mosquitoes, *Drosophila melanogaster*, migratory birds, bats, vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 5091
- Motor function, awake surgery, brain metastasis, intraoperative electrical stimulation mapping, subcortical metastasis, precentral gyrus, 1151
- Mouth neoplasms, diabetes mellitus, glucose metabolism disorder, maxillofacial surgery, epidemiology, 1899
- MpMRI, prostate cancer, <sup>68</sup>Ga-PSMA PET/CT, targeted prostate biopsy, 3011
- MPTP, *BAX* and *BCL2* silencing, SK-N-SH cells, casiopeína IIIa, cCRISPR/Cas9, Ca<sup>2+</sup> retention capacity, 885
- MRI, neuroendocrine tumor, liver, gadoteric acid, 911
- MRI, soft-tissue tumor, 2-5 cm, malignancy, needle biopsy, unplanned excision, 1555
- MTRR*, colorectal cancer, genotype, polymorphism, Taiwan, 2375
- MUC1, small cell lung cancer, biomarker, CD147, circulating tumor cells, 429
- Mucinous ovarian carcinoma, polycomb protein, BMI-1, chemoresistance, cancer stem cell, 1739
- Mulberry, stelic animal model, high-fat diet, streptozotocin, nonalcoholic hepatitis, nonalcoholic fatty liver disease, hepatocellular carcinoma, 4055
- Multicentric analysis, leiomyosarcoma, brachytherapy, radiotherapy, soft-tissue sarcoma, extremity, 4485
- Multidisciplinary treatment, intrahepatic cholangiocarcinoma, ablation, systemic chemotherapy, 3209
- Multifocal/multicentric tumors, breast cancer, thyroid hormones, carcinoma *in situ*, lymphovascular invasion, proliferation, prognosis, 253
- Multigene analysis, male breast cancer, next generation sequencing, genetic predisposition, 5795
- Multigene panel testing, hereditary cancer, genetic medicine, genetic testing, risk reduction, 4097
- Multiparametric magnetic resonance imaging, pancreas, pancreatic intraductal neoplasms, 3895
- Multiple gene expression analysis, intraductal papillary neoplasm type 1, intraductal papillary neoplasm type 2, DNMT1, DNA methylation, 2893
- Multiple myeloma, adoptive T cell therapy, dendritic cells, cytotoxic T cells, B cell maturation antigen, 1785
- Multiple myeloma, autologous, allogeneic, stem cell transplantation, overall survival, progression-free survival, non-relapse mortality, relapse incidence, 5825
- Multiple myeloma, melphalan, OCT3, *SLC22A3*, oral mucositis, 385
- Multiplex fluorescent labeling, cancer immunology, colorectal cancer, arginase 1, CD15, 459



- Multistep sorting, cancer cell, circulating tumor cell, liquid biopsy, microfluidic chip cell sorter, PD-L1, 407
- Multivariate analysis, carcinoma, renal cell, neoplasm grading, nephrectomy, prognosis, 2967
- Murine double minute 2, esophagus, nutlin-3, p53, p73, 2875
- Muscle fiber type, cachexia, resistance exercise, aerobic exercise, inflammation, colon cancer, colon-26, 397
- Muscle wasting, HPV, K14-HPV16, cancer cachexia, lncRNAs, 2443
- Muscle-invasive bladder cancer, NFIA, NFIB, bladder cancer, urothelial carcinoma, 493
- Myeloid-derived suppressor cell (MDSC), collapsin response mediator protein 4 (CRMP4), DPYSL3, CD163, M2 macrophage, cD11b, 791
- Myocardial imaging, radiotherapy, breast cancer, cyclic variation of the integrated backscatter, speckle tracking echocardiography, global longitudinal strain, 2507
- Myoepithelial carcinoma, *AGK-BRAF* gene fusion, mEK-inhibitor, cobimetinib, next generation sequencing, NGS, 373
- Myxoma, carney complex, fibroma, neurofibroma, melanoma, cerebello-pontine angle, PRKAR1A, 6121
- N factor, colorectal liver metastasis, prognostic factor, lymph node metastasis, TNM classification, 1997
- N-acetylcysteine,  $\gamma$ -glutamylcyclotransferase, reactive oxygen species, cyclin-dependent kinase inhibitors, pro-GA, breast cancer, 4311
- N-Trans-p*-coumaroyltyramine, nSAIDs, ER stress, apoptosis, potentiation, breast cancer cells, 1833
- Nab-paclitaxel, gastric cancer, ramucirumab, paclitaxel, prognosis, 1599
- Nab-paclitaxel, paclitaxel, relapsed tumor, small cell lung cancer, interstitial lung disease, 4921
- Nal-IRI, pancreatic cancer, second-line chemotherapy, FOLFIRINOX, peripheral neuropathy, pegfilgrastim, 3889
- Nano-textured, breast reconstruction, pre-pectoral, semi-smooth implant, acellular dermal matrix, 1013
- Nasoseptal flap, COVID-19, boron neutron capture therapy, salvage maxillectomy, recurrent oral cancer, 1653
- Nateglinide, pancreatic cancer, NO, nitrated compound, apoptosis, 1313
- National Health Insurance, hepatocellular carcinoma, sorafenib, barcelona Clinic Liver Cancer Stage C, transarterial chemoembolization, reimbursement criteria, 4461
- Natural killer cells, lysis, NK-92, K562, pBMCs, 4259
- Nausea, vomiting, radiotherapy, cervical cancer, cisplatin, 3117
- Navigation surgery, indocyanine green, biliary fistula, liver surgery, fluorescence imaging, 4787
- Navigation, colorectal cancer, laparoscopic surgery, mixed reality, virtual reality, 4849
- Near-infrared turn-on fluorescence probe, C5S-A, activity of aldehyde dehydrogenase, breast cancer, stem cells, 1199
- Neck dissection, squamous cell carcinoma, oral cancer, pN1, survival, adjuvant radiotherapy, metastatic lymphadenopathy, postoperative radiotherapy, 97
- Needle biopsy, soft-tissue tumor, 2-5 cm, malignancy, MRI, unplanned excision, 1555
- Neo-angiogenesis, eribulin, tGF- $\beta$ , endMT, adhesion molecules, 2859
- Neoadjuvant chemoradiotherapy, esophageal squamous cell carcinoma, docetaxel, cisplatin, 5-fluorouracil, 3905
- Neoadjuvant chemoradiotherapy, low rectal cancer, rectal surgery, intersphincteric resection, enhanced recovery after surgery, ERAS, clinical outcome, 1949
- Neoadjuvant chemoradiotherapy, rectal cancer, PME, upper rectum, sigmoid cancer, 155
- Neoadjuvant chemoradiotherapy, upper rectal cancer, local recurrence, side effects, surgical complications, 4833
- Neoadjuvant chemotherapy, esophageal cancer, esophageal wall thickness, tumor location, 5655
- Neoadjuvant chemotherapy, esophageal cancer, febrile neutropenia, predictive factors, pegfilgrastim, neutrophil count, 6071
- Neoadjuvant chemotherapy, gastric cancer, surgical diagnosis, 2719
- Neoadjuvant chemotherapy, immunoadjuvant molecules, breast cancer, pathological complete response, LAG-3, TIM-3, OX-40, 125
- Neoadjuvant chemotherapy, rectal cancer, adjuvant chemotherapy, prognosis, 1527
- Neoadjuvant chemotherapy, tumor-infiltrating lymphocytes, breast cancer, fibrotic foci, prognostic marker, 1421
- Neoadjuvant long course, conventional fractionated radiotherapy, chemoradiotherapy, population-based, radiotherapy dose escalation, locally advanced rectal cancer, 1143
- Neoadjuvant radiotherapy, rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, short-course radiotherapy, capecitabine, S-1, chemotherapy, radiotherapy, 5587
- Neoadjuvant therapy, cancer, esophagus, PET, surgery, survival, 6037
- Neoplasm grading, bone sarcoma, SEER program, hand, treatment outcome, orthopedic surgery, 1635
- Neoplasm grading, carcinoma, renal cell, multivariate analysis, nephrectomy, prognosis, 2967
- Neoplasms, breast, biopsy, ultrasonography, vacuum, 2159
- Neoplasms, thyroid cancer, second primary, radiotherapy, head and neck neoplasms, SEER program, 1359
- Nephrectomy, carcinoma, renal cell, multivariate analysis, neoplasm grading, prognosis, 2967
- Nephrotoxicity, cisplatin, short hydration, oral rehydration solution (ORS), risk factor, 3185
- Nerve growth factor, axonal growth, calcitonin gene-related peptide, dorsal root ganglion neurons, spinal metastasis, 581



- NETs, ovarian cancer, tumor marker, dsDNA, h3Cit-DNA, 965
- Neuro-oncology, cerebral ventricles, craniopharyngioma, intraventricular tumor, skull base, systematic review, 4189
- Neuroendocrine carcinoma, pancreatic neuroendocrine tumor, PNET, surgery, resection, review, 629
- Neuroendocrine prostate cancer, small cell carcinoma, somatostatin receptor scintigraphy, liver metastasis, prostate cancer, 2167
- Neuroendocrine tumor, <sup>68</sup>Ga-DOTATOC, gamma-knife radiosurgery, incidentaloma, meningioma, PET/CT scan, 5867
- Neuroendocrine tumor, liver, gadoxetic acid, MRI, 911
- Neuroendocrine tumours, p13KC2β, pharmacological inhibition, cell proliferation, migration, acute leukemia, brain tumours, 3217
- Neuroendocrine, cancer unknown primary, gene expression profiling, RT-PCR, 1381
- Neuroepithelium, immature teratoma, ETMR, C19MC, LIN28A, 4337
- Neurofibroma classification, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, NRG1, ki-67, 2327
- Neurofibroma, Carney complex, fibroma, myxoma, melanoma, cerebello-pontine angle, PRKAR1A, 6121
- Neurofibroma, neurofibromatosis type 1, plexiform neurofibroma, diffuse plexiform neurofibroma, classification, 1247
- Neurofibroma, neurofibromatosis type 1, plexiform neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, NRG1, ki-67, 2327
- Neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, classification, 1247
- Neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, NRG1, ki-67, 2327
- Neurofibromatosis type 1, plexiform neurofibroma, central giant cell granuloma, rASopathy, root resorption, 2945
- Neurofibromatosis type 1, plexiform neurofibroma, cephalometry, symmetry, bone, facial skeleton, 2607
- Neurofibromatosis type I, pheochromocytoma, van Recklinghausen's disease, pregnancy, 4647
- Neurotoxicity, polyphenol, PC12, SH-SY5Y, NGF, overlay method, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- Neutron, hepatocellular carcinoma, metformin, radiotherapy, radiosensitizer, xenograft, 867
- Neutrophil count, esophageal cancer, neoadjuvant chemotherapy, febrile neutropenia, predictive factors, pegfilgrastim, 6071
- Neutrophil count, osteosarcoma, metastasis, platelet-lymphocyte ratio, 1081
- Neutrophil-lymphocyte ratio, COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, gene expression, blood, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- Neutrophil-lymphocyte ratio, pembrolizumab, urothelial cancer, NLR, lactate dehydrogenase, LDH, c-reactive protein, CRP, immune checkpoint inhibitor, predictive factor, 2045
- Neutrophil-to-lymphocyte ratio, immune checkpoint inhibitor, esophageal squamous cell carcinoma, gastric/gastroesophageal adenocarcinoma, 2977
- Neutrophil-to-lymphocyte ratio, non-small cell lung cancer, sleeve lobectomy, pneumonectomy, platelet-to-lymphocyte ratio, 3029
- Neutrophil-to-lymphocyte ratio, oesophageal squamous cell carcinoma, trimodal therapy, prognosis, 1499
- Neutrophile-to-lymphocyte ratio, biomarkers, prognosis, overall survival, systemic immune-inflammation index, 1911
- Never-smokers, biomarker, gut microbiome, lung adenocarcinoma, 1589
- Next generation sequencing, *AGK-BRAF* gene fusion, myoepithelial carcinoma, mEK-inhibitor, cobimetinib, NGS, 373
- Next generation sequencing, male breast cancer, genetic predisposition, multigene analysis, 5795
- Next-generation sequencing, gastrointestinal stromal tumour, circulating tumour DNA, 5527
- Next-generation sequencing, glioma, gene fusion, targeted therapy, molecular genetics, 1933
- NF-κB, dimethyl fumarate, STAT3, c-IAP2, adult T-cell, leukemia, lymphoma, 2301
- NF-κB, magnolol, ERK, osteosarcoma, apoptosis, 4403
- NF-κB, magnolol, non-small-cell lung cancer, signal transducer and activator of transcription 3, STAT3, nuclear factor kappa B, 3825
- NFIB, NFIA, bladder cancer, urothelial carcinoma, muscle-invasive bladder cancer, 493
- NGF, polyphenol, PC12, SH-SY5Y, overlay method, neurotoxicity, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- NGS, *AGK-BRAF* gene fusion, myoepithelial carcinoma, mEK-inhibitor, cobimetinib, next generation sequencing, 373
- NIPBL-NACCI* fusion gene, intrahepatic cholangiocarcinoma, cholangioblastic variant, biphasic cytology, liver, inhibin A, 5475
- Nitrated compound, pancreatic cancer, nateglinide, NO, apoptosis, 1313
- Nivolumab plus ipilimumab, renal cell carcinoma, cytoreductive nephrectomy, 2727
- Nivolumab, advanced cancer, immunotherapy, checkpoint inhibitors, PD-1/PDL-1, CTLA-4, 1433
- Nivolumab, gastric cancer, immune-related adverse events, survival, 1535

- Nivolumab, immunotherapy, immune checkpoint inhibitor, metformin, safety, diabetic cancer patients, 1487
- Nivolumab, NSCLC, lung cancer, chemotherapy, overall survival, pemetrexed, taxanes, vinorelbine, 1987
- Nivolumab, PD-L1, recurrent/metastatic head and neck cancer, TPS, CPS, 1547
- Nivolumab, squamous cell carcinoma, head and neck, 1607
- Nivolumab, squamous cell carcinoma, head and neck, platinum-refractory, platinum-sensitive, 4907
- Nivolumab, tolerability, disease control, progressive disease, immune-related adverse events, 4973
- NK cells, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- NK-92, natural killer cells, lysis, K562, pBMCs, 4259
- NKT-like cells, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, NK cells, T regulatory cells, cytotoxic T cells, 3067
- NLR, NSCLC, lung cancer, PD-L1, inflammation, CRP, albumin, haemoglobin, 1563
- NLR, pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, lactate dehydrogenase, LDH, c-reactive protein, CRP, immune checkpoint inhibitor, predictive factor, 2045
- No residual tumor, esophageal squamous cell carcinoma, chemotherapy, prognostic factor, 195
- NO, pancreatic cancer, nateglinide, nitrated compound, apoptosis, 1313
- Nodal ratio, positive nodes, lymph nodes, head and neck cancer, 5567
- NOG mouse, pancreatic cancer, patient-derived orthotopic xenograft (PDOX), nude mouse red fluorescent protein (RFP), lymph-node metastasis, intravital imaging, personalized therapy, drug discovery, 739
- Non-alcoholic fatty liver disease, hepatectomy, liver steatosis, hepatitis, steatohepatitis, 4159
- Non-B non-C hepatocellular carcinoma, cellular proliferation, tumor size, ki-67, 449
- Non-cancer-specific survival, colon cancer, elderly patients, gRIIm score, postoperative complication, 5643
- Non-clear cell renal cell carcinoma, immune checkpoint inhibitor, 973
- Non-Hodgkin lymphoma, estrogen receptor  $\beta$ , silibinin, diffuse large B-cell lymphoma, cardiomyocytes, doxorubicin, apoptosis, autophagy, 767
- Non-Hodgkin's lymphoma, chemotherapy, medication guidance sheet, adverse events, ESHAP $\pm$ R therapy, 2053
- Non-invasive test, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Non-relapse mortality, multiple myeloma, autologous, allogeneic, stem cell transplantation, overall survival, progression-free survival, relapse incidence, 5825
- Non-small cell carcinoma, adenocarcinoma, chemotherapy, radiotherapy, chest wall, 5539
- Non-small cell lung cancer, chemoimmunotherapy, brain metastasis, radiotherapy, abscopal effect, 4805
- Non-small cell lung cancer, *EGFR* mutations, targeted therapies, epigenetic therapy, 441
- Non-small cell lung cancer, immunotherapy, immune-related adverse events, corticosteroids, 5961
- Non-small cell lung cancer, KAT6A, lysine acetyltransferase, 5731
- Non-small cell lung cancer, malignant melanoma, kidney cancer, systemic therapy, immune checkpoint inhibitor, 3061
- Non-small cell lung cancer, PET/CT, PD-L1, texture analysis, machine learning, 5875
- Non-small cell lung cancer, proton beam therapy, elderly patients, 2953
- Non-small cell lung cancer, sleeve lobectomy, pneumonectomy, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, 3029
- Non-small cell lung cancer, surgery, sarcopenia, postoperative muscle loss, 3159
- Non-small-cell lung cancer, discontinuation, immune checkpoint inhibitor, survival, driver gene mutation, 4589
- Non-small-cell lung cancer, epidermal growth factor receptor, osimertinib, pemetrexed, polo-like kinase 1, 709
- Non-small-cell lung cancer, magnolol, signal transducer and activator of transcription 3, STAT3, nuclear factor kappa B, NF- $\kappa$ B, 3825
- Non-union, clavícula pro humero reconstruction, malignant bone tumor, sarcoma, 2139
- Non-vascularized fibula, bone sarcoma, fibula, limb-sparing procedure, vascularized bone graft, 5443
- Non-Wnt/non-SHH, medulloblastoma, wnt, SHH, review, 2225
- Nonalcoholic fatty liver disease, fructose-containing western diet, hypertension, obesity, physical exercise, circadian rhythm, 609
- Nonalcoholic fatty liver disease, mulberry, stelic animal model, high-fat diet, streptozotocin, nonalcoholic hepatitis, hepatocellular carcinoma, 4055
- Nonalcoholic hepatitis, mulberry, stelic animal model, high-fat diet, streptozotocin, nonalcoholic fatty liver disease, hepatocellular carcinoma, 4055
- Nondysplastic crypts, field cancerization, colon, crypt branching, tubular adenomas, 5891
- Normal ovary, cancer-associated fibroblasts, ovarian cancer, stromal cells, mesenchymal stem cells, 1729
- Normal tissue exposure, delivery accuracy, ear keloid, customized bolus, tomoTherapy, 4411
- Novel anti-pancreatic cancer agent, coumarin derivative, selective cytotoxicity, autophagy, 2835
- NRG1, neurofibromatosis type 1, neurofibroma, plexiform neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, ki-67, 2327

- NRS pain score, cholelithiasis, surgery, IL-18, analgesic doses, 5521
- NSAIDs, *N-Trans-p-coumaroyltyramine*, ER stress, apoptosis, potentiation, breast cancer cells, 1833
- NSCLC, extracellular vesicles, *EGFR-TKI* resistance, t790M/L858R-mutation, 3835
- NSCLC, lung cancer, nivolumab, chemotherapy, overall survival, pemetrexed, taxanes, vinorelbine, 1987
- NSCLC, lung cancer, PD-L1, inflammation, CRP, albumin, haemoglobin, NLR, 1563
- NSCLC, radiotherapy, immunotherapy, SABR, SBRT, review, 2241
- Nuclear factor kappa B, magnolol, non-small-cell lung cancer, signal transducer and activator of transcription 3, STAT3, NF- $\kappa$ B, 3825
- Nuclear factor-kappa B, anticancer drug sensitivity trial, paclitaxel, cetuximab, bortezomib, 4273
- Nude mice, breast osteosarcoma, PDOX, combination therapy, methioninase, rapamycin, efficacy, synergy, Hoffman effect, 5217
- Nude mice, osteosarcoma, PDOX, methionine addiction, Hoffman effect, methioninase, methotrexate, resistance, combination therapy, efficacy, 731
- Nude mouse red fluorescent protein (RFP), pancreatic cancer, patient-derived orthotopic xenograft (PDOX), NOG mouse, lymph-node metastasis, intravital imaging, personalized therapy, drug discovery, 739
- Nutlin-3, esophagus, murine double minute 2, p53, p73, 2875
- Nutrition, colorectal cancer, stage III, prognostic score, 4989
- Nutrition, geriatric nutrition risk index, esophageal cancer, prognostic factor, c-reactive protein, 5999
- Nutritional assessment, inflammation assessment, gastric cancer, review, 5167
- Obesity, fructose-containing western diet, hypertension, nonalcoholic fatty liver disease, physical exercise, circadian rhythm, 609
- Obesity, gastric cancer, intramuscular adipose tissue content, postoperative complication, visceral fat, 4841
- Objective response, lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, child-Pugh, adverse events, progression-free survival, 173
- Observational study, tumor marker, colorectal neoplasms, survival analysis, 3921
- Occult anastomotic leakage, drain fluid culture, gram stain, 3091
- OCT3, multiple myeloma, melphalan, *SLC22A3*, oral mucositis, 385
- Ocular adverse reactions, anticancer drug, Japanese Adverse Drug Event Report, JADER, safety signal, pharmacovigilance database, 4439
- Oesogastric adenocarcinoma, perioperative chemotherapy, oxaliplatin, 185
- Oesophageal cancer, masseter muscle, prognosis, psoas muscle, sarcopenia, 301
- Oesophageal squamous cell carcinoma, neutrophil-to-lymphocyte ratio, trimodal therapy, prognosis, 1499
- Office lighting, ultraviolet Radiation, vitamin D, 25(OH)D, winter, cross-over trial, 5101
- Olaparib, apoptosis, epstein-Barr virus nuclear antigen-1, EBNA-1, ataxia telangiectasia and Rad3 related kinase, ATR, gastric cancer cell, 555
- Older adults, head and neck, chemoradiotherapy, radiotherapy, 3845
- Oligometastasis, stereotactic body radiotherapy, primary lung cancer, re-irradiation, radiation pneumonitis, 2701
- Oligoprogression, checkpoint inhibitors, radiotherapy, abscopal effect, volumetric assessment, 4795
- Oncogenes, scirrhous gastric cancer, intractable cancer, proliferation, molecular target, 5195
- Oncogenic phenotype, ELMO1, prognosis, tumor progression, colorectal neoplasm, 5343
- Oncology, annexin A10, gastric cancer, GI cancer, chemoresistance, 1707
- Oncology, meta-analysis, systematic review, adverse events, asthenia, fatigue, placebo, cancer, randomized trials, CTCAE, review, 45
- Oncology, meta-analysis, systematic review, adverse events, placebo, cancer, randomized trials, CTCAE, medDRA, review, 2805
- OPSCC, oropharyngeal squamous cell carcinoma, human papillomavirus, *Porphyromonas gingivalis*, gingipain, rgp, matrix metalloproteinase, survival analysis, 5415
- Oral cancer cell line, programmed cell death 1 antibody, low-dose topical administration, immune-related adverse events, buccal mucosa, programmed cell death 1-ligand 1, 4293
- Oral cancer cell line, programmed cell death 1 antibody, low-dose topical administration, immune-related adverse events, buccal mucosa, programmed cell death 1-ligand 1, 4293
- Oral cancer, diabetes, public health, smoking, impaired fasting glycemia, 109
- Oral cancer, FEN1, genotype, polymorphism, Taiwan, 4329
- Oral cancer, hand grip force, hand grip strength, head and neck cancer, microvascular reconstruction, 2771
- Oral cancer, head and neck cancer, cancer antigen, human leukocyte antigen class I, cancer vaccines, T cell therapy, 5751
- Oral cancer, radiotherapy, brachytherapy, reirradiation, complication, 293
- Oral cancer, squamous cell carcinoma, pN1, survival, adjuvant radiotherapy, metastatic lymphadenopathy, neck dissection, postoperative radiotherapy, 97

- Oral cavity cancer, machine learning, interpretability, sHapley values, prognosis, 5859
- Oral mucositis, multiple myeloma, melphalan, OCT3, *SLC22A3*, 385
- Oral recombinant methioninase, breast cancer patient, invasive lobular carcinoma, metastasis, methionine PET, METPET, methionine addiction, Hoffman effect, methionine restriction, low-methionine diet, doxorubicin, cyclophosphamide, docetaxel, combination therapy, Hoffman protocol, complete response, 5819
- Oral recombinant methioninase, pancreatic cancer, stage IV, FOLFIRINOX, supplement, combination therapy, stable disease, CA19-9, methionine addiction, Hoffman effect, 2567
- Oral recombinant methioninase, rectal cancer, patient, stable disease, methionine addiction, Hoffman effect, methionine restriction, low-methionine diet, 3857
- Oral rehydration solution (ORS), cisplatin, nephrotoxicity, short hydration, risk factor, 3185
- Oral squamous cell carcinoma, immune checkpoint, tumor-infiltrating lymphocytes, flow cytometry, regulatory T-lymphocytes, 2383
- Oral squamous cell carcinoma, prognostic factors, p16, HPV, adjuvant therapy, 2405
- Oral squamous cell carcinoma, RITA, apoptosis, p53, *MDM2*, 2931
- Oral squamous cell carcinoma, sirtuin, SIRT6, 3815
- Oral treatment, vitamin B12, deficiency, total gastrectomy, gastric cancer, randomized controlled trial, 3963
- Organoid, pancreatic cancer, EUS-FNB, 4103
- Oropharyngeal carcinoma, recurrence detection, surveillance, survival, 5597
- Oropharyngeal squamous cell carcinoma, CD109, prognosis, 2061
- Oropharyngeal squamous cell carcinoma, OPSCC, human papillomavirus, *Porphyromonas gingivalis*, gingipain, rgp, matrix metalloproteinase, survival analysis, 5415
- Orthopedic surgery, bone sarcoma, SEER program, neoplasm grading, hand, treatment outcome, 1635
- Osimertinib, lung cancer, afatinib, T790M, *EGFR* mutation, 2145
- Osimertinib, lung cancer, *EGFR* mutation, PD-L1, 2583
- Osimertinib, non-small-cell lung cancer, epidermal growth factor receptor, pemetrexed, polo-like kinase 1, 709
- Osteoblasts, 3D cell culture, bisphosphonates, PRP, PRF, 1295
- Osteomyelitis, artificial intelligence, ewing sarcoma, tumor detection, early diagnosis, deep learning, transfer learning, 4371
- Osteopenia, pancreaticoduodenectomy, pancreatic fistula, 5971
- Osteosarcoma, bortezomib, everolimus, synergistic effect, compound library, 4319
- Osteosarcoma, bortezomib, everolimus, synergistic effect, compound library, 4319
- Osteosarcoma, high-dose methotrexate (HD-MTX), hepatic dysfunction, clinical study, 1043
- Osteosarcoma, magnolol, ERK, NF- $\kappa$ B, apoptosis, 4403
- Osteosarcoma, metastasis, neutrophil count, platelet-lymphocyte ratio, 1081
- Osteosarcoma, nude mice, PDOX, methionine addiction, Hoffman effect, methioninase, methotrexate, resistance, combination therapy, efficacy, 731
- Outcome, mallampati score, head and neck cancer, chemoradiotherapy, trismus, restricted mouth opening, 5609
- Outcome, pancreatic neuroendocrine tumor, lymph node dissection, 2797
- Outcomes, malignant peritoneal mesothelioma, cytoreductive surgery, HIPEC, survival, 2939
- Ovarian cancer, bevacizumab, brain metastasis, salvage chemotherapy, survival, 2637
- Ovarian cancer, cancer-associated fibroblasts, stromal cells, mesenchymal stem cells, normal ovary, 1729
- Ovarian cancer, carboplatin desensitization, hypersensitivity reactions, criteria for discontinuation, erythema, arms, 1091
- Ovarian cancer, chemotherapy, clinical outcomes, overall survival, progression-free survival, platinum-free interval, platinum resistance, CA-125, 349
- Ovarian cancer, diagnostic biomarker, miRNA, *miR-1*, *miR-21*, 5839
- Ovarian cancer, pap test, liquid Pap specimen, cervical swab, review, 1
- Ovarian cancer, platinum-resistant recurrence, chemotherapy, platinum rechallenge therapy, 4603
- Ovarian cancer, pleural effusion, chemotherapy, overall survival, progression-free survival, 4937
- Ovarian cancer, primary debulking surgery, interval debulking surgery, hyperthermic intraperitoneal chemotherapy, cisplatin, review, 4659
- Ovarian cancer, sarcopenia, skeletal muscle index, skeletal muscle radiation attenuation, 947
- Ovarian cancer, screening, CA125, ultrasound, microRNA, *TP53* clonal variants, review, 4207
- Ovarian cancer, surgery, cytoreduction, ultra-radical, lactate, length of stay, 1979
- Ovarian cancer, tumor marker, nETs, dsDNA, h3Cit-DNA, 965
- Ovarian cancer, vitamin C, hyperthermia, anticancer activity, 5365
- Ovarian neoplasms, adverse drug event, bevacizumab, chemotherapy, gastrointestinal perforation, 4165
- Overall survival, adjuvant chemotherapy, resection, colorectal cancer liver metastases, recurrence, 5497
- Overall survival, advanced ovarian cancer, PCI, CT, complete cytoreductive surgery, 2541
- Overall survival, biomarkers, prognosis, systemic immune-inflammation index, neutrophile-to-lymphocyte ratio, 1911
- Overall survival, bone metastatic castration-resistant prostate cancer, androgen receptor axis targeted agent, docetaxel, cabazitaxel, 1465



- Overall survival, colorectal liver metastasis, lymphocyte-to-C-reactive protein ratio, prognosis, tumour, 4963
- Overall survival, gastric cancer, malnutrition, postoperative complication, prognosis, 4611
- Overall survival, multiple myeloma, autologous, allogeneic, stem cell transplantation, progression-free survival, non-relapse mortality, relapse incidence, 5825
- Overall survival, NSCLC, lung cancer, nivolumab, chemotherapy, pemetrexed, taxanes, vinorelbine, 1987
- Overall survival, ovarian cancer, chemotherapy, clinical outcomes, progression-free survival, platinum-free interval, platinum resistance, CA-125, 349
- Overall survival, ovarian cancer, pleural effusion, chemotherapy, progression-free survival, 4937
- Overall survival, pancreatic adenocarcinoma, infection, antibiotic resistance, bacteriobilia, surgery, 2743
- Overall survival, relative dose intensity, pancreatic ductal adenocarcinoma, adjuvant chemotherapy, S-1, 3133
- Overdiagnosis, melanoma, trends, incidence, mortality, sunburn, review, 5021
- Overlay method, polyphenol, PC12, SH-SY5Y, NGF, neurotoxicity, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- OX-40, immunoadjuvant molecules, breast cancer, pathological complete response, neoadjuvant chemotherapy, LAG-3, TIM-3, 125
- Oxaliplatin, gastric cancer, elderly, capecitabine, chemotherapy, phase 2 trial, 2683
- Oxaliplatin, JAK/STAT, CJ14939, JAK inhibitor, colorectal cancer, 1813
- Oxaliplatin, metastatic colorectal cancer, XELOX therapy, frail patients, 1859
- Oxaliplatin, oesogastric adenocarcinoma, perioperative chemotherapy, 185
- Oxidative stress, chemotherapy, alpha-tocopheryl succinate, apoptosis, 547
- Oxidative stress, chloroquine, doxorubicin, A549 cells, autophagy, apoptosis, caspase, extracellular-signal-regulated kinase, 4025
- P-glycoprotein, ko143, combinatorial treatment, BCRP, drug resistance, temozolomide, 723
- P-gp, jak2, pacritinib, co-treatment, drug resistance, 2433
- P16, oral squamous cell carcinoma, prognostic factors, HPV, adjuvant therapy, 2405
- P16/Ki-67 dual-stained cytology, HPV, cervical cancer, triage, CIN2, CIN3, HSIL, screening, risk stratification, pap test, 2599
- P21, *Asparagus* extract, cancer, mDAPanc-28, pancreatic cancer, P53, FAS, CDK4, 2425
- P38 MAPK, TP53, tumour repopulation, exosomes, bile duct cancer, 745
- P53, *Asparagus* extract, cancer, mDAPanc-28, pancreatic cancer, P21, FAS, CDK4, 2425
- P53, azoxystrobin, cancer, apoptosis, 1307
- P53, endometrial cancer, lymph node metastasis, MMR deficiency, heterogeneity, 4535
- P53, Epstein-Barr virus, advanced gastric cancer, gastric carcinoma with lymphoid stroma, 4955
- P53, esophagus, murine double minute 2, nutlin-3, p73, 2875
- P53, oral squamous cell carcinoma, RITA, apoptosis, MDM2, 2931
- P73, esophagus, murine double minute 2, nutlin-3, p53, 2875
- Paclitaxel, anticancer drug sensitivity trial, cetuximab, bortezomib, nuclear factor-kappa B, 4273
- Paclitaxel, gastric cancer, ramucirumab, nab-paclitaxel, prognosis, 1599
- Paclitaxel, nab-paclitaxel, relapsed tumor, small cell lung cancer, interstitial lung disease, 4921
- Paclitaxel, peripheral neuropathy, gastric neoplasms, survival, 4581
- Pacritinib, jak2, co-treatment, p-gp, drug resistance, 2433
- Pain management, chemotherapy-induced peripheral neuropathy, target therapy, immunotherapy, 4667
- Palbociclib, ER+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, abemaciclib, 1099
- Palliative care, magnetic resonance imaging, lattice radiotherapy, spatially fractionated radiation therapy, gynecological cancer, inoperable bulky tumors, palliative radiotherapy, 4641
- Palliative care, metastasis, prognosis, radiation oncologists, artificial intelligence, 1397
- Palliative care, pancreatic cancer, end-of-life care, service use, place of death, 5457
- Palliative radiation therapy, radiotherapy, bone metastases, brain metastases, prognostic model, comorbidity, 1477
- Palliative radiotherapy, 25 Gy/5 fr, pelvic tumors, 6099
- Palliative radiotherapy, magnetic resonance imaging, lattice radiotherapy, spatially fractionated radiation therapy, gynecological cancer, inoperable bulky tumors, palliative care, 4641
- Pancreas neck cancer, artery resection, artery reconstruction, indocyanine green fluorescence imaging, 217
- Pancreas, pancreatic ductal adenocarcinoma, immunohistochemistry, sulphite oxidase, 4145
- Pancreas, pancreatic intraductal neoplasms, multiparametric magnetic resonance imaging, 3895
- Pancreatectomy, DUPAN-2, pancreatic cancer, recurrence pattern, locoregional recurrence, 2071
- Pancreatectomy, zinc, pancreaticoduodenectomy, 5833
- Pancreatic adenocarcinoma, infection, antibiotic resistance, overall survival, bacteriobilia, surgery, 2743
- Pancreatic adenocarcinoma, metastasis, complement C3a, complement C3a receptor, epithelial-to-mesenchymal transition, 1207



- Pancreatic cancer, adjuvant therapy, gemcitabine, positive peritoneal lavage cytology, postoperative chemotherapy, S-1, 893
- Pancreatic cancer, adoptive immunotherapy (AIT), zoledronate, ZAK cells,  $\gamma\delta$ T cells, 1181
- Pancreatic cancer, *Asparagus* extract, cancer, mDAPanc-28, P21, P53, FAS, CDK4, 2425
- Pancreatic cancer, aspirin, cell cycle, microRNA, 4037
- Pancreatic cancer, distal pancreatectomy, laparoscopic, radical antegrade modular pancreatosplenectomy, robotic, review, 653
- Pancreatic cancer, DUPAN-2, recurrence pattern, locoregional recurrence, pancreatectomy, 2071
- Pancreatic cancer, EUS-FNB, organoid, 4103
- Pancreatic cancer, nateglinide, NO, nitrated compound, apoptosis, 1313
- Pancreatic cancer, palliative care, end-of-life care, service use, place of death, 5457
- Pancreatic cancer, patient-derived orthotopic xenograft (PDOX), NOG mouse, nude mouse red fluorescent protein (RFP), lymph-node metastasis, intravital imaging, personalized therapy, drug discovery, 739
- Pancreatic cancer, PTPN3, proliferation, invasion, MAPK, 2869
- Pancreatic cancer, recombinant thrombomodulin, gemcitabine, GPR15, 4679
- Pancreatic cancer, robot, distal pancreatectomy, surgical approach, splenic artery, 4471
- Pancreatic cancer, second-line chemotherapy, nal-IRI, FOLFIRINOX, peripheral neuropathy, pegfilgrastim, 3889
- Pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, supplement, combination therapy, stable disease, CA19-9, methionine addiction, Hoffman effect, 2567
- Pancreatic carcinoma, pancreatic intraepithelial neoplasia, platelet, lymphocyte, platelet/lymphocyte ratio, sarcopenia, jaundice, 1413
- Pancreatic ductal adenocarcinoma (PDAC), integrin  $\alpha 6$  (ITGA6), splice variant, extracellular vesicles, 1763
- Pancreatic ductal adenocarcinoma, metastasis, complement C3, epithelial-to-mesenchymal transition, 5743
- Pancreatic ductal adenocarcinoma, pancreas, immunohistochemistry, sulphite oxidase, 4145
- Pancreatic ductal adenocarcinoma, patient-derived xenograft, microenvironment, vascular endothelial cells, engraftment rate, 2395
- Pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- Pancreatic ductal adenocarcinoma, relative dose intensity, adjuvant chemotherapy, S-1, overall survival, 3133
- Pancreatic fistula, osteopenia, pancreaticoduodenectomy, 5971
- Pancreatic intraductal neoplasms, pancreas, multiparametric magnetic resonance imaging, 3895
- Pancreatic intraepithelial neoplasia, pancreatic carcinoma, platelet, lymphocyte, platelet/lymphocyte ratio, sarcopenia, jaundice, 1413
- Pancreatic neuroendocrine tumor, lymph node dissection, outcome, 2797
- Pancreatic neuroendocrine tumor, PNET, neuroendocrine carcinoma, surgery, resection, review, 629
- Pancreatic neuroendocrine tumors, effectiveness, everolimus, progression-free survival, real-world study, tolerability, 1941
- Pancreatic resection, hemostasis, interventional radiology, pseudoaneurysm, surgery, 1579
- Pancreaticoduodenectomy, osteopenia, pancreatic fistula, 5971
- Pancreaticoduodenectomy, zinc, pancreatectomy, 5833
- Pancreaticoenterostomy, distal pancreatectomy, postoperative pancreatic fistula (POPF), 4153
- Pap test, HPV, cervical cancer, p16/Ki-67 dual-stained cytology, triage, CIN2, CIN3, HSIL, screening, risk stratification, 2599
- Pap test, ovarian cancer, liquid Pap specimen, cervical swab, review, 1
- Papillary renal cell carcinoma, AXL, immunotherapy, KIT, MET, *VEGFR*, 3151
- Papillary thyroid carcinoma, circulating cell-free DNA, cfDNA integrity index, GAPDH,  $\beta$ -actin, 2289
- Parenchymal suture, renal function, robot-assisted partial nephrectomy, laparoscopic partial nephrectomy, 3055
- Parietal cell antibody, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, intrinsic factor antibody, 1517
- Parotid gland, SMARCB1 gene, cutaneous squamous cell carcinoma, metastasis, 3971
- PARP inhibitors, homologous recombination, chemotherapy, epithelial ovarian cancer, recurrence, 2017
- PARPi, *BRCA* mutation, heterozygosity, talazoparib, predictive marker, 5257
- Partial nephrectomy, scoring systems, t1b renal tumor, surgical complications, 6057
- Pathologic fracture, intramedullary nail, metastatic disease, functional outcomes, 919
- Pathological complete response, immunoadjuvant molecules, breast cancer, neoadjuvant chemotherapy, LAG-3, TIM-3, OX-40, 125
- Pathological fracture, appendicular skeletal metastases, tumor growth speed, impending fracture, prophylactic surgery, 229
- Pathological T3a, prognosis, renal cell carcinoma, tumor size, 2185
- Pathology, SMILE, stratified mucin-producing intraepithelial tumor, cervical tumor, robotic, 1175
- Patient reported outcomes, breast cancer, adjuvant radiotherapy, sleep disorders, prospective trial, 3085
- Patient-derived orthotopic xenograft (PDOX), pancreatic cancer, NOG mouse, nude mouse red fluorescent protein (RFP), lymph-node metastasis, intravital imaging, personalized therapy, drug discovery, 739

- Patient-derived xenograft, gastric tumor xenograft-derived cell line, gastric cancer, drug screening, high-throughput screening, 2883
- Patient-derived xenograft, invasive papillary cholangiocarcinoma, preclinical model, 599
- Patient-derived xenograft, pancreatic ductal adenocarcinoma, microenvironment, vascular endothelial cells, engraftment rate, 2395
- Patient, rectal cancer, stable disease, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, 3857
- PBMCs, natural killer cells, lysis, NK-92, K562, 4259
- PC12, polyphenol, SH-SY5Y, NGF, overlay method, neurotoxicity, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- PCa staging, prostate cancer, <sup>68</sup>Ga-PSMA PET/CT, bone scan, 1495
- PCI, advanced ovarian cancer, CT, complete cytoreductive surgery, overall survival, 2541
- PCNSL, elderly, CMT, chemotherapy, radiation, 1867
- PCR, rectal cancer, survival, metastasis; oxaliplatin, radiotherapy, total neoadjuvant therapy, 991
- PD-1 inhibitor, head and neck cancer, salivary gland carcinoma, PD-L1, mismatch repair protein, 981
- PD-1, endometrium cancer, PD-L1, immune checkpoint, prognostic factor, targeted therapy, 1367
- PD-1/PDL-1, nivolumab, advanced cancer, immunotherapy, checkpoint inhibitors, CTLA-4, 1433
- PD-L1, cancer cell, circulating tumor cell, liquid biopsy, microfluidic chip cell sorter, multistep sorting, 407
- PD-L1, cfDNA, LDH, VEGF, tumour-burden, 801
- PD-L1, endometrium cancer, PD-1, immune checkpoint, prognostic factor, targeted therapy, 1367
- PD-L1, head and neck cancer, salivary gland carcinoma, PD-1 inhibitor, mismatch repair protein, 981
- PD-L1, lung cancer, *EGFR* mutation, osimertinib, 2583
- PD-L1, nivolumab, recurrent/metastatic head and neck cancer, TPS, CPS, 1547
- PD-L1, non-small cell lung cancer, PET/CT, texture analysis, machine learning, 5875
- PD-L1, NSCLC, lung cancer, inflammation, CRP, albumin, haemoglobin, NLR, 1563
- PDAC, pancreatic ductal adenocarcinoma, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- PDOX, breast osteosarcoma, nude mice, combination therapy, methioninase, rapamycin, efficacy, synergy, Hoffman effect, 5217
- PDOX, osteosarcoma, nude mice, methionine addiction, Hoffman effect, methioninase, methotrexate, resistance, combination therapy, efficacy, 731
- PDTC, thyroid cancer, poorly differentiated thyroid cancers, 2531
- Pegfilgrastim, esophageal cancer, neoadjuvant chemotherapy, febrile neutropenia, predictive factors, neutrophil count, 6071
- Pegfilgrastim, pancreatic cancer, second-line chemotherapy, nal-IRI, FOLFIRINOX, peripheral neuropathy, 3889
- Pegylated liposomal doxorubicin, platinum refractory/ resistant, recurrent ovarian cancer, CA125, 3017
- Pelvic tumors, palliative radiotherapy, 25 Gy/5 fr, 6099
- Pelvis, radiation, proctitis, cancer, 5951
- Pembrolizumab, proton pump inhibitors, urothelial carcinoma, gut microbiota, immune checkpoint inhibitors, antibiotics, 1629
- Pembrolizumab, recurrent/metastatic squamous cell carcinoma, head and neck, programmed cell death protein 1, 4475
- Pembrolizumab, recurrent/metastatic squamous cell carcinoma, head and neck, programmed cell death protein 1, 4477
- Pembrolizumab, urothelial cancer, neutrophil-lymphocyte ratio, NLR, lactate dehydrogenase, LDH, c-reactive protein, CRP, immune checkpoint inhibitor, predictive factor, 2045
- Pembrolizumab, urothelial carcinoma, platelet-to-lymphocyte ratio, 1131
- Pemetrexed, non-small-cell lung cancer, epidermal growth factor receptor, osimertinib, polo-like kinase 1, 709
- Pemetrexed, NSCLC, lung cancer, nivolumab, chemotherapy, overall survival, taxanes, vinorelbine, 1987
- Pentoxifylline (PTX), colon cancer, tumor markers, cytokines, 5487
- Pepsinogen, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Perioperative chemotherapy, oesogastric adenocarcinoma, oxaliplatin, 185
- Peripheral blood biomarker, advanced breast cancer, CDK4/6 inhibitor, absolute lymphocyte count, prognostic factor, 4867
- Peripheral edema, hepatitis C virus, ritonavir, CYP3A4, calcium channel blockers, amlodipine, 2087
- Peripheral neuropathy, paclitaxel, gastric neoplasms, survival, 4581
- Peripheral neuropathy, pancreatic cancer, second-line chemotherapy, nal-IRI, FOLFIRINOX, pegfilgrastim, 3889
- Peritoneal cancer index, advanced ovarian cancer, complete surgery, primary debulking surgery, predictive index value, 115
- Peritoneal cancer index, high grade ovarian cancer, cytoreduction, surgical complexity, 4825
- Peritoneal cancer index, second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, colorectal, completeness of cytoreduction, 1001
- Peritoneal carcinomatosis, second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, appendiceal, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001

- Peritoneal lavage fluid, gastric cancer, peritoneal recurrence, *KRT20*, *CEACAM6*, 4003
- Peritoneal metastasis, pressurized intraperitoneal aerosol chemotherapy, survey, clinical desire, prerequisite, cost, 363
- Peritoneal recurrence, gastric cancer, *KRT20*, *CEACAM6*, peritoneal lavage fluid, 4003
- Peritonectomy, colorectal, appendiceal, adenocarcinoma, carcinoembryonic antigen, review, 4217
- Peritonectomy, second-look surgery, stoma-reversal, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001
- Permanent section diagnosis, breast cancer, breast-conserving surgery, gross evaluation, frozen section analysis, 4453
- Personalized therapy, pancreatic cancer, patient-derived orthotopic xenograft (PDOX), NOG mouse, nude mouse red fluorescent protein (RFP), lymph-node metastasis, intravital imaging, drug discovery, 739
- PET, cancer, esophagus, neoadjuvant therapy, surgery, survival, 6037
- PET/CT scan, <sup>68</sup>Ga-DOTATOC, gamma-knife radiosurgery, incidentaloma, meningioma, neuroendocrine tumor, 5867
- PET/CT, non-small cell lung cancer, PD-L1, texture analysis, machine learning, 5875
- PGE2, colon cancer, metastasis, 15-PGDH, epithelial-to-mesenchymal transition, 5385
- PH-responsive, micelles, three-dimensional cell culture, tumor microenvironment, anti-fibrotic drug, tumor-bearing mice, 2847
- Pharmacokinetics, vitamin D, 25-hydroxyvitamin D, clinical trial, intestinal absorption, 5095
- Pharmacological inhibition, p13KC2 $\beta$ , cell proliferation, migration, acute leukemia, brain tumours, neuroendocrine tumours, 3217
- Pharmacovigilance database, anticancer drug, ocular adverse reactions, japanese Adverse Drug Event Report, JADER, safety signal, 4439
- Pharyngeal squamous cell carcinoma, positron emission tomography-computed tomography, synchronous esophageal cancer, clinical T classification, detectability, 4597
- Phase 2 trial, gastric cancer, elderly, oxaliplatin, capecitabine, chemotherapy, 2683
- Phase I, CAR-T, clinical trial, study design, dose escalation, reporting, review, 5673
- Phenotype profile analysis, circulating tumor cells, microfluidic, epithelial mesenchymal transition, 4345
- Pheochromocytoma, neurofibromatosis type I, van Recklinghausen's disease, pregnancy, 4647
- Photodynamic therapy, actinic keratosis, adverse events, protoporphyrin IX, skin, review, 5017
- Photosynthetic bacteria, photosynthesis, plants, algae, cyanobacteria, chlorophyll, electron transport chain, aTPase, calvin cycle, 5035
- Physical exercise, fructose-containing western diet, hypertension, nonalcoholic fatty liver disease, obesity, circadian rhythm, 609
- PI3KC2 $\beta$ , pharmacological inhibition, cell proliferation, migration, acute leukemia, brain tumours, neuroendocrine tumours, 3217
- Pilot study, cancer treatment, radiotherapy, distress levels, elderly patients, 5561
- Pineal region glioma, glioma, pineal region tumors, systematic review, 1189
- Pistachios, mixed nuts, colon cell proliferation, 8-oxo-deoxyguanosine, cyclooxygenase 2, 4285
- Place of death, pancreatic cancer, palliative care, end-of-life care, service use, 5457
- Placebo, meta-analysis, systematic review, adverse events, asthenia, fatigue, cancer, oncology, randomized trials, CTCAE, review, 45
- Placebo, meta-analysis, systematic review, adverse events, cancer, oncology, randomized trials, CTCAE, medDRA, review, 2805
- Plan complexity, knowledge-based treatment planning, VMAT, delivery accuracy, prostate cancer, 5305
- Plant derived polyphenols, colorectal carcinoma therapy, anti-angiogenic drug, trans-resveratrol, quercetin, vitamin E, selenium, dogs, 4763
- Plant-derived compounds, lung cancer, cancer stem cell, anticancer, review, 4247
- Plants, photosynthesis, algae, photosynthetic bacteria, cyanobacteria, chlorophyll, electron transport chain, aTPase, calvin cycle, 5035
- Plasma markers, colorectal cancers, H19, LINC00675, lncRNA, 1301
- Platelet-lymphocyte ratio, osteosarcoma, metastasis, neutrophil count, 1081
- Platelet-to-lymphocyte ratio, biomarker, esophageal squamous cell carcinoma, 2775
- Platelet-to-lymphocyte ratio, non-small cell lung cancer, sleeve lobectomy, pneumonectomy, neutrophil-to-lymphocyte ratio, 3029
- Platelet-to-lymphocyte ratio, pembrolizumab, urothelial carcinoma, 1131
- Platelet, pancreatic intraepithelial neoplasia, pancreatic carcinoma, lymphocyte, platelet/lymphocyte ratio, sarcopenia, jaundice, 1413
- Platelet/lymphocyte ratio, pancreatic intraepithelial neoplasia, pancreatic carcinoma, platelet, lymphocyte, sarcopenia, jaundice, 1413
- Platinum rechallenge therapy, ovarian cancer, platinum-resistant recurrence, chemotherapy, 4603
- Platinum refractory/ resistant, pegylated liposomal doxorubicin, recurrent ovarian cancer, CA125, 3017

- Platinum resistance, ovarian cancer, chemotherapy, clinical outcomes, overall survival, progression-free survival, platinum-free interval, CA-125, 349
- Platinum-based chemotherapy pembrolizumab, advanced urothelial carcinoma, real-world clinical practice, 1571
- Platinum-refractory, nivolumab, squamous cell carcinoma, head and neck, platinum-sensitive, 4907
- Platinum-resistant recurrence, ovarian cancer, chemotherapy, platinum rechallenge therapy, 4603
- Platinum-resistant recurrence, ovarian cancer, chemotherapy, platinum rechallenge therapy, 4603
- Platinum-sensitive, nivolumab, squamous cell carcinoma, head and neck, platinum-refractory, 4907
- Platinum, lymphoid malignancies, gene-expression analysis, copy-number deletions, 1821
- Platinum/5-fluorouracil, esophageal cancer, geriatric oncology, trimodality therapy, carboplatin/paclitaxel, 59
- Pleural effusion, ovarian cancer, chemotherapy, overall survival, progression-free survival, 4937
- Plexiform neurofibroma, neurofibromatosis type 1, central giant cell granuloma, rASopathy, root resorption, 2945
- Plexiform neurofibroma, neurofibromatosis type 1, cephalometry, symmetry, bone, facial skeleton, 2607
- Plexiform neurofibroma, neurofibromatosis type 1, neurofibroma, diffuse plexiform neurofibroma, classification, 1247
- Plexiform neurofibroma, neurofibromatosis type 1, neurofibroma, diffuse plexiform neurofibroma, neurofibroma classification, malignant peripheral nerve sheath tumor, ERBB2, ERBB3, NRG1, ki-67, 2327
- PLX4032, BRAF V600E, imidazothiazole, chemoresistance, activator protein-1, melanoma, 2911
- PME, rectal cancer, neoadjuvant chemoradiotherapy, upper rectum, sigmoid cancer, 155
- PMI, squamous cell carcinoma of the cervix, concurrent chemoradiotherapy, sarcopenia, SMI, 4887
- PN1, squamous cell carcinoma, oral cancer, survival, adjuvant radiotherapy, metastatic lymphadenopathy, neck dissection, postoperative radiotherapy, 97
- PNET, pancreatic neuroendocrine tumor, neuroendocrine carcinoma, surgery, resection, review, 629
- Pneumonectomy, non-small cell lung cancer, sleeve lobectomy, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, 3029
- Pneumonitis, radiotherapy, lung cancer, risk factors, prognostic tool, 2029
- Polo-like kinase 1, non-small-cell lung cancer, epidermal growth factor receptor, osimertinib, pemetrexed, 709
- POLR2A, sarcomatoid renal cell carcinoma, RUNX2, micro-RNA378a-3p, ERK2 (MAPK1), 811
- Polycomb protein, BMI-1, mucinous ovarian carcinoma, chemoresistance, cancer stem cell, 1739
- Polymorphism, alcohol drinking, colorectal cancer, genotype, *MMP2*, metastasis, Taiwan, 5335
- Polymorphism, breast cancer, genotype, interleukin-8, Taiwan, 3799
- Polymorphism, childhood ALL, genotype, IL-18, Taiwan, 5283
- Polymorphism, colorectal cancer, genotype, *MTRR*, Taiwan, 2375
- Polymorphism, FEN1, genotype, oral cancer, Taiwan, 4329
- Polymorphism, gastric cancer, genotype, *MMP-2*, Taiwan, 1749
- Polymorphism, genotype, hepatocellular carcinoma, *MMP-7*, HCC, Taiwan, 5275
- Polymorphism, genotype, interleukin-8, lung cancer, Taiwan, 1229
- Polymorphism, x-Chromosome, x-linked, cancer, gender dimorphism, review, 2261
- Polymorphous adenocarcinoma, salivary gland tumor, polymorphous low-grade adenocarcinoma, PRKD1, cribriform adenocarcinoma of salivary glands, molecular diagnostics, 1455
- Polymorphous low-grade adenocarcinoma, salivary gland tumor, polymorphous adenocarcinoma, PRKD1, cribriform adenocarcinoma of salivary glands, molecular diagnostics, 1455
- Polyphenol, PC12, SH-SY5Y, NGF, overlay method, neurotoxicity, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- Polyphosphoesters, amphiphilic polymers, drug delivery, drug carriers, doxorubicin, 1801
- Poorly differentiated adenocarcinoma, adjuvant chemotherapy, invasive IPMC, lymph node metastasis, tubular type, 2645
- Poorly differentiated thyroid cancers, thyroid cancer, PDTTC, 2531
- Population-based, conventional fractionated radiotherapy, neoadjuvant long course, chemoradiotherapy, radiotherapy dose escalation, locally advanced rectal cancer, 1143
- Population, sacral, chordoma, survival, SEER, cancer, 929
- Porphyromonas gingivalis*, oropharyngeal squamous cell carcinoma, OPSCC, human papillomavirus, gingipain, rgp, matrix metalloproteinase, survival analysis, 5415
- Portal vein embolization, postoperative liver failure, hepatocellular carcinoma, right hepatectomy, mortality, 4089
- Positive nodes, nodal ratio, lymph nodes, head and neck cancer, 5567
- Positive peritoneal lavage cytology, adjuvant therapy, gemcitabine, pancreatic cancer, postoperative chemotherapy, S-1, 893
- Positron emission tomography-computed tomography, synchronous esophageal cancer, pharyngeal squamous cell carcinoma, clinical T classification, detectability, 4597
- Post anticancer therapy, transbronchial microwave ablation, stent placement, moderate sedation, 3125
- Post-progression survival, hepatocellular carcinoma, tyrosine kinase inhibitor, lenvatinib, sorafenib, sequential therapy, 6007
- Post-transplant lymphoproliferative disorders, epstein-Barr virus, primary central nervous lymphoma, glioblastoma, 3975







- Primate biology, recommended daily intake, RDA, clinical trial study design, evidence-based medicine, public health, primary disease prevention, COVID-19, evolution, vitamin D toxicity, review, 5027
- PRKAR1A, carney complex, fibroma, myxoma, neurofibroma, melanoma, cerebello-pontine angle, 6121
- PRKD1, salivary gland tumor, polymorphous adenocarcinoma, polymorphous low-grade adenocarcinoma, cribriform adenocarcinoma of salivary glands, molecular diagnostics, 1455
- PRKR-interacting protein 1, colorectal cancer, prognostic biomarker, 4701
- Pro-GA,  $\gamma$ -glutamylcyclotransferase, n-acetylcysteine, reactive oxygen species, cyclin-dependent kinase inhibitors, breast cancer, 4311
- Proctitis, radiation, pelvis, cancer, 5951
- Progeny virus, adenovirus vector, adenovirus death protein, cytopathic effect, 1719
- Prognosis, biomarkers, overall survival, systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, 1911
- Prognosis, breast cancer, immunohistochemistry, 279
- Prognosis, breast cancer, thyroid hormones, carcinoma *in situ*, multifocal/multicentric tumors, lymphovascular invasion, proliferation, 253
- Prognosis, breast, receptor-interacting serine/threonine-protein kinase 3, immunohistochemistry, triple-negative breast carcinoma, 2753
- Prognosis, carcinoma, renal cell, multivariate analysis, neoplasm grading, nephrectomy, 2967
- Prognosis, CD109, oropharyngeal squamous cell carcinoma, 2061
- Prognosis, colorectal liver metastasis, lymphocyte-to-C-reactive protein ratio, overall survival, tumour, 4963
- Prognosis, death receptor 6, glioma, low-grade glioma, survival, tumor necrosis factor receptor 21, 1237
- Prognosis, ELMO1, oncogenic phenotype, tumor progression, colorectal neoplasm, 5343
- Prognosis, gastric cancer, conversion surgery, 1541
- Prognosis, gastric cancer, malnutrition, overall survival, postoperative complication, 4611
- Prognosis, gastric cancer, ramucirumab, paclitaxel, nab-paclitaxel, 1599
- Prognosis, hepatocellular carcinoma, m2BPGi, sustained viral response, 245
- Prognosis, hepatocellular carcinoma, recurrent patients, repeat hepatectomy, 4553
- Prognosis, lung neoplasms, epidermal growth factor receptor, afatinib, 1615
- Prognosis, metastasis, radiation oncologists, palliative care, artificial intelligence, 1397
- Prognosis, neutrophil-to-lymphocyte ratio, oesophageal squamous cell carcinoma, trimodal therapy, 1499
- Prognosis, oesophageal cancer, masseter muscle, psoas muscle, sarcopenia, 301
- Prognosis, oral cavity cancer, machine learning, interpretability, sHapley values, 5859
- Prognosis, pathological T3a, renal cell carcinoma, tumor size, 2185
- Prognosis, rectal cancer, neoadjuvant chemotherapy, adjuvant chemotherapy, 1527
- Prognosis, squamous differentiation, urothelial carcinoma, upper urinary tract cancer, radical nephroureterectomy, 263
- Prognosis, thymidine kinase 1, soft tissue sarcomas, proliferation, 1509
- Prognostic biomarker, guanylate-binding protein 2, expression, clear-cell renal cell carcinoma, 2341
- Prognostic biomarker, pPRKR-interacting protein 1, colorectal cancer, 4701
- Prognostic factor, advanced breast cancer, CDK4/6 inhibitor, peripheral blood biomarker, absolute lymphocyte count, 4867
- Prognostic factor, breast cancer, DYRK2, TERT, 2079
- Prognostic factor, colorectal liver metastasis, lymph node metastasis, N factor, TNM classification, 1997
- Prognostic factor, concurrent chemoradiotherapy, squamous cell carcinoma, head and neck, TPF, 6047
- Prognostic factor, endometrium cancer, PD-L1, PD-1, immune checkpoint, targeted therapy, 1367
- Prognostic factor, esophageal cancer, systemic inflammation score, curative surgery, 2711
- Prognostic factor, esophageal squamous cell carcinoma, chemotherapy, no residual tumor, 195
- Prognostic factor, gastric cancer, 14-3-3 sigma protein, cell proliferation, tumor progression, metastasis, 519
- Prognostic factor, geriatric nutrition risk index, esophageal cancer, nutrition, c-reactive protein, 5999
- Prognostic factor, hepatocellular carcinoma, mALBI grade, stereotactic body radiotherapy, 5001
- Prognostic factors, oral squamous cell carcinoma, p16, HPV, adjuvant therapy, 2405
- Prognostic instrument, radiotherapy, lung cancer, discontinuation of treatment, risk factors, 1973
- Prognostic marker, breast cancer, CD58, cancer stem cell, ALDH1, basal-like, luminal, 5223
- Prognostic marker, copine 1, renal cell carcinoma, immunohistochemistry, bioinformatics, 355
- Prognostic marker, tumor-infiltrating lymphocytes, neoadjuvant chemotherapy, breast cancer, fibrotic foci, 1421
- Prognostic markers, renal cell carcinoma, miRNA, transcription factor, tissue expression, 2355
- Prognostic model, palliative radiation therapy, radiotherapy, bone metastases, brain metastases, comorbidity, 1477
- Prognostic nutrition index, lenvatinib, hepatocellular carcinoma, therapeutic response, 6019
- Prognostic score, colorectal cancer, stage III, nutrition, 4989
- Prognostic tool, head-and-neck cancer, radiotherapy, late xerostomia, treatment planning, 3035

- Prognostic tool, radiotherapy, lung cancer, pneumonitis, risk factors, 2029
- Prognostic value, *in silico* analysis, TCGA, gene expression, 9p, 9p22.1 locus, 5291
- Programmed cell death 1 antibody, low-dose topical administration, immune-related adverse events, buccal mucosa, oral cancer cell line, programmed cell death 1-ligand 1, 4293
- Programmed cell death 1 antibody, low-dose topical administration, immune-related adverse events, buccal mucosa, oral cancer cell line, programmed cell death 1-ligand 1, 4293
- Programmed cell death 1-ligand 1, programmed cell death 1 antibody, low-dose topical administration, immune-related adverse events, buccal mucosa, oral cancer cell line, 4293
- Programmed cell death protein 1, recurrent/metastatic squamous cell carcinoma, head and neck, pembrolizumab, 4475
- Progression-free survival, effectiveness, everolimus, pancreatic neuroendocrine tumors, real-world study, tolerability, 1941
- Progression-free survival, eribulin, absolute lymphocyte count, advanced or metastatic breast cancer, tumor immunology, 939
- Progression-free survival, lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, child-Pugh, adverse events, objective response, 173
- Progression-free survival, multiple myeloma, autologous, allogeneic, stem cell transplantation, overall survival, non-relapse mortality, relapse incidence, 5825
- Progression-free survival, ovarian cancer, chemotherapy, clinical outcomes, overall survival, platinum-free interval, platinum resistance, CA-125, 349
- Progression-free survival, ovarian cancer, pleural effusion, chemotherapy, overall survival, 4937
- Progression-free survival, recurrence of ovarian cancer, primary debulking surgery, interval debulking surgery, metastasis, 2003
- Progressive disease, nivolumab, tolerability, disease control, immune-related adverse events, 4973
- Project HOPE, tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs), automatic measurement, imaging analysis software, digital pathology, 419
- Proliferation, breast cancer, thyroid hormones, carcinoma *in situ*, multifocal/multicentric tumors, lymphovascular invasion, prognosis, 253
- Proliferation, cancer-associated fibroblasts, scirrhous-type gastric cancer, dipeptidyl peptidase-4, cancer microenvironment, 501
- Proliferation, liver cancer, microRNA-1303, TLN1, migration, invasion, 4715
- Proliferation, mangosteen, cervical cancer, apoptosis, 2903
- Proliferation, PTPN3, pancreatic cancer, invasion, MAPK, 2869
- Proliferation, scirrhous gastric cancer, intractable cancer, oncogenes, molecular target, 5195
- Proliferation, thymidine kinase 1, soft tissue sarcomas, prognosis, 1509
- Propensity score, adjuvant concurrent chemoradiotherapy, adjuvant chemotherapy, resection margin, 3195
- Prophylactic surgery, appendicular skeletal metastases, tumor growth speed, pathological fracture, impending fracture, 229
- Prospective study, predictive biomarker, high-grade glioma, glioblastoma, magnetic resonance spectroscopic imaging, 2665
- Prospective trial, breast cancer, adjuvant radiotherapy, sleep disorders, patient reported outcomes, 3085
- Prostate cancer radiotherapy, quality of life, acute side-effects, stereotactic body radiotherapy, rectal displacement device, 2553
- Prostate cancer, <sup>68</sup>Ga-PSMA PET/CT, bone scan, pCa staging, 1495
- Prostate cancer, <sup>68</sup>Ga-PSMA PET/CT, mpMRI, targeted prostate biopsy, 3011
- Prostate cancer, biochemical recurrent prostate cancer, radiotherapy timing, adjuvant radiotherapy, salvage radiotherapy, 2997
- Prostate cancer, bone metastases, androgen receptor-targeted agents, vintage hormone therapy, 3099
- Prostate cancer, cutaneous adverse event, drug eruption, apalutamide, body weight, maculopapular eruption, 2023
- Prostate cancer, hormone-sensitive, androgen-deprivation therapy, survival, prostate-specific antigen, 1107
- Prostate cancer, kindlin-3, immune cells, tumor growth, xenograft model, 1217
- Prostate cancer, knowledge-based treatment planning, VMAT, plan complexity, delivery accuracy, 5305
- Prostate cancer, metastatic castration-sensitive prostate cancer, mCSPC, PSA response, first-line therapy, 165
- Prostate cancer, neuroendocrine prostate cancer, small cell carcinoma, somatostatin receptor scintigraphy, liver metastasis, 2167
- Prostate cancer, radiotherapy, quality of life, docetaxel, 87
- Prostate-specific antigen, ethinylestradiol, ra-223, castration resistant prostate cancer, 1065
- Prostate-specific antigen, prostate cancer, hormone-sensitive, androgen-deprivation therapy, survival, 1107
- Protective factors, colorectal cancer patients, elderly, postoperative complications, risk factors, 1123
- Protein kinases, DYRK1A protein, DYRK1B protein, endoplasmic reticulum stress, autophagy, colorectal cancer, 589
- Proton beam therapy, elderly patients, non-small cell lung cancer, 2953
- Proton pump inhibitors, capecitabine, hand-foot syndrome, prevention strategies, 2591
- Proton pump inhibitors, urothelial carcinoma, gut microbiota, pembrolizumab, immune checkpoint inhibitors, antibiotics, 1629

- Protoporphyrin IX, actinic keratosis, adverse events, photodynamic therapy, skin, review, 5017
- Proximal colon, fecal immunochemical test, FIT, colorectal cancer screening, ROC, distal colon, 1879
- PRP, 3D cell culture, osteoblasts, bisphosphonates, PRF, 1295
- PSA decline, sequential therapy, enzalutamide, abiraterone, CRPC, 3041
- PSA response, prostate cancer, metastatic castration-sensitive prostate cancer, mCSPC, first-line therapy, 165
- Pseudoaneurysm, hemostasis, interventional radiology, pancreatic resection, surgery, 1579
- Psoas muscle, oesophageal cancer, masseter muscle, prognosis, sarcopenia, 301
- Psoralen, linear furocoumarin, antiproliferative activity, HL60 cells, structure and activity relationship, 1777
- Psycho-social, gastrointestinal stromal tumours, tyrosine kinase inhibitors, imatinib, discontinuation, qualitative research, side-effects, hope, 955
- PTBD, malignant biliary obstruction, 4063
- PTEN* hamartoma tumor syndrome, minimally invasive follicular thyroid carcinoma, *PTEN* gene mutation, cowden syndrome, *RECQL4* gene, germline mutation, surveillance, 1481
- PTLD, lymphoproliferative disorder, transplantation, EBV, CAR-T, review, 5181
- PTPN3, pancreatic cancer, proliferation, invasion, MAPK, 2869
- Public health, diabetes, oral cancer, smoking, impaired fasting glycemia, 109
- Public health, recommended daily intake, RDA, clinical trial study design, evidence-based medicine, primary disease prevention, COVID-19, evolution, primate biology, vitamin D toxicity, review, 5027
- Publication bias, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, effect size, review, 1679
- Pulmonary metastasis, microwave ablation, radiofrequency ablation, colorectal cancer, 4563
- Py, adjuvant radiation therapy, locoregional radiotherapy, breast cancer, toxicity, side-effects, 923
- Qualitative research, gastrointestinal stromal tumours, tyrosine kinase inhibitors, imatinib, discontinuation, side-effects, psycho-social, hope, 955
- Quality of life, prostate cancer radiotherapy, acute side-effects, stereotactic body radiotherapy, rectal displacement device, 2553
- Quality of life, radiotherapy, metastatic urothelial carcinoma, review, 3767
- Quality of life, radiotherapy, prostate cancer, docetaxel, 87
- Quercetin, colorectal carcinoma therapy, anti-angiogenic drug, plant derived polyphenols, trans-resveratrol, vitamin E, selenium, dogs, 4763
- R0 resection, indocyanine green, ICG, fluorescence-guided surgery, radiofrequency ablation, liver tumors, local recurrence, salvage hepatectomy, tumor margins, 1345
- Ra-223, ethinylestradiol, castration resistant prostate cancer, prostate-specific antigen, 1065
- Rab11, melanoma, leukemia, cancer cell migration, rhoGTPase, rac, rhoGAP, recycling endosome, actin cytoskeleton, 5763
- Rabbit models, loco-regional therapy, <sup>90</sup>Y-microspheres, 827
- Rac, melanoma, leukemia, cancer cell migration, rhoGTPase, rhoGAP, rab11, recycling endosome, actin cytoskeleton, 5763
- Race, adrenocortical carcinoma, ACC, hispanics, 5579
- Radiation oncologists, metastasis, prognosis, palliative care, artificial intelligence, 1397
- Radiation pneumonitis, stereotactic body radiotherapy, primary lung cancer, oligometastasis, re-irradiation, 2701
- Radiation therapy, gliomas, brain tumors, temozolomide, diffusion tensor imaging, 329
- Radiation, FLASH, ultra-high dose rate, carbon ions, cancer, fibroblast, 2469
- Radiation, head and neck cancer, survivorship care plans, hypothyroidism, thyroid stimulating hormone, disparities, 4429
- Radiation, PCNSL, elderly, CMT, chemotherapy, 1867
- Radiation, proctitis, pelvis, cancer, 5951
- Radical antegrade modular pancreatectomy, distal pancreatectomy, laparoscopic, pancreatic cancer, robotic, review, 653
- Radical cholecystectomy, gallbladder cancer, laparoscopic whole-layer cholecystectomy, laparoscopic gallbladder bed resection, 903
- Radical nephroureterectomy, squamous differentiation, urothelial carcinoma, upper urinary tract cancer, prognosis, 263
- Radio-chemotherapy, esophageal cancer, adenocarcinoma of the esophagogastric junction, sleep problems, prevalence, risk factors, 4529
- Radio-chemotherapy, head-and-neck cancer, radiotherapy, xerostomia, risk factors, 2657
- Radiofrequency ablation, indocyanine green, ICG, fluorescence-guided surgery, liver tumors, local recurrence, salvage hepatectomy, tumor margins, R0 resection, 1345
- Radiofrequency ablation, microwave ablation, pulmonary metastasis, colorectal cancer, 4563
- Radiography, faxitron, intra operative mammography, BCS, 1925
- Radiosensitivity, cell cycle, fucci, G1 phase, G2 arrest, DNA damage repair, 5407
- Radiosensitizer, hepatocellular carcinoma, metformin, radiotherapy, neutron, xenograft, 867
- Radiosurgery, very elderly patients, brain metastases, fractionated stereotactic radiotherapy, survival score, 5629
- Radiotherapy dose escalation, conventional fractionated radiotherapy, neoadjuvant long course, chemoradiotherapy, population-based, locally advanced rectal cancer, 1143

- Radiotherapy timing, prostate cancer, biochemical recurrent prostate cancer, adjuvant radiotherapy, salvage radiotherapy, 2997
- Radiotherapy, breast cancer, cardiac biomarkers, ECG, echocardiography, 2519
- Radiotherapy, breast cancer, myocardial imaging, cyclic variation of the integrated backscatter, speckle tracking echocardiography, global longitudinal strain, 2507
- Radiotherapy, breast, carcinoma, hypofractionation, mastectomy, segmental, 53
- Radiotherapy, breast, carcinoma, mastectomy, segmental, 93
- Radiotherapy, cancer treatment, distress levels, elderly patients, pilot study, 5561
- Radiotherapy, checkpoint inhibitors, oligoprogression, abscopal effect, volumetric assessment, 4795
- Radiotherapy, chemoimmunotherapy, brain metastasis, non-small cell lung cancer, abscopal effect, 4805
- Radiotherapy, esophageal cancer, T4, elderly, 2095
- Radiotherapy, head and neck cancer, cisplatin, HPV, SIB, IMRT, toxicity, 5909
- Radiotherapy, head and neck cancer, glottic carcinoma, chemoradiotherapy, laryngeal preservation, elective nodal irradiation, 205
- Radiotherapy, head and neck cancer, hearing loss, cisplatin, concomitant treatment, toxicity, cochlea, constraints, dose, 3003
- Radiotherapy, head and neck cancer, intensity modulated radiation therapy, hypofractionation, toxicity, 1845
- Radiotherapy, head and neck, chemoradiotherapy, older adults, 3845
- Radiotherapy, head-and-neck cancer, late xerostomia, prognostic tool, treatment planning, 3035
- Radiotherapy, head-and-neck cancer, radio-chemotherapy, xerostomia, risk factors, 2657
- Radiotherapy, hepatocellular carcinoma, metformin, neutron, radiosensitizer, xenograft, 867
- Radiotherapy, immunotherapy, NSCLC, SABR, SBRT, review, 2241
- Radiotherapy, leiomyosarcoma, brachytherapy, soft-tissue sarcoma, extremity, multicentric analysis, 4485
- Radiotherapy, leptomeningeal metastases, spine metastases, spine surgery, spine tumors, systematic review, 619
- Radiotherapy, lung cancer, discontinuation of treatment, risk factors, prognostic instrument, 1973
- Radiotherapy, lung cancer, lung metastasis, stereotactic body radiotherapy, syncTraX, real-time tumor tracking system, RTRT, 2989
- Radiotherapy, lung cancer, pneumonitis, risk factors, prognostic tool, 2029
- Radiotherapy, metastatic urothelial carcinoma, quality of life, review, 3767
- Radiotherapy, nausea, vomiting, cervical cancer, cisplatin, 3117
- Radiotherapy, non-small cell carcinoma, adenocarcinoma, chemotherapy, chest wall, 5539
- Radiotherapy, oral cancer, brachytherapy, reirradiation, complication, 293
- Radiotherapy, palliative radiation therapy, bone metastases, brain metastases, prognostic model, comorbidity, 1477
- Radiotherapy, prostate cancer, quality of life, docetaxel, 87
- Radiotherapy, rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, neoadjuvant radiotherapy, short-course radiotherapy, capecitabine, S-1, chemotherapy, 5587
- Radiotherapy, rectal cancer, colorectal surgery, low anastomoses, laparoscopic surgery, indocyanine green, 211
- Radiotherapy, rectal cancer, survival, pCR, metastasis; oxaliplatin, total neoadjuvant therapy, 991
- Radiotherapy, thyroid cancer, neoplasms, second primary, head and neck neoplasms, SEER program, 1359
- Radium-223, castration-resistant prostate cancer, 4981
- RAMP1, CGRP, CRLR, AML, EVI1, 4743
- Ramucirumab, alpha fetoprotein, atezolizumab plus bevacizumab, hepatocellular carcinoma, post-treatment, 1905
- Ramucirumab, gastric cancer, paclitaxel, nab-paclitaxel, prognosis, 1599
- Random effect, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, review, 1679
- Randomized controlled trial, vitamin B12, oral treatment, deficiency, total gastrectomy, gastric cancer, 3963
- Randomized trials, meta-analysis, systematic review, adverse events, asthenia, fatigue, placebo, cancer, oncology, CTCAE, review, 45
- Randomized trials, meta-analysis, systematic review, adverse events, placebo, cancer, oncology, CTCAE, medDRA, review, 2805
- Rapamycin, breast osteosarcoma, PDOX, nude mice, combination therapy, methioninase, efficacy, synergy, Hoffman effect, 5217
- Rapamycin, medulloblastoma, daoy, immunotherapy, gemcitabine, lipopolysaccharide, 1697
- RASopathy, neurofibromatosis type 1, plexiform neurofibroma, central giant cell granuloma, root resorption, 2945
- Rat model, trimetazidine, liver, thermic damage, colorectal, 4395
- RDA, recommended daily intake, clinical trial study design, evidence-based medicine, public health, primary disease prevention, COVID-19, evolution, primate biology, vitamin D toxicity, review, 5027
- Re-irradiation, stereotactic body radiotherapy, primary lung cancer, oligometastasis, radiation pneumonitis, 2701
- Reactive oxygen species, GPX4, ferroptosis, gastric cancer, 5719



- Reactive oxygen species,  $\gamma$ -glutamylcyclotransferase, antisense, lung cancer, AMPK, cyclin-dependent kinase inhibitor, 1221
- Reactive oxygen species,  $\gamma$ -glutamylcyclotransferase, n-acetylcysteine, cyclin-dependent kinase inhibitors, pro-GA, breast cancer, 4311
- Real-time tumor tracking system, lung cancer, lung metastasis, stereotactic body radiotherapy, syncTraX, RTRT, radiotherapy, 2989
- Real-world clinical practice, advanced urothelial carcinoma, platinum-based chemotherapy pembrolizumab, 1571
- Real-world study, effectiveness, everolimus, pancreatic neuroendocrine tumors, progression-free survival, tolerability, 1941
- Receptor-interacting serine/threonine-protein kinase 3, breast, immunohistochemistry, triple-negative breast carcinoma, prognosis, 2753
- Rechallenge, hepatocellular carcinoma, lenvatinib, atezolizumab plus bevacizumab, 5479
- Recombinant thrombomodulin, gemcitabine, GPR15, pancreatic cancer, 4679
- Recommended daily intake, RDA, clinical trial study design, evidence-based medicine, public health, primary disease prevention, COVID-19, evolution, primate biology, vitamin D toxicity, review, 5027
- RECQL4* gene, minimally invasive follicular thyroid carcinoma, *PTEN* gene mutation, cowden syndrome, *PTEN* hamartoma tumor syndrome, germline mutation, surveillance, 1481
- Rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, neoadjuvant radiotherapy, short-course radiotherapy, capecitabine, S-1, chemotherapy, radiotherapy, 5587
- Rectal cancer, CD133, HIF-1 $\alpha$ , cD133(+)/HIF-1 $\alpha$ (-), chemoradiotherapy, 2033
- Rectal cancer, colorectal surgery, low anastomoses, laparoscopic surgery, radiotherapy, indocyanine green, 211
- Rectal cancer, neoadjuvant chemoradiotherapy, PME, upper rectum, sigmoid cancer, 155
- Rectal cancer, neoadjuvant chemotherapy, adjuvant chemotherapy, prognosis, 1527
- Rectal cancer, patient, stable disease, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, 3857
- Rectal cancer, survival, pCR, metastasis; oxaliplatin, radiotherapy, total neoadjuvant therapy, 991
- Rectal displacement device, prostate cancer radiotherapy, quality of life, acute side-effects, stereotactic body radiotherapy, 2553
- Rectal surgery, low rectal cancer, neoadjuvant chemoradiotherapy, intersphincteric resection, enhanced recovery after surgery, ERAS, clinical outcome, 1949
- Recurrence detection, oropharyngeal carcinoma, surveillance, survival, 5597
- Recurrence of ovarian cancer, primary debulking surgery, interval debulking surgery, progression-free survival, metastasis, 2003
- Recurrence pattern, DUPAN-2, pancreatic cancer, locoregional recurrence, pancreatectomy, 2071
- Recurrence, adjuvant chemotherapy, resection, colorectal cancer liver metastases, overall survival, 5497
- Recurrence, concurrent chemoradiotherapy, chemotherapy regimen, 1073
- Recurrence, dicycloplatin capsules, bladder cancer, remission, tolerable side effects, 1339
- Recurrence, differentiated thyroid cancer, lobectomy, risk factors, thyroglobulin, 5619
- Recurrence, esophagogastric cancer, adenocarcinoma, lymph node metastasis, 1051
- Recurrence, hepatocellular carcinoma, liver resection, mortality, surgery, 2573
- Recurrence, hepatocellular carcinoma, liver transplantation, lenvatinib, 1161
- Recurrence, homologous recombination, PARP inhibitors, chemotherapy, epithelial ovarian cancer, 2017
- Recurrence, lung adenocarcinoma, TNM staging, surgical resection, 1137
- Recurrence, sinonasal malignancy, surveillance imaging, sensitivity, specificity, 5449
- Recurrent glioblastoma, bevacizumab, fotemustine, second line cytotoxic, 5847
- Recurrent laryngeal nerve palsy, esophagectomy, postoperative pneumonia, forced expiratory volume, 3023
- Recurrent oral cancer, COVID-19, boron neutron capture therapy, salvage maxillectomy, nasoseptal flap, 1653
- Recurrent ovarian cancer, pegylated liposomal doxorubicin, platinum refractory/ resistant, CA125, 3017
- Recurrent patients, hepatocellular carcinoma, repeat hepatectomy, prognosis, 4553
- Recurrent patients, hepatocellular carcinoma, repeat hepatectomy, prognosis, 4553
- Recurrent/metastatic head and neck cancer, nivolumab, PD-L1, TPS, CPS, 1547
- Recurrent/metastatic squamous cell carcinoma, head and neck, programmed cell death protein 1, pembrolizumab, 4477
- Recycling endosome, melanoma, leukemia, cancer cell migration, rhoGTPase, rac, rhoGAP, rab11, actin cytoskeleton, 5763
- Refractory, chemotherapy, anaplastic ependymoma, 3863
- Refractory, glioblastoma, relapsed, bevacizumab, 6091
- Regulatory T-lymphocytes, oral squamous cell carcinoma, immune checkpoint, tumor-infiltrating lymphocytes, flow cytometry, 2383
- Reimbursement criteria, hepatocellular carcinoma, sorafenib, Barcelona Clinic Liver Cancer Stage C, transarterial chemoembolization, National Health Insurance, 4461



- Reirradiation, oral cancer, radiotherapy, brachytherapy, complication, 293
- Relapse incidence, multiple myeloma, autologous, allogeneic, stem cell transplantation, overall survival, progression-free survival, non-relapse mortality, 5825
- Relapsed tumor, paclitaxel, nab-paclitaxel, small cell lung cancer, interstitial lung disease, 4921
- Relapsed, glioblastoma, refractory, bevacizumab, 6091
- Relative dose intensity, pancreatic ductal adenocarcinoma, adjuvant chemotherapy, S-1, overall survival, 3133
- Remission, colon biopsies, crypts, asymmetric branching, ulcerative colitis, 4493
- Remission, dicycloplatin capsules, bladder cancer, recurrence, tolerable side effects, 1339
- Renal angiomyolipomas, kruppel-like factor 2, IL-6, JAK, STAT3, 4753
- Renal carcinoma, tumor thrombus, surgical reconstruction, inferior vena cava, 1351
- Renal cell carcinoma, copine 1, immunohistochemistry, prognostic marker, bioinformatics, 355
- Renal cell carcinoma, immuno-oncology combination therapy, molecular targeted therapy, first-line therapy, 4573
- Renal cell carcinoma, kidney, SBRT, SABR, review, 667
- Renal cell carcinoma, miRNA, transcription factor, tissue expression, prognostic markers, 2355
- Renal cell carcinoma, nivolumab plus ipilimumab, cytoreductive nephrectomy, 2727
- Renal cell carcinoma, pathological T3a, prognosis, tumor size, 2185
- Renal cell, carcinoma, multivariate analysis, neoplasm grading, nephrectomy, prognosis, 2967
- Renal function, parenchymal suture, robot-assisted partial nephrectomy, laparoscopic partial nephrectomy, 3055
- Renin angiotensin system, skin cancer, basal cell carcinoma, chymase, *CMAI* gene, G1903A, rs1800875, angiotensin 2, 5547
- Repeat hepatectomy, hepatocellular carcinoma, recurrent patients, prognosis, 4553
- Reporting, CAR-T, phase I, clinical trial, study design, dose escalation, review, 5673
- Repurposing, drug repositioning, MDMX, HDMX, 4727
- Resection margin, adjuvant concurrent chemoradiotherapy, adjuvant chemotherapy, propensity score, 3195
- Resection, adjuvant chemotherapy, colorectal cancer liver metastases, recurrence, overall survival, 5497
- Resection, pancreatic neuroendocrine tumor, PNET, neuroendocrine carcinoma, surgery, review, 629
- Resistance exercise, cachexia, aerobic exercise, inflammation, colon cancer, colon-26, muscle fiber type, 397
- Resistance, osteosarcoma, nude mice, PDOX, methionine addiction, Hoffman effect, methioninase, methotrexate, combination therapy, efficacy, 731
- Restricted mouth opening, mallampati score, head and neck cancer, chemoradiotherapy, trismus, outcome, 5609
- Review, actinic keratosis, adverse events, photodynamic therapy, protoporphyrin IX, skin, 5017
- Review, breast cancer, endocrine therapy, aromatase inhibitors, side effects, adverse events, community pharmacy services, community pharmacists, health knowledge, educational intervention, 661
- Review, cancer, methionine addiction, Hoffman effect, methionine restriction, methioninase, clinical treatment, 641
- Review, CAR-T, phase I, clinical trial, study design, dose escalation, reporting, 5673
- Review, cardiophrenic lymph nodes, advanced ovarian cancer, lymphadenectomy, 13
- Review, carotid body tumor, surgical resection, feeding arteries, preoperative embolization, 645
- Review, colorectal, appendiceal, peritonectomy, adenocarcinoma, carcinoembryonic antigen, 4217
- Review, conversion hepatectomy, surgery, hepatocellular carcinoma, lenvatinib, molecular therapy, 35
- Review, COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, 5043
- Review, distal pancreatectomy, laparoscopic, pancreatic cancer, radical antegrade modular pancreatectomy, robotic, 653
- Review, epithelial to mesenchymal transition, lung cancer, potential compounds targeting EMT, 4237
- Review, esophageal cancer, adenocarcinoma, squamous cell carcinoma, toll-like receptors, microbiome, 2813
- Review, esophageal cancer, transhiatal esophagectomy, transcervical mediastinoscopy, minimally invasive surgery, robotic-assisted surgery, 675
- Review, exosomes, extracellular vesicles, gastric cancer, exo-miR, exo-lncRNA, exo-circRNA, exo-DNA, DNA methylation, gastric juice, 2249
- Review, gastric cancer, metachronous liver metastasis, liver resection, 25
- Review, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, subgroup meta-analysis, heterogeneity, publication bias, effect size, 1679
- Review, host-mediated *in vivo/in vitro* assay, carcinogens, tumorigenic potential, 4199
- Review, kidney, renal cell carcinoma, SBRT, SABR, 667
- Review, lung cancer, cancer stem cell, anticancer, plant-derived compounds, 4247
- Review, lymphoproliferative disorder, transplantation, EBV, PTLT, CAR-T, 5181
- Review, medulloblastoma, wnt, SHH, non-Wnt/non-SHH, 2225
- Review, melanoma, trends, incidence, mortality, overdiagnosis, sunburn, 5021
- Review, meta-analysis, systematic review, adverse events, asthenia, fatigue, placebo, cancer, oncology, randomized trials, CTCAE, 45

- Review, meta-analysis, systematic review, adverse events, placebo, cancer, oncology, randomized trials, CTCAE, medDRA, 2805
- Review, nutritional assessment, inflammation assessment, gastric cancer, 5167
- Review, ovarian cancer, pap test, liquid Pap specimen, cervical swab, 1
- Review, ovarian cancer, primary debulking surgery, interval debulking surgery, hyperthermic intraperitoneal chemotherapy, cisplatin, 4659
- Review, ovarian cancer, screening, CA125, ultrasound, microRNA, *TP53* clonal variants, 4207
- Review, pancreatic neuroendocrine tumor, PNET, neuroendocrine carcinoma, surgery, resection, 629
- Review, radiotherapy, immunotherapy, NSCLC, SABR, SBRT, 2241
- Review, radiotherapy, metastatic urothelial carcinoma, quality of life, 3767
- Review, recommended daily intake, RDA, clinical trial study design, evidence-based medicine, public health, primary disease prevention, COVID-19, evolution, primate biology, vitamin D toxicity, 5027
- Review, UV exposure, diabetes mellitus, cancer, melanoma, cardiovascular disease, mortality, 1671
- Review, vitamin D deficiency, food fortification, supplementation, vitamin D status, 25-hydroxyvitamin D serum concentration, 5009
- Review, x-chromosome, x-linked, polymorphism, cancer, gender dimorphism, 2261
- Rgp, oropharyngeal squamous cell carcinoma, OPSCC, human papillomavirus, *Porphyromonas gingivalis*, gingipain, matrix metalloproteinase, survival analysis, 5415
- RhoGTPase, melanoma, leukemia, cancer cell migration, rac, rhoGAP, rab11, recycling endosome, actin cytoskeleton, 5763
- Right hepatectomy, portal vein embolization, postoperative liver failure, hepatocellular carcinoma, mortality, 4089
- Right lower lobe lung cancer, sleeve lobectomy, bronchoplasty, 5977
- Ring drape, surgical site infection, unused sterile instruments, hepatectomy, 1007
- Risk assessment, cytogenetic analysis, chromosome aberrations, aneuploidy, cancer, medical workers, 1059
- Risk factor, abemaciclib, aromatase inhibitor, breast cancer, liver injury, 6027
- Risk factor, cisplatin, nephrotoxicity, short hydration, oral rehydration solution (ORS), 3185
- Risk factors, abdominal aortic calcification, comprehensive complication index, complications, HBP surgery, 5983
- Risk factors, colorectal cancer patients, elderly, postoperative complications, protective factors, 1123
- Risk factors, differentiated thyroid cancer, lobectomy, recurrence, thyroglobulin, 5619
- Risk factors, esophageal cancer, adenocarcinoma of the esophagogastric junction, radio-chemotherapy, sleep problems, prevalence, 4529
- Risk factors, head-and-neck cancer, radiotherapy, radio-chemotherapy, xerostomia, 2657
- Risk factors, radiotherapy, lung cancer, discontinuation of treatment, prognostic instrument, 1973
- Risk factors, radiotherapy, lung cancer, pneumonitis, prognostic tool, 2029
- Risk factors, sleep disturbances, bladder cancer, irradiation, frequency, 4511
- Risk reduction, hereditary cancer, genetic medicine, genetic testing, multigene panel testing, 4097
- Risk score, germ tumors, lung metastases, 4517
- Risk stratification, HPV, cervical cancer, p16/Ki-67 dual-stained cytology, triage, CIN2, CIN3, HSIL, screening, pap test, 2599
- RITA, oral squamous cell carcinoma, apoptosis, p53, *MDM2*, 2931
- Ritonavir, hepatitis C virus, CYP3A4, calcium channel blockers, amlodipine, peripheral edema, 2087
- Rituximab, bendamustine, mantle cell lymphoma, 6083
- Robot-assisted hysterectomy, cumulative summation analysis, learning curve, endometrial cancer, benign gynecological tumor, 4111
- Robot-assisted partial nephrectomy, renal function, parenchymal suture, laparoscopic partial nephrectomy, 3055
- Robot, distal pancreatectomy, surgical approach, splenic artery, pancreatic cancer, 4471
- Robotic surgical procedure, hemoglobin, blood transfusion, hysterectomy, endometrial neoplasm, cost analysis, 1893
- Robotic surgical procedure, laparoscopy, laparotomy, endometrial neoplasm, aged, survival, 75
- Robotic-assisted surgery, esophageal cancer, transhiatal esophagectomy, transcervical mediastinoscopy, minimally invasive surgery, review, 675
- Robotic, distal pancreatectomy, laparoscopic, pancreatic cancer, radical antegrade modular pancreatosplenectomy, review, 653
- Robotic, SMILE, stratified mucin-producing intraepithelial tumor, cervical tumor, pathology, 1175
- ROC, fecal immunochemical test, FIT, colorectal cancer screening, proximal colon, distal colon, 1879
- Root resorption, neurofibromatosis type 1, plexiform neurofibroma, central giant cell granuloma, rASopathy, 2945
- Rs1800875, skin cancer, basal cell carcinoma, renin angiotensin system, chymase, *CMA1* gene, G1903A, angiotensin 2, 5547
- RT-PCR, cancer unknown primary, neuroendocrine, gene expression profiling, 1381
- TRT, lung cancer, lung metastasis, stereotactic body radiotherapy, syncTraX, real-time tumor tracking system, radiotherapy, 2989
- RUNX2, sarcomatoid renal cell carcinoma, POLR2A, micro-RNA378a-3p, ERK2 (MAPK1), 811

- S-1, adjuvant therapy, gemcitabine, pancreatic cancer, positive peritoneal lavage cytology, postoperative chemotherapy, 893
- S-1, head and neck squamous cell carcinoma, preoperative chemotherapy, surgical case, adverse event, 3177
- S-1, irinotecan, bevacizumab, SIRB, cetuximab, second-line treatment, 2675
- S-1, rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, neoadjuvant radiotherapy, short-course radiotherapy, capecitabine, chemotherapy, radiotherapy, 5587
- S-1, relative dose intensity, pancreatic ductal adenocarcinoma, adjuvant chemotherapy, overall survival, 3133
- SABR, kidney, renal cell carcinoma, SBRT, review, 667
- SABR, radiotherapy, immunotherapy, NSCLC, SBRT, review, 2241
- SABR, stereotactic ablative body radiotherapy, SBRT, cyberKnife, lung cancer, 321
- Sacral, chordoma, survival, population, SEER, cancer, 929
- Safety signal, anticancer drug, ocular adverse reactions, Japanese Adverse Drug Event Report, JADER, pharmacovigilance database, 4439
- Safety, advanced breast cancer, everolimus, first line, effectiveness, 1031
- Safety, immunotherapy, immune checkpoint inhibitor, nivolumab, metformin, diabetic cancer patients, 1487
- Saline, gemcitabine, vascular pain, 5% glucose, lyophilized formulation, liquid formulation, 343
- Salivary gland carcinoma, head and neck cancer, PD-1 inhibitor, PD-L1, mismatch repair protein, 981
- Salivary gland tumor, polymorphous adenocarcinoma, polymorphous low-grade adenocarcinoma, PRKD1, cribriform adenocarcinoma of salivary glands, molecular diagnostics, 1455
- Salvage chemotherapy, bevacizumab, brain metastasis, ovarian cancer, survival, 2637
- Salvage hepatectomy, indocyanine green, ICG, fluorescence-guided surgery, radiofrequency ablation, liver tumors, local recurrence, tumor margins, R0 resection, 1345
- Salvage maxillectomy, COVID-19, boron neutron capture therapy, recurrent oral cancer, nasoseptal flap, 1653
- Salvage radiotherapy, prostate cancer, biochemical recurrent prostate cancer, radiotherapy timing, adjuvant radiotherapy, 2997
- Sarcoma, clavícula *pro humero* reconstruction, malignant bone tumor, non-union, 2139
- Sarcomatoid renal cell carcinoma, POLR2A, RUNX2, microRNA378a-3p, ERK2 (MAPK1), 811
- Sarcopenia, non-small cell lung cancer, surgery, postoperative muscle loss, 3159
- Sarcopenia, oesophageal cancer, masseter muscle, prognosis, psoas muscle, 301
- Sarcopenia, pancreatic intraepithelial neoplasia, pancreatic carcinoma, platelet, lymphocyte, platelet/lymphocyte ratio, jaundice, 1413
- Sarcopenia, skeletal muscle index, skeletal muscle radiation attenuation, ovarian cancer, 947
- Sarcopenia, squamous cell carcinoma of the cervix, concurrent chemoradiotherapy, PMI, SMI, 4887
- SARS-CoV-2, COVID-19, vitamin D, 25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- SBRT, kidney, renal cell carcinoma, SABR, review, 667
- SBRT, radiotherapy, immunotherapy, NSCLC, SABR, review, 2241
- SBRT, stereotactic ablative body radiotherapy, SABR, cyberKnife, lung cancer, 321
- Scalp, angiosarcoma, chemoradiation, unresectable, intensity-modulated radiotherapy, 5991
- Scapula, Ewing sarcoma, shoulder girdle, limb salvage, 3869
- Scirrhous gastric cancer, intractable cancer, proliferation, oncogenes, molecular target, 5195
- Scirrhous-type gastric cancer, cancer-associated fibroblasts, dipeptidyl peptidase-4, proliferation, cancer microenvironment, 501
- Scoring systems, partial nephrectomy, t1b renal tumor, surgical complications, 6057
- Screening, HPV, cervical cancer, p16/Ki-67 dual-stained cytology, triage, CIN2, CIN3, HSIL, risk stratification, pap test, 2599
- Screening, ovarian cancer, CA125, ultrasound, microRNA, TP53 clonal variants, review, 4207
- SEC11A, gastric cancer, SPC18, 5885
- Second line cytotoxic, recurrent glioblastoma, bevacizumab, fotemustine, 5847
- Second primary, thyroid cancer, neoplasms, radiotherapy, head and neck neoplasms, SEER program, 1359
- Second-line chemotherapy, pancreatic cancer, nal-IRI, FOLFIRINOX, peripheral neuropathy, pegfilgrastim, 3889
- Second-line treatment, S-1, irinotecan, bevacizumab, SIRB, cetuximab, 2675
- Second-look surgery, stoma-reversal, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001
- Secondary prophylactic G-CSF, breast cancer, chemotherapy, febrile neutropenia, filgrastim, 5945
- SEER program, bone sarcoma, neoplasm grading, hand, treatment outcome, orthopedic surgery, 1635
- SEER program, thyroid cancer, neoplasms, second primary, radiotherapy, head and neck neoplasms, 1359
- SEER, sacral, chordoma, survival, population, cancer, 929
- Segmental, breast, carcinoma, hypofractionation, mastectomy, radiotherapy, 53

- Segmental, breast, carcinoma, mastectomy, radiotherapy, 93
- Selective cytotoxicity, novel anti-pancreatic cancer agent, coumarin derivative, autophagy, 2835
- Selective ER $\beta$  agonists, breast cancer, G protein-coupled estrogen receptor 1 (GPER1), invasion, tamoxifen resistance, 5187
- Selenium, colorectal carcinoma therapy, anti-angiogenic drug, plant derived polyphenols, trans-resveratrol, quercetin, vitamin E, dogs, 4763
- Semi-smooth implant, breast reconstruction, pre-pectoral, nano-textured, acellular dermal matrix, 1013
- Sensitivity, sinonasal malignancy, surveillance imaging, recurrence, specificity, 5449
- Sequential therapy, hepatocellular carcinoma, tyrosine kinase inhibitor, lenvatinib, sorafenib, post-progression survival, 6007
- Sequential therapy, PSA decline, enzalutamide, abiraterone, CRPC, 3041
- Sequential treatment, abiraterone acetate, docetaxel, enzalutamide, CRPC, 2123
- Serological biomarker panel, atrophic gastritis, autoimmune, gastroPanel<sup>®</sup>, non-invasive test, updated Sydney System, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517
- Serum, trace element, breast cancer, surgery, ICP-MS, 5323
- Service use, pancreatic cancer, palliative care, end-of-life care, place of death, 5457
- SH-SY5Y, polyphenol, PC12, NGF, overlay method, neurotoxicity, tumor-specificity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- SHapley values, oral cavity cancer, machine learning, interpretability, prognosis, 5859
- SHH, medulloblastoma, wnt, non-Wnt/non-SHH, review, 2225
- Short hydration, cisplatin, nephrotoxicity, oral rehydration solution (ORS), risk factor, 3185
- Short-course radiotherapy, rectal cancer, accelerated hyperfractionated radiotherapy, preoperative radiotherapy, neoadjuvant radiotherapy, capecitabine, S-1, chemotherapy, radiotherapy, 5587
- Shoulder girdle, Ewing sarcoma, scapula, limb salvage, 3869
- SIB, head and neck cancer, cisplatin, radiotherapy, HPV, IMRT, toxicity, 5909
- Side effects, breast cancer, endocrine therapy, aromatase inhibitors, adverse events, community pharmacy services, community pharmacists, health knowledge, educational intervention, review, 661
- Side effects, upper rectal cancer, neoadjuvant chemoradiotherapy, local recurrence, surgical complications, 4833
- Side-effects, adjuvant radiation therapy, py, locoregional radiotherapy, breast cancer, toxicity, 923
- Side-effects, gastrointestinal stromal tumours, tyrosine kinase inhibitors, imatinib, discontinuation, qualitative research, psycho-social, hope, 955
- Sigmoid cancer, rectal cancer, neoadjuvant chemoradiotherapy, PME, upper rectum, 155
- Signal transducer and activator of transcription 3, magnolol, non-small-cell lung cancer, STAT3, nuclear factor kappa B, NF- $\kappa$ B, 3825
- Signal, lenalidomide, lung toxicity, Japanese Adverse Drug Reaction Reporting database, time to onset, 5917
- SIL-2R, biomarker, metastases prediction, uveal melanoma, 1447
- Silibinin, estrogen receptor  $\beta$ , non-Hodgkin lymphoma, diffuse large B-cell lymphoma, cardiomyocytes, doxorubicin, apoptosis, autophagy, 767
- Sinonasal malignancy, surveillance imaging, recurrence, sensitivity, specificity, 5449
- SIRB, S-1, irinotecan, bevacizumab, cetuximab, second-line treatment, 2675
- SiRNA, canine mammary gland tumors, cell cycle, hIF1 $\alpha$ , metastasis, TSG-6, 5803
- SIRT6, oral squamous cell carcinoma, sirtuin, 3815
- Sirtuin, oral squamous cell carcinoma, SIRT6, 3815
- Size criterion, predictors, lateral pelvic lymph node metastasis, advanced low rectal cancer, magnetic resonance imaging, 2113
- SK-N-SH cells, *BAX* and *BCL2* silencing, casiopeína IIIa, mPTP, cRISPR/Cas9, Ca<sup>2+</sup> retention capacity, 885
- Skeletal muscle index, sarcopenia, skeletal muscle radiation attenuation, ovarian cancer, 947
- Skeletal muscle radiation attenuation, sarcopenia, skeletal muscle index, ovarian cancer, 947
- Skin cancer, basal cell carcinoma, renin angiotensin system, chymase, *CMAI* gene, G1903A, rs1800875, angiotensin 2, 5547
- Skin damage, bendamustine, Japanese Adverse Drug Reaction Reporting Database, time to onset, 2737
- Skin, actinic keratosis, adverse events, photodynamic therapy, protoporphyrin IX, review, 5017
- Skull base, cerebral ventricles, craniopharyngioma, intraventricular tumor, neuro-oncology, systematic review, 4189
- SLC22A3*, multiple myeloma, melphalan, OCT3, oral mucositis, 385
- Sleep disorders, breast cancer, adjuvant radiotherapy, prospective trial, patient reported outcomes, 3085
- Sleep disturbances, bladder cancer, irradiation, frequency, risk factors, 4511
- Sleep problems, esophageal cancer, adenocarcinoma of the esophagogastric junction, radio-chemotherapy, prevalence, risk factors, 4529
- Sleeve lobectomy, non-small cell lung cancer, pneumonectomy, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, 3029
- Sleeve lobectomy, right lower lobe lung cancer, bronchoplasty, 5977



- Small cell carcinoma, neuroendocrine prostate cancer, somatostatin receptor scintigraphy, liver metastasis, prostate cancer, 2167
- Small cell lung cancer, biomarker, MUC1, CD147, circulating tumor cells, 429
- Small cell lung cancer, paclitaxel, nab-paclitaxel, relapsed tumor, interstitial lung disease, 4921
- Small chemical compound library, *in silico* screening, ELISA for inhibition of PD-1/PD-L1 binding, mHC-dKO NOG mouse, ADME evaluation, 5233
- Small extracellular vesicles, gastrointestinal stromal tumor, biomarker, EV array, 5699
- Small interfering RNA, TYRO3, TAM family, leukaemia, 1757
- Small-cell lung cancer, liver X receptors, cholesterol metabolism, ABCA1, T0901317, 2923
- Small-cell lung cancer, malignant central airway obstruction, extraluminal obstruction, stent placement, concurrent chemoradiotherapy, 6113
- SMARCB1 gene, cutaneous squamous cell carcinoma, parotid gland, metastasis, 3971
- SMI, squamous cell carcinoma of the cervix, concurrent chemoradiotherapy, sarcopenia, PMI, 4887
- SMILE, stratified mucin-producing intraepithelial tumor, cervical tumor, pathology, robotic, 1175
- Smoking, breast cancer, ductal carcinoma *in situ*, invasive ductal carcinoma, biopsy, 311
- Smoking, breast cancer, hormone receptor, endocrine therapy, cigarette, 3937
- Smoking, diabetes, oral cancer, public health, impaired fasting glycemia, 109
- SNAIL, epithelial–mesenchymal transition, colon cancer, lymph node metastasis, SNAIL, 5927
- Snail mucus, anti-cancer, apoptosis, TNBC, chemotherapy, 845
- SNAIL, epithelial–mesenchymal transition, colon cancer, lymph node metastasis, SNAIL, 5927
- Soft tissue sarcoma, thigh, compartment, 3143
- Soft tissue sarcomas, thymidine kinase 1, proliferation, prognosis, 1509
- Soft tissue tumor, limb-sparing tumor surgery, vascular reconstruction, extremity, bone tumor, 4619
- Soft-tissue sarcoma, leiomyosarcoma, brachytherapy, radiotherapy, extremity, multicentric analysis, 4485
- Soft-tissue tumor, 2-5 cm, malignancy, MRI, needle biopsy, unplanned excision, 1555
- Solid tumor, immune-cell therapy, adjuvant therapy,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4179
- Somatostatin receptor scintigraphy, neuroendocrine prostate cancer, small cell carcinoma, liver metastasis, prostate cancer, 2167
- Sorafenib, circulating tumor cells, drug resistance, chemotherapy, *ex vivo* culture, 2479
- Sorafenib, hepatocellular carcinoma, barcelona Clinic Liver Cancer Stage C, transarterial chemoembolization, national Health Insurance, reimbursement criteria, 4461
- Sorafenib, hepatocellular carcinoma, tyrosine kinase inhibitor, lenvatinib, post-progression survival, sequential therapy, 6007
- Sorafenib, maintenance chemotherapy, advanced hepatocellular carcinoma, very high risk of recurrence, 6127
- Spatially fractionated radiation therapy, magnetic resonance imaging, lattice radiotherapy, gynecological cancer, inoperable bulky tumors, palliative care, palliative radiotherapy, 4641
- SPC18, gastric cancer, SEC11A, 5885
- Specificity, sinonasal malignancy, surveillance imaging, recurrence, sensitivity, 5449
- Speckle tracking echocardiography, radiotherapy, breast cancer, myocardial imaging, cyclic variation of the integrated backscatter, global longitudinal strain, 2507
- Spheroid, etoposide, microRNA, miRNA-205-5p, breast cancer, ERBB4, 4265
- Spheroid, TNBC,  $\beta$ -tubulin isoform, docetaxel, 3D culture, morphology, 4735
- Spinal metastasis, axonal growth, calcitonin gene-related peptide, dorsal root ganglion neurons, nerve growth factor, 581
- Spine metastases, cauda equina, intradural metastases, spine oncology, systematic review, 1661
- Spine metastases, leptomeningeal metastases, radiotherapy, spine surgery, spine tumors, systematic review, 619
- Spine oncology, cauda equina, intradural metastases, spine metastases, systematic review, 1661
- Spine surgery, leptomeningeal metastases, radiotherapy, spine metastases, spine tumors, systematic review, 619
- Spine tumors, leptomeningeal metastases, radiotherapy, spine metastases, spine surgery, systematic review, 619
- Spiral array, annexin A10, lung cancer, adenocarcinoma, 1289
- Spiral array, chloride intracellular channel 1, immunohistochemistry, lung adenocarcinoma, 271
- Spirometry, colorectal surgery, gastric surgery, postoperative complication, COVID-19, 1623
- Splenectomy, type 4 gastric cancer, laparoscopic surgery, 5937
- Splenic artery, robot, distal pancreatectomy, surgical approach, pancreatic cancer, 4471
- Splice variant, pancreatic ductal adenocarcinoma (PDAC), integrin  $\alpha 6$  (ITGA6), extracellular vesicles, 1763
- Squamous cell carcinoma of the cervix, concurrent chemoradiotherapy, sarcopenia, PMI, SMI, 4887
- Squamous cell carcinoma, concurrent chemoradiotherapy, head and neck, prognostic factor, TPF, 6047
- Squamous cell carcinoma, esophageal cancer, adenocarcinoma, toll-like receptors, microbiome, review, 2813
- Squamous cell carcinoma, head and neck, nivolumab, 1607



- Squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- Squamous cell carcinoma, nivolumab, head and neck, platinum-refractory, platinum-sensitive, 4907
- Squamous cell carcinoma, oral cancer, pN1, survival, adjuvant radiotherapy, metastatic lymphadenopathy, neck dissection, postoperative radiotherapy, 97
- Squamous cell carcinoma, tongue cancer, ultrasonography, doppler, cervical lymph node metastasis, 287
- Squamous differentiation, urothelial carcinoma, upper urinary tract cancer, radical nephroureterectomy, prognosis, 263
- SREBP1, galectin-3, thyroid cancer, 2487
- Stable disease, pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, supplement, combination therapy, CA19-9, methionine addiction, Hoffman effect, 2567
- Stable disease, rectal cancer, patient, methionine addiction, Hoffman effect, methionine restriction, oral recombinant methioninase, low-methionine diet, 3857
- Stable isotope, zinc, light isotope, anticancer effect, cytotoxicity, apoptosis, 5685
- Stage III, colorectal cancer, nutrition, prognostic score, 4989
- Stage IV, pancreatic cancer, FOLFIRINOX, oral recombinant methioninase, supplement, combination therapy, stable disease, CA19-9, methionine addiction, Hoffman effect, 2567
- Staging laparoscopy, gastric cancer, gastric outlet obstruction, laparoscopic gastrojejunostomy, 5571
- STAT3 inhibition, hepatocellular carcinoma, anti-PD-1 therapy, CD8<sup>+</sup> T cell infiltration, tumor microenvironment, immunosuppression, 5205
- STAT3, cancer-associated fibroblasts, bcl-xL, mcl-1, IL-6, colorectal cancer, apoptosis, 1277
- STAT3, dimethyl fumarate, NF-κB, c-IAP2, adult T-cell, leukemia, lymphoma, 2301
- STAT3, fluoxetine, triple-negative breast cancer, apoptosis, epithelial-to-mesenchymal transition, 3807
- STAT3, Kruppel-like factor 2, renal angiomyolipomas, IL-6, JAK, 4753
- STAT3, magnolol, non-small-cell lung cancer, signal transducer and activator of transcription 3, nuclear factor kappa B, NF-κB, 3825
- Steatohepatitis, non-alcoholic fatty liver disease, hepatectomy, liver steatosis, hepatitis, 4159
- Stelic animal model, mulberry, high-fat diet, streptozotocin, nonalcoholic hepatitis, nonalcoholic fatty liver disease, hepatocellular carcinoma, 4055
- Stem cell transplantation, multiple myeloma, autologous, allogeneic, overall survival, progression-free survival, non-relapse mortality, relapse incidence, 5825
- Stem cells, near-infrared turn-on fluorescence probe, C5S-A, activity of aldehyde dehydrogenase, breast cancer, 1199
- Stent placement, malignant central airway obstruction, small-cell lung cancer, extraluminal obstruction, concurrent chemoradiotherapy, 6113
- Stent placement, transbronchial microwave ablation, post anticancer therapy, moderate sedation, 3125
- Stereotactic ablative body radiotherapy, SABR, SBRT, cyberKnife, lung cancer, 321
- Stereotactic body radiotherapy, hepatocellular carcinoma, mALBI grade, prognostic factor, 5001
- Stereotactic body radiotherapy, lung cancer, lung metastasis, syncTraX, real-time tumor tracking system, RTRT, radiotherapy, 2989
- Stereotactic body radiotherapy, primary lung cancer, oligometastasis, re-irradiation, radiation pneumonitis, 2701
- Stereotactic body radiotherapy, prostate cancer radiotherapy, quality of life, acute side-effects, rectal displacement device, 2553
- Stereotactic body radiotherapy, uveal melanoma, intensity-modulated radiotherapy, eye preservation, 1965
- Stereotactic radiotherapy, brain metastasis, thymic carcinoma, cerebellar metastasis, 1169
- Steroid refractory, ICANS, intrathecal chemotherapy, CAR T-cell therapy, potential treatment, 3853
- Stoma-reversal, second-look surgery, peritonectomy, cytoreductive surgery, heated intraperitoneal chemotherapy, peritoneal carcinomatosis, appendiceal, colorectal, completeness of cytoreduction, peritoneal cancer index, 1001
- Strain difference, breast cancer, heredity, susceptibility, gene-environmental interaction, 2415
- Stratified mucin-producing intraepithelial tumor, SMILE, cervical tumor, pathology, robotic, 1175
- Streptozotocin, mulberry, stelic animal model, high-fat diet, nonalcoholic hepatitis, nonalcoholic fatty liver disease, hepatocellular carcinoma, 4055
- Stromal cells, cancer-associated fibroblasts, ovarian cancer, mesenchymal stem cells, normal ovary, 1729
- Structure and activity relationship, linear furocoumarin, psoralen, antiproliferative activity, HL60 cells, 1777
- Study design, CAR-T, phase I, clinical trial, dose escalation, reporting, review, 5673
- Subcortical metastasis, language function, awake craniotomy, brain metastasis, intraoperative electrical stimulation mapping, 1641
- Subcortical metastasis, motor function, awake surgery, brain metastasis, intraoperative electrical stimulation mapping, precentral gyrus, 1151
- Subgroup meta-analysis, gastroPanel<sup>®</sup>, meta-analysis, diagnostic accuracy, atrophic gastritis, corpus, random effect, bivariate model, hierarchical summary ROC, forest plot, meta regression, heterogeneity, publication bias, effect size, review, 1679
- Subungual melanoma, clear cell sarcoma, cell line, cell culture, 5315

- Sulphite oxidase, pancreas, pancreatic ductal adenocarcinoma, immunohistochemistry, 4145
- Sunburn, melanoma, trends, incidence, mortality, overdiagnosis, review, 5021
- Superficial esophageal carcinoma, endoscopic resection, esophagectomy, chemoradiotherapy, 2791
- Supplement, pancreatic cancer, stage IV, FOLFIRINOX, oral recombinant methioninase, combination therapy, stable disease, CA19-9, methionine addiction, Hoffman effect, 2567
- Supplementation, vitamin D deficiency, food fortification, vitamin D status, 25-hydroxyvitamin D serum concentration, review, 5009
- Supratentorial ependymoma, contralateral interhemispheric approach, extraventricular ependymoma, 3203
- Surgery, cancer, esophagus, neoadjuvant therapy, PET, survival, 6037
- Surgery, cholelithiasis, IL-18, NRS pain score, analgesic doses, 5521
- Surgery, conversion hepatectomy, hepatocellular carcinoma, lenvatinib, molecular therapy, review, 35
- Surgery, hemostasis, interventional radiology, pancreatic resection, pseudoaneurysm, 1579
- Surgery, hepatocellular carcinoma, liver resection, mortality, recurrence, 2573
- Surgery, non-small cell lung cancer, sarcopenia, postoperative muscle loss, 3159
- Surgery, ovarian cancer, cytoreduction, ultra-radical, lactate, length of stay, 1979
- Surgery, pancreatic adenocarcinoma, infection, antibiotic resistance, overall survival, bacteriobilia, 2743
- Surgery, pancreatic ductal adenocarcinoma, PDAC, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- Surgery, pancreatic neuroendocrine tumor, PNET, neuroendocrine carcinoma, resection, review, 629
- Surgery, serum, trace element, breast cancer, ICP-MS, 5323
- Surgical approach, robot, distal pancreatectomy, splenic artery, pancreatic cancer, 4471
- Surgical case, head and neck squamous cell carcinoma, S-1, preoperative chemotherapy, adverse event, 3177
- Surgical complexity, peritoneal cancer index, high grade ovarian cancer, cytoreduction, 4825
- Surgical complications, partial nephrectomy, scoring systems, t1b renal tumor, 6057
- Surgical complications, upper rectal cancer, neoadjuvant chemoradiotherapy, local recurrence, side effects, 4833
- Surgical diagnosis, gastric cancer, neoadjuvant chemotherapy, 2719
- Surgical reconstruction, renal carcinoma, tumor thrombus, inferior vena cava, 1351
- Surgical resection, carotid body tumor, feeding arteries, preoperative embolization, review, 645
- Surgical resection, lung adenocarcinoma, TNM staging, recurrence, 1137
- Surgical sarcopenia, gastric cancer, long-term survival, 4545
- Surgical site infection, ring drape, unused sterile instruments, hepatectomy, 1007
- Surgical site infection, transumbilical incision, laparoscopic, colorectal, hernia, 1115
- Surgical waiting list, breast cancer, awake breast surgery, COVID-19 strategies, 4913
- Surveillance imaging, sinonasal malignancy, recurrence, sensitivity, specificity, 5449
- Surveillance, minimally invasive follicular thyroid carcinoma, *PTEN* gene mutation, cowden syndrome, *PTEN* hamartoma tumor syndrome, *RECQLA* gene, germline mutation, 1481
- Surveillance, oropharyngeal carcinoma, recurrence detection, survival, 5597
- Survey, pressurized intraperitoneal aerosol chemotherapy, peritoneal metastasis, clinical desire, prerequisite, cost, 363
- Survival analysis, oropharyngeal squamous cell carcinoma, OPSCC, human papillomavirus, *Porphyromonas gingivalis*, gingipain, rgp, matrix metalloproteinase, 5415
- Survival analysis, tumor marker, colorectal neoplasms, observational study, 3921
- Survival score, very elderly patients, brain metastases, radiosurgery, fractionated stereotactic radiotherapy, 5629
- Survival, acute myeloid leukemia, children, therapeutic era, 4499
- Survival, albumin, bilirubin, gastric cancer, 3929
- Survival, bevacizumab, brain metastasis, salvage chemotherapy, ovarian cancer, 2637
- Survival, cancer, esophagus, neoadjuvant therapy, PET, surgery, 6037
- Survival, death receptor 6, glioma, low-grade glioma, prognosis, tumor necrosis factor receptor 21, 1237
- Survival, discontinuation, immune checkpoint inhibitor, non-small-cell lung cancer, driver gene mutation, 4589
- Survival, epithelial ovarian cancer, *BRCA* mutation, 4945
- Survival, esophageal neoplasms, chemoradiotherapy, 4929
- Survival, gastric cancer, nivolumab, immune-related adverse events, 1535
- Survival, malignant peritoneal mesothelioma, cytoreductive surgery, HIPEC, outcomes, 2939
- Survival, oropharyngeal carcinoma, recurrence detection, surveillance, 5597
- Survival, paclitaxel, peripheral neuropathy, gastric neoplasms, 4581
- Survival, paclitaxel, peripheral neuropathy, gastric neoplasms, 4581
- Survival, prostate cancer, hormone-sensitive, androgen-deprivation therapy, prostate-specific antigen, 1107
- Survival, rectal cancer, pCR, metastasis; oxaliplatin, radiotherapy, total neoadjuvant therapy, 991
- Survival, robotic surgical procedure, laparoscopy, laparotomy, endometrial neoplasm, aged, 75

- Survival, sacral, chordoma, population, SEER, cancer, 929
- Survival, squamous cell carcinoma, oral cancer, pN1, adjuvant radiotherapy, metastatic lymphadenopathy, neck dissection, postoperative radiotherapy, 97
- Survivorship care plans, head and neck cancer, hypothyroidism, radiation, thyroid stimulating hormone, disparities, 4429
- Susceptibility, breast cancer, heredity, strain difference, gene-environmental interaction, 2415
- Sustained viral response, prognosis, hepatocellular carcinoma, m2BPGi, 245
- Switzerland, chemotherapy, targeted therapy, Germany, Austria, treatment reality, disease characteristics, 4773
- Symmetry, neurofibromatosis type 1, plexiform neurofibroma, cephalometry, bone, facial skeleton, 2607
- Synchronous esophageal cancer, positron emission tomography-computed tomography, pharyngeal squamous cell carcinoma, clinical T classification, detectability, 4597
- Synchronous other primary cancer, metachronous other primary cancer, esophageal cancer, 5635
- SyncTraX, lung cancer, lung metastasis, stereotactic body radiotherapy, real-time tumor tracking system, RTRT, radiotherapy, 2989
- Synergistic effect, osteosarcoma, bortezomib, everolimus, compound library, 4319
- Synergistic effect, osteosarcoma, bortezomib, everolimus, compound library, 4319
- Synergy, breast osteosarcoma, PDOX, nude mice, combination therapy, methioninase, rapamycin, efficacy, Hoffman effect, 5217
- Systematic review, cauda equina, intradural metastases, spine oncology, spine metastases, 1661
- Systematic review, cerebral ventricles, craniopharyngioma, intraventricular tumor, neuro-oncology, skull base, 4189
- Systematic review, leptomeningeal metastases, radiotherapy, spine metastases, spine surgery, spine tumors, 619
- Systematic review, meta-analysis, adverse events, asthenia, fatigue, placebo, cancer, oncology, randomized trials, CTCAE, review, 45
- Systematic review, meta-analysis, adverse events, placebo, cancer, oncology, randomized trials, CTCAE, medDRA, review, 2805
- Systematic review, pineal region glioma, glioma, pineal region tumors, 1189
- Systemic chemotherapy, colorectal liver metastases, fluorouracil plus leucovorin, microwave ablation, 1645
- Systemic chemotherapy, intrahepatic cholangiocarcinoma, multidisciplinary treatment, ablation, 3209
- Systemic immune-inflammation index, biomarkers, prognosis, overall survival, neutrophile-to-lymphocyte ratio, 1911
- Systemic inflammation score, esophageal cancer, curative surgery, prognostic factor, 2711
- Systemic therapy, non-small cell lung cancer, malignant melanoma, kidney cancer, immune checkpoint inhibitor, 3061
- T cell therapy, head and neck cancer, oral cancer, cancer antigen, human leukocyte antigen class I, cancer vaccines, 5751
- T cells, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, NK cells, nKT-like cells, T regulatory cells, cytotoxic T cells, 3067
- T regulatory cells, pancreatic ductal adenocarcinoma, PDAC, surgery, mFOLFIRINOX, gemcitabine, B lymphocytes, T cells, NK cells, nKT-like cells, cytotoxic T cells, 3067
- T0901317, liver X receptors, small-cell lung cancer, cholesterol metabolism, ABCA1, 2923
- T1b renal tumor, partial nephrectomy, scoring systems, surgical complications, 6057
- T4, radiotherapy, esophageal cancer, elderly, 2095
- T790M, lung cancer, afatinib, osimertinib, *EGFR* mutation, 2145
- T790M/L858R-mutation, extracellular vesicles, NSCLC, *EGFR-TKI* resistance, 3835
- Taiwan, alcohol drinking, colorectal cancer, genotype, *MMP-2*, metastasis, polymorphism, 5335
- Taiwan, breast cancer, genotype, interleukin-8, polymorphism, 3799
- Taiwan, childhood ALL, genotype, IL-18, polymorphism, 5283
- Taiwan, colorectal cancer, genotype, *MTRR*, polymorphism, 2375
- Taiwan, FEN1, genotype, oral cancer, polymorphism, 4329
- Taiwan, gastric cancer, genotype, *MMP-2*, polymorphism, 1749
- Taiwan, genotype, hepatocellular carcinoma, *MMP-7*, polymorphism, HCC, 5275
- Taiwan, genotype, interleukin-8, lung cancer, polymorphism, 1229
- Talazoparib, pARPi, *BRCA* mutation, heterozygosity, predictive marker, 5257
- TAM family, TYRO3, small interfering RNA, leukaemia, 1757
- Tamoxifen resistance, breast cancer, G protein-coupled estrogen receptor 1 (GPER1), invasion, selective ER $\beta$  agonists, 5187
- Tamoxifen, breast cancer, drug resistance, cholesterol, acetyl plumbagin, 565
- Tap73, eupatilin, AMPK, glucose uptake, cell cycle arrest, 483
- Target therapy, chemotherapy-induced peripheral neuropathy, pain management, immunotherapy, 4667
- Targeted prostate biopsy, prostate cancer, <sup>68</sup>Ga-PSMA PET/CT, mpMRI, 3011
- Targeted therapies, non-small cell lung cancer, *EGFR* mutations, epigenetic therapy, 441
- Targeted therapy, chemotherapy, germany, austria, switzerland, treatment reality, disease characteristics, 4773
- Targeted therapy, endometrium cancer, PD-L1, PD-1, immune checkpoint, prognostic factor, 1367
- Targeted therapy, glioma, gene fusion, next-generation sequencing, molecular genetics, 1933
- Taxanes, NSCLC, lung cancer, nivolumab, chemotherapy, overall survival, pemetrexed, vinorelbine, 1987

- TCGA, *in silico* analysis, prognostic value, gene expression, 9p, 9p22.1 locus, 5291
- Temozolomide chemotherapy, *MGMT*, methylation status, *ATRX* loss, hypermethylation, low methylation, glioblastoma, wild-type *IDH*, glioblastoma, 335
- Temozolomide, gliomas, brain tumors, radiation therapy, diffusion tensor imaging, 329
- Temozolomide, ko143, combinatorial treatment, p-glycoprotein, BCRP, drug resistance, 723
- TERT, breast cancer, *DYRK2*, prognostic factor, 2079
- Tertiary lymphoid structures, colorectal cancer, fibroblast activation protein, 5897
- Texture analysis, non-small cell lung cancer, PET/CT, PD-L1, machine learning, 5875
- TGF- $\beta$ , eribulin, endMT, neo-angiogenesis, adhesion molecules, 2859
- Therapeutic era, acute myeloid leukemia, children, survival, 4499
- Therapeutic response, lenvatinib, prognostic nutrition index, hepatocellular carcinoma, 6019
- Therapeutic target, thymic carcinoma, thymoma, trkB, BDNF, 3779
- Thermic damage, trimetazidine, liver, rat model, colorectal, 4395
- Thigh, soft tissue sarcoma, compartment, 3143
- Three-dimensional cell culture, micelles, pH-responsive, tumor microenvironment, anti-fibrotic drug, tumor-bearing mice, 2847
- Three-dimensional model, breast cancer cells, endothelial cells, *in vivo* mimicking, 4689
- Thymic carcinoma, brain metastasis, cerebellar metastasis, stereotactic radiotherapy, 1169
- Thymic carcinoma, thymoma, trkB, BDNF, therapeutic target, 3779
- Thymidine dimer, CPD, cyclobutane pyrimidine dimer, DNA damage, LC-MS/MS, urine, bioanalysis, 5069
- Thymidine kinase 1, soft tissue sarcomas, proliferation, prognosis, 1509
- Thymidine phosphorylase, colorectal cancer, 5-fluorouracil, inhibitor of methylation, 837
- Thymoma, thymic carcinoma, trkB, BDNF, therapeutic target, 3779
- Thyroglobulin, differentiated thyroid cancer, lobectomy, risk factors, recurrence, 5619
- Thyroid cancer, neoplasms, second primary, radiotherapy, head and neck neoplasms, SEER program, 1359
- Thyroid cancer, PDTC, poorly differentiated thyroid cancers, 2531
- Thyroid cancer, SREBP1, galectin-3, 2487
- Thyroid hormones, breast cancer, carcinoma *in situ*, multifocal/multicentric tumors, lymphovascular invasion, proliferation, prognosis, 253
- Thyroid stimulating hormone, head and neck cancer, survivorship care plans, hypothyroidism, radiation, disparities, 4429
- TIM-3, immunoadjuvant molecules, breast cancer, pathological complete response, neoadjuvant chemotherapy, LAG-3, OX-40, 125
- Time to onset, alectinib, lung toxicity, Japanese adverse drug event report database, 3109
- Time to onset, bendamustine, skin damage, Japanese Adverse Drug Reaction Reporting Database, 2737
- Tirabrutinib, primary central nervous system lymphoma, bruton's tyrosine kinase inhibitor, 4173
- Tissue expression, renal cell carcinoma, miRNA, transcription factor, prognostic markers, 2355
- TLN1, liver cancer, microRNA-1303, proliferation, migration, invasion, 4715
- TNBC, snail mucus, anti-cancer, apoptosis, chemotherapy, 845
- TNBC,  $\beta$ -tubulin isoform, docetaxel, 3D culture, spheroid, morphology, 4735
- TNM classification, colorectal liver metastasis, prognostic factor, lymph node metastasis, N factor, 1997
- TNM staging, lung adenocarcinoma, surgical resection, recurrence, 1137
- Tolerability, effectiveness, everolimus, pancreatic neuroendocrine tumors, progression-free survival, real-world study, 1941
- Tolerability, nivolumab, disease control, progressive disease, immune-related adverse events, 4973
- Tolerable side effects, dicycloplatin capsules, bladder cancer, recurrence, remission, 1339
- Toll-like receptors, esophageal cancer, adenocarcinoma, squamous cell carcinoma, microbiome, review, 2813
- TomoTherapy, delivery accuracy, normal tissue exposure, ear keloid, customized bolus, 4411
- Tongue cancer, squamous cell carcinoma, ultrasonography, doppler, cervical lymph node metastasis, 287
- Total gastrectomy, vitamin B12, oral treatment, deficiency, gastric cancer, randomized controlled trial, 3963
- Total neoadjuvant therapy, rectal cancer, survival, pCR, metastasis; oxaliplatin, radiotherapy, 991
- Toxic cardiomyopathy, cardio-oncology, global longitudinal strain, treatment-related side effects, breast cancer, 3075
- Toxicity, adjuvant radiation therapy, py, locoregional radiotherapy, breast cancer, side-effects, 923
- Toxicity, head and neck cancer, cisplatin, radiotherapy, HPV, SIB, IMRT, 5909
- Toxicity, head and neck cancer, hearing loss, cisplatin, radiotherapy, concomitant treatment, cochlea, constraints, dose, 3003
- Toxicity, head and neck cancer, radiotherapy, intensity modulated radiation therapy, hypofractionation, 1845
- TP53* clonal variants, ovarian cancer, screening, CA125, ultrasound, microRNA, review, 4207
- TP53* mutation-TGF- $\beta$ 1-PAX7 pathway, tumor microenvironment (TME), epithelial-mesenchymal transition, tumor-infiltrating lymphocytes, human papillomavirus, 4417



- TP53, MDM2, CDKN2A*, breast cancer, copy number alteration, 2277
- TP53*, p38 MAPK, tumour repopulation, exosomes, bile duct cancer, 745
- TPF, concurrent chemoradiotherapy, squamous cell carcinoma, head and neck, prognostic factor, 6047
- TPS, nivolumab, PD-L1, recurrent/metastatic head and neck cancer, CPS, 1547
- Trace element, serum, breast cancer, surgery, ICP-MS, 5323
- Trans-resveratrol, colorectal carcinoma therapy, anti-angiogenic drug, plant derived polyphenols, quercetin, vitamin E, selenium, dogs, 4763
- Transarterial chemoembolization, hepatocellular carcinoma, sorafenib, barcelona Clinic Liver Cancer Stage C, National Health Insurance, reimbursement criteria, 4461
- Transbronchial microwave ablation, stent placement, post anticancer therapy, moderate sedation, 3125
- Transcervical mediastinoscopy, esophageal cancer, transhiatal esophagectomy, minimally invasive surgery, robotic-assisted surgery, review, 675
- Transcription factor, renal cell carcinoma, miRNA, tissue expression, prognostic markers, 2355
- Transfer learning, artificial intelligence, ewing sarcoma, osteomyelitis, tumor detection, early diagnosis, deep learning, 4371
- Transhiatal esophagectomy, esophageal cancer, transcervical mediastinoscopy, minimally invasive surgery, robotic-assisted surgery, review, 675
- Transient transfection, annexin V, dissociative enzymes, miRNA, flow cytometry, trypsin, 2819
- Transplantation, lymphoproliferative disorder, EBV, PTLD, CAR-T, review, 5181
- Transumbilical incision, laparoscopic, surgical site infection, colorectal, hernia, 1115
- Treatment outcome, bone sarcoma, SEER program, neoplasm grading, hand, orthopedic surgery, 1635
- Treatment planning, head-and-neck cancer, radiotherapy, late xerostomia, prognostic tool, 3035
- Treatment reality, chemotherapy, targeted therapy, Germany, Austria, Switzerland, disease characteristics, 4773
- Treatment sequence, hepatocellular carcinoma, atezolizumab plus bevacizumab, albumin-bilirubin grade, lenvatinib, 1403
- Treatment-related side effects, cardio-oncology, global longitudinal strain, toxic cardiomyopathy, breast cancer, 3075
- Treatment, breast cancer, disparity, inequality, 5813
- Trends, melanoma, incidence, mortality, overdiagnosis, sunburn, review, 5021
- Treosulfan, allogenic hematopoietic cell transplantation, case series, fludarabine, primary immunodeficiency, 4505
- Treosulfan, allogenic hematopoietic cell transplantation, case series, fludarabine, primary immunodeficiency, 4505
- Triage, HPV, cervical cancer, p16/Ki-67 dual-stained cytology, CIN2, CIN3, HSIL, screening, risk stratification, pap test, 2599
- Trifluoperazine, glioblastoma multiforme, COX-2, pPAR $\gamma$ , 5773
- Trimetazidine, liver, thermic damage, rat model, colorectal, 4395
- Trimodal therapy, neutrophil-to-lymphocyte ratio, oesophageal squamous cell carcinoma, prognosis, 1499
- Trimodality therapy, esophageal cancer, geriatric oncology, platinum/5-fluorouracil, carboplatin/paclitaxel, 59
- Triple-negative breast cancer (TNBC), A20/TNFAIP3, cell division cycle 20 (Cdc20), cASP1/Caspase-1, inflammation, metastasis, inflammation inhibitors, 681
- Triple-negative breast cancer, fluoxetine, STAT3, apoptosis, epithelial-to-mesenchymal transition, 3807
- Triple-negative breast carcinoma, breast, receptor-interacting serine/threonine-protein kinase 3, immunohistochemistry, prognosis, 2753
- Trismus, mallampati score, head and neck cancer, chemoradiotherapy, restricted mouth opening, outcome, 5609
- TrkB, thymic carcinoma, thymoma, BDNF, therapeutic target, 3779
- Trypsin, annexin V, transient transfection, dissociative enzymes, miRNA, flow cytometry, 2819
- TSG-6, canine mammary gland tumors, cell cycle, HIF1 $\alpha$ , metastasis, siRNA, 5803
- Tubular adenomas, field cancerization, colon, nondysplastic crypts, crypt branching, 5891
- Tubular type, adjuvant chemotherapy, invasive IPMC, poorly differentiated adenocarcinoma, lymph node metastasis, 2645
- Tumor bed boost volume, bioZorb<sup>®</sup> marker, adaptive boost planning, 2961
- Tumor detection, artificial intelligence, ewing sarcoma, osteomyelitis, early diagnosis, deep learning, transfer learning, 4371
- Tumor growth speed, appendicular skeletal metastases, pathological fracture, impending fracture, prophylactic surgery, 229
- Tumor growth, kindlin-3, immune cells, prostate cancer, xenograft model, 1217
- Tumor growth, WWC1, KIBRA, matrix metalloproteinases, predictive marker, upper urinary tract cancer, 2311
- Tumor immunology, eribulin, absolute lymphocyte count, progression-free survival, advanced or metastatic breast cancer, 939
- Tumor infiltrating lymphocytes, Merkel cell carcinoma, cancer-associated fibroblasts, 4359
- Tumor interstitial fluid, breast cancer, cytokine, clinical research methods, 1327
- Tumor location, esophageal cancer, esophageal wall thickness, neoadjuvant chemotherapy, 5655
- Tumor margins, indocyanine green, ICG, fluorescence-guided surgery, radiofrequency ablation, liver tumors, local recurrence, salvage hepatectomy, R0 resection, 1345



- Tumor marker, biomarker, head and neck cancer, tumor recurrence, 137
- Tumor marker, colorectal neoplasms, observational study, survival analysis, 3921
- Tumor marker, ovarian cancer, nETs, dsDNA, h3Cit-DNA, 965
- Tumor markers, colon cancer, pentoxifylline (PTX), cytokines, 5487
- Tumor microenvironment (TME), epithelial-mesenchymal transition, tumor-infiltrating lymphocytes, human papillomavirus, *TP53* mutation-TGF- $\beta$ 1-PAX7 pathway, 4417
- Tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs), automatic measurement, imaging analysis software, digital pathology, project HOPE, 419
- Tumor microenvironment, dog, endothelial cell, macrophage, melanoma, 5397
- Tumor microenvironment, hepatocellular carcinoma, STAT3 inhibition, anti-PD-1 therapy, CD8<sup>+</sup> T cell infiltration, immunosuppression, 5205
- Tumor microenvironment, melanoma, EB13, biomarker, 511
- Tumor microenvironment, micelles, pH-responsive, three-dimensional cell culture, anti-fibrotic drug, tumor-bearing mice, 2847
- Tumor necrosis factor receptor 21, death receptor 6, glioma, low-grade glioma, prognosis, survival, 1237
- Tumor progression, ELMO1, oncogenic phenotype, prognosis, colorectal neoplasm, 5343
- Tumor progression, gastric cancer, 14-3-3 sigma protein, cell proliferation, metastasis, prognostic factor, 519
- Tumor recurrence, tumor marker, biomarker, head and neck cancer, 137
- Tumor size, non-B non-C hepatocellular carcinoma, cellular proliferation, ki-67, 449
- Tumor size, pathological T3a, prognosis, renal cell carcinoma, 2185
- Tumor thrombus, renal carcinoma, surgical reconstruction, inferior vena cava, 1351
- Tumor-bearing mice, micelles, pH-responsive, three-dimensional cell culture, tumor microenvironment, anti-fibrotic drug, 2847
- Tumor-infiltrating lymphocytes (TILs), tumor microenvironment (TME), automatic measurement, imaging analysis software, digital pathology, project HOPE, 419
- Tumor-infiltrating lymphocytes, neoadjuvant chemotherapy, breast cancer, fibrotic foci, prognostic marker, 1421
- Tumor-infiltrating lymphocytes, oral squamous cell carcinoma, immune checkpoint, flow cytometry, regulatory T-lymphocytes, 2383
- Tumor-infiltrating lymphocytes, tumor microenvironment (TME), epithelial-mesenchymal transition, human papillomavirus, *TP53* mutation-TGF- $\beta$ 1-PAX7 pathway, 4417
- Tumor-specificity, polyphenol, PC12, SH-SY5Y, NGF, overlay method, neurotoxicity, bortezomib, cell cycle, chlorogenic acid, caffeic acid, 781
- Tumorigenic potential, host-mediated *in vivo/in vitro* assay, carcinogens, review, 4199
- Tumour repopulation, p38 MAPK, *TP53*, exosomes, bile duct cancer, 745
- Tumour-burden, cfDNA, LDH, VEGF, PD-L1, 801
- Tumour, colorectal liver metastasis, lymphocyte-to-C-reactive protein ratio, prognosis, overall survival, 4963
- Type 2 diabetes, adipocyte, anti-inflammation, insulin signal, lipopolysaccharide, 3983
- Type 4 gastric cancer, splenectomy, laparoscopic surgery, 5937
- TYRO3, TAM family, small interfering RNA, leukaemia, 1757
- Tyrosine kinase inhibitor, hepatocellular carcinoma, lenvatinib, sorafenib, post-progression survival, sequential therapy, 6007
- Tyrosine kinase inhibitor, lenvatinib, hepatocellular carcinoma, child-Pugh, adverse events, progression-free survival, objective response, 173
- Tyrosine kinase inhibitors, gastrointestinal stromal tumours, imatinib, discontinuation, qualitative research, side-effects, psycho-social, hope, 955
- Ulcerative colitis-associated colorectal cancer, lysophospholipids, lysophosphatidylinositol, lysophosphatidylserine, 2461
- Ulcerative colitis, colitis-associated cancer, *CHI3L1*, *CEACAM6*, *CLND2*, 4119
- Ulcerative colitis, colon biopsies, crypts, asymmetric branching, remission, 4493
- Ulcerative colitis, crypt branching, histopathology, 147
- Ultra-high dose rate, FLASH, radiation, carbon ions, cancer, fibroblast, 2469
- Ultra-radical, ovarian cancer, surgery, cytoreduction, lactate, length of stay, 1979
- Ultrasonography, breast, biopsy, vacuum, neoplasms, 2159
- Ultrasonography, tongue cancer, squamous cell carcinoma, doppler, cervical lymph node metastasis, 287
- Ultrasound, ovarian cancer, screening, CA125, microRNA, *TP53* clonal variants, review, 4207
- Ultraviolet Radiation, vitamin D, 25(OH)D, winter, cross-over trial, office lighting, 5101
- Ultraviolet-B, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, VDR, CYP24A1, 5049
- Unplanned excision, soft-tissue tumor, 2-5 cm, malignancy, MRI, needle biopsy, 1555
- Unresectable, angiosarcoma, chemoradiation, scalp, intensity-modulated radiotherapy, 5991
- Unused sterile instruments, surgical site infection, ring drape, hepatectomy, 1007
- Updated Sydney System, atrophic gastritis, autoimmune, serological biomarker panel, gastroPanel<sup>®</sup>, non-invasive test, *Helicobacter pylori*, pepsinogen, gastrin-17, hp IgG antibody, parietal cell antibody, intrinsic factor antibody, 1517

- Upper rectal cancer, neoadjuvant chemoradiotherapy, local recurrence, side effects, surgical complications, 4833
- Upper rectum, rectal cancer, neoadjuvant chemoradiotherapy, PME, sigmoid cancer, 155
- Upper urinary tract cancer, squamous differentiation, urothelial carcinoma, radical nephroureterectomy, prognosis, 263
- Upper urinary tract cancer, WWC1, KIBRA, tumor growth, matrix metalloproteinases, predictive marker, 2311
- Urine-based diagnostics, luminometric method, chelates, bladder cancer, 5249
- Urine, CPD, cyclobutane pyrimidine dimer, DNA damage, thymidine dimer, LC-MS/MS, bioanalysis, 5069
- Urology, COVID-19 vaccine, cancer, anticancer agent, adverse drug event, 2105
- Urothelial cancer, pembrolizumab, neutrophil-lymphocyte ratio, NLR, lactate dehydrogenase, LDH, c-reactive protein, CRP, immune checkpoint inhibitor, predictive factor, 2045
- Urothelial carcinoma, NFIA, NFIB, bladder cancer, muscle-invasive bladder cancer, 493
- Urothelial carcinoma, pembrolizumab, platelet-to-lymphocyte ratio, 1131
- Urothelial carcinoma, proton pump inhibitors, gut microbiota, pembrolizumab, immune checkpoint inhibitors, antibiotics, 1629
- Urothelial carcinoma, squamous differentiation, upper urinary tract cancer, radical nephroureterectomy, prognosis, 263
- UTX-51, molecular design, BSA, boron tracedrugs, 4017
- UV exposure, diabetes mellitus, cancer, melanoma, cardiovascular disease, mortality, review, 1671
- Uveal melanoma, intensity-modulated radiotherapy, stereotactic body radiotherapy, eye preservation, 1965
- Uveal melanoma, sIL-2R, biomarker, metastases prediction, 1447
- UVR, vitamin D, d-vitamin, cholecalciferol, hairless mice, 25-hydroxyvitamin D<sub>3</sub>, 5083
- Vacuum, breast, biopsy, ultrasonography, neoplasms, 2159
- Van Recklinghausen's disease, pheochromocytoma, neurofibromatosis type I, pregnancy, 4647
- Vascular endothelial cell, macrophages, monocytes, inflammatory cytokine gene, blood coagulation-related gene, lipopolysaccharide, 4049
- Vascular endothelial cells, patient-derived xenograft, pancreatic ductal adenocarcinoma, microenvironment, engraftment rate, 2395
- Vascular pain, gemcitabine, 5% glucose, saline, lyophilized formulation, liquid formulation, 343
- Vascular plexus, chorioallantoic membrane, MCF-7, mesenchymal stem cells, vasculogenesis, 877
- Vascular reconstruction, limb-sparing tumor surgery, extremity, bone tumor, soft tissue tumor, 4619
- Vascularized bone graft, bone sarcoma, fibula, limb-sparing procedure, non-vascularized fibula, 5443
- Vasculogenesis, chorioallantoic membrane, MCF-7, mesenchymal stem cells, vascular plexus, 877
- Vater papilla-preserving strategy, hepatocellular carcinoma, bile duct tumor thrombus, liver resection, 5663
- VDR, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, vitamin D receptor, CYP24A1, 5049
- VDRE, COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, review, 5043
- VEGF, cfDNA, LDH, PD-L1, tumour-burden, 801
- VEGFR, AXL, immunotherapy, KIT, MET, papillary renal cell carcinoma, 3151
- Vertical location, anterior wall, lymph node metastasis, gastric cancer, 237
- Very elderly patients, brain metastases, radiosurgery, fractionated stereotactic radiotherapy, survival score, 5629
- Very high risk of recurrence, maintenance chemotherapy, sorafenib, advanced hepatocellular carcinoma, 6127
- Viability, eriodictyol, HMOX1, FAK, cholangiocarcinoma, 3789
- Vinorelbine, NSCLC, lung cancer, nivolumab, chemotherapy, overall survival, pemetrexed, taxanes, 1987
- Vintage hormone therapy, prostate cancer, bone metastases, androgen receptor-targeted agents, 3099
- Virtual reality, colorectal cancer, laparoscopic surgery, mixed reality, navigation, 4849
- Visceral fat, gastric cancer, intramuscular adipose tissue content, obesity, postoperative complication, 4841
- Vitamin B12, oral treatment, deficiency, total gastrectomy, gastric cancer, randomized controlled trial, 3963
- Vitamin C, hyperthermia, ovarian cancer, anticancer activity, 5365
- Vitamin D deficiency, food fortification, supplementation, vitamin D status, 25-hydroxyvitamin D serum concentration, review, 5009
- Vitamin D metabolites, cancer prevention, LC-MS/MS assay development, vitamin D synthesis, 5077
- Vitamin D receptor, squamous cell carcinoma, keratinocytes, 1, 25-dihydroxyvitamin D<sub>3</sub>, ultraviolet-B, 25-hydroxyvitamin D<sub>3</sub>, CH223191, aryl hydrocarbon receptor, AHR, cytochrome P450 1A1, cyclooxygenase-2, VDR, CYP24A1, 5049
- Vitamin D response element, COVID-19, sARS-CoV-2, vitamin D, 25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, VDRE, review, 5043
- Vitamin D status, vitamin D deficiency, food fortification, supplementation, 25-hydroxyvitamin D serum concentration, review, 5009
- Vitamin D synthesis, cancer prevention, vitamin D metabolites, LC-MS/MS assay development, 5077

- Vitamin D toxicity, recommended daily intake, RDA, clinical trial study design, evidence-based medicine, public health, primary disease prevention, COVID-19, evolution, primate biology, review, 5027
- Vitamin D, 25-hydroxyvitamin D, pharmacokinetics, clinical trial, intestinal absorption, 5095
- Vitamin D, COVID-19, sARS-CoV-2, 25(OH)D, gene expression, blood, neutrophil-lymphocyte ratio, 1, 25(OH)2D, vitamin D response element, VDRE, review, 5043
- Vitamin D, d-vitamin, cholecalciferol, UVR, hairless mice, 25-hydroxyvitamin D<sub>3</sub>, 5083
- Vitamin D, mosquitoes, *Aedes aegypti* mosquitoes, *Drosophila melanogaster*, migratory birds, bats, vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 5091
- Vitamin D, ultraviolet Radiation, 25(OH)D, winter, cross-over trial, office lighting, 5101
- Vitamin D<sub>3</sub>, vitamin D, mosquitoes, *Aedes aegypti* mosquitoes, *Drosophila melanogaster*, migratory birds, bats, vitamin D<sub>2</sub>, 5091
- Vitamin E, colorectal carcinoma therapy, anti-angiogenic drug, plant derived polyphenols, trans-resveratrol, quercetin, selenium, dogs, 4763
- VMAT, knowledge-based treatment planning, plan complexity, delivery accuracy, prostate cancer, 5305
- Volumetric assessment, checkpoint inhibitors, radiotherapy, oligoprogression, abscopal effect, 4795
- Vomiting, nausea, radiotherapy, cervical cancer, cisplatin, 3117
- Wild-type *IDH*, *MGMT*, methylation status, *ATRX* loss, hypermethylation, low methylation, glioblastoma, temozolomide chemotherapy, glioblastoma, 335
- Winter, ultraviolet radiation, vitamin D, 25(OH)D, cross-over trial, office lighting, 5101
- Wnt, medulloblastoma, SHH, non-Wnt/non-SHH, review, 2225
- World Health Organization Classification, cervix, endocervical adenocarcinoma, human papillomavirus, 4627
- Wrist, ewing sarcoma, hand, finger, 1377
- WWC1, KIBRA, tumor growth, matrix metalloproteinases, predictive marker, upper urinary tract cancer, 2311
- X-Chromosome, x-linked, polymorphism, cancer, gender dimorphism, review, 2261
- X-linked, x-Chromosome, polymorphism, cancer, gender dimorphism, review, 2261
- XELOX therapy, metastatic colorectal cancer, oxaliplatin, frail patients, 1859
- Xenograft model, kindlin-3, immune cells, prostate cancer, tumor growth, 1217
- Xenograft, hepatocellular carcinoma, metformin, radiotherapy, neutron, radiosensitizer, 867
- Xerostomia, head-and-neck cancer, radiotherapy, radio-chemotherapy, risk factors, 2657
- ZAK cells, adoptive immunotherapy (AIT), zoledronate,  $\gamma\delta$ T cells, pancreatic cancer, 1181
- Zinc, light isotope, stable isotope, anticancer effect, cytotoxicity, apoptosis, 5685
- Zinc, pancreatectomy, pancreaticoduodenectomy, 5833
- Zoledronate, acridine orange, metastasis, breast cancer, 5357
- Zoledronate, adoptive immunotherapy (AIT), ZAK cells,  $\gamma\delta$ T cells, pancreatic cancer, 1181

## Authors Index

(Figures refer to page numbers)

- Aanes SG, 3061  
 Abbona A, 2859  
 Abdelsalam A, 1851  
 Abdul S, 1979  
 Abe K, 581, 1043, 1081, 1555, 5357  
 Abe M, 4603  
 Abe S, 2033, 2461, 5927  
 Abe T, 6099  
 Abobaker S, 1739  
 Abu-Gharbieh E, 355  
 Achilla C, 2261  
 Acs M, 13, 1019, 3681  
 Adachi A, 1439  
 Adachi T, 903, 3049, 3133  
 Adam BA, 1157  
 Addley S, 1979  
 Adelstein DJ, 3845  
 Adenis A, 185  
 Adeoye J, 5859  
 Aderhold C, 3403  
 Aggerholm-Pedersen N, 5527, 5699  
 Agiannitopoulos K, 5795  
 Agocs GR, 4773  
 Ahle G, 3863  
 Ahmadi N, 2939, 3665  
 Ahn J, 4453  
 Aida T, 4603  
 Aihara Y, 173, 1607  
 Ajisawa K, 4581  
 Akagi Y, 4003, 4011, 4063, 4079, 4089, 4119, 4129, 4139, 4153, 4159  
 Akahane T, 4895, 5465  
 Akahoshi S, 35, 1645, 3209  
 Akamatsu N, 1161  
 Akamine Y, 3895  
 Akashi K, 2053  
 Akashi M, 4079, 4089  
 Akiba J, 449, 4079, 4119, 4129, 4145, 4159  
 Akimoto E, 5571  
 Akimoto K, 3299, 5223  
 Akin I, 3075  
 Akino Y, 3529  
 Akiyama N, 837  
 Akiyama Y, 419, 3537, 4417, 5233  
 Al Diffalha S, 1381  
 Al Khudari S, 5449  
 Al-Jumayli M, 59  
 Al-Obaidi A, 59  
 Alamer OB, 619, 1661  
 Aldarazi G, 3583  
 Alduhaymi M, 1189  
 Alexopoulos A, 1031  
 Ali MKM, 1867  
 Allweis TM, 253  
 Almubarak S, 105  
 Alonsozana E, 5475  
 Alsharif U, 97  
 Altoukhi K, 1001  
 Alzahrani N, 1001, 4563  
 Amanie J, 2665  
 Amano R, 2395  
 Amano S, 781  
 Amaro B, 1893  
 Amato A, 827  
 Amico P, 3203  
 Amornphimoltham P, 2689  
 An J-H, 5397, 5803  
 An J, 2131  
 An JY, 2883  
 Anagnou NP, 2599  
 Ando F, 1599  
 Ando K, 1131, 3341  
 Ando T, 5233  
 Andreadis C, 1941  
 Angelicone I, 211  
 Angelis L, 2261  
 Angrisani M, 2743  
 Ann T, 173  
 Annicchiarico A, 2249  
 Antolino L, 25  
 Antonelli A, 5579  
 Anttonen A, 5457  
 Anzai H, 2033, 2461  
 Aoki I, 547  
 Aoki J, 2461  
 Aoki T, 67, 1115, 1345  
 Aoki Y, 731, 2567, 3017, 3857, 4887, 5217, 5819  
 Aoshika T, 2095, 6099  
 Aoun SG, 619, 1661, 3251  
 Aoyagi K, 4003  
 Aoyama T, 1535, 2711, 2719, 2763, 3873, 3929, 3963, 4545, 5167, 5635, 5885  
 Apossos A, 5795  
 Apostolidis S, 4199  
 Arai F, 4879  
 Arai S, 4063  
 Arakaki Y, 3017, 4887  
 Arakane T, 4305  
 Araki K, 245, 5971  
 Araki M, 1527  
 Araki Y, 229, 1081, 1555  
 Arasaki CH, 4381  
 Arcaro A, 3217  
 Ardavanis A, 1031  
 Ardizzoia A, 2017  
 Ariga H, 6047  
 Ariga T, 4887  
 Arigami T, 3373, 3905, 3953  
 Arima K, 381  
 Arita J, 1161  
 Arita T, 1623, 3349, 3645  
 Armstrong BK, 5021  
 Arora R, 4647  
 Arranto C, 4505  
 Artigiani R, 4381  
 Asada T, 1763  
 Asagi A, 893  
 Asahina A, 2023  
 Asakura H, 4417  
 Asamura S, 217  
 Asano K, 2301  
 Asano Y, 125, 229, 311, 939, 1081, 1421, 3143, 3937, 4619  
 Asanuma K, 4319  
 Asanuma Y, 4319  
 Asaoka M, 4735  
 Asawa P, 3595, 3853  
 Ascione B, 767  
 Ashary MA, 5813  
 Asher V, 1979  
 Ashida R, 3169  
 Ashizawa T, 419, 3537, 4417, 5233  
 Asp M, 2541  
 Aspinen S, 5521  
 Assumpção PP, 4381  
 Astigiano S, 2859  
 Astore S, 1487  
 Atake Y, 4867  
 Athanasiadis A, 1031  
 Athanasiadis I, 1941  
 Atsumi Y, 2763  
 Attwood K, 5813  
 Atula T, 5415  
 Aula H, 2519  
 Aurello P, 25, 3285  
 Avallone A, 4667  
 Avgoustidis D, 5547  
 Baba H, 381, 1007  
 Baba K, 2953  
 Baba T, 4603  
 Baba Y, 2727  
 Baco E, 2967  
 Bae GE, 4453  
 Bae H, 4627  
 Bae JM, 2883  
 Bae KB, 5385  
 Bae SK, 1161  
 Bæk R, 5699  
 Bagheri MS, 1933  
 Bai J, 3325  
 Bai Q, 2425, 2903, 3275  
 Baider L, 5487  
 Baik H, 5385  
 Bailey C, 3523  
 Bajric T, 1413  
 Baka S, 1031  
 Bakalova R, 547  
 Bakulina N, 1517  
 Balakin A, 5685  
 Baldaccini D, 2997  
 Baldinu M, 2249  
 Baldoncini M, 3203  
 Bali A, 1979  
 Bando H, 4879  
 Bando Y, 195, 973  
 Bandoh T, 2071  
 Bansal A, 59  
 Banyai D, 109  
 Barak V, 1447, 5487  
 Baranda J, 59  
 Barat S, 2939  
 Barbieri O, 2859  
 Barletta F, 5579  
 Barlow JD, 3869  
 Barone F, 1851, 5867

- Bartscht T, 4511, 4529  
 Bassanelli M, 2241  
 Bassermann F, 5431  
 Bassi P, 1487  
 Basso U, 165  
 Bastian S, 4773  
 Bastos MMSM, 2443  
 Batra PS, 5449  
 Bau D-T, 1229, 1749, 2375, 3381, 3799, 4329, 5275, 5283, 5335  
 Bauerschmitz G, 5187  
 Bech ES, 5083  
 Beck-Broichsitter B, 2405  
 Beeck AV, 4485  
 Beige A, 5847  
 Bekki T, 5983  
 Belch J, 3261  
 Belko E, 1517  
 Belyakov I, 1517  
 Benbow J, 4429  
 Bengtsson J, 2541  
 Beppu N, 5587  
 Beppu S, 1653  
 Beppu T, 35, 1333, 1645, 3209, 5663  
 Berg RE, 2967  
 Bergman H, 4259  
 Bernasconi DP, 2743  
 Berzava PL, 1313  
 Bhattarai PY, 2911  
 Bhayani M, 5449  
 Biczo Z, 109  
 Bidinotto LT, 5291  
 Bieńkowska-Tokarczyk A, 5365  
 Bilal T, 4879  
 Bilek O, 1987  
 Bili C, 5795  
 Biliatis I, 2003  
 Bimonte S, 4667  
 Bin Alamer O, 1189, 3251, 4189  
 Birk R, 3403  
 Biskup E, 1  
 Blaj S, 1019  
 Blanck O, 5629  
 Blazek J, 1563, 1987  
 Blockhuys K, 4485  
 Blomqvist C, 1509  
 Boecker W, 1455  
 Bogiel T, 3607  
 Bohnet S, 1973, 2029  
 Boller D, 3217  
 Bolm L, 2743  
 Booka E, 2977  
 Borazan E, 1301  
 Borges PM, 1481  
 Borgfeldt C, 965  
 Borsotti F, 5847  
 Bose D, 5475  
 Botaitis S, 2363  
 Boukovinas I, 1031, 5795  
 Boulos C, 2355  
 Bourdeau I, 5579  
 Bourlier P, 1949, 4833  
 Bournakis E, 5795  
 Boutis A, 1031  
 Bouvet M, 731, 739, 5217  
 Bove P, 1487  
 Bradford KL, 1697  
 Braicu EI, 1739  
 Braitsch K, 5431  
 Bratova M, 1563, 1987  
 Brescia A, 211  
 Bria E, 1487  
 Brickman DS, 4429  
 Briganti A, 5579  
 Brinch CM, 5527, 5699  
 Brock MV, 697  
 Brodin D, 2827  
 Broida SE, 3869  
 Bronnimann C, 3863  
 Brozova L, 1987  
 Bruchhage KL, 2657, 3035, 3551  
 Bruland ØS, 955  
 Brunasso L, 5867  
 Buchs NC, 929  
 Bulleri A, 947  
 Bulsara S, 5673  
 Bun A, 4813, 4867  
 Buonomo C, 4913  
 Buonomo OC, 3879, 4913  
 Burgkart RHH, 4371  
 Burkey BB, 1845, 2531  
 Bustamante G, 1397  
 Buti S, 1487  
 Byeon J-H, 3789  
 Byun H, 589  
 Caffo O, 165  
 Cai J, 3325  
 Caires Santos L, 4381  
 Calais G, 155, 1949, 4833  
 Calistri E, 2997  
 Campbell SR, 1845  
 Campero A, 3203  
 Caponnetto S, 991  
 Capretti G, 2743  
 Carbajal-Mamani SL, 75, 1893  
 Cardenas-Goicoechea J, 75, 1893  
 Cardone C, 4667  
 Cardoso Smith MA, 4381  
 Careddu G, 767  
 Carlo-Stella C, 767  
 Carmon E, 253  
 Carrara HHA, 1327  
 Carrico-Moniz D, 2835  
 Carriero PL, 827  
 Carrizosa D, 4429  
 Casadei C, 165  
 Cascella M, 4667  
 Caspi J, 4913  
 Catalano M, 3261  
 Cattry-Thomas I, 3863  
 Ceausu A-R, 877  
 Cerbu S, 1313  
 Ceribelli A, 2241  
 Cerruto MA, 5579  
 Cervelli V, 3879  
 Chae SW, 5601  
 Chainey J, 2665  
 Chairoungdua A, 3835  
 Chaisuparat R, 2689  
 Chan D, 3523  
 Chan N, 93  
 Chandra P, 4199  
 Chang C-F, 2145  
 Chang C-P, 3427  
 Chang H-W, 3389  
 Chang JH, 335  
 Chang JT-C, 5609  
 Chang JW-C, 2145  
 Chang S-J, 363  
 Chang T-H, 4753  
 Chang W-C, 845  
 Chang W-S, 1229, 1749, 2375, 3381, 3799, 4329, 5275, 5283, 5335  
 Chang Y-H, 4753  
 Chang YS, 1615  
 Chanvorachote P, 4237, 4247  
 Chao KSC, 1143  
 Chapet S, 155, 1949, 4833  
 Characiejus D, 3067  
 Charalabopoulos A, 675, 2813  
 Charalampidou S, 5547  
 Charoenngam N, 5095  
 Chatzikyriakidou A, 2261  
 Chaurasia B, 3203  
 Chen AL, 3251  
 Chen B-R, 845  
 Chen C-C, 5275, 5283  
 Chen C-H, 2145, 2375, 3389  
 Chen C-J, 531  
 Chen C-P, 2375, 5275  
 Chen C-S, 2185, 4857  
 Chen C-T, 4461  
 Chen ES, 4381  
 Chen F, 3595  
 Chen H-J, 3195  
 Chen J-C, 1749  
 Chen J-H, 3825, 4403  
 Chen JY-F, 3389  
 Chen K-Y, 3799  
 Chen K, 3665  
 Chen L-H, 3381  
 Chen M, 3325  
 Chen S-Y, 4857  
 Chen W-L, 3825  
 Chen WT-L, 1143  
 Chen X, 2425  
 Chen Y-K, 3389  
 Chen Y-S, 845  
 Chen-Yoshikawa TF, 5539  
 Cheng A-L, 4461  
 Cheng C-L, 2185, 4857  
 Cheng E, 2939, 3665  
 Cheng S-P, 2487  
 Cheong SH, 555  
 Chiao PJ, 4679  
 Chiba H, 2923  
 Chiba N, 1997, 2009  
 Chien C-R, 1143, 3195  
 Chien W-C, 4329, 5275  
 Chieochansin T, 1785  
 Chikamatsu K, 1439  
 Chikui K, 4573  
 Chin K, 2683  
 Chin Y-T, 5283  
 Chiocchi M, 4913  
 Chiou Y-E, 811  
 Chiraphapphaiboon W, 1785  
 Chiu K-Y, 2185, 4857  
 Chiu S-C, 3427  
 Chiu S-W, 6105  
 Chiu Y-J, 531  
 Cho D-Y, 3427



- Cho H, 2711, 3929, 3963, 4545, 5635  
 Cho I-J, 5951  
 Cho J-S, 5619  
 Cho J, 6091  
 Cho KR, 6091  
 Cho S-B, 5343, 5951  
 Cho S-Y, 5343  
 Choderlos X, 3863  
 Choi CM, 1615  
 Choi HS, 2911  
 Choi HY, 3445  
 Choi J-W, 2131  
 Choi JW, 6091  
 Choi M-G, 2883  
 Choi S-W, 5859  
 Choi SI, 599  
 Choi YS, 6083  
 Chomiccki S, 155, 4833  
 Chong GO, 349  
 Chou F-I, 3413  
 Chou S-H, 1143  
 Chou W-C, 5609  
 Choucair K, 59  
 Christ G, 2607  
 Christofi C, 5049  
 Chu J, 4453  
 Chu P-Y, 3807  
 Chu QS, 1157  
 Chuang C-K, 4753  
 Chuang Y-J, 3413  
 Chueh F-S, 3825  
 Chun FKH, 5579  
 Chun HJ, 3463  
 Chung KY, 4359  
 Chung M-W, 5343  
 Chung Y, 2753  
 Chute DJ, 3845  
 Ciancio G, 1351  
 Ciccicarese C, 165, 1487  
 Cichoń T, 4763  
 Cimpean A-M, 877, 1313  
 Clausen S, 1455  
 Claxton RM, 105  
 Coccia N, 1965  
 Cohen S, 5257  
 Cohen-Gadol AA, 1189, 4189  
 Collins S, 2003  
 Comsa S, 877, 1313  
 Condic M, 4825, 5839  
 Consalvo S, 4371  
 Coordes A, 2405  
 Copper C, 1377  
 Coppola D, 1381  
 Coraggio G, 2997  
 Corsale G, 5867  
 Cortesi E, 991  
 Cosentino S, 3011, 5867  
 Cosio S, 947, 2017, 4207, 4659  
 Cosma A, 1313  
 Cosmi B, 3261  
 Cosnita ADR, 1313  
 Costa NR, 2443  
 Costanzo R, 5867  
 Costi R, 2249  
 Courtot L, 1949  
 Crea A, 1851, 5867  
 Cremers F, 2657, 3035, 3551  
 Cresti F, 1965  
 Cristaudo AT, 4217  
 Cristaudo C, 5867  
 Crossland H, 1979  
 Crovetto A, 3285  
 Cullimore V, 1979  
 Cuomo A, 4667  
 Cuttone G, 5867  
 Czapla J, 4763  
 Czyzewski K, 3607  
 D'Ambrosio G, 991  
 D'Angelo F, 25, 3285  
 D'Urso P, 3003  
 D'Urso R, 2249  
 Da Costa RMG, 2443  
 Da Ros V, 1851, 5867  
 Dahm F, 1821  
 Daino K, 2415  
 Dalla Via V, 4505  
 Damen PJJ, 4795  
 Dammerer D, 4485, 4647  
 Dantas FT, 1327  
 Darb-Esfahani S, 1739  
 Daskalakis G, 2599  
 Dauksa A, 2289  
 Dauksiene D, 2289  
 Davakis S, 675, 2813  
 David IB, 5257  
 De Cobelli O, 5579  
 De Felice F, 991, 3003, 3285, 5909  
 De Giorgi U, 165  
 De Grève J, 1433  
 De Gruijl FR, 5009, 5021  
 De Heer P, 5527, 5699  
 De La Pinta C, 667  
 De Laurentiis A, 3217  
 De Paepe P, 1175  
 De Souza SLS, 1327  
 De Toma G, 991  
 De Vincentiis M, 3003  
 Debbi K, 4833  
 Debs T, 3285  
 Debski R, 3607  
 Decoster L, 1433  
 Dekalo S, 3569  
 Delattre O, 3217  
 Delikanli C, 5561, 5629  
 Delrue C, 1175  
 Demachki S, 4381  
 Dembélé P, 4689  
 Demichelis ME, 3203  
 Demkow U, 5365  
 Denaro N, 2859  
 Denda T, 2675  
 Deng F, 3601  
 Deng Z, 2425  
 Denkert C, 1739  
 Depledge P, 3217  
 Dias TR, 2443  
 Dicipinigaitis AJ, 2225  
 Dideban B, 1893  
 Dimakakos E, 3261  
 Dimitroulis D, 675  
 Ding D, 2341  
 Dinh DTD, 1237, 2319  
 Dlouha Z, 1987  
 Do J, 4453  
 Do S-I, 2753, 4453, 5601  
 Dobilas A, 965  
 Doepfner KT, 3217  
 Doi H, 5587  
 Doi R, 2893  
 Doki Y, 1859, 3759, 4701, 4989, 5897  
 Dokuni R, 1289  
 Dolezal D, 1987  
 Doll C, 2405  
 Domali E, 2599  
 Domb C, 3845  
 Domen A, 373  
 Dominguez A, 2425  
 Dominguez DE, 929  
 Dong C, 5443  
 Dos Reis FJC, 1327  
 Dosaka-Akita H, 3185, 3693  
 Doty A, 2819  
 Dou X, 4345  
 Drif AI, 3483  
 Drifa M, 4833  
 Drosslerova M, 1563, 1987  
 Drzyzga A, 4763  
 Duda DG, 5205  
 Duerschmied D, 3075  
 Dupuis ML, 767  
 Durando X, 3583  
 Dutton N, 3595  
 Dziedzic M, 3607  
 Dziegiel P, 5731  
 Dziggel L, 3085  
 Ecke TH, 5249  
 Efferth T, 3483  
 Egashira N, 2053  
 Egawa S, 2023  
 Egen L, 1911  
 Egger E, 4825, 5839  
 Egger EK, 1367  
 Eguchi H, 1859, 3759, 4701, 4989, 5897, 6127  
 Eguchi S, 903, 2395, 3049, 3133  
 Eichler C, 1925  
 Eisterer W, 4773  
 Ejima K, 4573  
 El Ahmadieh TY, 1189, 4189  
 El Sharouni SY, 4795  
 El-Huneidi W, 355  
 Eladl M, 355  
 Emi A, 5945  
 Emi M, 1499, 2791, 6037  
 Emoto S, 2033, 2461, 5927  
 Enami Y, 1115, 1345  
 Endo I, 791, 2573, 5497  
 Endo K, 3929  
 Endo M, 2931  
 Endo S, 4025  
 Endo T, 2583, 3159  
 Endo Y, 3735  
 Engelmann BE, 5699  
 Enokida H, 1465, 3099  
 Enokida Y, 1123  
 Enomoto M, 459, 2113, 4895, 5465  
 Enomoto Y, 2079  
 Eom H-S, 6083  
 Eppinga WSC, 4795  
 Epstein E, 1671  
 Erba PA, 2997  
 Erben P, 1911  
 Eren T, 5917  
 Eskelinen Maaret, 1879, 3557, 5521

- Eskelinen Matti, 1879, 3557, 5521  
 Esmaeili A, 4199  
 Estêvão D, 2443  
 Eto K, 837, 301, 3023  
 Falanga A, 3261  
 Falchetto Osti M, 211  
 Falk M, 1455  
 Falougy M, 97  
 Fang F, 3971  
 Fang H-Y, 3195  
 Fang Y-F, 2145  
 Fang Y, 2425, 2903, 3275  
 Fanning N, 801  
 Farah W, 5847  
 Farkas G, 1059  
 Fattet S, 3217  
 Fauske L, 955  
 Fauzi YR, 1763  
 Fazal S, 3595, 3853  
 Fehr A, 1455  
 Fenchel K, 4773  
 Ferencz S, 4395  
 Ferguson PC, 105  
 Ferician AM, 1313  
 Ferician OC, 1313  
 Ferini G, 1661, 1851, 3203, 3251, 4189, 4641, 5867  
 Ferrara MG, 1487  
 Ferreira Leal M, 4381  
 Fertmann J, 4517  
 Fidler MJ, 5449  
 Fimmers R, 1367  
 Fincsur A, 4395  
 Fischer O, 1563, 1987  
 Fisher OM, 4563  
 Fishman D, 75  
 Fleming CW, 1845, 3845  
 Florentin L, 5795  
 Fontaine C, 1433  
 Foschi N, 1487  
 Fountzilias G, 5795  
 Fraggetta F, 3011  
 Frappaz D, 3863  
 Fredenburg KM, 2819  
 Frei K, 3217  
 Frenkel CH, 4429  
 Frey J, 947  
 Friedrich RE, 1247, 1455, 2327, 2607, 2945, 6121  
 Fritsch R, 4773  
 Fu C-K, 1749  
 Fu J, 4679  
 Fuderer L, 4647  
 Fuentes R, 667  
 Fuentes T, 1965, 2997  
 Fuji T, 2797, 4471  
 Fujihara S, 1263, 4037  
 Fujii H, 3117, 4581  
 Fujii M, 2675  
 Fujii S, 3125, 6113  
 Fujii T, 2277, 4305  
 Fujii Y, 1763  
 Fujikawa H, 2719  
 Fujimori A, 67, 1115, 1345  
 Fujimoto K, 581  
 Fujimoto M, 3361  
 Fujimoto N, 263, 1107, 1629, 3041  
 Fujimoto Y, 4813, 4867, 4895, 5465  
 Fujimura A, 2869  
 Fujimura Y, 407  
 Fujinaga Y, 4895, 5465  
 Fujino S, 3759, 4989, 5897  
 Fujioka N, 4305  
 Fujioka S, 1579  
 Fujisawa F, 6027  
 Fujisawa M, 973  
 Fujishima F, 2875  
 Fujishima Y, 1403  
 Fujita F, 4003, 4011  
 Fujita K, 1263, 4037, 6105  
 Fujita M, 287, 4173  
 Fujita N, 911, 4037  
 Fujiwara H, 237, 1623, 3645  
 Fujiwara K, 321  
 Fujiwara M, 2045, 2123, 5587  
 Fujiwara R, 2045, 2123  
 Fujiwara S, 195  
 Fujiwara T, 2797, 3637, 4471  
 Fujiwara T, 653  
 Fujiwara Y, 2177, 4787, 5719  
 Fukasawa Y, 3743  
 Fukuda A, 3041  
 Fukuda H, 3151  
 Fukuda J, 4011  
 Fukuda S, 1073  
 Fukugawa Y, 205  
 Fukui R, 4813, 4867  
 Fukui S, 3133  
 Fukui T, 2009  
 Fukumitsu K, 1073  
 Fukumoto K, 5539  
 Fukumoto T, 1403, 5479  
 Fukumura Y, 2893  
 Fukunaga J-I, 5305  
 Fukunaga T, 4841  
 Fukuoka H, 1527  
 Fukushima T, 5315  
 Fukushima G, 459  
 Fukushima K, 5479  
 Fukushima M, 5001  
 Fukushima N, 2009  
 Fukutomi S, 4089  
 Fukuyama M, 5323  
 Fumimoto Y, 3529  
 Funaki S, 321  
 Funakoshi Y, 1199  
 Funasaka C, 3743  
 Funasaka K, 1905  
 Funayama Y, 2583  
 Furubayashi N, 1571  
 Furuhashi S, 3313  
 Furukawa A, 4879  
 Furukawa J, 973  
 Furukawa K, 2583, 3621, 4679  
 Furukawa T, 1043, 2645  
 Furuke H, 3349  
 Furuse J, 893  
 Furuta M, 1535  
 Fuse Y, 301  
 Fushimi C, 1607, 3177, 4907  
 Futagawa Y, 1579  
 Futsukaichi T, 2071  
 Fuxius S, 4773  
 Gabriel E, 5813  
 Gabriel M, 1949  
 Gadducci A, 947, 2017, 4207, 4659  
 Gaessler J, 1899  
 Gahin AEA, 67  
 Galli L, 2997  
 Gallwas J, 5187  
 Galtung KF, 2967  
 Gambino A, 2017  
 Gandhi CD, 2225  
 Garcia CC, 5579  
 Garnier O, 4689  
 Garrison J, 397  
 Garrone O, 2859  
 Gasparrini M, 211  
 Gavazzi F, 2743  
 Gawrychowski K, 5365  
 Gehrt F, 137  
 Geiger JL, 2531, 3845  
 Gelfend Y, 5257  
 Gemma A, 709  
 Genovesi-Ebert F, 1965  
 George A, 5813  
 George M, 2961  
 Georgoulis V, 5795  
 Gerger A, 4773  
 Gerken M, 1019  
 Gerotziafas G, 3261  
 Gerull K, 2657, 3035, 3551  
 Gesk S, 1455  
 Gevensleben H, 1367  
 Ghiringhelli F, 3863, 5847  
 Ghosh S, 2665  
 Gianotti L, 2743  
 Giarnieri E, 2249  
 Giassas S, 1031  
 Giger-Pabst U, 155, 1949  
 Ginman C, 87  
 Gintoni I, 5547  
 Giulitti D, 3285  
 Givens NT, 2903  
 Glatzel E, 1973, 2029  
 Glenn D, 4563  
 Go G, 857  
 Goan Y-G, 3389  
 Gobin CM, 2819  
 Goda K, 1169  
 Godai T, 2763  
 Goertz L, 1237  
 Gohno T, 759  
 Goldbrunner R, 1237, 2319  
 Goly N, 1911  
 Gomatou G, 3261  
 Gomes Lourenço L, 4381  
 Gon H, 5479  
 Gonçalves PG, 5291  
 Gong JH, 1813  
 González IB, 6057  
 Gorski SM, 5443  
 Görtz L, 2319  
 Goshima Y, 791  
 Goto H, 1051, 2775, 5553  
 Goto K, 2177, 4787, 4849  
 Goto M, 195, 2683  
 Goto S, 1115, 4179, 4417  
 Goto T, 1403, 5479  
 Goto W, 125, 311, 939, 1421, 3937  
 Goto Y, 4063, 4089  
 Götze K, 5431  
 Grant WB, 5009  
 Greil R, 4773

- Griffin AM, 105  
 Griffith CC, 3845  
 Groß-Weege M, 1911  
 Grotzer MA, 3217  
 Gründker C, 5187  
 Grüne B, 1911  
 Grützner U, 4517  
 Guerreiro AS, 3217  
 Gugenheim A, 5257  
 Guido F, 1965  
 Guimarães DP, 1879, 3557  
 Gunji T, 1997  
 Günsilius E, 5825  
 Guo P, 4707  
 Guo Y, 1339  
 Gupta A, 53  
 Gupta AD, 1189  
 Habu T, 5571  
 Hachim M, 355  
 Häder D-P, 5035  
 Haedersdal M, 5083  
 Haffty B, 53  
 Haffty BG, 93, 2961  
 Hagel C, 1247, 2327, 2945  
 Hager S, 441  
 Hagi T, 4319  
 Hagiwara K, 245, 5971  
 Hagiwara N, 1599  
 Hagiwara S, 1653  
 Hagiwara T, 697  
 Hagiwara Y, 2139  
 Haglund C, 5415  
 Hagström J, 5415  
 Haider AS, 619, 1189, 1661, 3261, 4189  
 Haider M, 1189, 1381  
 Hakim SG, 97, 1295, 2657, 3035, 3551  
 Hakozaiki T, 67, 1345  
 Halbe J, 1367, 3523  
 Hallmann S, 5249  
 Halmy L, 1019, 3681  
 Halon A, 493  
 Hama Y, 329  
 Hamabe A, 5897  
 Hamad H, 5257  
 Hamada K, 731, 3613, 3857, 5819  
 Hamada T, 3049, 3133, 4553  
 Hamada Y, 4103  
 Hamai Y, 1499, 6037  
 Hamakawa T, 5655  
 Hämäläinen E, 5521  
 Hamano R, 4963  
 Hamasaki M, 5315  
 Hamauchi S, 4417  
 Hamaya S, 1263, 4037  
 Hamilton G, 429  
 Han B, 5951  
 Han JW, 3463  
 Han M, 2277  
 Han NY, 599  
 Han Q, 641, 731, 2567, 3857, 5217, 5819  
 Han S-I, 3789  
 Hanada N, 381  
 Hanai N, 1653, 4597  
 Hanaki T, 2177, 4787  
 Hanamura T, 759  
 Hanawa T, 3299  
 Handa A, 911  
 Haneda R, 2977  
 Hannouche D, 929  
 Hanstein B, 1925  
 Hanyu K, 1607, 4907  
 Hara K, 2711, 3929, 3963, 4545, 4849, 5167, 5635, 5719  
 Hara M, 1277  
 Hara T, 903, 973, 3049, 3133  
 Hara Y, 1645, 3299, 5223  
 Harada H, 1051, 2775, 4417, 5553  
 Harada J, 5571  
 Harada K, 263, 1629, 3041, 3099  
 Harada M, 1629, 3495  
 Harada Y, 1607, 3299, 4071, 5223  
 Haraga J, 4535  
 Haraguchi M, 5001  
 Harano K, 3743  
 Harata S, 1277, 5357  
 Haratake N, 1137  
 Hargiss JB, 3869  
 Harikar MM, 5867  
 Harimoto N, 245, 5971  
 Härmä H, 5249  
 Hartung F, 1911  
 Harui S, 5587  
 Haruki K, 3621  
 Haruna M, 2383  
 Haruta M, 1131  
 Hasebe R, 5763  
 Hasegawa H, 1051, 1541, 2775, 2931, 5553  
 Hasegawa J, 1859  
 Hasegawa K, 1161  
 Hasegawa S, 4103  
 Hasegawa T, 2177, 4787  
 Hasegawa Y, 263, 1729, 3637  
 Hashimoto H, 1043  
 Hashimoto I, 1535, 2711, 3873, 3929, 5635, 5885  
 Hashimoto K, 981, 3653  
 Hashimoto M, 1207  
 Hashimoto S, 1905, 3091, 5643  
 Hashimoto Y, 3151  
 Hashine K, 1465, 3099  
 Hashmi FH, 1339  
 Hassan N, 5249  
 Hata K, 2023  
 Hata S, 2875  
 Hata T, 3759, 4989, 5897  
 Hatano E, 6127  
 Hatano K, 3529  
 Hatano T, 4477  
 Hathout L, 2961  
 Hatori T, 3159  
 Hattori A, 4867  
 Hattori M, 3735  
 Hattori N, 3889  
 Hattori R, 3627  
 Hattori S, 4589  
 Hatz R, 4517  
 Hauch H, 45, 2805  
 Haug M, 5443  
 Haughian JM, 397  
 Haukland EC, 923, 3061  
 Hayakawa M, 3217  
 Hayami S, 217  
 Hayasaki Y, 3117  
 Hayase S, 5897  
 Hayashi H, 35, 1007, 3117, 4581  
 Hayashi K, 229, 321, 1081, 1535, 3143, 3529, 4063, 4153, 4619  
 Hayashi M, 3889  
 Hayashi R, 5751  
 Hayashi S-I, 759  
 Hayashi S, 4071, 4097  
 Hayashi T, 4545, 4973  
 Hayashi Y, 6007  
 Haybaeck J, 1413  
 Hayward R, 397  
 Hazama D, 271  
 He J-L, 4329  
 Hecking T, 1367  
 Heeney J, 1013  
 Heerfordt IM, 5017  
 Heffron CC, 801  
 Heidenreich MJ, 1377  
 Heiland M, 2405  
 Heim D, 4505  
 Heino P, 5507  
 Henriques Palma GB, 565  
 Heo SH, 4265  
 Herhaus P, 5431  
 Hermann P, 109  
 Hermanson E, 4259  
 Hermansson S, 5069  
 Herold Z, 3681  
 Herrmann J, 1911  
 Heugl M, 429  
 Heydenreich J, 5069  
 Hidaka E, 1997  
 Hidaka M, 903, 3049, 3133  
 Higashijima K, 1629  
 Higuchi A, 2763  
 Higuchi R, 893  
 Higuchi T, 739, 1081, 1555, 4813, 4867  
 Hikichi T, 1207  
 Himoto T, 1263  
 Hinterwimmer F, 4371  
 Hirabayashi K, 2893  
 Hirai F, 4103  
 Hirai H, 1547  
 Hirai M, 6105  
 Hirai R, 6099  
 Hirai T, 67, 1345  
 Hiraide T, 3313  
 Hirakawa K, 125, 311, 939, 1421  
 Hiramatsu Y, 2977, 3313  
 Hiranuma O, 4921  
 Hirao M, 5655  
 Hirashima Y, 3537  
 Hirata H, 321  
 Hirata M, 2383, 4037  
 Hirata T, 321, 3529  
 Hirji A, 1157  
 Hirohata R, 1499, 2791, 6037  
 Hirokawa T, 1277  
 Hirono S, 217  
 Hirooka Y, 1905  
 Hirose K, 2383  
 Hiroshige T, 3041, 4573

- Hiroshima Y, 791, 2953, 2989, 3873, 5323, 5885  
Hirota Y, 2469  
Hiruma T, 3701  
Hirvonen O, 5457  
Hisaka T, 4063, 4079, 4089, 4129, 4153, 4159  
Hisakane K, 709  
Hisamatu Y, 4701  
Hisamori S, 5937  
Hisanori S, 1091  
Hishikawa Y, 5587  
Hishimura R, 1635  
Hiyoshi M, 1763, 4553  
Hizawa N, 2583, 4589  
Hjäl m-Eriksson M, 87  
Hmai Y, 2791  
Ho C-Y, 845  
Ho W-C, 845  
Hoch S, 137  
Hoffman RM, 67, 641, 697, 731, 739, 1345, 2341, 2567, 3857, 4707, 4715, 5217, 5819  
Hofheinz R-D, 3075  
Hofmann W-K, 3075  
Hofmeister CC, 385  
Hogan T, 1339  
Hogdall C, 1  
Hogdall E, 1, 5527, 5699  
Hohneck A, 3075  
Höland K, 3217  
Holick MF, 5009, 5043, 5091, 5095  
Holopainen A, 5521  
Homma Y, 791, 2573  
Hompland I, 955  
Honda A, 3913  
Honda M, 3613, 3921  
Honda T, 3947, 4049  
Honeck P, 1911  
Hong DG, 349, 4937  
Hong EK, 599  
Hong J-Y, 5343  
Hong J, 3445  
Hong JK, 1813  
Hong MY, 4285  
Hong S-E, 3475  
Hong S-W, 1813  
Hong Y-Y, 3789  
Hongo M, 5357  
Hongo T, 981, 3653  
Honjo K, 697  
Honselmann KC, 2743  
Hontsu S, 4305  
Hoque MM, 3495  
Hörer TM, 2827  
Hori A, 2087  
Hori H, 4017  
Hori Y, 1571  
Horikawa M, 3313  
Horikawa Y, 3613  
Horikoshi H, 3099  
Horisawa N, 3735  
Horiuchi M, 1073  
Hormann B, 1019  
Horozoglu C, 1301  
Hosaka H, 2683  
Hosaka M, 6105  
Hoshi M, 6105  
Hoshino K, 5971  
Hosogi H, 5937  
Hosohata K, 2053  
Hosokawa M, 3717  
Hosomi K, 1589  
Hosono A, 3743  
Hosono M, 5305  
Hosoya K, 279  
Hosoya M, 2277  
Hosoya S, 115  
Houdek MT, 105, 919, 1377, 3869  
Hough JT, 2425  
Hour T-C, 3389  
Howard LN, 5475  
Hozaka Y, 3373  
Hozumi C, 2567, 5217, 5819  
Hrnciarik M, 1563, 1987  
Hsia N-Y, 1749, 3381  
Hsia T-C, 1229, 2495, 3195, 3381, 4329  
Hsiao C-H, 3427, 2479, 4753  
Hsu C-C, 5609  
Hsu C-H, 4461  
Hsu C-L, 4329  
Hsu CY, 4857  
Hsu F-T, 2495, 3807, 3825, 4403  
Hsu L-C, 4403  
Hsu P-C, 2145, 5283  
Hsu Y-M, 531  
Hsu Y-N, 5283  
Hsueh S-W, 5609  
Hu D-W, 845  
Huang C-Y, 2145, 3413  
Huang G, 5475  
Huang H-C, 845  
Huang J, 4715  
Huang L, 4563  
Huang S-H, 3427  
Huang S-Y, 2487  
Huang T-L, 2375  
Huang T-S, 2487  
Huang W-C, 845  
Huang Y-H, 2479  
Huber L, 3403  
Hudson JM, 3523  
Huhtala H, 2507, 2519  
Hung C-Y, 5609  
Hung S-C, 2185, 4857  
Hung Y-C, 5275, 5335  
Hur DY, 555, 5265, 5385  
Hur W, 3463  
Hussein A, 355  
Huttunen T, 87  
Hwang J, 589  
Hyodo M, 3361  
Hyun SH, 5875  
Iacovelli R, 165, 1487  
Iacovelli V, 1487  
Iafrate F, 991  
Ibe H, 4179  
Ibrahim R, 2355  
Ibuki Y, 1499, 6037  
Ichida A, 1161  
Ichikawa T, 1465, 1763, 3099, 4743  
Ichikawa W, 2675, 2683  
Ichikawa Y, 4477  
Ichimura H, 2583  
Ichinoe M, 2061  
Ida S, 1439  
Ide K, 5983  
Idel C, 3551  
Ideta Y, 3815  
Idichi T, 3373  
Ieiri I, 2053  
Igarashi D, 2727  
Igarashi K, 229, 1081, 3143, 4619  
Igarashi S, 5357  
Igari M, 6099  
Igawa T, 3041, 4573  
Iguchi K, 2625, 2763  
Ihara K, 3725  
Ihara T, 3717  
Ii H, 1221, 4311  
Iida Y, 115, 3495  
Iihara H, 3117, 4581  
Iijima M, 2105  
Iijima Y, 781  
Imori N, 3937  
Iino M, 2095, 6099  
Iizuka A, 419, 3537, 4417, 5233  
Iizuka J, 3151  
Iizuka T, 1131  
Ike S, 1635  
Ikebe M, 2071  
Ikeda A, 645, 6047  
Ikeda M, 407  
Ikeda T, 1333, 4165  
Ikegami T, 1579, 3621  
Ikemura K, 2591  
Ikenaga M, 1859  
Ikoma H, 1623, 3645  
Ikuta S, 6063  
Ilie SM, 5847  
Illari SI, 4641  
Ilori EO, 1845  
Im C-M, 5343, 5951  
Im JE, 599  
Im NG, 1237  
Imai H, 2009  
Imai K, 35, 1007, 5323  
Imai N, 3947  
Imamura A, 3341  
Imamura H, 903, 2683, 3049, 3133  
Imamura M, 4867  
Imamura N, 1763, 4553  
Imamura Y, 1199  
Imano N, 293  
Imaoka K, 5983  
Imaoka T, 2415  
Imaoka Y, 5983  
Imasato M, 1859  
Imoto S, 1333  
Inadome Y, 3159  
Inagaki M, 2583, 4963  
Inagaki T, 6071  
Inagawa H, 3983, 4049  
Inage K, 581  
Inage Y, 3159  
Inakawa T, 3151  
Inaki N, 2783, 4611, 4841  
Incesu R-B, 5579  
Innamaa A, 2003  
Inokawa Y, 3889  
Inokuchi S, 2071  
Inokuchi Y, 1535  
Inoue D, 1555

- Inoue H, 3029, 5977  
 Inoue K-I, 609  
 Inoue K, 1763, 5663  
 Inoue M, 581, 1131  
 Inoue S, 195, 3627  
 Inoue T, 609, 4895, 5465  
 Inoue Y, 2645  
 Inserra F, 1851, 5867  
 Inukai Y, 3947  
 Ioka T, 6127  
 Ippolito M, 3011, 5867  
 Irie H, 1207, 5743  
 Irie T, 697  
 Ise K, 2875  
 Isgandarova S, 1019  
 Ishibashi Y, 5999  
 Ishida H, 2875  
 Ishida J, 1403  
 Ishida S, 2053  
 Ishida T, 2989  
 Ishida Y, 4103  
 Ishigami K, 3895  
 Ishigami M, 3947  
 Ishige M, 407  
 Ishiguro M, 5315  
 Ishiguro T, 3929, 5635  
 Ishihara H, 3151  
 Ishihara S, 125, 2033, 2461, 5927  
 Ishii F, 4103  
 Ishii H, 2461  
 Ishii J, 2923  
 Ishii N, 245, 5971  
 Ishii T, 2139  
 Ishikawa A, 1707  
 Ishikawa H, 2953  
 Ishikawa T, 4735  
 Ishikawa Y, 3023, 5233  
 Ishiko T, 3209  
 Ishikura S, 3993  
 Ishikura Y, 3717  
 Ishima Y, 1333  
 Ishimatsu K, 3895  
 Ishioka C, 2009  
 Ishiyama K, 5323  
 Ishizaki T, 459, 2113, 5833  
 Ishizawa T, 1161  
 Ishizu T, 1043  
 Ishizu Y, 3947  
 Ishizuka N, 2683  
 Isiko T, 5663  
 Isobe T, 4003  
 Isohashi F, 321, 3529  
 Ita MI, 801  
 Itami H, 1169  
 Ito A, 3099  
 Ito E, 301  
 Ito H, 2311, 2645  
 Ito K, 2875  
 Ito M, 3117  
 Ito N, 4573  
 Ito R, 3029, 4849, 5977  
 Ito S, 2301  
 Ito T, 1547, 1607, 3169, 3947, 4111, 4305, 4907  
 Ito Y, 1073, 4439  
 Itoh M, 1757  
 Itoh S, 245  
 Itoh T, 1289, 1589  
 Itoi N, 3913  
 Itoyama R, 1007  
 Ivanova D, 547  
 Iwahori K, 2383  
 Iwaki S, 1653  
 Iwama H, 1263, 4037  
 Iwamoto H, 1065, 2105, 2167  
 Iwamoto N, 2869, 3779  
 Iwasaki A, 2079  
 Iwasaki H, 5315  
 Iwasaki K, 1635, 5833  
 Iwasaki N, 1635  
 Iwasaku M, 4921  
 Iwata H, 3735  
 Iwata S, 1043  
 Iwatsu S, 5001  
 Izumi K, 1065, 1131, 2105, 2167  
 Izumi N, 5977  
 Izumi O, 3029  
 Jaamaa S, 1509  
 Jagarlamudi K, 1509  
 Jahkola T, 5507  
 Jaime-Martinez LA, 885  
 Jain N, 1397  
 Jain S, 1397  
 Jakobsen J, 5083  
 Jakse N, 1899  
 Jan I, 53, 93  
 Jang H, 4955  
 Jang S-K, 3475  
 Jang SH, 1615  
 Jang TW, 1615  
 Jang WI, 867  
 Janiulioniene A, 3067  
 Jank P, 1739  
 Janpipatkul K, 3835  
 Janssen S, 3085, 5561, 5629  
 Jansson K, 2827  
 Janvilisri T, 3507  
 Jarczyk J, 1911  
 Jaremek K, 3607  
 Jelinek MJ, 5449  
 Jennings SB, 4217  
 Jeon A-R, 599  
 Jeong H-R, 1813  
 Jeong J-H, 867  
 Jeong JY, 5773  
 Jeong K-S, 589  
 Jhan J-W, 811  
 Jhanwar-Uniyal M, 2225  
 Ji G, 4707  
 Jianmongkol S, 1833  
 Jimbo N, 271, 1289  
 Jiménez Romero ME, 6057  
 Jin D-H, 1813  
 Jin H-O, 3475  
 Jin L, 3463  
 Jin MC, 1359  
 Jin S-B, 3789  
 Jin XY, 4707  
 Jirapongwattana N, 1785  
 Jiromaru R, 981, 3653  
 Jo J-C, 6083  
 Jogiat UM, 1157  
 Johnson BD, 2903  
 Johnson JA, 385  
 Johrens K, 2405  
 Jojima T, 609  
 Joncour A, 3863  
 Joo Y-E, 5343, 5951  
 Jorgensen MM, 5699  
 Joris S, 1433  
 Joseph ZM, 1377  
 Joshi N, 2531, 5449  
 Joshi NP, 1845, 3845  
 Jouhi L, 5415  
 Ju M, 2711, 2763, 3929, 5635  
 Jung J, 1813  
 Jung JY, 519  
 Jung S-A, 1813  
 Jung Y, 3789  
 Jungbauer F, 3403  
 Junker T, 4505  
 Junking M, 1785  
 Jurányi Z, 1059  
 Kabha M, 3569  
 Kaburagi T, 2583, 2989  
 Kaczorowski M, 493  
 Kadomatsu Y, 5539  
 Kadomoto S, 1065, 2105, 2167  
 Kadono Y, 1065, 2105, 2167  
 Kadouri L, 253  
 Kadoya T, 5945  
 Kagabu M, 4603  
 Kagawa S, 3637  
 Kagawa Y, 1073, 1859  
 Kage M, 4129  
 Kageyama K, 2395  
 Kageyama S, 1221, 4311  
 Kageyama Y, 1131  
 Kahyo T, 3313  
 Kai K, 4553  
 Kai M, 4071, 4097  
 Kaida A, 5407  
 Kaida T, 1007  
 Kaido Y, 4603  
 Kainulainen S, 2771  
 Kaizawa H, 3217  
 Kaji K, 4895, 5465  
 Kajikawa H, 2383  
 Kajiwara M, 4103  
 Kajiyama T, 3361  
 Kakeji Y, 1051, 1541, 2775, 5553  
 Kakimoto N, 287, 293  
 Kakinuma D, 1599  
 Kakinuma S, 2415  
 Kakolyris S, 1031  
 Kaku H, 4003  
 Kalafati E, 2599  
 Kalbermatten DF, 929  
 Kalickman I, 1447  
 Kaltsas G, 1941  
 Kamada H, 4037  
 Kamada T, 301, 2095, 3701  
 Kamata S-E, 3177  
 Kamei D, 1091  
 Kamei T, 2875, 6105  
 Kamiga T, 3921  
 Kamigaki T, 4179  
 Kamijima T, 3099  
 Kamijo T, 1131  
 Kamikonya N, 5587  
 Kamima T, 5305  
 Kamiyama M, 1465, 3099  
 Kammerhofer G, 109  
 Kamoda H, 2139  
 Kamoto T, 4981  
 Kampletsas E, 5795



- Kanai M, 6127  
 Kanai Y, 2893  
 Kanaji S, 1051, 1541, 2775, 5553  
 Kananazawa Y, 1599  
 Kanao H, 1091  
 Kanao K, 2727  
 Kanaoka H, 4813, 4867, 6027  
 Kanaya S, 5937  
 Kanda M, 3889, 6105  
 Kandzari SJ, 1339  
 Kaneko G, 2727  
 Kaneko J, 1161  
 Kanematsu A, 419, 3537, 5233  
 Kanemitsu Y, 1073  
 Kaneshiro K, 4071, 4097  
 Kaneta Y, 1535  
 Kanetaka K, 3049  
 Kang B-Y, 3463  
 Kang C-Y, 531  
 Kang MS, 5385  
 Kang SS, 5773  
 Kannisto P, 2541  
 Kano H, 1065  
 Kano K, 1535, 2095, 2461, 2711, 2719, 2763, 3177, 3701, 3873, 3929, 3963, 4545, 5635  
 Kao J, 1397  
 Kapanen M, 2553  
 Kapelouzou A, 2813  
 Karakiewicz PI, 5579  
 Karam E, 155, 1949  
 Karanikiotis C, 1031  
 Kardamakis D, 3767  
 Karna R, 3595  
 Karpes J, 3665  
 Karpes JB, 2939  
 Kartika ID, 3495  
 Karwowski P, 1397  
 Kasahara K, 459, 2113  
 Kasahara Y, 1221  
 Kasai M, 4055  
 Kasama F, 5357  
 Kasashima H, 5195  
 Kasbi AA, 5813  
 Kashii Y, 6007  
 Kashiwabara K, 3125, 6113  
 Kashiwagi K, 2923  
 Kashiwagi M, 2737  
 Kashiwagi S, 125, 311, 939 1421, 3937  
 Kasik P, 1933  
 Kassir R, 3285  
 Kasuga A, 2645  
 Kasuga M, 237  
 Kasukawa Y, 5357  
 Katagiri H, 3537  
 Katagiri K, 645, 6047  
 Kataoka A, 3735  
 Kataoka S, 3349  
 Katata Y, 1181  
 Katayama H, 1527  
 Katayama Y, 4921  
 Kato A, 1859  
 Kato I, 791, 3815  
 Kato K, 2053, 4337  
 Kato M, 3627  
 Kato S, 1599, 2277, 3759, 4989, 5897, 6099  
 Kato T, 1207, 1555, 1859, 2061, 2775, 5539, 5655  
 Kato Y, 1905  
 Kato-Hayashi H, 3117  
 Katoh H, 2095, 3701  
 Katsila T, 3767  
 Katsumata K, 459, 2113  
 Katsuta M, 2023  
 Kattner L, 5077  
 Kaur M, 565  
 Kawabata R, 2683  
 Kawabe N, 1905  
 Kawabe T, 4545  
 Kawachi S, 1997  
 Kawada N, 6019  
 Kawaguchi K, 739  
 Kawaguchi S, 2105  
 Kawaguchi T, 4305  
 Kawaguchi Y, 1161  
 Kawahara A, 4119, 4153  
 Kawai K, 2033, 2461, 5927, 6007  
 Kawai M, 217, 697  
 Kawai R, 2737  
 Kawaii S, 1777  
 Kawaji H, 4071  
 Kawakami K, 1091  
 Kawamura H, 1439, 3613, 3921, 5991  
 Kawanishi H, 3627  
 Kawano H, 3209  
 Kawano S, 697  
 Kawano Y, 1043, 3717  
 Kawaratani H, 4895, 5465  
 Kawasaki T, 173, 3743  
 Kawashima A, 2383, 3529  
 Kawashima H, 3947  
 Kawashiri T, 2053, 2737  
 Kawata S, 2977  
 Kawata T, 419  
 Kawate T, 4735  
 Kawauchi A, 1221, 4311  
 Kazama K, 2625, 2763, 5167, 5635  
 Kazokaite M, 2289  
 Ke T-W, 1143, 5335  
 Keck T, 2743  
 Keil D, 5561  
 Kellokumpu-Lehtinen P-L, 87, 2507, 2519, 2553  
 Kendi AT, 681  
 Kenessey I, 1059  
 Kenfack YJ, 619  
 Kenmotsu H, 3537  
 Kentepozidis N, 1031  
 Keski-Pukkila K, 2519  
 Ketscher C, 4517  
 Khan C, 1867, 3853  
 Kharbat AF, 619  
 Khatab Z, 2355  
 Khellaf L, 185  
 Kiatwuthinon P, 3507  
 Kido H, 2277  
 Kido M, 1403, 5479  
 Kielb P, 493  
 Kift RC, 5101  
 Kihara K, 2177, 5719  
 Kii T, 4273, 4293  
 Kijima K, 4411  
 Kikuchi E, 4055  
 Kikuchi H, 2977, 3313  
 Kikuchi M, 3725  
 Kikuchi N, 2583  
 Kikuchi S, 2583, 3637  
 Kikuchi Y, 5497  
 Kim C-H, 3475  
 Kim C, 471, 589, 3435  
 Kim D, 471, 3435  
 Kim DY, 1813  
 Kim EH, 1813  
 Kim G, 2911  
 Kim H-S, 2753, 4453, 4627  
 Kim H, 2131  
 Kim HK, 5619  
 Kim HM, 2675  
 Kim HS, 363, 483, 2433  
 Kim J-K, 599  
 Kim J-O, 3453  
 Kim J-Y, 2159  
 Kim J, 363, 1813  
 Kim JH, 2159, 3789  
 Kim JM, 349  
 Kim JR, 519  
 Kim JS, 867, 5265  
 Kim JY, 4359, 4945  
 Kim K-B, 5397, 5803  
 Kim K-H, 3453, 5343, 5951  
 Kim K-P, 471, 3435  
 Kim KY, 589  
 Kim M-H, 1615  
 Kim M-S, 867  
 Kim M, 335, 4955  
 Kim MJ, 1813, 4945  
 Kim N-H, 5397  
 Kim S-H, 5385  
 Kim S, 2753, 5343  
 Kim SC, 1813  
 Kim SH, 335  
 Kim SJ, 1615, 6083  
 Kim SM, 1813, 2883, 3463  
 Kim SY, 2883  
 Kim T-H, 5397, 5803  
 Kim TI, 589  
 Kim TW, 1813  
 Kim W, 867  
 Kim WJ, 3463  
 Kim WS, 6083  
 Kim Y-H, 599  
 Kim Y-S, 2131  
 Kim YJ, 3475  
 Kim YS, 555  
 Kimoto T, 2701  
 Kimura H, 1555  
 Kimura K, 2395  
 Kimura M, 1277  
 Kimura T, 2023, 4981  
 Kimura Y, 5885, 5945  
 Kimuro R, 263, 1629  
 Kin M, 6071  
 King K, 5449  
 Kinjo N, 4887  
 Kinjo Y, 4145, 5937  
 Kinoshita D, 173  
 Kinoshita F, 1137  
 Kinoshita H, 173, 2139  
 Kinoshita I, 3185, 3693  
 Kinoshita J, 2783  
 Kinoshita T, 1099  
 Kinoshita T, 5571  
 Kinowaki Y, 2893  
 Kinugasa T, 4119

- Kinuta S, 3921  
 Kioi M, 3815  
 Kircher B, 5825  
 Kiriu T, 271, 1289  
 Kise S, 4887  
 Kishi Y, 5999  
 Kishida T, 1607, 5783  
 Kishikawa J, 2033, 2461  
 Kita K, 4319  
 Kita Y, 3373  
 Kitada K, 4963  
 Kitagawa K, 4895, 5465  
 Kitagawa T, 4849  
 Kitagawa Y, 5205  
 Kitaguchi T, 4103  
 Kitahara S, 5205  
 Kitahata Y, 217  
 Kitaichi K, 2087  
 Kitajima K, 4813  
 Kitamura A, 4165  
 Kitamura C, 2461  
 Kitamura E, 4553  
 Kitanaka C, 4727  
 Kitano S, 3913  
 Kitano Y, 1007  
 Kitasaki N, 1499, 6037  
 Kitasato A, 3133  
 Kittaka N, 6027  
 Kiuchi J, 1623, 3349  
 Kiyohara Y, 3537  
 Kiyoshima M, 2989  
 Kiyota N, 1199  
 Kizaki J, 4003  
 Kjaer TW, 3085, 4511, 4529  
 Klimaite R, 2289  
 Knebel C, 4371  
 Knuettel M, 3403  
 Ko B-G, 5803  
 Ko H-J, 3453  
 Kobara H, 1263, 4037  
 Kobashi R, 1207  
 Kobayashi E, 1043  
 Kobayashi I, 3627  
 Kobayashi K, 271, 1091, 1289, 1589, 3133, 4037  
 Kobayashi M, 3185  
 Kobayashi R, 217, 3117, 4581  
 Kobayashi S, 6127  
 Kobayashi T, 1997, 4305, 5983  
 Kobayashi Y, 1653, 4701  
 Koch K, 5431  
 Koch S, 5249  
 Kochi M, 2675  
 Kocsis ZS, 1059  
 Kodali SK, 723  
 Kodama T, 4589  
 Kodama Y, 1403, 5479  
 Kodera Y, 3889  
 Koeberle D, 4773  
 Koensgen D, 5839  
 Koga S, 2869  
 Koga T, 4103  
 Koga Y, 3895  
 Kogawa T, 3743  
 Koge H, 3701  
 Kogo M, 6071  
 Koh D-I, 1813  
 Koh HK, 6091  
 Koh SA, 519  
 Koh Y-C, 6091  
 Koh Y, 407  
 Koh YW, 5875  
 Kohatu H, 4887  
 Kohchi C, 3983  
 Kohlrusch FK, 2945  
 Kohmura T, 2625  
 Kohno K, 2923  
 Kohno M, 1137  
 Koizumi M, 5783  
 Koizumi T, 67, 1115, 1345, 3217  
 Kojima K, 3725  
 Kojima S, 4063  
 Kojima Y, 697  
 Kokubo T, 2415  
 Komai Y, 2045, 2123  
 Komatsu H, 3029, 5977  
 Komatsu K-I, 4055  
 Komatsu M, 5571  
 Komatsu S, 237, 1403, 3349, 5479  
 Komatsu Y, 343  
 Komazaki H, 115  
 Komine C, 1123  
 Komohara Y, 381, 1645, 3209, 5663  
 Komori H, 1571  
 Komori K, 2711, 2719, 3929, 3963, 4545, 5635  
 Komori M, 3361  
 Kondo E, 1635, 4165  
 Kondo K, 449  
 Kondo M, 4439, 4963  
 Kondo R, 449  
 Kondo T, 1607, 2311, 3151, 4907  
 Kondoh C, 3743  
 Kondou R, 419, 3537, 4417  
 Kondou R, 5233  
 Kondrotiene A, 2289  
 Kong MX, 1481, 3601  
 Konieczek J, 3607  
 Konishi H, 237, 1623, 3349, 3645  
 Konishi M, 287, 293, 893  
 Konno H, 3313  
 Konno S, 3613  
 Konno T, 2875  
 Kono K, 3921  
 Kono T, 4037  
 Kopelke S, 4511, 4529  
 Kopra K, 5249  
 Korantzis I, 5795  
 Kornprat P, 1413  
 Koseki T, 4439  
 Koshikawa N, 5783  
 Kosmidis P, 1941  
 Kotaka M, 2675  
 Kotani H, 3495, 3735  
 Kotori M, 3299  
 Kotsakis A, 5795  
 Kotsugi M, 1151, 1641  
 Koubkova L, 1987  
 Kouhashi R, 3937  
 Koukourakis MI, 2363  
 Koumakis G, 1031  
 Koumariou A, 5795  
 Koushi K, 4011  
 Kouzu K, 5999  
 Kowalewski K-F, 1911  
 Kowzun M, 2961  
 Koyama M, 837  
 Koyama N, 2583  
 Koyanagi R, 3613  
 Koyfman SA, 1845, 3845  
 Kozono S, 5833  
 Kramer B, 3403  
 Krarup-Hansen A, 5527, 5699  
 Krejci D, 1563  
 Krejci J, 1987  
 Krieg AH, 5443  
 Kriegmair M, 1911  
 Kristiansen G, 1367  
 Kristiansson S, 5597  
 Krizova A, 2355  
 Krug B, 1925  
 Ku J, 1845, 2531  
 Ku M-C, 4403  
 Ku M, 589  
 Kubo K, 293, 5305  
 Kubo M, 4071, 4097  
 Kubo N, 1439, 5991  
 Kubo S, 2395  
 Kubo T, 3725  
 Kubo-Kaneda M, 4165  
 Kubota T, 237, 1623, 3645  
 Kubota Y, 731, 2567, 3857, 5217, 5819  
 Kudaka W, 3017, 4887  
 Kudo A, 4055  
 Kudo C, 5323  
 Kudo D, 5357  
 Kudo T, 1859  
 Kuga R, 981, 3653  
 Kugiyama T, 3133  
 Kuhl S, 1237, 2319  
 Kulbe H, 1739  
 Kumagai M, 3947  
 Kumamoto T, 2573, 5497  
 Kumano K, 2797, 4471  
 Kumano T, 3117  
 Kumar S, 53, 93, 2961  
 Kumazaki Y, 6099  
 Kumazu Y, 4545  
 Kundu S, 723  
 Kunihisa T, 1199  
 Kunisawa J, 1589  
 Kuniski C, 5497  
 Kunte S, 2531  
 Kuo C-C, 5283  
 Kuo C-HS, 2145  
 Kuo Y-C, 1143, 2495  
 Kurahara H, 3373, 3905, 3953  
 Kuramitsu K, 1403, 5479  
 Kuraoka K, 1707  
 Kurashina R, 1131  
 Kurata H, 2311  
 Kurata K, 4071  
 Kuratomi Y, 981, 3653  
 Kurihara S, 3159  
 Kurimoto K, 3889  
 Kurishima K, 2583  
 Kuriu Y, 1623, 3349, 3645  
 Kuriyama K, 4929  
 Kuroda K, 501, 5195  
 Kuroda S, 3637, 5983  
 Kurogochi T, 3023  
 Kuroiwa K, 1571

- Kurokawa T, 1499, 6037  
 Kuroki T, 3133  
 Kurose H, 4573  
 Kurosumi M, 759  
 Kusaka E, 2835  
 Kusaka T, 645, 6047  
 Kusama H, 6027  
 Kusano H, 449  
 Kusano T, 67, 1345  
 Kushihashi Y, 1607  
 Kushiya S, 501, 5195  
 Kusuhara S, 3743  
 Kusunoki C, 5655  
 Kuwabara H, 2113  
 Kuwai T, 1707  
 Kuznetz A, 5257  
 Kuzuya T, 1905  
 Kwak J-Y, 6083  
 Kylvä AK, 5415  
 Kyros E, 675  
 Labott JR, 3869  
 Lacos DE, 3863  
 Lai G-S, 2185  
 Lai J, 1481, 3601, 3971, 5475  
 Lai M-W, 2479  
 Lai Z-Y, 3413  
 Laing B, 1157  
 Laliscia C, 1965  
 Lamarre E, 2531  
 Lamarre ED, 1845  
 Lambin S, 373  
 Lammert A, 3403  
 Lamnis L, 5049  
 Landin-Olsson M, 1671  
 Landoni F, 2017  
 Landström F, 5597  
 Lang-Schwarz C, 147, 1919, 4499, 5891  
 Langen P, 137  
 Lasky III JL, 1697  
 Latorre RG, 667  
 Lattimore CC, 2819  
 Laudani ME, 2017  
 Lauritzen PM, 2967  
 Law C, 3523  
 Lazarova D, 547  
 Lecka M, 3607  
 Lecomte T, 155, 1949  
 Lecuelle J, 5847  
 Lee CH, 4265  
 Lee DS, 471, 3435  
 Lee DW, 4945  
 Lee E, 471  
 Lee EJ, 363  
 Lee ES, 2131  
 Lee EY, 1813  
 Lee G-W, 6083  
 Lee H-T, 3799, 5335  
 Lee H, 589  
 Lee HJ, 3445  
 Lee HN, 4945  
 Lee HS, 6091  
 Lee J-H, 75, 2131, 5397, 5803  
 Lee J-J, 2487  
 Lee J-O, 6083  
 Lee J-S, 2433  
 Lee J, 349, 363, 1813, 2425, 3789, 4937  
 Lee JE, 1615  
 Lee JH, 857, 2883  
 Lee JS, 2433  
 Lee K-C, 4403  
 Lee KE, 4945  
 Lee KH, 519  
 Lee KY, 1615  
 Lee MR, 599  
 Lee S, 471, 681, 1813, 3435, 3445  
 Lee SG, 4359  
 Lee SH, 857, 1615, 4453  
 Lee SJ, 5875  
 Lee ST, 1867  
 Lee Shin Yup, 1615  
 Lee Sung Yong, 1615  
 Lee T, 3913  
 Lee W-S, 5343, 5951  
 Lee WJ, 1813  
 Lee Y-C, 3807, 3825  
 Lee Y-H, 4403  
 Lee Y-S, 599  
 Lee Y, 4627  
 Lee YH, 349  
 Lehmann A, 2405  
 Lehtonen M, 87  
 Leichtle A, 2657, 3035  
 Lenze U, 4371, 5443  
 Lequio M, 2903  
 Lerche CM, 5069, 5083  
 Lertnitikul N, 1833  
 Leskela R-L, 5457  
 Li C-C, 1143, 3195  
 Li C-H, 1229, 4403  
 Li D-Y, 3413  
 Li J-R, 2185, 4857  
 Li J, 385  
 Li M, 4345  
 Li N, 3325  
 Li S, 4359  
 Li T-S, 845, 1729  
 Li X, 3325  
 Liakakos T, 2813  
 Liang J-A, 1143  
 Liao P-A, 3807  
 Liauw W, 4563  
 Liew A, 3261  
 Lim CCH, 801  
 Lim CH, 5875  
 Lim S, 5927  
 Lim SD, 6091  
 Lim SNS, 5283  
 Lin C-C, 3427  
 Lin NX, 5101  
 Lin R-F, 4403  
 Lin Y-C, 5609  
 Linardou H, 5795  
 Lindqvist C, 4259  
 Lindqvist PG, 1671  
 Ling J, 4679  
 Lippiatt J, 2003  
 Lippolis PV, 4659  
 Lissoni AA, 2017  
 Lister J, 1867  
 Liu A, 1481  
 Liu C-Y, 4753  
 Liu C, 1217  
 Liu D, 4345  
 Liu H-M, 3413  
 Liu K-C, 2495  
 Liu L, 3325  
 Liu Q, 2341  
 Locatelli SL, 767  
 Loening T, 1455  
 Loganadane G, 4833  
 Lohneis P, 2405  
 Longo B, 3879  
 Longo SL, 723  
 Lorenz RR, 2531  
 Lowe VJ, 681  
 Lu C-H, 5609  
 Lu K, 4857  
 Lu R, 2893  
 Lu RJ, 5043  
 Lu Y, 4679  
 Luangwattananun P, 1785  
 Luebke AM, 2945  
 Lugo D, 1397  
 Luo S-C, 2573  
 Luoma M-L, 5507  
 Lustig SD, 723  
 Luukkaala T, 2553  
 Luzzi S, 3203  
 Lypas G, 5795  
 Ma B, 3325  
 Ma Y-Q, 1217  
 Maas C, 4773  
 Mabjeesh NJ, 3569  
 Machida D, 2711  
 Machida N, 1535  
 Madaffari I, 211  
 Maeda A, 1277  
 Maeda C, 419, 3537, 5233  
 Maeda K, 5195  
 Maeda M, 3627  
 Maeda N, 3637  
 Maeda T, 1555  
 Maeda Y, 1277  
 Maeda-Minami A, 1043, 3717  
 Maeno K, 1073  
 Maeta T, 2301  
 Maezawa Y, 2711, 2719, 3929, 3963, 4545, 5167, 5635  
 Magarifuchi N, 4337  
 Maggi F, 211  
 Magkana E, 2599  
 Magkana M, 2599  
 Magliocca FM, 991  
 Maimon O, 253  
 Maines F, 165  
 Maiuri V, 3003  
 Majkova P, 1987  
 Makino K, 1801, 2847  
 Makino T, 1065, 2167  
 Makita C, 3117  
 Mäkitie A, 5415  
 Makiyama A, 4581  
 Makrantonakis P, 1031  
 Malakoutikhah M, 5249  
 Malander S, 2541  
 Mańeckı M, 5365  
 Malkiewicz B, 493  
 Malkov V, 1517  
 Mallett KE, 105, 1377  
 Malorni W, 767  
 Malter W, 1925  
 Maly B, 253  
 Mamishin K, 3743  
 Manako T, 981, 3653  
 Manda-Handzlik A, 5365

- Manfredi B, 2997  
 Maniwa Y, 271, 1289, 1589  
 Mannsåker B, 923, 1477  
 Mano M, 5655  
 Mano Y, 1043, 3717  
 Manome Y, 837  
 Mansour DA, 67  
 Mantso T, 2363  
 Maraveyas A, 3261  
 Marchetti C, 3003, 5909  
 Marconi M, 767  
 Marel M, 1563  
 Marinov M, 3217  
 Marinova M, 4825  
 Mario D, 4913  
 Marjanska A, 5181  
 Markson G, 1821  
 Marschang P, 3261  
 Martin DK, 4689  
 Martinek P, 1933  
 Martinez-Pacheco ML, 885  
 Martini S, 2859  
 Marukuchi R, 4679, 4849  
 Maruo K, 5195  
 Maruyama R, 1131  
 Maruzzo M, 165  
 März W, 5009  
 Masaki N, 731, 2567, 3857, 5217, 5819  
 Masaki T, 1263, 4037  
 Masato M, 2311  
 Massa T, 4199  
 Massari F, 1487  
 Masubuchi T, 1607, 3177, 4907  
 Masuda M, 981, 1535, 2719, 3653, 3873, 5885  
 Masuda T, 4701, 4879  
 Masuda Y, 1599  
 Masuyama H, 4535  
 Matakai Y, 3373  
 Matar A, 1001  
 Matarrese P, 767  
 Materazzo M, 3879, 4913  
 Mathias A, 397  
 Matia B, 1845, 3845  
 Matsubara N, 3743  
 Matsuda A, 3299  
 Matsuda C, 3299, 4989  
 Matsuda K-I, 4727  
 Matsuda K, 67, 709, 1345  
 Matsuda R, 781, 1151, 1169, 1641, 3975  
 Matsuda T, 1051, 1541, 2775, 5553  
 Matsuda Y, 745  
 Matsui H, 3627  
 Matsui R, 4611, 4841  
 Matsui S, 3169, 5205, 6027  
 Matsui Y, 4921  
 Matsukawa T, 1107  
 Matsukawa Y, 3627  
 Matsuki T, 1607, 3177, 4907  
 Matsumi Y, 5719  
 Matsumoto A, 3023  
 Matsumoto K, 4103  
 Matsumoto S, 4103  
 Matsumoto T, 2977  
 Matsumura K, 1645, 3209, 5663  
 Matsunaga K, 2383  
 Matsunaga T, 2177, 4787, 5719  
 Matsuno K, 1599  
 Matsuo M, 981, 3117, 3653, 4573  
 Matsuo T, 2311, 3055  
 Matsuo Y, 1277  
 Matsuoka A, 2637, 3707  
 Matsuoka H, 4973  
 Matsuoka M, 1635  
 Matsuoka Y, 1777  
 Matsusaka S, 4879  
 Matsushima H, 903, 3049, 3133  
 Matsushita D, 3373, 3905, 3953  
 Matsuura K, 5751  
 Matsuyama H, 1465, 3099  
 Matsuyama M, 2645  
 Matsuyama R, 791, 2573  
 Matsuyama T, 205  
 Matsuyama Y, 4319  
 Matsuzaki H, 5927  
 Matsuzaki S, 4097  
 Matteazzi F, 4505  
 Matthew TL, 1339  
 Mattioni R, 1965  
 Matushima S, 4139  
 Matuszczak S, 4763  
 Matuzeviciene R, 3067  
 Matysiak J, 493  
 Matzkin H, 3569  
 Maugeri R, 1851, 5867  
 Mavratzas A, 3075  
 Mavroudis D, 1941  
 Mayo ZS, 1845  
 Mazaki A, 581  
 Mazaki J, 459, 2113, 5833  
 Mazard T, 185  
 Mazilu I, 5847  
 Mcgowan M, 1979  
 Mcvie G, 827  
 Medeiros R, 2443  
 Medeiros-Fonseca B, 2443  
 Medinger M, 4505  
 Meehan AD, 2827  
 Megwalu UC, 1359  
 Meirovitz A, 253, 5257, 5487  
 Mejia C, 885  
 Meklin J, 1879, 3557  
 Melaiu O, 3879  
 Melichar B, 1987  
 Menefee JN, 2819  
 Mentzelopoulou P, 2599  
 Menyok O, 5449  
 Mercinelli C, 2997  
 Merker F, 4825  
 Merlano M, 2859  
 Messeha SS, 441  
 Mestre VF, 2443  
 Mezzapapa F, 947  
 Mian T, 3595  
 Miao S, 2341  
 Miccoli M, 947  
 Michalaki V, 1031, 5795  
 Michielsen J, 4485  
 Michot N, 155  
 Michot N, 1949  
 Midorikawa R, 4063  
 Mie T, 2645  
 Mihara Y, 1161  
 Miinalainen S, 5457  
 Mikayama Y, 2625  
 Miki K, 1199  
 Miki Y, 501  
 Milas ZL, 4429  
 Milella M, 165  
 Miller I, 5431  
 Milot L, 3523  
 Mima K, 1007  
 Mimori K, 4701  
 Mimura S, 1263  
 Minami H, 1199  
 Minami S, 3759, 4989, 5897  
 Minami T, 4003  
 Minamiya Y, 5323  
 Minato A, 263, 1629, 3041  
 Mine S, 6105  
 Minegishi Y, 791  
 Minemura M, 6007  
 Minervini A, 25  
 Mintz I, 3569  
 Mirii H, 263  
 Misawa T, 1579  
 Mischinger HJ, 1413  
 Mishima S, 4805  
 Misumi T, 5497  
 Mitani K, 1131  
 Mitobe Y, 4727  
 Mitoro A, 4895, 5465  
 Mitsopoulos V, 2003  
 Mitsuda M, 1623  
 Mitsudo K, 3815  
 Mitsui A, 1277  
 Mitsui T, 1169  
 Mitsuka Y, 5833  
 Mitsunari K, 2311, 3055  
 Miura S, 5001  
 Miura A, 1571  
 Miura K, 1607, 1729, 3177, 4907  
 Miura M, 5407, 6105  
 Miura S, 1729  
 Miwa S, 229, 1081, 3143, 4619  
 Miyaaki H, 3049, 5001  
 Miyagi Y, 3299, 3873, 5783, 5885  
 Miyaguchi J, 645, 6047  
 Miyahara D, 4111  
 Miyahara K, 4735  
 Miyahara R, 1905  
 Miyahara Y, 2087  
 Miyakawa T, 3613  
 Miyake K, 739  
 Miyake M, 5655  
 Miyakoshi N, 5357  
 Miyama Y, 2727  
 Miyamoto A, 217, 5655  
 Miyamoto H, 1645, 3209, 5663  
 Miyamoto S, 2061, 3177, 4111  
 Miyamoto T, 2053  
 Miyao T, 3099  
 Miyasou H, 4963  
 Miyata H, 419, 3537, 4417, 5233  
 Miyata T, 35, 1007, 3209, 5663

- Miyata Y, 2311, 3055, 3627  
Miyatani K, 2177, 2583, 4589  
Miyazaki S, 1043  
Miyazawa M, 217  
Miyazawa T, 2923  
Miyoshi K, 459, 3779  
Miyoshi N, 1859, 3759, 4989, 5897  
Miyoshi Y, 4813, 4867  
Mizoguchi E, 4119  
Mizoguchi N, 2095, 3701  
Mizokami A, 1065, 1465, 2105, 2167, 3099  
Mizrahi AG, 5257  
Mizuguchi H, 1719  
Mizuguchi K, 1589  
Mizui T, 2087  
Mizumoto M, 2953  
Mizuno N, 893  
Mizuno T, 4973  
Mizuo T, 1263, 4037  
Mizuochi S, 449  
Mizushima T, 1859  
Mizushima Y, 3041  
Mizuuchi Y, 4097  
Mochizuki N, 3299  
Mochizuki Y, 2311, 3055  
Modest DP, 4773  
Mogi S, 2061  
Mohamed H, 5415  
Mohan AL, 2225  
Mokbel Kefah, 661, 1013  
Mokbel Kinan, 661, 1013  
Molnar I, 3583  
Momiya K, 1607, 2061, 3177  
Momose H, 697  
Mong M-C, 1749, 2375, 5275  
Montagnini M, 2249  
Montali F, 2249  
Monzen H, 4411, 5305  
Moon DK, 3445  
Moon J-H, 1813  
Moon KM, 3445  
Moon SH, 555  
Moore J, 4285  
Moran SL, 1377  
Morganti R, 1965, 2997  
Mori K, 419, 3537  
Mori M, 1137, 1859, 3117, 4701, 5763  
Mori S, 3905, 3953  
Mori T, 4879  
Mori Y, 3895  
Morikawa H, 2053  
Morimoto K, 4921  
Morimoto M, 2177, 4787, 5719  
Morimoto T, 1151, 1641  
Morimoto Y, 4921  
Morimura R, 1623, 3645  
Morinaga S, 229, 893, 1081, 3143, 4619  
Morioka D, 2573  
Moris D, 629  
Morisaki T, 125, 311, 939, 1421, 3937, 4097  
Morishige K-I, 3117  
Morishita A, 1263, 4037, 5323  
Morishita K, 1763, 4743  
Morishita Y, 5751  
Morita J, 3929, 5635  
Morita K, 3895, 4305  
Morita S, 3725  
Morita Y, 3313  
Moriya K, 4895  
Moriyama H, 2783  
Morley C, 1339  
Morokuma F, 1571  
Morris DL, 1001, 2939, 3665, 4217, 4563  
Morshidi NAAB, 3789  
Mortensen HJ, 5699  
Mosillo C, 165  
Motofuji Y, 6007  
Motohara T, 1645, 3209, 5663  
Motoi F, 893  
Motomura H, 3299, 5223  
Motoyama S, 6105  
Mourregot A, 185  
Moussata D, 155, 1949  
Mouzannar A, 1351  
Mpoura M, 2813  
Mracek J, 1933  
Muders M, 4825  
Mueller PM, 5095  
Muguruma M, 4735  
Mühlbauer J, 1911  
Mui J, 3665  
Mukae Y, 2311  
Mukai S, 4981  
Mukaigawa T, 4417  
Mukohara T, 3743  
Müller H-H, 5567  
Muller O, 155  
Müller T, 1367  
Mullerova A, 1563  
Mun J, 363  
Munakata S, 697  
Muraishi N, 6007  
Murakami D, 205  
Murakami M, 1115, 2023, 2953, 6071  
Murakami N, 4003  
Murakami T, 2977  
Murakami Y, 293, 2177, 2791, 4787  
Murakawa Y, 2009  
Muraki Y, 5305  
Murakumo Y, 2061  
Muramatsu K, 419, 4417  
Muranushi R, 5971  
Murase K, 4867  
Murase R, 1091  
Murata K, 1859, 4895, 5465  
Murata S, 2053, 5917  
Murayama A, 6007  
Murayama S, 4417  
Muroi H, 3725  
Muroi K, 2033, 2461, 5927  
Murotani K, 5961  
Muroya D, 4063, 4153  
Murtha A, 2665  
Musacchio A, 3003  
Musha A, 1439  
Musio D, 991, 3003, 5909  
Mustea A, 1367, 4825, 5839  
Mustonen HK, 5415  
Muttillio EM, 211  
Mwesige B, 599  
Mylläri P, 5507  
Myrehaug S, 3523  
Myung D-S, 5343, 5951  
Myung E, 5343  
Na K, 5601  
Naas AM, 2967  
Nabeshima K, 2079  
Nacarkahya G, 1301  
Nachbaur D, 5825  
Nagae A, 5897  
Nagahara A, 697  
Nagahara Y, 1307  
Nagahashi M, 4813, 4867  
Nagahashi T, 3613  
Nagai S, 2869  
Nagai Y, 2033, 2461, 5927  
Nagakawa Y, 459, 2113, 5833  
Nagano H, 893, 6127  
Nagano M, 4981  
Nagano T, 271, 1289, 1589  
Nagao T, 1547  
Nagao Y, 4063, 4153  
Nagasaka M, 1905  
Nagasawa H, 5357  
Nagasawa S, 4545, 5885  
Nagasawa T, 4603  
Nagashima F, 2683  
Nagashima T, 419, 3537, 4417  
Nagashima Y, 3299, 3299  
Nagata H, 5571  
Nagata K, 5001  
Nagata R, 1161  
Nagata Y, 293, 1107, 1629, 3041  
Nagatani Y, 1199  
Nagayama J, 3627  
Nagayama K, 6019  
Nagayama Y, 5663  
Nagayasu T, 1527, 3091, 4553, 5643  
Nagayoshi K, 4097  
Nagendran J, 1157  
Naito R, 1065  
Naito Y, 449, 3743, 4079, 4145  
Naka T, 3361  
Nakabayashi K, 3993  
Nakabayashi R, 1263, 4037  
Nakabayashi Y, 1579, 4849  
Nakagawa A, 4285  
Nakagawa I, 1151, 1169, 1641, 3975  
Nakagawa M, 3725  
Nakagawa N, 5833  
Nakagawa R, 2167  
Nakagawa T, 981, 3653  
Nakagawa Y, 1905  
Nakagawa-Saito Y, 4727  
Nakahara M, 1263  
Nakahata S, 1763, 4743  
Nakahodo J, 2893  
Nakai K, 2953  
Nakai M, 321  
Nakai N, 1277  
Nakajima K, 1465, 3099  
Nakajima M, 3725



- Nakajima S, 3815, 6027  
 Nakajo A, 3373, 3905, 3953  
 Nakamatsu K, 5305  
 Nakamichi S, 709  
 Nakamoto T, 3017  
 Nakamura H, 279, 2583  
 Nakamura J, 1207  
 Nakamura K, 2783, 2869, 3779, 4319, 4411, 4535  
 Nakamura M, 1571, 2675, 2683, 2953, 3779, 3975, 4071, 4097  
 Nakamura R, 3159  
 Nakamura S, 5539  
 Nakamura T, 2053, 3725, 4319  
 Nakamura Y, 2311, 2875, 3055, 5783, 6019  
 Nakanishi E, 321, 3529  
 Nakanishi H, 3055  
 Nakano K, 3575  
 Nakano R, 5983  
 Nakano T, 3653  
 Nakano Y, 973  
 Nakanuma Y, 2893  
 Nakao K, 5001  
 Nakao M, 2469  
 Nakao T, 3743, 4173  
 Nakao Y, 1007  
 Nakase H, 1151, 1169, 1641, 3975  
 Nakase K, 1641  
 Nakaseko Y, 301, 3621  
 Nakashima K, 301, 3621  
 Nakashima O, 449, 4129  
 Nakashima R, 4103  
 Nakashima T, 981  
 Nakasone T, 3017  
 Nakata A, 4025, 4055  
 Nakata K, 1859  
 Nakata S, 1221, 4311  
 Nakatani T, 173  
 Nakatsura T, 5751  
 Nakauchi M, 4973  
 Nakayama C, 3373  
 Nakayama G, 3889, 4079  
 Nakayama K, 2869  
 Nakayama M, 449, 4153  
 Nakayama T, 6027  
 Nakayama Y, 5719  
 Nakazawa K, 2727  
 Nakazawa N, 4929  
 Nakazono M, 2711, 3929, 4545  
 Nakiri M, 4573  
 Nam T-K, 5951  
 Namima D, 4037  
 Namisaki T, 173, 4895, 5465  
 Nanashima A, 1763, 4553  
 Nanjo H, 5323  
 Nappo G, 2743  
 Nara S, 893  
 Narvaez CA, 3085  
 Nasioulas G, 5795  
 Nasr C, 2531  
 Natori K, 4867  
 Nawachi K, 3637  
 Nechushtan H, 5257  
 Nedelcut D-S, 3681  
 Neelands B, 4429  
 Negishi K, 3717  
 Negishi T, 1571  
 Nemeth B, 4395  
 Nemeth Z, 109  
 Nemoto Y, 3151  
 Neri E, 947  
 Nesi A, 1313  
 Neuberger M, 1911  
 Neumann J, 4371  
 Neumann K, 2405  
 Nevala R, 1509  
 Nezami MA, 441  
 Ngaokrajang U, 3507  
 Ngoc NTM, 3389  
 Ni T, 845  
 Nicolai G, 4913  
 Nieder C, 923, 1477, 3061, 3675  
 Nientiedt M, 1911  
 Nigri G, 25, 3285  
 Niguma K, 3743  
 Nii M, 4165  
 Nii T, 1801, 2847  
 Niimi A, 1073  
 Nikiteas N, 675  
 Nikkuni O, 1439  
 Nikus K, 2519  
 Nilsson KF, 2827  
 Ninomiya I, 2783, 6105  
 Nishi K, 1333, 3993  
 Nishibuchi I, 293, 2791  
 Nishida K, 731  
 Nishie A, 3895  
 Nishigaki Y, 2087  
 Nishihara K, 4573  
 Nishikawa D, 1653  
 Nishikawa K, 3023, 5655, 6105  
 Nishikawa T, 4305  
 Nishikimi K, 2637, 3707  
 Nishimae F, 1719  
 Nishimoto K, 205, 1465, 2727, 3099  
 Nishimura E, 459  
 Nishimura F, 1151, 1641  
 Nishimura G, 4477  
 Nishimura M, 1199, 2415  
 Nishimura N, 4895, 5465  
 Nishimura S, 501  
 Nishimura T, 4417  
 Nishimura Y, 271, 1289, 1589, 2415  
 Nishino T, 195  
 Nishio K, 2395  
 Nishio M, 6027  
 Nishioka T, 2931  
 Nishiyama N, 3029, 5977  
 Nisman B, 253, 5265  
 Nitschke K, 1911  
 Nitta H, 1007  
 Nitta H, 35  
 Nobeyama Y, 2023  
 Nobukuni Y, 4011  
 Noce A, 4913  
 Noda M, 3905, 3953  
 Noda S-E, 4929, 6099  
 Nogaki K, 67, 1345  
 Noguchi H, 263, 1777  
 Noguchi T, 3185, 3693, 4011  
 Noguchi Y, 4111  
 Noh MH, 555  
 Noh S, 2159  
 Nohara T, 2105, 2167  
 Nohara Y, 2079, 4311  
 Nojima T, 229, 3143, 4619  
 Nolan Y, 801  
 Noma K, 3637  
 Nomura K, 5323  
 Nomura S, 3743  
 Nomura T, 1599, 2009  
 Nomura Y, 4129, 4159  
 Nonaka T, 1527, 3091, 5643  
 Nonomura N, 3529  
 Nopora A, 3233  
 Norimoto M, 581  
 Nörnberg LKN, 1247, 2327  
 Noro R, 709  
 Nosaka K, 279  
 Notsu A, 419, 3537  
 Novak P, 5685  
 Nozaka K, 5357  
 Nozawa H, 2033, 2461, 5927  
 Nozawa K, 3735  
 Nuhn P, 1911  
 Nukada S, 2625  
 Numao N, 2045, 2123  
 Numata M, 2719, 2763, 4545  
 Numata T, 2583, 3159  
 Numazaki K, 2931  
 Nungaray V, 4285  
 O'Neil H, 5101  
 Oba A, 2645  
 Obama K, 5937  
 Obara K, 3857, 5217, 5819  
 Obara W, 3041  
 Obermayr E, 429  
 Obika S, 1221  
 Ochiai S, 1997  
 Oda E, 1645, 3209, 5663  
 Oda Y, 3779, 4337  
 Odajima S, 115  
 Oe M, 1199  
 Oesterling F, 1455  
 Ogasawara C, 4189  
 Ogasawara M, 4189  
 Ogasawara N, 4573  
 Ogasawara S, 449  
 Ogata N, 4011, 4139  
 Ogata S, 4011, 4139  
 Ogata T, 1535, 2719, 3873, 4145, 4545, 5885  
 Ogawa H, 1123, 4417, 4929  
 Ogawa K, 115, 321, 3529, 6127  
 Ogawa R, 1277  
 Ogawa T, 4293  
 Ogino T, 3759, 4989, 5897  
 Oguchi T, 2045, 2123  
 Oguma E, 4179  
 Oguri T, 1073  
 Oh C-H, 2911  
 Oh H-H, 5343, 5951  
 Oh HE, 2131  
 Oh MY, 2883  
 Oh SE, 2883  
 Oh SS, 4265  
 Oh SY, 6083  
 Oh Y-I, 5397  
 Oh Y, 2433  
 Ohana M, 173  
 Ohara G, 4589

- Ohashi K, 1729  
 Ohashi T, 237, 1623, 3645  
 Ohashi Y, 6047  
 Ohata K, 4581  
 Ohba K, 2311, 3055  
 Ohbayashi C, 4305  
 Ohdaira H, 301  
 Ohdan H, 5983  
 Ohde Y, 3537  
 Ohe K, 1199  
 Ohgi K, 3169  
 Ohira G, 2395  
 Ohira H, 1207, 5743  
 Ohira M, 125, 311, 501, 939,  
 1421, 3937, 5195, 5983  
 Ohishi T, 3217  
 Ohkawara T, 3361  
 Ohkubo H, 1073  
 Ohkura K, 4017  
 Ohkura Y, 6105  
 Ohnishi K, 2953  
 Ohno S, 3299, 5223  
 Ohno T, 1439, 2469, 3341,  
 4929, 5991  
 Ogori H, 2009  
 Ohri N, 53, 93, 2961  
 Ohsawa M, 1499, 6037  
 Ohshima K, 419, 3537, 4417  
 Ohshima T, 2763, 3993  
 Ohta T, 6099  
 Ohta Y, 5763  
 Ohtori S, 581, 2139  
 Ohtsuka T, 3373, 3905, 3953  
 Ohtsuru T, 1859  
 Ohue M, 4989, 5897  
 Oida Y, 2087  
 Oie Y, 3947  
 Oikawa S-I, 645, 6047  
 Oike T, 2469, 3341  
 Oikonomakis I, 2827  
 Oishi Y, 781, 4337  
 Okabayashi K, 5205  
 Okabe H, 35, 5663  
 Okabe K, 4981  
 Okabe Y, 4153  
 Okada K-I, 217  
 Okada K, 1439, 5991  
 Okada M, 1499, 2791, 4727,  
 5945, 6037  
 Okada S, 4179, 4417  
 Okada T, 1123, 1547, 1607,  
 4119, 4907  
 Okada Y, 2727  
 Okamoto A, 115, 1199, 4849  
 Okamoto H, 2625  
 Okamoto I, 1547, 1607, 4907  
 Okamoto K, 237, 1623,  
 2783, 3645, 4165, 4535  
 Okamoto T, 1579, 2645,  
 4319  
 Okamura Y, 973, 3169  
 Okano A, 173  
 Okano K, 4037  
 Okano N, 1439, 5991  
 Okano S, 3049  
 Okauchi S, 4589  
 Okawaki M, 1181  
 Okayama T, 5571  
 Okazawa Y, 697  
 Okita A, 2009  
 Oku Y, 1137  
 Okubo Y, 1207, 5783  
 Okubo-Sato M, 3815  
 Okuda K, 4071, 4089, 4129,  
 4153  
 Okuda M, 2591  
 Okuda T, 4173  
 Okuhata K, 4411  
 Okui N, 3621  
 Okumura N, 4581  
 Okumura T, 2953, 2989  
 Okuno T, 501  
 Okuyama H, 893  
 Olbrich D, 3085  
 Olinic D-M, 3261  
 Oliveira Gigeck C, 4381  
 Oliveira PA, 2443  
 Omura G, 1607, 4907  
 Onaga C, 3299, 5223  
 Onda S, 1579, 3621  
 Onishi H, 2869, 3779  
 Onishi M, 2277  
 Onishi T, 3743  
 Onizuka C, 4981  
 Ono M, 1263, 4037  
 Ono S, 2079  
 Ono Y, 1137, 2645  
 Onoda A, 3717  
 Onodera A, 3929  
 Onodera T, 1635  
 Onoe T, 4417  
 Onozawa Y, 4417  
 Onuma H, 2023  
 Onuma S, 3929, 5885  
 Ooyama T, 3017  
 Oranges CM, 929  
 Oridate N, 1607, 4477, 4907  
 Orita S, 581  
 Orita Y, 205  
 Ortona E, 767  
 Osada E, 837  
 Osakabe H, 5833  
 Osaki Y, 6063  
 Osawa M, 745, 2791  
 Oshikiri T, 1051, 1541, 2775,  
 5553  
 Oshima T, 1535, 2625, 2711,  
 2719, 3873, 3929, 3963,  
 4545, 5635, 5885  
 Oshima Y, 279  
 Oshiro H, 739  
 Osone K, 1123  
 Osswald L, 5431  
 Osu N, 1439  
 Ota K, 3159  
 Ota N, 4025  
 Ota T, 1555  
 Otagiri M, 1333  
 Otori T, 6019  
 Otoshi T, 1589  
 Otsu T, 3889  
 Otsuji E, 237, 1623, 3349,  
 3645  
 Otsuka K, 1115, 6071  
 Otsuka S, 2637, 3169, 3707,  
 4963  
 Otten L, 1367  
 Otuka I, 4981  
 Ou Y-C, 2185  
 Ouaisi M, 155, 1949, 4833  
 Oue N, 5885  
 Uji-Sageshima N, 4305  
 Oura K, 1263  
 Owen AR, 919  
 Oya N, 205  
 Oya Y, 5961  
 Oyama M, 2727  
 Oyama S, 3091, 5643  
 Oyama Y, 2869, 6027  
 Oyanagi J, 407  
 Ozaka M, 2645  
 Ozaki A, 3299, 5223  
 Ozaki K, 2033  
 Ozaki Y, 3735  
 Ozato Y, 4701  
 Ozawa H, 4813, 4867  
 Ozawa N, 1123  
 Ozawa Y, 407, 2875  
 Ozeki N, 5539  
 Ozono K, 2869, 3779  
 Paccagnella M, 2859  
 Pace M, 25, 3285  
 Paganelli G, 827  
 Pagano MT, 767  
 Paiar F, 1965, 2997  
 Paik H, 363  
 Pak Y, 1697  
 Palermo G, 1487  
 Palioto DB, 1327  
 Palkovics A, 4395  
 Palm H, 5049  
 Palmisciano P, 619, 1189,  
 1661, 1851, 3203, 3251,  
 4189, 5867  
 Pampanos A, 2599  
 Pan S-H, 4329  
 Pan Y, 3427  
 Panayiotidis MI, 2363  
 Panczel I, 3681  
 Pang JS-T, 4753  
 Pang S-N, 811  
 Pang S-T, 811  
 Pang Y, 3325  
 Panichi M, 2997  
 Panosyan EH, 1697  
 Panovska R, 547  
 Panunzio A, 5579  
 Panvongsa W, 3835  
 Panya A, 1785  
 Paolini F, 5867  
 Papadimitriou C, 1031  
 Papadopoulou E, 5795  
 Papagiannopoulos P, 5449  
 Papakosta V, 5547  
 Papavramidis T, 2261  
 Papazisis K, 1031  
 Papp A, 4395  
 Pappa KI, 2599  
 Parisi S, 4641  
 Park A, 589  
 Park Chan Kwon, 1615  
 Park Cheol Kyu, 1615  
 Park D, 5343  
 Park H, 3445, 4945  
 Park HJ, 857  
 Park HL, 2159  
 Park I-C, 3475  
 Park J, 1589, 3453, 5773  
 Park JH, 739, 2433, 6091  
 Park JK, 4265  
 Park JM, 911  
 Park KS, 3475

- Park MJ, 3445  
 Park N-S, 555  
 Park R, 59  
 Park S-J, 599  
 Park S-M, 5397  
 Park S-Y, 5343  
 Park SG, 3453  
 Park SJ, 363  
 Park SS, 1813  
 Park TH, 483  
 Park Y-L, 5343  
 Partynska A, 5731  
 Pasic M, 2355  
 Pasqualetti F, 2997  
 Passweg JR, 4505  
 Patani N, 1013  
 Patel C, 3523  
 Patel S, 2665  
 Pau M, 1899  
 Pauwels P, 373  
 Pawelczyk K, 5731  
 Payão SLM, 4381  
 Payer M, 109, 1899  
 Pazaitou-Panayiotou K, 1941  
 Pe'er J, 1447  
 Peeters M, 373  
 Pei J-S, 1749, 2375, 5275, 5283, 5335  
 Pei M, 4359  
 Pellicciaro M, 3879, 4913  
 Peng H, 4715  
 Penninga L, 5527, 5699  
 Pennisi M, 1495, 3011  
 Pepe G, 5795  
 Pepe L, 3011  
 Pepe P, 1495, 3011  
 Peretz T, 253, 5257, 5487  
 Pergolizzi S, 4641  
 Perrone F, 1965  
 Persaud AK, 385  
 Peshkova N, 1517  
 Pesta M, 1933  
 Petrakis G, 2363  
 Petrucciani N, 25, 3285  
 Petruch N, 2743  
 Petsri K, 4237  
 Phelps MA, 385  
 Philipsen PA, 5069, 5083  
 Phillips A, 1979  
 Piccinelli M, 5579  
 Picone V, 991  
 Pierdominici M, 767  
 Pilny E, 4763  
 Pilz S, 5009  
 Pinto CA, 4381  
 Pinto FE, 5083  
 Pinto-Cuberos JM, 3971  
 Piotrowska A, 5731  
 Pipolo DO, 3203  
 Piso P, 13, 1019, 3681  
 Pitta P, 5795  
 Podhorska-Okolow M, 5731  
 Pohrt A, 2405  
 Poi MJ, 385  
 Polgár C, 1059  
 Polivka J, 1933  
 Pontoriero A, 4641  
 Popescu R, 877  
 Popp K, 5813  
 Portales F, 185  
 Portarena I, 4913  
 Potdevin L, 2961  
 Potuznik P, 1933  
 Poudel M, 2911  
 Poulsen TS, 5527  
 Power DG, 801  
 Prader S, 13  
 Prathaphan P, 3507  
 Preissler G, 4517  
 Prendes B, 2531  
 Prendes BL, 1845  
 Prenen H, 373  
 Priban V, 1933  
 Pries R, 3035  
 Primi F, 1487  
 Proietti A, 2249  
 Psyrra A, 1031  
 Ptakova N, 1933  
 Punnakitikashem P, 1785  
 Puppe J, 1925  
 Qian ZJ, 1359  
 Queiroz Calcagno D, 4381  
 Quesada S, 185  
 Quon H, 2665  
 Raatikainen P, 2507, 2519  
 Rades D, 97, 1973, 2029, 2657, 3035, 3085, 3551, 4511, 4529, 5561, 5629  
 Radosevic-Robin N, 3583  
 Radzevicius M, 3067  
 Raguse J-D, 2405  
 Raica M, 877  
 Rajha A, 3681  
 Ralli M, 3003  
 Ralser DJ, 4825, 5839  
 Ramacciato G, 25, 3285  
 Ramamurthy P, 5859  
 Ramella S, 2241  
 Randén-Brady R, 5415  
 Räsänen P, 5507  
 Rasmussen LT, 4381  
 Rasschaert M, 373  
 Ratajczak-Wielgomas K, 5731  
 Rath B, 429  
 Rauch E, 5077  
 Rauch R, 5449  
 Real Karia BT, 4381  
 Reamtong O, 3507  
 Recher M, 4505  
 Recker F, 1367  
 Reddy CA, 1845, 3845  
 Redmond HP, 801  
 Reichenbach F, 4773  
 Reichrath J, 5009, 5049  
 Reinikainen P, 2553  
 Reis RM, 5291  
 Reizenstein J, 5597  
 Remschmidt B, 1899  
 Renner C, 1821  
 Ressenheim J, 923  
 Reungwetwattana T, 3835  
 Reuter I, 5567  
 Reviello M, 53  
 Richert-Przygonska M, 3607, 5181  
 Richter M, 2405  
 Richter R, 1739  
 Riner AN, 75  
 Rino Y, 1535, 2625, 2711, 2719, 2763, 3873, 3929, 3963, 4545, 5635, 5885  
 Rissanen A, 5457  
 Roa W, 2665  
 Robson A, 3217  
 Rodolakis A, 2599  
 Rodríguez Bocanegra JC, 6057  
 Rodríguez Burbano R, 4381  
 Rodríguez-Freixinos V, 3523  
 Roh MR, 4359  
 Roh PR, 3463  
 Roine RP, 5507  
 Römer K, 5049  
 Ronecker JS, 2225  
 Rose D, 1295  
 Rose PS, 105, 919, 1377, 3869  
 Rosenkaimer S, 3075  
 Rossen PB, 5699  
 Rossi E, 1487  
 Rotter N, 3403  
 Rowe SE, 1189  
 Rowland L, 1397  
 Roy S, 5449  
 Roy TM, 3275  
 Ruatta F, 2859  
 Rubio CA, 147, 1919, 4493, 5891  
 Rud E, 2967  
 Rudhart SA, 137  
 Rueckert D, 4371  
 Ruiz-Azuara L, 885  
 Ryu JS, 1615  
 Ryu S, 4849  
 Ryu YS, 1813  
 Ryuno Y, 6099  
 Rzechonek A, 5731  
 Saad F, 5579  
 Saarto T, 5457  
 Sabini MG, 1851, 5867  
 Sadaka S, 4581  
 Sadaka Y, 2087  
 Sadashima E, 4145  
 Sadlok J, 5181  
 Saeed A, 59  
 Saeed MEM, 3483  
 Saeki H, 1123, 2763, 4929  
 Saghir N, 3217  
 Sagoo NS, 619, 1661  
 Sahara K, 2573  
 Saigusa N, 1547  
 Saigusa Y, 3963  
 Saimanen I, 5521  
 Sainato A, 2997  
 Saito A, 1707  
 Saito D, 645, 6047  
 Saito H, 2783, 4929, 5357  
 Saito K, 67, 173, 1345, 2583, 5763  
 Saito M, 115  
 Saito S, 229, 2095, 3143, 5991, 6099  
 Saito T, 205, 1757, 2893, 2953, 2989  
 Saito Y, 343, 3185, 3693, 3753, 4743  
 Saitoh J-I, 1439  
 Saitou S, 2683  
 Saiura A, 2645  
 Saji S, 3921  
 Sakabe T, 279

- Sakagami H, 781  
 Sakaguchi H, 4305  
 Sakaguchi M, 5937  
 Sakaguchi T, 3313  
 Sakai D, 1859  
 Sakai H, 2311, 4063, 4079, 4089, 4129, 4153  
 Sakai M, 4929, 4973  
 Sakai Y, 6063  
 Sakamaki K, 5885  
 Sakamoto K, 697, 1645, 3125, 6113  
 Sakamoto T, 343, 2177, 4787, 5719  
 Sakamoto Y, 2009  
 Sakanashi K, 2869  
 Sakarellos P, 675  
 Sakashita S, 5751  
 Sakata J, 745  
 Sakellariou S, 2813  
 Sakuma K, 4273, 4293  
 Sakuma T, 5195  
 Sakurada A, 1099  
 Sakurai F, 1719  
 Sakurai H, 2953, 2989  
 Sakurai T, 1099  
 Sakurai Y, 4963  
 Sakurazawa N, 1599  
 Salame E, 155, 1949  
 Salkini MW, 1339  
 Saller JJ, 1381  
 Saloustros E, 5795  
 Salvemini C, 2249  
 Salzmann M, 4371  
 Samalin E, 185  
 Samhoury Y, 1867, 3595, 3853  
 Sammarco E, 2997  
 Samonte C, 5217  
 Sampo M, 1509  
 Sanches Almeida R, 4381  
 Sánchez Hurtado MA, 6057  
 Sandini M, 2743  
 Sano A, 4929  
 Sano D, 4477  
 Sano M, 781  
 Sano T, 1997  
 Sanoyan DA, 4773  
 Santos JMO, 2443  
 Santos Pereira B, 4381  
 Santotoribio JD, 6057  
 Sanui A, 4111  
 Saotome T, 2683  
 Sarb S, 877, 1313  
 Sartor H, 2541  
 Sartori E, 2017  
 Sasada S, 5945  
 Sasahara N, 2893  
 Sasahara Y(I), 2009  
 Sasahira N, 2645  
 Sasaki A, 2071  
 Sasaki E, 1653  
 Sasaki K, 2033, 2461, 3299, 3905, 3953, 5223, 5927  
 Sasaki R, 3049, 5001  
 Sasaki S, 4129  
 Sasaki T, 2645, 4103, 5205  
 Sasano H, 2875  
 Sasao A, 3209  
 Sasatani Y, 4589  
 Sassa N, 3627  
 Sato E, 459  
 Sato F, 1151  
 Sato H, 1439, 1547, 1607, 3341, 4907, 5655  
 Sato J, 3109, 3575, 5917  
 Sato K, 3299, 4025, 4055, 5223, 5539, 5983  
 Sato M, 6071  
 Sato S, 791, 2625, 2763, 4589, 5783  
 Sato T, 1777, 2079, 2301, 2645, 3299, 3313, 4079, 4089, 4545, 5635  
 Sato Y, 1207, 2583, 5323, 5743  
 Sato-Yazawa H, 2923  
 Satoh H, 2583, 3159, 4589  
 Satoh T, 1859  
 Saura M, 5249  
 Savarese-Brenner B, 429  
 Sawabata N, 4305  
 Sawabe M, 1653  
 Sawad R, 5553  
 Sawada R, 1051, 2775  
 Sawada T, 2989  
 Sawada Y, 2573, 4895, 5497  
 Sawai T, 1527, 3091, 5643  
 Sawaki A, 1181  
 Sawaki M, 3735  
 Sawasaki M, 6063  
 Sawazaki S, 2763, 5635  
 Sayan M, 53, 93, 2961  
 Sborov DW, 385  
 Scalia G, 619, 1661, 1851, 5867  
 Scampa M, 929  
 Scharpf J, 1845, 2531  
 Schatz S, 1455  
 Scheibert A, 1295  
 Schemmer P, 1413  
 Scherl C, 3403  
 Scheuer HA, 2607  
 Schild SE, 1973, 2657, 3035, 3085, 3551, 4511, 4529, 5561, 5629  
 Schiller C, 1367  
 Schinzari G, 1487  
 Schlatterer K, 4199  
 Schmidt J, 2425  
 Schmitz K, 4647  
 Schmitz R, 629  
 Schmitz V, 5187  
 Schneider C, 4517  
 Schober P, 5825  
 Schüller U, 2945  
 Schulman S, 3261  
 Schwager M, 4773  
 Schweizer C, 429  
 Schweri-Olac A, 3217  
 Sciortino A, 5867  
 Scislawski M, 5249  
 Segami K, 2711, 3929, 3963, 5635  
 Segelov E, 373  
 Sehoul J, 1739  
 Seidl F, 4371  
 Seike M, 709  
 Seike R, 4805  
 Seilitz J, 2827  
 Seishima R, 5205  
 Seki H, 1099  
 Seki T, 115  
 Sekido Y, 3759, 4989, 5897  
 Sekihara K, 3815  
 Sekine A, 5763  
 Sekine I, 2583  
 Sekiya R, 1589  
 Selander T, 1879, 3557, 5521  
 Senuki K, 3963  
 Seo AN, 4955  
 Seo K-W, 5397  
 Seo S, 6127  
 Seo Y-J, 5951  
 Seo Y, 321, 3529  
 Seol A, 363  
 Sera T, 501, 5195  
 Serada S, 3361  
 Serizawa A, 4973  
 Serizawa I, 3701  
 Serizawa N, 697  
 Serpone M, 5909  
 Seto Y, 6027  
 Setou M, 3313  
 Shah A, 2531  
 Shalaby T, 3217  
 Sham NO, 3275  
 Shamavonian R, 2939, 3665  
 Shao Y-Y, 4461  
 Sharett J, 2531  
 Shariat SF, 5579  
 Sharma D, 5859  
 Sharma M, 3251, 4189  
 Shen T-C, 1229, 3381, 3799  
 Shen Y-C, 1229, 3381, 3427, 3799  
 Sheng W, 4707  
 Shetti D, 1933  
 Sheva K, 5257  
 Shi T, 1263, 2425  
 Shibamoto J, 3349  
 Shibano M, 6019  
 Shibasaki S, 4973  
 Shibasaki Y, 1123  
 Shibata H, 67, 1345  
 Shibata N, 1091, 1763  
 Shibata R, 3349  
 Shibata T, 1905  
 Shibutani M, 125, 311, 939, 1421, 3937  
 Shiga K, 645, 1277, 6047  
 Shiga Y, 581  
 Shigehara K, 2105, 2167  
 Shigekawa K, 4111  
 Shigeta K, 5205  
 Shih H-J, 3427  
 Shih L-C, 4329  
 Shih P-H, 3427  
 Shiina H, 1465, 3099  
 Shikata K, 3637  
 Shim S-H, 363  
 Shima S, 2095, 3701  
 Shimabukuro K, 287, 293  
 Shimada K, 2675  
 Shimada M, 2783  
 Shimada S, 3717  
 Shimada T, 1065  
 Shimada Y, 2415  
 Shimazaki A, 4071, 4097  
 Shimazu K, 2591  
 Shimizu D, 3889  
 Shimizu H, 1623, 3349, 3645

- Shimizu K, 1099, 4055  
 Shimizu S, 3529  
 Shimizu T, 2737, 3109, 3575, 5917  
 Shimizu Y, 3185, 3693, 5305, 6007  
 Shimoda Y, 3537, 4545  
 Shimodaira H, 2009  
 Shimoi T, 1043  
 Shimoji Y, 3017  
 Shimokobe H, 4063  
 Shimokoube H, 4153  
 Shimomura H, 3373  
 Shimomura K, 5961  
 Shimonosono M, 3905, 3953  
 Shimozaki S, 1555  
 Shimozato N, 173  
 Shin E, 2159  
 Shin J-S, 1813  
 Shin JE, 2159, 4945  
 Shin JY, 2159  
 Shin S, 2911  
 Shin SJ, 589  
 Shinagawa N, 3185  
 Shinagawa T, 5927  
 Shinden Y, 3373  
 Shindo Y, 2009, 2683  
 Shinkawa H, 2395  
 Shinno E, 6007  
 Shino M, 1439  
 Shinoda K, 2989  
 Shinomiya T, 1307  
 Shintani T, 2591  
 Shintani Y, 321  
 Shioiga T, 449  
 Shioji K, 893  
 Shiomi A, 419, 3537  
 Shiomi H, 321  
 Shiota A, 1719  
 Shiotsu S, 4921  
 Shiozaki A, 237, 1623, 3349, 3645  
 Shiozawa M, 2625  
 Shiozawa T, 2583, 4589  
 Shirabe K, 245, 1123, 4929, 5971  
 Shirahama N, 4089  
 Shirahama T, 4063  
 Shirai K, 1439  
 Shirai Y, 3621  
 Shiraishi T, 1123, 2683, 3091, 5643  
 Shirakawa H, 893  
 Shirakawa T, 4981  
 Shirasawa S, 3993, 4103  
 Shiota H, 2009  
 Shirotake S, 2727  
 Shirvani P, 5043  
 Shishido Y, 2177  
 Shiwa Y, 3613  
 Shlobin NA, 1661  
 Shoda H, 4805  
 Shoji R, 5357  
 Shoji T, 4603  
 Shoraka M, 75, 1893  
 Shozu M, 2637, 3707  
 Sieburg T, 3075  
 Sileikis A, 3067  
 Sill D, 5475  
 Silva PHF, 1327  
 Sim W, 3789  
 Simon M, 641  
 Simonetti E, 947  
 Sindayigaya R, 155, 1949  
 Singh S, 3523  
 Skladny J, 1911  
 Skoog P, 2827  
 Skovrider-Ruminski W, 5527  
 Skytta T, 2507, 2519  
 Slominski AT, 5009  
 Smile TD, 1845, 3845  
 Smolarczyk R, 4763  
 So S, 5479  
 Sobhy I, 355  
 Soda M, 2087  
 Sodergren SC, 3767  
 Soeda Y, 3627  
 Sohda M, 1123, 4929  
 Sohn J, 1001  
 Sohn TS, 2883  
 Soliman KFA, 441  
 Soma A, 6027  
 Soma G-I, 3983  
 Somasundaram V, 919  
 Somogyi KS, 109  
 Son S, 5343  
 Son SW, 4265  
 Sone K, 1073  
 Sone M, 4597  
 Soneda W, 2977  
 Song C, 681  
 Song J, 2341  
 Song SE, 5385  
 Sonoda H, 2033, 2461, 5927  
 Sonoda T, 6063  
 Sonoda Y, 4727  
 Sormunen J, 87  
 Sorsa T, 5415  
 Soyama A, 903, 3049, 3133  
 Spaak J, 3261  
 Spangler M, 1339  
 Sperduti I, 211  
 Spertini O, 3217  
 Spletstösser L, 3085  
 Spyropoulos AC, 3261  
 Stacher-Priehse E, 4517  
 Stang A, 1455  
 Stanislavljevic L, 3675  
 Stankiewicz J, 4499  
 Stankovic P, 137  
 Stark A, 5049  
 Stastny M, 1987  
 Stathopoulos G, 4517  
 Steffen C, 2405  
 Stegmann SK, 1237  
 Steinborn M, 4371  
 Steiner N, 5825  
 Steller D, 97, 1295  
 Stelmes A, 4505  
 Stenman G, 1455  
 Stenson K, 5449  
 Stephanos S, 5487  
 Stergiou D, 2813  
 Stickler S, 429  
 Stoddard PK, 5091  
 Stojacki K, 4763  
 Stoleriu MG, 4517  
 Stope M, 4825  
 Stope MB, 1367, 5839  
 Strigari L, 1851  
 Strobl N, 4517  
 Stromberger C, 2405  
 Stuck BA, 137  
 Sturmheit T, 1295  
 Styczynski J, 3607, 4499, 5181  
 Styczynski T, 5181  
 Su C-H, 531, 3799  
 Su P-H, 5609  
 Su Y-F, 3389  
 Suda K, 4973  
 Sudhakar SM, 4429  
 Sudo A, 4319  
 Sudo T, 4003, 4119, 4129  
 Sudou T, 4011, 4139  
 Suekane A, 4743  
 Suekane S, 4573  
 Suematsu H, 1535, 3873, 5885  
 Suenaga M, 3993  
 Suetsugu K, 2053  
 Suga K, 1123  
 Sugai A, 4727  
 Sugamata M, 3717  
 Sugano T, 709  
 Sugawara M, 343, 3185, 3693, 3753  
 Sugawara S, 2931  
 Sugaya S, 2023  
 Sugezawa K, 5719  
 Sugihara A, 5587, 6063  
 Sugihara R, 4139  
 Sugimachi K, 893  
 Sugimoto A, 501, 5195  
 Sugimoto K, 697  
 Sugimoto M, 1207, 5743  
 Sugino T, 419, 3537, 4417, 5233  
 Sugioka A, 1905  
 Sugisawa N, 739  
 Sugiura K, 3815  
 Sugiura T, 3169  
 Sugiyama E, 3313  
 Sugiyama Y, 1465, 3099  
 Suijkerbuijk KPM, 4795  
 Sukniam K, 5813  
 Sukprasansap M, 4247  
 Sumida Y, 1527, 3133  
 Sumiya T, 2953  
 Sumrall AL, 4429  
 Sun W, 59  
 Sun Y, 4679, 4715  
 Sunada K, 4165  
 Sunaguchi T, 2177  
 Sunakawa Y, 2675  
 Sung PS, 3463  
 Suojanen J, 2771  
 Suraya R, 271  
 Sursal T, 2225  
 Suto H, 1199  
 Suttisri R, 1833  
 Suzuki A, 3117, 4581  
 Suzuki G, 2701  
 Suzuki H, 1653, 4597  
 Suzuki K, 4973, 5945  
 Suzuki M, 581  
 Suzuki O, 321, 3529  
 Suzuki R, 1207, 5743  
 Suzuki S, 1051, 1541, 3029, 4293, 4727, 5977  
 Suzuki T, 1277, 1707, 3627



- Suzuki Y, 279, 301, 1635, 3621, 3963, 5205  
 Svajdler M, 1933  
 Svaton M, 1563, 1987  
 Svoboda M, 1563  
 Swain S, 1351  
 Swainson NM, 3507  
 Syrigos K, 3261  
 Syrjänen K, 1517, 1679, 1879, 3557  
 Szasz AM, 3681  
 Székely G, 1059  
 Taba Junior M, 1327  
 Tabata A, 4017  
 Tabata T, 1589  
 Tabchouri N, 155, 1949  
 Tacconi F, 4913  
 Tachibana H, 3151  
 Tachihara M, 1289, 1589  
 Tachikawa Y, 2033  
 Tada H, 2931  
 Tada K, 4619  
 Tada Y, 1607, 3177, 4907  
 Tadokoro T, 1263  
 Tafuri A, 5579  
 Tagawa T, 1137  
 Tago T, 459, 2113  
 Taguchi K, 4337  
 Tahara H, 5983  
 Tahata K, 5223  
 Tahira K, 4553  
 Taira Y, 3017  
 Tajima H, 2727  
 Tajiri K, 6007  
 Tajiri T, 1073  
 Tajudeen B, 5449  
 Tak E, 3463  
 Takabatake K, 3349, 3645  
 Takabatake M, 2415  
 Takabe Y, 5571  
 Takacs I, 4395  
 Takada K, 125, 311, 939, 1421, 3937  
 Takada Y, 6127  
 Takagane A, 2675  
 Takagi K, 653, 2797, 3637, 4471  
 Takagi M, 2923  
 Takagi T, 1207, 3151, 5743  
 Takahara T, 1905, 6007  
 Takahari D, 2683  
 Takahashi E, 5323  
 Takahashi H, 1277, 1607, 1859, 3177, 3759, 4293, 4477, 4907, 4989, 5897  
 Takahashi J, 301  
 Takahashi JC, 4173  
 Takahashi K, 1535, 2719, 3023, 3873, 6019  
 Takahashi M, 697, 2009, 3537, 6019  
 Takahashi S, 1307, 1465, 3099  
 Takahashi T, 2675, 2931  
 Takahashi Y, 2645  
 Takai R, 1199  
 Takaki W, 3349  
 Takakusagi Y, 2095, 3701  
 Takakuwa O, 1073  
 Takamatsu M, 2645  
 Takami H, 3889  
 Takami K, 5655  
 Takamori H, 4981  
 Takamura Y, 3091, 5643  
 Takano H, 115  
 Takano N, 709  
 Takano Y, 3921  
 Takao S, 3895, 4701  
 Takao Y, 4071, 4097, 4139  
 Takashima S, 5323  
 Takashima Y, 237  
 Takasumi M, 1207  
 Takata M, 6105  
 Takata N, 3637  
 Takatori E, 4603  
 Takatsuka D, 3735  
 Takatsuka Y, 4867  
 Takaya H, 4895, 5465  
 Takayama K, 4921  
 Takayama Y, 3895, 4805  
 Takayasu Y, 1439  
 Takeda K, 407, 2573, 3717, 5497  
 Takeda M, 3313  
 Takeda S, 4895, 5465  
 Takeda T, 2645, 4921  
 Takeda Y, 321  
 Takei H, 759  
 Takekuma Y, 343, 3185, 3693, 3753  
 Takemura M, 1073, 2591  
 Takemura S, 2395  
 Takenaka M, 115, 3117  
 Takenaka T, 1137  
 Takenobu H, 1131  
 Takenouchi K, 5751  
 Takeshima H, 781  
 Takeshita H, 1527  
 Takeshita T, 3693, 3753  
 Takeuchi A, 229, 1081, 3143, 4619  
 Takeuchi H, 2977, 3313  
 Takeuchi I, 1801, 2847  
 Takeuchi M, 2675  
 Takeuchi S, 3185, 3693  
 Takeuchi T, 981, 3653  
 Takeuchi Y, 293  
 Taki I, 1091  
 Takiguchi S, 1277  
 Takimoto R, 4179  
 Takise S, 3725  
 Takishita C, 5833  
 Takizawa H, 195  
 Takuma K, 1263  
 Talaat IM, 355  
 Tamae A, 981  
 Tamagawa A, 2711, 3929, 5635  
 Tamagawa H, 1535, 2711, 2719, 2763, 3873, 3929, 3963, 4545, 5635, 5885  
 Tamaki T, 4597  
 Tamaki Y, 2989  
 Tamari K, 321, 3529  
 Tamiya N, 4921  
 Tamori S, 3299, 5223  
 Tamura A, 645  
 Tamura J, 3963  
 Tamura M, 5305  
 Tamura N, 781  
 Tamura T, 2583  
 Tan C, 4563  
 Tan JY, 5859  
 Tan Z-L, 3807  
 Tanabe H, 115  
 Tanabe K, 3151  
 Tanabe S, 3637, 6105  
 Tanaka A, 4273, 4293  
 Tanaka C, 3889  
 Tanaka H, 125, 311, 939, 1421, 3889, 3937, 3975  
 Tanaka J, 4439  
 Tanaka K, 1527, 2625  
 Tanaka M, 2079  
 Tanaka N, 3889  
 Tanaka R, 981, 2395  
 Tanaka S, 2395  
 Tanaka T, 903, 3049, 3133, 4973  
 Tanaka Y, 1289, 1589, 3023, 4003, 4581, 5983  
 Tang C-H, 845  
 Tangoku A, 195  
 Tani J, 1263  
 Tani N, 2395  
 Tanigawa M, 4153  
 Taniguchi A, 6027  
 Taniguchi K, 4311  
 Taniguchi Y, 1081, 1555, 4619  
 Tanino H, 1199  
 Tanioka H, 2675  
 Tanishima Y, 3023  
 Taniuchi R, 2095  
 Taniwaki Satoshi, 4063, 4153  
 Taniwaki Shinichi, 4063  
 Taniyama K, 1707  
 Taniyama Y, 2875  
 Tanno K, 6047  
 Tanoue K, 3373  
 Tanoue Y, 4553  
 Tappero S, 5579  
 Tarvainen L, 2771  
 Tashiro H, 1707  
 Tashiro K, 2023  
 Tashiro M, 2469  
 Tashiro Y, 67, 1345  
 Tate E, 329  
 Tate S, 2637, 3707  
 Tatebe K, 5449  
 Tatekawa S, 321  
 Tatsuki S, 4603  
 Tatsumi S, 4305  
 Tatsunami R, 4025  
 Tatsuta I, 2923  
 Taube ET, 1739  
 Tauchi Y, 3937  
 Taura M, 981, 3653  
 Taura N, 5001  
 Tay YS, 1481  
 Tazawa H, 1707  
 Techigawara K, 3613  
 Tei M, 1859  
 Teishikata Y, 4165  
 Temnik M, 5685  
 Terada H, 1653  
 Terada N, 4981  
 Terai S, 2783  
 Terajima D, 5571

- Terakawa T, 973  
Terao H, 5783  
Teraoka S, 407, 4735  
Terashi T, 2071  
Terashima M, 419, 3537  
Terata K, 5323  
Terrone C, 5579  
Tessitore E, 929  
Thalin C, 965  
Thangavelu K, 137  
Tharun L, 97  
Thellenberg-Karlsson C, 87  
Thezenas S, 185  
Thielemans K, 1433  
Thielen MM, 2805  
Thiesler T, 1367  
Thomakos N, 2599  
Thomas D, 641  
Thompson LDR, 1481  
Thomson P, 5859  
Thongsom S, 4237  
Tian Z, 5579  
Tiemann K, 1455  
Tikhonov S, 1517  
Tilki D, 5579  
Timmer M, 1237, 2319  
Tintori R, 947  
Tiusanen T, 1879, 3557  
To K, 1527  
Tobias ME, 2225  
Tobita R, 3159  
Tochigi K, 3627  
Todaka A, 893  
Togano S, 501, 5195  
Togashi K, 4727  
Toh S, 981, 3653  
Toh U, 4139  
Tohda S, 1757  
Tohyama K, 5407  
Tokashiki K, 1547, 1607, 4907  
Tokimitsu Y, 6007  
Tokuda S, 4921  
Tokudome N, 407  
Tokuhisa M, 4477  
Tokunaga N, 4963  
Tokuyasu N, 2177, 4787, 5719  
Tomabechi H, 4603  
Tomasi SO, 1851  
Tomberger A, 1413  
Tombolini V, 991, 3003, 5909  
Tome Y, 731  
Tominaga T, 1527, 3091, 5643  
Tominaga Y, 4305  
Tomiooka K, 67, 1115, 1345  
Tomisaki I, 263, 1107, 1629, 3041  
Tomita E, 2087  
Tomita K, 1997  
Tomoda T, 1571  
Topolcan O, 1933  
Toriyabe K, 4165  
Tornwall J, 2771  
Tortora G, 165, 1487  
Toshima T, 4701  
Toshiyama R, 893  
Toulouse A, 801  
Toya R, 205  
Toyama H, 1403, 5479  
Toyoda S, 609  
Toyokawa T, 6105  
Toyosawa S, 2383  
Toyozumi Y, 2591  
Tozzi F, 991  
Trevino JG, 75  
Troev K, 1801  
Truc G, 5847  
Trufan SJ, 4429  
Truntzer C, 5847  
Tryfonopoulos D, 5795  
Tsai C-W, 1229, 1749, 2375, 3381, 3799, 4329, 5275, 5283, 5335  
Tsai J-J, 2495  
Tsao H-Y, 4329, 5275  
Tsaousis GN, 5795  
Tse A, 1001  
Tsoi K, 105  
Tsoukalas N, 5795  
Tsourouflis G, 675  
Tsubamoto H, 6063  
Tsuchida A, 459, 2113  
Tsuchida K, 645, 2095, 3701, 3963, 6047  
Tsuchie H, 5357  
Tsuchiya H, 229, 1081, 1555, 3143, 4619  
Tsuchiya N, 4103  
Tsuji A, 2675  
Tsuji T, 2053, 4611, 4841  
Tsuji Y, 4895, 5465  
Tsujiyama H, 5999  
Tsujiyama G, 5195  
Tsukagoshi M, 245, 5971  
Tsukahara K, 1547, 1607, 4907  
Tsukigawa K, 1333  
Tsukioka T, 3029, 5977  
Tsumura H, 893  
Tsumura S, 3125, 6113  
Tsunemitsu Y, 4963  
Tsunoda T, 2567, 3857, 3993, 4103, 4119, 5819  
Tsuru H, 4063, 4153  
Tsuruda Y, 3905, 3953  
Tsutsui K, 449  
Tsutsumi S, 2061, 2071, 3177  
Tsuzuki H, 4597  
Tu C-Y, 845, 3195  
Tucci M, 165  
Tukiainen E, 1509  
Tulyte S, 3067  
Tung C-W, 3389  
Tung K-C, 3413  
Tuohinen SS, 2507, 2519  
Turchetta R, 3003  
Tvilsted S, 3085, 4511, 4529, 5561  
Tzeng H-E, 5283  
Ubukata Y, 4929  
Uchibori S, 1333  
Uchida K, 5961  
Uchida M, 2053, 2737, 3109, 3575, 5917  
Uchida S, 4929  
Uchida-Kobayashi S, 6019  
Uchihara T, 381  
Uchikado Y, 3905, 3953  
Uchiyama K, 343  
Udo R, 459, 2113  
Ueda A, 4879  
Ueda H, 407  
Ueda K, 115, 4573  
Ueda M, 2591  
Ueda Y, 1403, 3117, 5305, 5479  
Uehara H, 195  
Uehata N, 5999  
Uejima C, 5719  
Uemura K, 4573  
Uemura M, 1859, 3529, 3759, 4701, 4989, 5897  
Uemura S, 381  
Uemura T, 1073  
Ueno H, 5539, 5999  
Ueno M, 217, 6105  
Ueno T, 4981  
Uesaka K, 3169, 3537  
Uesawa Y, 781, 2737  
Ueyama A, 2383  
Uhlig J, 4773  
Ujpal M, 109  
Umana GE, 619, 1661, 1851, 3203, 3251, 4189, 4641, 5867  
Umeda H, 3637  
Umeda Y, 653, 2797, 3637, 4471  
Umekita Y, 279, 5719  
Umetani Y, 4003  
Umimura T, 581  
Unno M, 739  
Uno A, 3117  
Urade T, 5479  
Urakami K, 419, 3537, 4417  
Urakawa N, 1051, 1541, 2775, 5553  
Urasaki T, 2045  
Urso M, 1397  
Uryu H, 981  
Usami Y, 2727  
Ushigome H, 1277  
Ushijima Y, 3895  
Usuba T, 1579  
Uto Y, 4017  
Utsumi M, 4963  
Utsunomiya T, 2071  
Uvodich ME, 919  
Uzawa N, 2383  
Valabrega S, 25, 3285  
Valenti V, 4641  
Van den Berg J, 4505  
Van der Zande BMI, 5101  
Van Lindert ASR, 4795  
Van Paesschen C, 373  
Van Trappen P, 1175  
Vanderauwera J, 1433  
Vankova B, 1563  
Vanni G, 3879, 4913  
Vanwalleghem L, 1175  
Vashistha K, 3595  
Vaslamatzis M, 1941  
Vassiliou S, 5547  
Vassiliou V, 3767  
Vatsaas CJ, 629  
Vauleon E, 3863  
Vavalle G, 5909  
Vegh A, 109

- Vegh D, 109, 1899  
 Velasquez MC, 1351  
 Venclicek O, 1563  
 Venkataram T, 5867  
 Verbeek M, 5431  
 Vereczkei A, 4395  
 Vergalaso I, 53, 93  
 Verhoeff JJC, 4795  
 Verkauskiene R, 2289  
 Veysseyre H, 3583  
 Viapiano MS, 723  
 Vieth M, 147, 1919, 4493, 5891  
 Vieth R, 5009, 5027  
 Vilgrain I, 4689  
 Villalonga JF, 3203  
 Villani S, 2249  
 Vincent J, 5847  
 Viola A, 4641  
 Virgilio E, 2249  
 Virtanen V, 2507, 2519  
 Vlachakis D, 5547  
 Vogt T, 5009, 5049  
 Von der Heyde E, 4773  
 Von Hardenberg J, 1911  
 Vorobyev S, 1517  
 Vrachnis N, 2599  
 Vuolle S, 5249  
 Vusqa U, 3595, 3853  
 Wabro K, 4485  
 Wachowicz K, 2665  
 Wada H, 2383  
 Wada Y, 67, 217, 1345, 4063, 4153  
 Waelput W, 1433  
 Wærstad PH, 955  
 Wagner D, 1413  
 Wakabayashi H, 3109  
 Wakabayashi M, 3743  
 Wakahara M, 279  
 Wakai T, 745  
 Wakame K, 4055  
 Wakasaki T, 981, 3653  
 Wakasu S, 1137  
 Wakefield MR, 2425, 2903, 3275  
 Wakita A, 5323, 6105  
 Walach MT, 1911  
 Waldbillig F, 1911  
 Wallace B, 3569  
 Wallen H, 965  
 Wang B, 3325  
 Wang C-H, 5283  
 Wang D, 2341  
 Wang H-M, 5609  
 Wang H-Y, 3825  
 Wang JH, 801  
 Wang L, 3325  
 Wang MH, 2665  
 Wang S-S, 2185, 4857  
 Wang T, 5673  
 Wang W-C, 4403  
 Wang Y-C, 1229, 3381, 3799, 4329  
 Wang Y, 75, 1697, 2835  
 Wang Z-H, 1749, 2375, 3381, 3799, 5275, 5335  
 Ward MC, 4429  
 Warm M, 1925  
 Warren C, 1893  
 Warwas B, 2657, 3035, 3551  
 Washimi K, 5783  
 Watakabe T, 205  
 Watanabe A, 245  
 Watanabe H, 1535, 2053, 2719, 3873, 4139  
 Watanabe J, 5497  
 Watanabe K, 419, 1277, 5971  
 Watanabe M, 1115, 1535, 6105  
 Watanabe N, 6027  
 Watanabe S, 2701  
 Watanabe T, 2675, 4929  
 Watanabe Y, 2023  
 Waterfield MD, 3217  
 Wazir U, 1013  
 Webb A, 2835  
 Webb AR, 5101  
 Wegner R, 1867  
 Wei W, 2531  
 Weide R, 4773  
 Weidle UH, 3233  
 Weiß C, 1911  
 Wellner U, 2743  
 Welslau M, 4773  
 Wen X, 2277  
 Weng W-H, 811  
 Weng Y-S, 3825  
 Werner EM, 1973, 2029  
 Werner Z, 1339  
 Wessels F, 1911  
 Westerhoff A, 1925  
 Westhoff N, 1911  
 Wiegand S, 5567  
 Wieland I, 2945  
 Wienerroither V, 1413  
 Wilhelm T, 137  
 Wilkman T, 2771  
 Willenbacher W, 5825  
 Williams DJ, 1339  
 Wils RS, 1  
 Winter L, 3075  
 Wisnieski F, 4381  
 Wolf D, 5825  
 Wolff BJ, 45, 2805  
 Wolff JE, 45, 2805  
 Wongpanuwich W, 2689  
 Wongratwanich P, 287, 293  
 Wongsakul A, 1833  
 Woo DK, 3445  
 Woo HY, 5601  
 Woo SM, 599  
 Wood NR, 397  
 Woody NM, 1845, 3845  
 Worakitchanon W, 3835  
 Worst TS, 1911  
 Wright D, 5101  
 Wu C-E, 2145  
 Wu H-J, 3807  
 Wu J-Y, 3825  
 Wu J, 5217  
 Wu M-F, 3381  
 Wu M-H, 2375, 2495, 5275  
 Wu M, 5673  
 Wu NF, 5217  
 Wu S-C, 3427  
 Wu Y-C, 845  
 Wulf HC, 5017, 5069, 5083  
 Wunder JS, 105  
 Xi Q, 4715  
 Xiao H, 2425, 2903, 3275  
 Xiong J, 4715  
 Xiong Y, 3299, 5223  
 Xu Z, 1217  
 Xue J, 1821  
 Xynogalos S, 5795  
 Yabumoto A, 3937  
 Yabusaki H, 2683  
 Yabushita Y, 791, 2573  
 Yaegashi H, 1065, 2105, 2167, 3099  
 Yagi T, 653, 2797, 4471  
 Yahya A, 2665  
 Yamada H, 2583  
 Yamada K, 115, 1345, 2701  
 Yamada M, 3169, 4071, 4097  
 Yamada S, 4439  
 Yamada T, 1535, 2719, 2763, 3873, 4545, 4921, 5885  
 Yamada Y, 2645, 4337  
 Yamagishi H, 609  
 Yamaguchi A, 4929  
 Yamaguchi K, 419, 2683, 3537, 4417, 5233  
 Yamaguchi M, 1043, 1091, 5571  
 Yamaguchi S, 2277, 3725  
 Yamaguchi T, 2009, 2783, 5961, 6105  
 Yamaguchi Y, 759, 1181, 759  
 Yamaguma H, 1221  
 Yamakado K, 4813  
 Yamakawa M, 3963  
 Yamamichi S, 5001  
 Yamamoto A, 1403, 2395, 5479  
 Yamamoto H, 981, 1859, 3653, 3759, 4989, 5897  
 Yamamoto J, 641, 731, 2567  
 Yamamoto K, 3947, 3983  
 Yamamoto M, 271, 2177, 4787, 5719  
 Yamamoto N, 229, 407, 1081, 1555, 3143, 4619  
 Yamamoto S, 2045, 2123, 3117  
 Yamamoto T, 2023, 3349  
 Yamamoto W, 2683  
 Yamamoto Y, 501, 1623, 2583, 3169, 3349, 3645, 4305  
 Yamamoto Y, 501, 5195  
 Yamamura K, 35, 1645, 3209, 5663  
 Yamamura M, 1181  
 Yamana H, 4037  
 Yamanaka N, 5587  
 Yamanaka T, 245, 5971  
 Yamasaki A, 2869  
 Yamasaki K, 1333  
 Yamashita G, 1547, 1607  
 Yamashita H, 4025  
 Yamashita K, 381, 1051, 1541, 2775, 5553  
 Yamashita M, 3133, 3983  
 Yamashita S-I, 2079  
 Yamashita T, 1589, 1607, 2061, 3177, 4907  
 Yamashita Y-I, 1007  
 Yamashita Y, 4981

- Yamauchi K, 581  
 Yamauchi M, 981, 3653  
 Yamauchi N, 5553  
 Yamauchi Y, 3627  
 Yamaue H, 217  
 Yamazaki H, 2701  
 Yamazaki K, 1115  
 Yamazaki T, 67, 1345, 5001  
 Yamochi T, 67  
 Yanagi H, 5587  
 Yanagi Y, 4411  
 Yanagimoto H, 1403, 5479  
 Yanagisawa T, 2023  
 Yanagita T, 1277  
 Yanai H, 3159  
 Yanai K, 2869  
 Yanaihara N, 115  
 Yaneva Z, 547  
 Yang B, 2159  
 Yang C-C, 845, 3413, 4403  
 Yang C-J, 2495  
 Yang C-K, 2185, 4857  
 Yang C-T, 2145  
 Yang H, 4715  
 Yang J-S, 531, 3799  
 Yang J, 589  
 Yang M-D, 1749, 5335  
 Yang SH, 1615  
 Yang X, 1339  
 Yang Y-C, 1229, 1749, 2375, 3381, 5275, 5335  
 Yang Y, 3325  
 Yang Z, 4707  
 Yano A, 1333  
 Yano F, 3023  
 Yano H, 449, 4079, 4129, 4153, 4159  
 Yano J, 4805  
 Yano K, 4553  
 Yano Y, 1403, 4145, 5479  
 Yao C-H, 845  
 Yao T, 2893  
 Yapijakis C, 5547  
 Yashiro M, 501, 2395  
 Yasuda I, 6007  
 Yasuda J, 3621  
 Yasuda M, 2727, 5991  
 Yasuda Y, 271  
 Yasue K, 2989  
 Yasue M, 3117  
 Yasufuku I, 4581  
 Yasui K, 2797, 4417, 4471  
 Yasui M, 4989, 5897  
 Yasui W, 1707, 5885  
 Yasumatsu R, 981, 3653  
 Yasunaga S, 4111  
 Yatsuyanagi M, 5323  
 Yaylim I, 1301  
 Yazaki R, 3993  
 Yazawa K, 791  
 Yazawa T, 2923  
 Ychou M, 185  
 Yeh C-T, 2479  
 Yeh K-Y, 5609  
 Yehia ZA, 53, 2961  
 Yen C-M, 3799  
 Yen J-H, 3799  
 Yenchitsomanus P-T, 1785  
 Yi JH, 6083  
 Yim GW, 363  
 Yobuta R, 1477  
 Yoda M, 4273  
 Yodsanga S, 2689  
 Yokobori T, 4929  
 Yokoi M, 1653  
 Yokoo S, 1439  
 Yokose T, 5783  
 Yokota I, 1635  
 Yokota T, 4417  
 Yokoyama H, 5587  
 Yokoyama S, 3947  
 Yokoyama Y, 2033, 2461, 4165, 5927  
 Yomogida Y, 5743  
 Yonekura S, 511  
 Yonemitsu H, 2053  
 Yonemoto T, 2139  
 Yonemura Y, 4701  
 Yonese J, 2045, 2123  
 Yoneyama S, 3159  
 Yonezawa H, 229, 1081, 3143  
 Yoo C, 471, 3435  
 Yoo DS, 4359  
 Yoo J, 335  
 Yoo JC, 3445  
 Yoon J, 2961  
 Yoon S, 2433  
 Yoon SH, 1615  
 Yoon SK, 3463  
 Yoon SY, 6091  
 Yoshida D, 2095, 3701  
 Yoshida H, 1599  
 Yoshida K, 1645, 2797, 3151, 3993, 4165, 4319  
 Yoshida M, 173, 301, 5571  
 Yoshida R, 653, 2797, 4471  
 Yoshida T, 195, 981, 4011  
 Yoshida Y, 2469  
 Yoshihara M, 5783  
 Yoshii H, 3815  
 Yoshiji H, 173, 4895, 5465  
 Yoshikawa A, 709  
 Yoshikawa K, 1801, 2847, 4111, 4293  
 Yoshikawa T, 1499, 2791, 4545, 6037  
 Yoshimoto Y, 3341, 4063, 4153  
 Yoshimura A, 3735  
 Yoshinaga Y, 2079  
 Yoshinami T, 2591  
 Yoshino K, 3133  
 Yoshioka E, 5783  
 Yoshioka H, 4173  
 Yoshioka T, 2009  
 Yoshioka Y, 5927  
 Yoshitomi M, 4063  
 Yoshiya T, 4311  
 Yoshiyuki T, 1599  
 Yoshizawa Y, 1777  
 Yoshizumi T, 245  
 Yotsumoto F, 4111  
 Youn H-Y, 5397, 5803  
 Young K, 4189  
 Yousef P, 2355  
 Yousefi O, 4189  
 Yu C-C, 1749  
 Yu D, 589  
 Yu H-J, 5951  
 Yu HN, 1813  
 Yu JJ, 1339  
 Yu K-J, 811  
 Yu K, 1189, 4189  
 Yuan BJ, 919  
 Yuasa T, 2045, 2123  
 Yuda M, 3023  
 Yueh P-F, 4403  
 Yueh T-C, 2375, 5275, 5335  
 Yuguchi Y, 3627  
 Yuichi G, 4079  
 Yujiro N, 263  
 Yukawa N, 1535, 2711, 2719, 2763, 3873, 3929, 3963, 4545, 5635  
 Yuki H, 1645  
 Yumisaki H, 1439, 5991  
 Yumura M, 1289  
 Yun CW, 857  
 Yunokawa M, 1091  
 Yunoki K, 4963  
 Yura M, 5571  
 Yusa K, 2469  
 Yusa T, 1007  
 Yusef M, 3285  
 Zaccaro L, 3003  
 Zagouri F, 5795  
 Zaidi SE, 1661  
 Zaitsu J, 1707  
 Zander T, 1821  
 Zaraei S-O, 2911  
 Zarrinpar A, 1893  
 Zeitler C, 4647  
 Zekan D, 1339  
 Zemann W, 1899  
 Zenker M, 2945, 6121  
 Zerbi A, 2743  
 Zeuli M, 2241  
 Zhang H, 3325  
 Zhang J, 2341, 2835, 4345  
 Zhang Q, 3971  
 Zhang R, 4707  
 Zhang X, 4345  
 Zhao L, 2903, 3275  
 Zhao X, 3325  
 Zhelev Z, 547  
 Zheng Y-W, 5223  
 Zheng Z, 4359  
 Zhou R, 2835  
 Zhou Ying, 1217  
 Zhou Yu, 1217  
 Zhu D, 4707  
 Zhu H, 3325  
 Zhu Z, 2425, 2903, 3275  
 Zick A, 5257  
 Zilaitiene B, 2289  
 Ziogas IA, 629  
 Ziras N, 1031  
 Zlateva G, 547  
 Zola P, 2017  
 Zucker A, 1397  
 Zuna P, 1563  
 Zvirblis T, 3067  
 Zwaenepoel K, 373

## Corrigenda

Vol. 23, No. 5b, page 4347, the name of fifth Author should read:

NADIA M. HAMDY

Volume 40, No. 4, page 2214: The Acknowledgements section should read:

This work was supported by AZV grant No. 17-30748A.

Volume 40, no. 12, page 7077, the first sentence of Patients and Methods section should read:

Twenty-eight patients irradiated for recurrent GBM (re-irradiation)


Vol. 41, No. 4, page 2102, left column, lines 11-12 should read:

more accurate and rectal sparing dose delivery (IGRT-VMAT) without a systematic use of support therapy, which was administered only on-demand

Vol. 41, No. 4, p. 2103, left column, lines 1-4 should read:

but not its overall incidence, as evidenced by a significantly lower rate of grade G2 toxicity in the group B ( $p < 0.05$ ) in the face of a comparable rate of grade  $\geq G1$  toxicity rate with respect to group A. Putting together group A and group B into the

Vol. 42, No. 2, page 873, Figure 5 should be:






Volume 42, No. 3, page 1382, right column, 35th line should read:

Here we present four cases of NENs, where the diagnosis


Vol. 42, No. 4, page 2055, right column, 6th line should read:

125 events) for grade 1, 64.3% (27 of 42) for grade 2, 38.7%

Vol. 42, No. 4, page 2055 Figure 1 should be:



**[ESHAP±R therapy]**  
**(Rituximab + Etoposide + Cisplatin + Methylprednisolone + Cytarabine)**



Patient's name \_\_\_\_\_

Course

**Names of chemicals and treatment schedule**  
(To prevent adverse effects, subsequent treatment may be postponed if potent effects of the anticancer drug remain.)

Names of drugs	Drug class	Administration	Date																												
			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	1
			12/8	12/9	12/10	12/11	12/12	12/13	12/14	12/15	12/16	12/17	12/18	12/19	12/20	12/21	12/22	12/23	12/24	12/25	12/26	12/27	12/28	12/29	12/30	12/31	1/1	1/2	1/3	1/4	1/5
			Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue
<b>Supportive care medicine</b>																															
Ibuprofen 100mg Tablet	Anti-allergic drug	Once a day	2Tabs/onc																												
d-Chlorpheniramine Maleate 5mg injection	Anti-allergic drug	15 minutes	1Cap/once																												
Aprepitant 125mg capsule (day 1) 80mg capsule (days 2-3)	Antiemetic drug	Once a day	On the first day, the above chemicals are prescribed 60-90 minutes before the start of administration of an anticancer																												
Granisetron 3mg injection	Antiemetic drug	30 minutes before chemo	A stomach medicine is prescribed to prevent gastritis. Hand washing and gargling are recommended in consideration to an immunocompromised																												
<b>Chemotherapy</b>																															
Rituximab injection	Anti-cancer drug	3-6 hours	No treatment is conducted during this week.																												
Etoposide injection	Anti-cancer drug	1 hour	No treatment is conducted during this week.																												
Methylprednisolone	Steroid drug	30 minutes	No treatment is conducted during this week.																												
Cisplatin injection	Anti-cancer drug	24 hours	To protect the kidneys, infusion is performed in a large volume. Moderate hydration is needed for frequent urination.																												
Cytarabine injection	Anti-cancer drug	3 hours																													
Betamethason instillation	Anti-inflammatory agent	Instillation four times daily																													

**Adverse effects**

	Original version Modified version	Caution should be exercised for the following symptoms:																												
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	1
		12/8	12/9	12/10	12/11	12/12	12/13	12/14	12/15	12/16	12/17	12/18	12/19	12/20	12/21	12/22	12/23	12/24	12/25	12/26	12/27	12/28	12/29	12/30	12/31	1/1	1/2	1/3	1/4	1/5
		Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Mon	Tue
Subjective symptoms	Infusion reactions such as rash, itching sensation, and fever	If you notice symptoms such as itching, facial burning, urticaria, rapid pulse, or breathlessness, notify us immediately.																												
	Nausea/Vomiting	Nausea and vomiting may occur. Ingest easy-to-digest foods and sufficient fluids.																												
	Anorexia	Anorexia may occur. Ingest easy-to-digest foods and sufficient fluids. Careful monitoring is continued until disappearance of symptom																												
	Insomnia	Insomnia may occur. Consult us if you have any symptoms.																												
	Stomach discomfort	Consult us if you develop symptoms such as stomach pain, belching, retching, abdominal fullness, or loss of appetite.																												
	Stomatitis	Stomatitis may occur with pain. Brush your teeth, and gargle gently and sufficiently. Careful monitoring is continued until disappearance of symptom.																												
	Diarrhea	Consult us if you have frequent stools, strong abdominal pain, or watery stools.																												
	Symptoms due to Cycloide [Skin] Rash and itching, [Eyes] Congestion, itching, and pain	Consult us if you have symptoms such as itching, hot flashes, urticaria, tachycardia, or stinging.																												
	Shivering, blurred vision, headaches, cramps, etc.	Consult us if you have symptoms such as tremor or headache.																												
Blood exam data	Depilation (e.g., hair, eyelashes, and eyebrows)	Hair may thin slightly. Do not be worried as hair will regrow within approximately six months after treatment.																												
	Leukopenia	Hand washing and gargling are recommended because of the increased susceptibility to infection. Injections may be performed to increase the white blood cell count, as needed. Consult us if you have a fever of >38°C.																												
	Erythropenia (anemia)	Symptoms of anemia (dizziness and wobble) may occur. Caution should be exercised to prevent falling.																												
	Thrombocytopenia	Thrombocytopenia may cause easy bleeding, resulting in red spots or bruises on the limbs and gum hemorrhage. Caution should be exercised to prevent falling.																												
	Renal dysfunction (increase in Scr)	Symptoms, such as swelling of the face and limbs and oliguria and anuria, may occur.																												
	Liver dysfunction (increase in ALT, AST)	Fatigue, anorexia, itchy skin, and yellowing of the skin and eyes.																												

\* Consult us immediately if you have discomfort, edema, or pain at the stab site.  
 \* The above table shows the treatment schedule and the frequent times of onset of adverse effects, although unexpected events may occur.  
 \* Medication may be considered depending on adverse effects, as needed.

Department of Pharmacy, Kyushu University Hospital

Vol. 42, No. 4, page 2056, right column, 5th line should read:

was started on the 7<sup>th</sup> day rather than on the 12<sup>th</sup> day of

Vol. 42, No. 4, page 2056, right column, 22nd line should read:  
149 events of 246 AEs, the onset timing and duration of

Vol. 42, No. 4, page 2059, left column, 3rd and 4th line should read:  
of 246 AEs occurred with different onset timings, all of  
which were predictable AE items. Among those AEs, 149

Vol. 42, No. 5, page 2544, right column, line 11 should read:  
(Figure 3A). The mean survival for patients with S-PCI

Vol. 42, No. 5, page 2545, left column, line 9 should read:  
The mean OS (in months) for the entire cohort was 40.4

Vol. 42, No. 5, page 2547, Table V, row 5 should read:  
ECOG $\geq$ 1


Vol. 42, No. 5, page 2547, Table V, rows 29 and 30 should read:  
PFS Mean (months)  
OS Mean (months)

Vol. 42, No. 5, page 2701, name of the third author should read:  
TAKUYA KIMOTO


Vol. 42, No. 5, page 2707, left column, 25th line should read:  
25.0% and 10.0% of patients, respectively, which is consistent

Volume 42, no. 5, page 2791, the names of the second and fifth Author should read:  
YOICHI HAMAI and MANATO OHSAWA

Vol. 42, No. 7, page 3332, Figure 4B should be replaced with:



Vol. 42, No. 7, page 3336, Figures 6A and 6B should be replaced with:



Vol. 42, No. 10, page 4890, Table IV, row 1 should read:

PMI < 3.92 cm <sup>2</sup> /m <sup>2</sup> (n=68)	PMI $\geq$ 3.92 cm <sup>2</sup> /m <sup>2</sup> (n=66)
--	---

Vol. 42, No. 10, page 4890, Table V, row 1 should read:

PMI < 3.92 cm <sup>2</sup> /m <sup>2</sup> (n=68)	PMI $\geq$ 3.92 cm <sup>2</sup> /m <sup>2</sup> (n=66)
--	---

## Instructions for Authors 2022

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

AR provides for the prompt print and online publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

AR is a hybrid open-access journal (a subscription journal in which some of the articles are open access). All articles that are published as open access are with gold OA, which means that the final published version is permanently and freely available to anyone. Our open access articles are distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0>).

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**UKRI Open Access Policy.** UKRI-funded Authors retain the right to distribute the final published version of their accepted article, such as via an institutional and/or subject repository (e.g. EuropePMC), under a Creative Commons Attribution 4.0 International (CC BY 4.0) licence (<https://creativecommons.org/licenses/by/4.0/>).

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work (without supplementary data), and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work or before the Acknowledgements); (b) *Abstract* not exceeding 250 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors’ Contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures (graphs and photographs).** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Figures should be prepared at a width of 8 or 17cm with eligible symbols, lettering and numbers. The number of each figure must be indicated. Pages that include color figures are subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Each table may have 2-10 vertical columns. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalgleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924 (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at: [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html) [Last accessed on April 3, 2018]. (The web address should link directly to the cited information and not to a generic webpage).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email ([iar@iar-anticancer.org](mailto:iar@iar-anticancer.org)) within 24 hours.

**Erratum.** An erratum is published to correct any error(s) that might have been introduced to the article by the publisher during the publication process. Authors who may notice an error in the final published article should contact directly the Editorial Office.

**Corrigendum.** A corrigendum is published to change a part or to correct any error(s) that might have been introduced by the author(s). Authors should contact our Editorial Office, and our Editor will decide on the appropriate course of action.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.



2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 5 days from submission, the author should contact the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for peer-review (single-blind) in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and Discussion should not be combined into one section.
  - Results given in figures should not be repeated in tables.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably in red. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. All Authors will be asked to supply author contribution and conflict of interest forms.
10. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2021): 69%).
11. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
12. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
13. Authors who wish to organize and edit a special issue on a particular topic should contact the Managing Editor.
14. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2022** – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

## Editorial Staff

Managing Editor and Executive Publisher: GEORGE J. DELINASIOS, Athens, Greece  
Production Editor: E. ILIADIS, Athens, Greece

## Editorial Office

International Institute of Anticancer Research,  
1st km Kapandritiou-Kalamou Rd.,  
Kapandriti, P.O.Box 22, Attiki 19014, Greece  
Tel and Fax: +30-22950-53389

## U.S. Branch

Anticancer Research USA, Inc.,  
111 Bay Avenue, Highlands, NJ, USA

*E-mails:* Editor: editor@iiar-anticancer.org; Journals: journals@iiar-anticancer.org; IIAR: iiar@iiar-anticancer.org

*IIAR websites:* [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.iiarjournals.org](http://www.iiarjournals.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published monthly. Each annual volume contains twelve issues and index.

**Copyright:** Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

**ANTICANCER RESEARCH is available in print (ISSN: 0250-7005) and online (ISSN: 1791-7530) through Stanford University HighWire Press with access to full text/PDF articles from all previous volumes since January 1st, 2004. For online/print subscription rates, please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.ar.iiarjournals.org](http://www.ar.iiarjournals.org)**

**Annual Subscription Rates 2022:** Institutional subscription online: US\$ 1,898.00. Institutional subscription print & online: US\$ 2,277.00. Personal subscription online: US\$ 897.00. Personal subscription print & online: US\$ 1,277.00. Prices include rapid delivery and insurance. Previous volumes of Anticancer Research (Vol. 1-41, 1981-2021) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the publisher (e-mail: [subscriptions@iiar-anticancer.org](mailto:subscriptions@iiar-anticancer.org)).

**Correspondence:** (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, advertising rates requests, and general editorial matters) should be directed to Dr. G.J. Delinasios, Executive Publisher and Managing Editor, Editorial Office.

**Advertising:** Correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents Life Sciences and Medical Sciences*, *Science Citation Index Expanded*, *Index Medicus*, *Biological Abstracts*, *PubMed*, *PubMed Central*, *Chemical Abstracts*, *BIOSIS Previews*, *Essential Science Indicators*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Elsevier Bibliographic Database*, *EMBASE*, *Compendex*, *GEOBASE*, *EMBiology*, *Elsevier BIOBASE*, *FLUIDEX*, *World Textiles*, *Scopus*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase*, *CAB Abstracts/Global Health Databases*, *Investigational Drugs Database*, *VINITI Abstracts Journal*, *Leeds Medical Information*, *PubsHub*, *Sociedad Iberoamericana de Información Científica (SIIC) Databases*.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit [www.copyright.com](http://www.copyright.com) and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: [info@copyright.com](mailto:info@copyright.com).

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

PHOTOCOMPOSITION BY IIAR  
PRINTED BY ENTYPPO, GREECE  
PRINTED ON ACID-FREE PAPER